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1.1 INTRODUCTION
Menopause is a major milestone in the aging process in women and starts after the last menstrual cycle.
The cessation of ovarian function causes the almost complete absence of female sex steroid hormone
secretion by the ovaries in postmenopausal life. Consequently, before and after the menopausal
transition very different physiological hormonal regimens prevail, which have a major impact on
healthy aging of women and their quality of life. After menopause, due to the loss of exposure to
protective female sex steroid hormones, women have an increased risk for different health problems,
such as osteoporosis (Gibaldi, 1997), and changes in cognitive function (e.g. Alzheimer’s disease)
(Kesslak, 2002). Furthermore, it has been suggested that the risk for cardiovascular diseases increases
after the menopause (Mijatovic, et al., 1999), although these findings are under debate (Tunstall-Pedoe,
1998). Since the age at menopause affects the length of the postmenopausal period, it is of utmost
importance to understand the process leading to menopause.
Menopause is caused by the exhaustion of the follicle stock in the ovaries. The limited supply of
follicles is formed during fetal life, from the 1000-2000 germ cells which migrate from the allantois to
the gonadal ridge to populate the ovary. The germ cells divide 10-15 times until the maximal number
of oocytes, about 7 million, is reached at 20 weeks of gestation. From that moment on the number of
oocytes decreases in a logarithmic fashion and at birth about 1 million oocytes remain present. A further
decrease of the number of oocytes occurs during childhood, resulting in 300,000-500,000 oocytes at
menarche (te Velde, et al., 1998; Macklon and Fauser, 1999). Loss of primordial follicles, which form
the limited resting follicle stock, continues with approximately 1000 follicles/month by primordial
follicles entering the growth phase or undergoing atresia. This rate of loss may even increase after the
age of 35 years (Gougeon, et al., 1994; Gougeon, 1996; Macklon and Fauser, 1999). Only about 400
oocytes are destined to full maturation and ovulation during female reproductive life in the human
(Macklon and Fauser, 1999).
At menopause, the size of the follicle pool is approximately 100-1000 and a permanent cessation
of menstrual cycles occurs because of this exhaustion of the follicle pool. This number of follicles is
unable to maintain the hormonal concentrations necessary for normal menstrual cycles (te Velde and
van Leusden, 1994). The median age at menopause in the Western world is 51 years, with a variation
of 40-60 years (te Velde, et al., 1998; Macklon and Fauser, 1999). Menopause is preceded by a
premenopausal transition period of 15-20 years. During this transition period fertility decreases,
culminating through sub-fertility into complete infertility 10 years before menopause. There are
indications that these intervals are fixed, implying that early infertility may indicate early menopause.
In general, this means that optimal fertility in women occurs up to 30 years of age and decreases
thereafter (te Velde, et al., 1998).
Since the size of the primordial follicle pool is determined during embryogenesis and is not replenished
at any time thereafter, the size of this pool and its rate of depletion determine the end of fertility and
the timing of onset of menopause. Thus, in view of early infertility and the health problems of women
associated with menopause, it is of key importance to understand the mechanisms that determine the
early growth and differentiation of primordial follicles. In the remainder of this Chapter, primordial
follicle recruitment and effects of members of the transforming growth factor b (TGFb) superfamily
of growth and differentiation factors, which play an important role in this early follicular development,
are described in more detail.
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At birth, the ovaries of mice only contain naked oocytes (type 1 follicles), which are enclosed by
pregranulosa cells into primordial follicle structures one day later (Peters, 1987). Oocytes which fail
to recruit (pre)granulosa cells and to form a follicle will degenerate (Byskov, 1986). As soon as the
primordial follicles arise, the basement membrane, which consists of collagen, laminin and fibronectin,
is formed around the granulosa cells (Hirshfield, 1991). The primordial follicle pool forms the resting
stock of follicles in the ovary. Start of growth of primordial follicles occurs at different times during
the life of the animal.
The histological feature, that characterizes the first growth of the primordial follicle (type 2 follicle)
in rodents is an increase in the size of the oocyte. Thereafter, granulosa cells proliferate and transform
from squamous to cuboidal cells. From this moment on, follicles are called type 3a or intermediary
follicles. When the oocyte is surrounded by one complete layer of cuboidal granulosa cells the follicle
is referred to as type 3b. As soon as the oocyte starts to grow, the zona pellucida is formed. This
extracellular glycoprotein matrix is located between the oocyte and granulosa cells and consists of
three zona pellucida (ZP) proteins (ZP1, ZP2, ZP3), all produced by the oocyte. Granulosa cells probably
do not contribute to the formation of this matrix (Zamboni and Upadhyay, 1983). During the
development from type 3b to type 5a follicles, granulosa cells proliferate extensively. In mice, oocyte
growth is completed in type 5a follicles when the follicle contains three layers of granulosa cells. These
follicles contain the first theca cells recruited from the stromal cells (Pedersen and Peters, 1968).
Theca and granulosa cells are separated by the basement membrane and both cell types proliferate
during further development, although theca cells not as extensively as granulosa cells (Peters, 1969).
Scattered areas of fluid are found in type 6 follicles, which will form the antrum in type 7 follicles
(Pedersen and Peters, 1968). As soon as fluid spaces are found in the follicle, it is called an antral
follicle. The follicle diameter further increases due to granulosa- and theca cell proliferation. 
At this point theca cells also undergo a morphological and functional change. Theca cells lying next to
the basement membrane (theca interna) acquire morphological hallmarks of steroidogenesis, like smooth
endoplasmatic reticulum and mitochondria with tubular cristae, while theca cells that are located
more peripheral (theca externa) stay small and compact (Stevens and Lowe, 1992). The pre-ovulatory
follicle (type 8) is characterized by an oocyte that is surrounded by specialized granulosa cells called
cumulus cells (Pedersen and Peters, 1968). The oocyte and cumulus cells are located in the antrum
and connected to the follicle wall through a stalk. Granulosa cells of the pre-ovulatory follicle stop
dividing in response to the luteinizing hormone (LH) surge and initiate a program of final differentiation
(Hirshfield, 1991). In response to the LH peak the oocyte with cumulus cells will be ovulated. The
remaining cells form the corpus luteum which plays an important role as a steroid hormone
producing structure.
In women, folliculogenesis occurs along a similar pathway. However, some differences in timing
of histological changes between woman and mouse have been described. Primordial follicle formation
occurs already during the fetal period in women (Gougeon, 1996), while in mice this occurs after
birth. In addition, histological changes of the primordial follicles are described before the follicles
enter the growing phase. The flat granulosa cells of primordial follicles become cuboidal
(intermediary follicle) and proliferate until one layer of cuboidal granulosa cells is formed. However,
this class 3a follicle is still considered a resting follicle (Gougeon, 1996). From the moment on which
1-2 layers of granulosa cells surround the oocyte, the follicle is called “growing”. 
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1.2 FOLLICULOGENESIS: 
A MORPHOLOGICAL OVERVIEW
In this section, the histological changes during follicle development from the primordial to the 
pre-ovulatory stage are described. These histological characteristics are important as they are used to
describe effects of hormones and growth factors on different types of follicles. The histological changes
during folliculogenesis will be described for both mouse and human, since there are important
differences between these species in the histological characteristics of the follicles and the developmental
stage they have reached. A summary of these characteristics combined with the nomenclature is given
in Table 1.1 (mouse) and Table 1.2 (human). In addition, Figure 1.1 shows an overview of follicle
development and effects on follicle types of LH, FSH and TGFb superfamily members.
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Table 1.1: Summary of nomenclature and characteristics of follicular development in the mouse. 
(Pedersen and Peters, 1968).
Type: Diameter Number of Characteristics of the follicle: Other nomenclature:
oocyte granulosa 
(µm): cells:
1 20 0 small naked oocyte
2 20 few flat granulosa cells small primordial primordial
3a ‡ 20 ≤20 cuboidal and flat granulosa cells small intermediary
3b 20-70 21-60 one layer of cuboidal granulosa cells medium (small) pre-antral primary
4 20-70 61-100 two layers of granulosa cells medium pre-antral secondary
5a ‡ 70 101-200 three layers of granulosa cells medium pre-antral secondary
5b 70 201-400 first theca cells are recruited large pre-antral secondary
6 70 401-600 scattered areas of fluid large (small) antral tertiary
7 70 >600 one fluid cavity, cumulus 
oophorus, but no stalk large antral tertiary
8 70 >600 cumulus stalk large pre-ovulatory tertiary
Table 1.2: Summary of nomenclature and characteristics of follicular development in the human.
(Gougeon, 1996).
Class: Diameter Number of Characteristics of the follicle: Other nomenclature:
follicle: granulosa 
(µm): cells:
<80 <15 flat granulosa cells resting follicle primordial
<80 <15 cuboidal and flat granulosa cells resting follicle intermediary
<80 <15 one layer of cuboidal granulosa cells resting follicle small primary
<80 15 1-2 layers of granulosa cells, 
oocyte diameter >19 µm growing follicle secondary
80-100 15-600 own blood supply growing follicle secondary
1 0.1 600 first theca interna cells, 3-6 layers 
of granulosa cells growing follicle pre-antral tertiary
2 0.2 3-5x103 growing follicle early antral tertiary
3 0.4 15x103 growing follicle antral tertiary
4 0.9 75x103 growing follicle antral tertiary
5 2 375x103 recruitable growing follicle antral tertiary
6 5 1.87x106 selected growing follicle antral tertiary
7 10 9.4x106 growing follicle early preovulatory tertiary
8 16-20 47x106 growing follicle preovulatory tertiary
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stimulated by FSH through upregulation of the aromatase enzyme (Xiao, et al., 1990, 1992; Burns, 
et al., 2001). Thus, FSH and LH play an important role in folliculogenesis and their effects will be
described in more detail in the following sections.
1.3.1 Primordial follicle recruitment and early 
follicular development
Primordial follicles enter the growing pool at an unknown rate and in an ordered sequence. Entering
the growing pool commits the follicle to grow to the pre-ovulatory stage or to atresia. Some primordial
follicles start growing immediately after they are formed, but most of them stay dormant for months
(mice) or years (human). FSH is not necessary for primordial follicle recruitment since FSHb null mice
still contain growing follicles (Kumar, et al., 1997) and in vitro culture of ovaries of several species results
in recruitment of primordial follicles into the growing pool without addition of gonadotropins 
(Eppig and O'Brien, 1996; Braw-Tal and Yossefi, 1997; Mayerhofer, et al., 1997). In addition, in vitro
experiments showed that FSH did not stimulate primordial follicle recruitment (Braw-Tal and Yossefi,
1997; Mayerhofer, et al., 1997; Fortune, et al., 1998; Vitt, et al., 2000b). These results are supported by
the observation that FSH and LH receptors are not expressed in primordial follicles (Rannikki, et al.,
1995; Teerds and Dorrington, 1995; O'Shaughnessy, et al., 1996, 1997; Oktay, et al., 1997).
Although no direct effect of FSH on primordial follicle recruitment is found, indirect stimulatory
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pool of primordial and less growing follicles (Jones and Krohn, 1961; Ataya, et al., 1989, 1995; Wang
and Greenwald, 1993). In addition, higher FSH and LH serum levels stimulate the recruitment of
primordial follicles into the growing pool (Richardson, et al., 1987; Faddy, et al., 1992; Meredith, 
et al., 1992; Marcus, et al., 1993; Gougeon, et al., 1994; Flaws, et al., 1997). For example, in humans
and rats the depletion of the resting follicle pool accelerates when FSH and LH levels start to rise as a
result of aging (Richardson, et al., 1987; Faddy, et al., 1992; Marcus, et al., 1993; Gougeon, et al.,
1994). These effects of LH and FSH on primordial follicles are indirect, e.g. through pre-antral or
antral follicles which do express FSH and LH receptors. These follicles in turn probably produce one
or more factors that have an effect on the primordial follicle pool.
FSH and LH stimulate the growth of small follicles, although these hormones are not essential.
Ovaries of mice and rats exposed to low FSH and/or LH serum levels contain all types of follicles until
the early antral stage (Lane and Greep, 1935; Paesi, 1949; Halpin and Charlton, 1988; Wang and
Greenwald, 1993), like for example the FSHb null mice (Kumar, et al., 1997). However, a decreased
serum FSH level leads to a decreased number of pre-antral follicles (van Cappellen, et al., 1989;
McGee, et al., 1997). Furthermore, high FSH serum levels stimulate pre-antral follicle development
and the number of pre-antral follicles present in the ovary (Pedersen, 1969; Dullaart, et al., 1975;
Uilenbroek, et al., 1976; Hage, et al., 1978; McGee, et al., 1997; Vitt, et al., 2000b). In addition, also
LH stimulates growth of pre-antral follicles cultured in vitro (Cortvrindt, et al., 1998; Wu, et al., 2000).
FSH stimulates the production of estrogen in granulosa cells, which is important for (late)
folliculogenesis. Both granulosa and theca cells are necessary for production of estrogens. Theca cells
produce androgens and this production is stimulated by LH and inhibin (Hsueh, et al., 1987; Hillier,
1991; Wrathall and Knight, 1995). FSH induces the expression of aromatase (Xiao, et al., 1990, 1992;
Burns, et al., 2001), LH receptor (LHR) (Richards, et al., 1976) and inhibin production in granulosa cells
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General Introduction
A small antrum is formed in class 2 follicles. In mice, antrum formation coincides with follicle stimulating
hormone (FSH)-dependency and selection of follicles for pre-ovulatory growth. This is different from
human follicular development where antrum formation occurs in class 2 follicles, while class 5
follicles are selected for pre-ovulatory growth by FSH. In women the oocytes of class 1 to class 8 follicles
continue to grow while in mice the oocytes stop growing in type 5a follicles (Gougeon, 1996).
1.3 FOLLICULOGENESIS: 
REGULATION BY LH AND FSH
Folliculogenesis describes the development of primordial follicles to pre-ovulatory follicles in the
ovary. Two important regulatory points are found during folliculogenesis: recruitment and selection
(Figure 1.1). At recruitment, primordial follicles enter the growth phase from the dormant follicle
pool, while at selection follicles are selected for growth until the pre-ovulatory stage. Folliculogenesis
is a tightly regulated process in which factors produced by the oocyte, granulosa- and theca cells have
important roles to fulfill. In addition, the gonadotropins LH and FSH produced by the pituitary
gland, play a dominant role during follicular development.
No direct effects of gonadotropins on primordial follicle recruitment have been found, although
indirect effects have been described. Granulosa cell proliferation and growth of pre-antral follicles is
stimulated by FSH. After selection of follicles on basis of their FSH-sensitivity, follicles become
dependent of FSH for survival, growth, antrum formation and oocyte maturation. LH is essential for
successful ovulation of the oocyte. The effects of FSH and LH on follicle recruitment are partly
mediated through estrogens. LH stimulates synthesis of testosterone in the theca cells. Testosterone
is converted by aromatase, which is expressed in the granulosa cells, to estrogens. This conversion is
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Figure 1.1: Overview of follicle development and effects of LH, FSH and TGFb superfamily members in mammals.
TGFb superfamily members, LH and FSH influence the growth and/or differentiation of follicles from the
primordial to the pre-ovulatory stage.
stimulated by FSH through upregulation of the aromatase enzyme (Xiao, et al., 1990, 1992; Burns, 
et al., 2001). Thus, FSH and LH play an important role in folliculogenesis and their effects will be
described in more detail in the following sections.
1.3.1 Primordial follicle recruitment and early 
follicular development
Primordial follicles enter the growing pool at an unknown rate and in an ordered sequence. Entering
the growing pool commits the follicle to grow to the pre-ovulatory stage or to atresia. Some primordial
follicles start growing immediately after they are formed, but most of them stay dormant for months
(mice) or years (human). FSH is not necessary for primordial follicle recruitment since FSHb null mice
still contain growing follicles (Kumar, et al., 1997) and in vitro culture of ovaries of several species results
in recruitment of primordial follicles into the growing pool without addition of gonadotropins 
(Eppig and O'Brien, 1996; Braw-Tal and Yossefi, 1997; Mayerhofer, et al., 1997). In addition, in vitro
experiments showed that FSH did not stimulate primordial follicle recruitment (Braw-Tal and Yossefi,
1997; Mayerhofer, et al., 1997; Fortune, et al., 1998; Vitt, et al., 2000b). These results are supported by
the observation that FSH and LH receptors are not expressed in primordial follicles (Rannikki, et al.,
1995; Teerds and Dorrington, 1995; O'Shaughnessy, et al., 1996, 1997; Oktay, et al., 1997).
Although no direct effect of FSH on primordial follicle recruitment is found, indirect stimulatory
effects of FSH and LH on primordial recruitment have been described. Low FSH and LH levels after
hypophysectomy or gonadotropin-releasing hormone (GnRH)-agonist treatment, result in a larger
pool of primordial and less growing follicles (Jones and Krohn, 1961; Ataya, et al., 1989, 1995; Wang
and Greenwald, 1993). In addition, higher FSH and LH serum levels stimulate the recruitment of
primordial follicles into the growing pool (Richardson, et al., 1987; Faddy, et al., 1992; Meredith, 
et al., 1992; Marcus, et al., 1993; Gougeon, et al., 1994; Flaws, et al., 1997). For example, in humans
and rats the depletion of the resting follicle pool accelerates when FSH and LH levels start to rise as a
result of aging (Richardson, et al., 1987; Faddy, et al., 1992; Marcus, et al., 1993; Gougeon, et al.,
1994). These effects of LH and FSH on primordial follicles are indirect, e.g. through pre-antral or
antral follicles which do express FSH and LH receptors. These follicles in turn probably produce one
or more factors that have an effect on the primordial follicle pool.
FSH and LH stimulate the growth of small follicles, although these hormones are not essential.
Ovaries of mice and rats exposed to low FSH and/or LH serum levels contain all types of follicles until
the early antral stage (Lane and Greep, 1935; Paesi, 1949; Halpin and Charlton, 1988; Wang and
Greenwald, 1993), like for example the FSHb null mice (Kumar, et al., 1997). However, a decreased
serum FSH level leads to a decreased number of pre-antral follicles (van Cappellen, et al., 1989;
McGee, et al., 1997). Furthermore, high FSH serum levels stimulate pre-antral follicle development
and the number of pre-antral follicles present in the ovary (Pedersen, 1969; Dullaart, et al., 1975;
Uilenbroek, et al., 1976; Hage, et al., 1978; McGee, et al., 1997; Vitt, et al., 2000b). In addition, also
LH stimulates growth of pre-antral follicles cultured in vitro (Cortvrindt, et al., 1998; Wu, et al., 2000).
FSH stimulates the production of estrogen in granulosa cells, which is important for (late)
folliculogenesis. Both granulosa and theca cells are necessary for production of estrogens. Theca cells
produce androgens and this production is stimulated by LH and inhibin (Hsueh, et al., 1987; Hillier,
1991; Wrathall and Knight, 1995). FSH induces the expression of aromatase (Xiao, et al., 1990, 1992;
Burns, et al., 2001), LH receptor (LHR) (Richards, et al., 1976) and inhibin production in granulosa cells
7
General Introduction
A small antrum is formed in class 2 follicles. In mice, antrum formation coincides with follicle stimulating
hormone (FSH)-dependency and selection of follicles for pre-ovulatory growth. This is different from
human follicular development where antrum formation occurs in class 2 follicles, while class 5
follicles are selected for pre-ovulatory growth by FSH. In women the oocytes of class 1 to class 8 follicles
continue to grow while in mice the oocytes stop growing in type 5a follicles (Gougeon, 1996).
1.3 FOLLICULOGENESIS: 
REGULATION BY LH AND FSH
Folliculogenesis describes the development of primordial follicles to pre-ovulatory follicles in the
ovary. Two important regulatory points are found during folliculogenesis: recruitment and selection
(Figure 1.1). At recruitment, primordial follicles enter the growth phase from the dormant follicle
pool, while at selection follicles are selected for growth until the pre-ovulatory stage. Folliculogenesis
is a tightly regulated process in which factors produced by the oocyte, granulosa- and theca cells have
important roles to fulfill. In addition, the gonadotropins LH and FSH produced by the pituitary
gland, play a dominant role during follicular development.
No direct effects of gonadotropins on primordial follicle recruitment have been found, although
indirect effects have been described. Granulosa cell proliferation and growth of pre-antral follicles is
stimulated by FSH. After selection of follicles on basis of their FSH-sensitivity, follicles become
dependent of FSH for survival, growth, antrum formation and oocyte maturation. LH is essential for
successful ovulation of the oocyte. The effects of FSH and LH on follicle recruitment are partly
mediated through estrogens. LH stimulates synthesis of testosterone in the theca cells. Testosterone
is converted by aromatase, which is expressed in the granulosa cells, to estrogens. This conversion is
6
Chapter 1
follicle 
recruitment
follicle 
selection
primordial 
follicle
pre -antral follicleprimary 
follicle
antral follicle
AMH
BMP4
BMP7
GDF9 GDF9
BMP15
BMP3
BMP7
GDF9 
AMH
BMP6
FSH
GDF9
activin
TGFb
AMH
pre -ovulatory follicle
LH
FSH
LH
FSH
LH
FSH
AMH BMP3
BMP4
BMP7
Figure 1.1: Overview of follicle development and effects of LH, FSH and TGFb superfamily members in mammals.
TGFb superfamily members, LH and FSH influence the growth and/or differentiation of follicles from the
primordial to the pre-ovulatory stage.
p27kip1, which in turn inhibits cell cycle progression by binding to the cyclin D2-cdk4/6 complex. The
LH peak terminates granulosa cell proliferation by stimulating expression of p27kip1 and p21cip1, both
inhibitors of cell proliferation (Robker and Richards, 1998).
Not only granulosa cell proliferation, but also antrum formation and oocyte maturation are under
control of FSH. Ovaries of FSHb null mice contain no antral follicles (Kumar, et al., 1997) and
antrum formation of in vitro cultured pre-antral follicles is stimulated by FSH (Hartshorne, et al.,
1994; Itoh, et al., 2002; Mao, et al., 2002; Mitchell, et al., 2002). Furthermore, LH enhances FSH-induced
antrum formation in vitro (Cortvrindt, et al., 1998). During late follicular development, oocytes complete
the first meiotic division up to metaphase II of meiotic stage. This process is stimulated by FSH or LH
and a synergistic effect is found when FSH and LH both are present (Cortvrindt, et al., 1998).
The stimulation of estrogen synthesis by FSH and LH, like in the pre-antral follicles, is also important
for late follicle development. Ovaries of aromatase-deficient mice contain almost no antral follicles,
which demonstrates the importance of estrogen in late follicular development (Fisher, et al., 1998). 
A similar phenotype is found in ovaries of mice deficient for both ERa and ERb (Couse, et al., 1999).
The effects of LH on late follicular development can be partly explained through its effect on estrogen
biosynthesis. However, also estrogen-independent effects of LH are described. In rats, treated with a
GnRH-antagonist and in which also oestradiol synthesis was inhibited by an aromatase inhibitor,
FSH and LH treatment resulted in a larger increase in the number of antral follicles compared to animals
which did not receive LH (Uilenbroek, et al., 1997). Thus, during the last phase of folliculogenesis,
LH is involved in successful maturation of the follicles. Furthermore, LH is essential for ovulation of
the oocyte (Filicori, et al., 2002).
In summary, follicular development after selection is dependent on FSH. FSH rescues follicles from
atresia, stimulates antrum formation, granulosa cell proliferation, LHR expression, oocyte maturation
and estrogen production. LH inhibits granulosa cell proliferation but enhances other effects of FSH.
In addition, LH is necessary for ovulation of the oocyte.
The systemic factors LH and FSH are very important for follicle development from small pre-antral
to pre-ovulatory follicles, but they are not the only factors involved. As described above, follicular
development until the antral stage can occur without these gonadotropins and this implies a role for
local factors. Indeed, several growth factors are produced by the oocyte, granulosa- and theca cells.
These growth factors can play an important role, often by modulating the effects of FSH and LH, and
folliculogenesis can be disregulated when such a growth factor is absent. The next section describes
the effects of members of the TGFb superfamily during folliculogenesis.
1.4 FOLLICULOGENESIS: 
ROLE OF MEMBERS OF THE TGFb SUPERFAMILY
The transforming growth and differentiation factor b (TGFb) family is the largest family of growth
and differentiation factors. This family can be divided in several subfamilies, such as the TGFbs
(TGFb1-5), activins (inhibin a, bA-C, E) and bone morphogenetic proteins (e.g. BMP1-15, GDF1-9)
(reviewed by Massagué, 1998), which have a broad range of functions in cell cycle, differentiation, cell
adhesion and morphology.
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(Richards, et al., 1976; Lee, et al., 1982; LaPolt, et al., 1989; Xiao, et al., 1990, 1992; Campbell, 
et al., 1996; Harlow, et al., 2002). In this way, FSH stimulates the production of estrogens . Estrogen
and FSH together stimulate expression of FSH receptor (FSHR) in granulosa cells. 
In addition, estrogens, like FSH, stimulate granulosa cell proliferation by increasing expression
of cyclin D2 expression, which is an important regulator of cell cycle progression (Robker and
Richards, 1998).
Estrogens have no important role in primordial follicle recruitment or pre-antral follicle
development since ovaries of the aromatase null mice contain pre-antral follicles, just like the mice
lacking the estrogen receptor a and b (ERa, ERb) (Fisher, et al., 1998; Couse, et al., 1999). However,
effects of estrogen on early folliculogenesis have been described. Estrogens stimulate the expression of
epithelial growth factor (EGF) receptor in pre-antral granulosa cells (Garnett, et al., 2002). EGF and
transforming growth factor a (TGFa) are signaling through the EGF receptor and both growth
factors are involved in early folliculogenesis. Fertility of female TGFa overexpressor mice is severely
decreased after two pregnancies, which suggests that TGFa is involved in regulation of follicle
recruitment (Ma, et al., 1994). Furthermore, a seven-fold increase in the number of antral follicles,
caused by higher FSH levels or a decrease of apoptosis, is found in ovaries of these mice (Tilly, et al.,
1992; Ma, et al., 1994). EGF induces, after binding to the EGF receptor, granulosa cell proliferation
and pre-antral follicle growth (Roy and Greenwald, 1991a, 1991b; Roy, 1993; Gutierrez, et al., 2000;
Saha, et al., 2000). These results show a role of estrogen in early follicular development. Interestingly, also
androgens stimulate pre-antral follicle development of in vitro cultured follicles since non-aromatizible
androgens stimulate follicle diameter and antrum development (Murray, et al., 1998).
In summary, FSH and LH have no direct effect on primordial follicle recruitment, but stimulate
pre-antral follicle growth and development. Production of estrogen is stimulated by FSH, however
estrogen does not seem to play a very important role in early folliculogenesis.
1.3.2 Selection and late follicular development
All large pre-antral and small antral follicles will undergo atresia, except for a proportion of follicles
that will be rescued by FSH and selected to grow until the pre-ovulatory stage. This process is referred
to as selection. Ovaries of FSHb and FSHR null mice contain no antral follicles, indicating the
essential role of FSH for follicular growth after the pre-antral stage (Kumar, et al., 1997; Dierich, 
et al., 1998; Burns, et al., 2001). In addition, higher FSH levels increase the number of follicles selected
for pre-ovulatory growth (Lunenfeld and Insler, 1993). Ovaries of LHR null mice contain follicles
until the antral stage but no pre-ovulatory follicles or corpora lutea, indicating that LH becomes
essential in pre-ovulatory follicle development (Lei, et al., 2001; Zhang, et al., 2001). Indeed, LH as
well as FSH inhibits atresia of large pre-antral and antral follicles cultured in vitro (Hartshorne, et al.,
1994; Gaytan, et al., 1996; Cortvrindt, et al., 1998; Mao, et al., 2002).
FSH stimulates granulosa cell proliferation as shown by the larger diameter of in vitro cultured
follicles when FSH is added to the culture medium (Hartshorne, et al., 1994; Itoh, et al., 2002; 
Mao, et al., 2002). This effect is at least partly caused by the regulation of cyclin D2 expression. Cyclin D2
expressed in granulosa cells is an important positive regulator of cell cycle progression (Xiong, et al., 1992;
Robker and Richards, 1998). Ovaries of cyclin D2 deficient mice contain no follicles beyond the pre-antral
stage, illustrating the important role of cyclin D2 in late follicular development (Sicinski, et al., 1996).
In vivo experiments showed that FSH stimulates expression of cyclin D2 and inhibits expression of
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Growth and Differentiation Factor-9
Growth and differentiation factor-9 (GDF9) protein and messenger RNA (mRNA) is expressed in
oocytes from early primary follicles onward with most extensive staining in primary and pre-antral
follicles in rat (Hayashi, et al., 1999; Jaatinen, et al., 1999), human (Aaltonen, et al., 1999) and mouse
(Elvin, et al., 1999a). The type II receptor for GDF9, BMP receptor II (BMPRII), is expressed in
granulosa cells and oocytes (Vitt, et al., 2002; Erickson and Shimasaki, 2003). This pattern of receptor
expression suggests that GDF9 acts on granulosa cells and oocytes. It is unclear which type I receptors
are involved in GDF9-signaling. Binding to the BMPRII suggests involvement of ALK2, ALK3 or
ALK6 during signal transduction (see Chapter 2). However, signaling through these type I receptors
can be questioned, since Smad2 is activated in GDF9-signaling (Roh, et al., 2003).
Studying the ovaries of GDF9 null mice revealed that GDF9 is not necessary for primordial follicle
recruitment. These mice are infertile due to a block in folliculogenesis from stage 3b onwards after
normal recruitment of primordial follicles (Dong, et al., 1996). In addition, in vitro culture of 4-day-
old neonatal rat ovaries in the presence of GDF9 had no effect on primordial follicle recruitment
(Nilsson and Skinner, 2002). Interestingly, the number of primordial follicles decreased by 29% in
ovaries of rats treated with GDF9 (Vitt, et al., 2000b). This effect on primordial follicle recruitment
can be explained by the enhancement of primary follicle progression which could lead to an indirect
stimulation of primordial follicle recruitment (Hirshfield, 1994).
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The next sections describe the roles of TGFb superfamily members, expressed by oocytes, theca- and
granulosa cells during folliculogenesis. Since the focus of experiments described in this thesis
(Chapters 3-7) is on primordial and pre-antral follicles, the effects of TGFb family members on early
folliculogenesis will be described in more detail compared to the effects on antral and pre-ovulatory
follicles. Furthermore, the signal transduction characteristics of the TGFb superfamily members are
described in Chapter 2. Here, only the localization of the expression of receptors in the ovary is
summarized (Table 1.3).
1.4.1 TGFb superfamily members expressed by the oocyte
Folliculogenesis is a tightly regulated process in which the interactions between oocyte, granulosa-
and theca cells play an important role. At least three members of the TGFb superfamily are expressed
in the oocyte: growth and differentiation factor-9 (GDF9), bone morphogenetic protein-15 (BMP15)
and bone morphogenetic protein-6 (BMP6). A summary of the effect of these TGFb family members
expressed by the oocyte is given in Table 1.4 and Figure1.1.
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Tabel 1.3: Summary of TGFb superfamily ligand-receptor combinations and the localization of expression in
the ovary. For more detailed information about signaling of TGFb superfamily members, see Chapter 2.
Ligand: Receptor: Localization of expression of 
the receptor: References:
GDF9 BMPRII • oocyte of all follicle types Shimasaki et al., 1999; Vitt et al., 2002; 
• granulosa cells all of growing follicles Erickson and Shimasaki, 2003
BMP15 BMPRII • oocyte of all follicle types Shimasaki et al., 1999; Moore et al., 2002; 
• granulosa cells all of growing follicles Erickson and Shimasaki, 2003
BMP6 BMPRII • oocyte of all follicle types Ebisawa et al., 1999; Shimasaki et al., 1999;
• granulosa cells all of growing follicles Erickson and Shimasaki, 2003
ActRII • oocyte of all follicle types Cameron et al., 1994; van den Hurk and Van 
• granulosa cells all of growing follicles de Pavert, 2001; Drummond et al., 2002; 
Pangas et al., 2002
BMP3 BMPRII? • oocyte of all follicle types Shimasaki et al., 1999; Erickson and Shimasaki, 2003
ActRII • granulosa cells all of growing follicles
BMP4 BMPRII • oocyte of all follicle types Koenig et al., 1994; ten Dijke et al., 1994;
• granulosa cells all of growing follicles Yamaji et al., 1994; Nohno et al., 1995; Shimasaki 
et al., 1999; Erickson and Shimasaki, 2003
BMP7 BMPRII • oocyte of all follicle types ten Dijke et al., 1994; Rosenzweig et al., 1995;
• granulosa cells all of growing follicles Shimasaki et al., 1999; Erickson and Shimasaki, 2003
BMP2 BMPRII • oocyte of all follicle types Koenig et al., 1994; ten Dijke et al., 1994;
• granulosa cells all of growing follicles Yamaji et al., 1994; Nohno et al., 1995; Shimasaki
et al., 1999; Erickson and Shimasaki, 2003
activin ActRII • oocyte of all follicle types Cameron et al., 1994; van den Hurk and Van
• granulosa cells all of growing follicles de Pavert, 2001; Drummond et al., 2002; 
Pangas et al., 2002
ActRIIB • oocyte of all follicle types Cameron et al., 1994; Drummond et al., 2002;
• granulosa cells all of growing follicles Pangas et al., 2002
TGFb TbRII • oocyte of primordial and primary follicles
• granulosa cells 
• theca cells Roy and Kole, 1998; Qu et al., 2000
AMH AMHRII • granulosa cells of pre-antral, small antral Baarends et al., 1994; di Clemente et al., 1994;
and probably also primordial follicles. Baarends et al., 1995; Ingraham et al., 2000
• theca cells of pre-antral and small antral follicles
Table 1.4: Overview of the effects on follicle development of TGFb family members expressed by the oocyte.
Family Site of action: Effects: References:
member:
GDF9 granulosa cells • obligatory for growth of primary follicles Dong et al., 1996
oocyte? • stimulates granulosa cell proliferation, Elvin et al., 1999b; Hayashi et al., 1999;
synergistic effect with FSH Vitt et al., 2000b; Nilsson and Skinner, 2002
• downregulates KL and inhibin a-subunit Dong et al., 1996; Carabatsos et al., 1998; 
expression in small primary follicles but Elvin et al., 1999b; Hayashi et al., 1999; 
upregulates KL and inhibin a-subunit Nilsson and Skinner, 2002;
expression in granulosa cells of larger 
follicles Roh et al., 2003
• survival factor for in vitro culture of follicles Hreinsson et al.., 2002
• (indirectly) involved in theca cell recruitment   Elvin et al., 1999b; Vitt et al., 2000b
• inhibits FSH-induced differentiation in Elvin et al., 1999a; Vitt et al., 2000a;
antral follicles, by inhibiting progesterone Roh et al., 2003
and estrogen synthesis, LHR expression 
and stimulating inhibin A and B production
• regulates expression of several key Elvin et al., 1999a, 1999b 
granulosa cell enzymes necessary for 
normal ovulation
BMP15 granulosa cells • stimulates granulosa cell mitosis Otsuka et al., 2000
oocyte? • stimulates KL mRNA expression Otsuka and Shimasaki, 2002
• inhibits FSH induced differentiation by Otsuka et al., 2000, 2001b
inhibiting FSHR mRNA expression and 
FSH-induced progesterone production 
• involved in ovulation Yan et al., 2001
BMP6 granulosa cells • inhibits FSH-induced differentiation by Otsuka et al., 2001a
oocyte? inhibiting FSH-induced progesterone 
production and FSHR mRNA expression
Growth and Differentiation Factor-9
Growth and differentiation factor-9 (GDF9) protein and messenger RNA (mRNA) is expressed in
oocytes from early primary follicles onward with most extensive staining in primary and pre-antral
follicles in rat (Hayashi, et al., 1999; Jaatinen, et al., 1999), human (Aaltonen, et al., 1999) and mouse
(Elvin, et al., 1999a). The type II receptor for GDF9, BMP receptor II (BMPRII), is expressed in
granulosa cells and oocytes (Vitt, et al., 2002; Erickson and Shimasaki, 2003). This pattern of receptor
expression suggests that GDF9 acts on granulosa cells and oocytes. It is unclear which type I receptors
are involved in GDF9-signaling. Binding to the BMPRII suggests involvement of ALK2, ALK3 or
ALK6 during signal transduction (see Chapter 2). However, signaling through these type I receptors
can be questioned, since Smad2 is activated in GDF9-signaling (Roh, et al., 2003).
Studying the ovaries of GDF9 null mice revealed that GDF9 is not necessary for primordial follicle
recruitment. These mice are infertile due to a block in folliculogenesis from stage 3b onwards after
normal recruitment of primordial follicles (Dong, et al., 1996). In addition, in vitro culture of 4-day-
old neonatal rat ovaries in the presence of GDF9 had no effect on primordial follicle recruitment
(Nilsson and Skinner, 2002). Interestingly, the number of primordial follicles decreased by 29% in
ovaries of rats treated with GDF9 (Vitt, et al., 2000b). This effect on primordial follicle recruitment
can be explained by the enhancement of primary follicle progression which could lead to an indirect
stimulation of primordial follicle recruitment (Hirshfield, 1994).
11
General Introduction
The next sections describe the roles of TGFb superfamily members, expressed by oocytes, theca- and
granulosa cells during folliculogenesis. Since the focus of experiments described in this thesis
(Chapters 3-7) is on primordial and pre-antral follicles, the effects of TGFb family members on early
folliculogenesis will be described in more detail compared to the effects on antral and pre-ovulatory
follicles. Furthermore, the signal transduction characteristics of the TGFb superfamily members are
described in Chapter 2. Here, only the localization of the expression of receptors in the ovary is
summarized (Table 1.3).
1.4.1 TGFb superfamily members expressed by the oocyte
Folliculogenesis is a tightly regulated process in which the interactions between oocyte, granulosa-
and theca cells play an important role. At least three members of the TGFb superfamily are expressed
in the oocyte: growth and differentiation factor-9 (GDF9), bone morphogenetic protein-15 (BMP15)
and bone morphogenetic protein-6 (BMP6). A summary of the effect of these TGFb family members
expressed by the oocyte is given in Table 1.4 and Figure1.1.
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Tabel 1.3: Summary of TGFb superfamily ligand-receptor combinations and the localization of expression in
the ovary. For more detailed information about signaling of TGFb superfamily members, see Chapter 2.
Ligand: Receptor: Localization of expression of 
the receptor: References:
GDF9 BMPRII • oocyte of all follicle types Shimasaki et al., 1999; Vitt et al., 2002; 
• granulosa cells all of growing follicles Erickson and Shimasaki, 2003
BMP15 BMPRII • oocyte of all follicle types Shimasaki et al., 1999; Moore et al., 2002; 
• granulosa cells all of growing follicles Erickson and Shimasaki, 2003
BMP6 BMPRII • oocyte of all follicle types Ebisawa et al., 1999; Shimasaki et al., 1999;
• granulosa cells all of growing follicles Erickson and Shimasaki, 2003
ActRII • oocyte of all follicle types Cameron et al., 1994; van den Hurk and Van 
• granulosa cells all of growing follicles de Pavert, 2001; Drummond et al., 2002; 
Pangas et al., 2002
BMP3 BMPRII? • oocyte of all follicle types Shimasaki et al., 1999; Erickson and Shimasaki, 2003
ActRII • granulosa cells all of growing follicles
BMP4 BMPRII • oocyte of all follicle types Koenig et al., 1994; ten Dijke et al., 1994;
• granulosa cells all of growing follicles Yamaji et al., 1994; Nohno et al., 1995; Shimasaki 
et al., 1999; Erickson and Shimasaki, 2003
BMP7 BMPRII • oocyte of all follicle types ten Dijke et al., 1994; Rosenzweig et al., 1995;
• granulosa cells all of growing follicles Shimasaki et al., 1999; Erickson and Shimasaki, 2003
BMP2 BMPRII • oocyte of all follicle types Koenig et al., 1994; ten Dijke et al., 1994;
• granulosa cells all of growing follicles Yamaji et al., 1994; Nohno et al., 1995; Shimasaki
et al., 1999; Erickson and Shimasaki, 2003
activin ActRII • oocyte of all follicle types Cameron et al., 1994; van den Hurk and Van
• granulosa cells all of growing follicles de Pavert, 2001; Drummond et al., 2002; 
Pangas et al., 2002
ActRIIB • oocyte of all follicle types Cameron et al., 1994; Drummond et al., 2002;
• granulosa cells all of growing follicles Pangas et al., 2002
TGFb TbRII • oocyte of primordial and primary follicles
• granulosa cells 
• theca cells Roy and Kole, 1998; Qu et al., 2000
AMH AMHRII • granulosa cells of pre-antral, small antral Baarends et al., 1994; di Clemente et al., 1994;
and probably also primordial follicles. Baarends et al., 1995; Ingraham et al., 2000
• theca cells of pre-antral and small antral follicles
Table 1.4: Overview of the effects on follicle development of TGFb family members expressed by the oocyte.
Family Site of action: Effects: References:
member:
GDF9 granulosa cells • obligatory for growth of primary follicles Dong et al., 1996
oocyte? • stimulates granulosa cell proliferation, Elvin et al., 1999b; Hayashi et al., 1999;
synergistic effect with FSH Vitt et al., 2000b; Nilsson and Skinner, 2002
• downregulates KL and inhibin a-subunit Dong et al., 1996; Carabatsos et al., 1998; 
expression in small primary follicles but Elvin et al., 1999b; Hayashi et al., 1999; 
upregulates KL and inhibin a-subunit Nilsson and Skinner, 2002;
expression in granulosa cells of larger 
follicles Roh et al., 2003
• survival factor for in vitro culture of follicles Hreinsson et al.., 2002
• (indirectly) involved in theca cell recruitment   Elvin et al., 1999b; Vitt et al., 2000b
• inhibits FSH-induced differentiation in Elvin et al., 1999a; Vitt et al., 2000a;
antral follicles, by inhibiting progesterone Roh et al., 2003
and estrogen synthesis, LHR expression 
and stimulating inhibin A and B production
• regulates expression of several key Elvin et al., 1999a, 1999b 
granulosa cell enzymes necessary for 
normal ovulation
BMP15 granulosa cells • stimulates granulosa cell mitosis Otsuka et al., 2000
oocyte? • stimulates KL mRNA expression Otsuka and Shimasaki, 2002
• inhibits FSH induced differentiation by Otsuka et al., 2000, 2001b
inhibiting FSHR mRNA expression and 
FSH-induced progesterone production 
• involved in ovulation Yan et al., 2001
BMP6 granulosa cells • inhibits FSH-induced differentiation by Otsuka et al., 2001a
oocyte? inhibiting FSH-induced progesterone 
production and FSHR mRNA expression
Primary follicle development is dependent on GDF9, since development of primary follicles is blocked
in GDF9 null mice ovaries (Dong, et al., 1996). Furthermore, GDF9 stimulates primary follicle
development as indicated by an increase in mature primary and a decrease in early primary follicle
numbers in ovaries cultured in the presence of GDF9 (Nilsson and Skinner, 2002). In addition,
treatment of immature rats with GDF9 caused an increase in the number of primary and secondary
follicles by 30% and 60% respectively (Vitt, et al., 2000b). Furthermore, GDF9 stimulates proliferation
of granulosa cells since a low expression of the proliferation markers proliferating cell nuclear antigen
(PCNA) and Ki-67 in granulosa cells of GDF9 null mice was found (Elvin, et al., 1999b). In addition,
culturing pre-antral rat follicles in the presence of GDF9 increases their diameter, caused by the
proliferation of granulosa cells, of these follicles to the same extent as FSH treatment. GDF9 and FSH
together have a synergistic effect on granulosa cell proliferation (Hayashi, et al., 1999).
How GDF9 exerts its effect on proliferation of the granulosa cells is still unclear because cyclin D2,
which is the most important cyclin for entering S-phase, is normally expressed in GDF9 null mice.
Also p27kip1 and p21cip1, which bind to cyclin D2-cdk4/6 complexes and prevent their activation and
thus cell cycle progression, are expressed normally (Elvin, et al., 1999b). It is likely that GDF9 influences
other cell cycle regulators, which are necessary for normal cell division.
Interestingly, GDF9 is not only involved in growth of follicles but also in their survival and death.
In vitro culture studies of human primordial follicles revealed that GDF9 acts as a survival factor since
less atretic follicles were detected in ovarian tissue cultured with added GDF9 (Hreinsson, et al., 2002).
Furthermore, GDF9 is also necessary for apoptosis of granulosa cells as almost no apoptotic cells are
found in GDF9 null mice. Follicular structures do not disappear after the oocyte has degenerated, but
the granulosa cells form a steroidogenic cluster, which is positive for antral granulosa cell markers like
the inhibin a-subunit and aromatase and for periovulatory and luteal granulosa cell markers like LHR
and P450 side chain cleavage (P450scc). These results suggest that the expression of LHR and P450scc,
which are normally only expressed in corpora lutea (LHR and P450scc) or granulosa cells of 
pre-ovulatory follicles (LHR), are probably inhibited by the oocyte through GDF9 (Elvin, et al., 1999b).
The different effects of GDF9 on apoptosis, survival and proliferation could be explained by differences
in expression of transcription factors, co-activators or co-repressors, which result in differences in gene
transcription by GDF9.
Maturation of oocytes of type 3b follicles in GDF9 null mice is comparable to that of oocytes
found in antral follicles of heterozygote mice. Nevertheless, in vitro maturation of homozygous GDF9
knockout oocytes revealed that the majority of oocytes fail to complete meiotic maturation. This
discrepancy can be explained by a defect in communication between granulosa cells and oocyte.
Indeed, modified interactions between these cells were found using electron and fluorescence
microscopy. Although the follicles of GDF9 null mice stop growing at the early primary stage, the
oocytes continue to grow as can be seen by the changes in germinal vesicle chromatin patterns
(Carabatsos, et al., 1998).
GDF9 regulates mRNA expression of kit-ligand (KL) and inhibin a-subunit. GDF9 null mice
overexpress KL and this probably results in faster and larger growing oocytes compared to their wild-type
littermates (Dong, et al., 1996; Carabatsos, et al., 1998; Elvin, et al., 1999b). Follicles with dying
oocytes in GDF9 null mice express an even higher level of KL, but this expression disappears together
with the oocyte (Elvin, et al., 1999b). Like KL, the inhibin a-subunit also is expressed at a higher level
12
Chapter 1
in ovaries of GDF9 null mice (Elvin, et al., 1999b). The effect of GDF9 on KL and inhibin a-subunit
expression is dependent on the developmental stage of the follicle. GDF9 stimulates KL and inhibin
a-subunit expression in rat ovaries, which contain larger follicles than type 3b, in an in vitro culture
system (Hayashi, et al., 1999; Nilsson and Skinner, 2002; Roh, et al., 2003). The GDF9-related gene
BMP15 is not differentially expressed in GDF9 null mice ovaries and therefore abnormalities in these
ovaries are not caused by a changed expression of this gene (Yan, et al., 2001).
Theca cell recruitment also appears to be dependent on GDF9, since theca cell markers such as
17a-hydroxylase (P450c17), LHR and c-kit are not expressed in the stromal cells surrounding the
follicles in GDF9 mice (Elvin, et al., 1999b). In addition, treatment of immature rats with GDF9 results
in an increase of 17a-hydroxylase mRNA, a typical theca cell marker, in the stromal cells surrounding
the granulosa cells (Vitt, et al., 2000b). The effects of GDF9 on theca cells are indirect, because theca
cells do not express BMPRII, which is the type II receptor for GDF9 (Erickson and Shimasaki, 2003).
In antral follicles, GDF9 acts as an inhibitor of luteinization because it stimulates granulosa cell
proliferation and inhibits FSH-induced differentiation of granulosa cells. FSH-induced LHR expression
and production of estrogen and progesterone are inhibited by GDF9 in granulosa cells cultured in vitro
(Vitt, et al., 2000a). Interestingly, GDF9 alone stimulates estrogen synthesis in granulosa cell culture
of antral follicles and progesterone synthesis in granulosa cell culture of pre-ovulatory follicles (Elvin,
et al., 1999a; Vitt, et al., 2000a). Granulosa cells cultured in vitro can produce progesterone because
they express P450scc, which is not expressed in granulosa cells of pre-antral and antral follicles in vivo
(Elvin, et al., 1999b; Otsuka, et al., 2001b). However, the stimulatory effect on estrogen and progesterone
synthesis changes to inhibition when FSH (5 ng/ml) is present (Vitt, et al., 2000a). Therefore, during
folliculogenesis GDF9 would probably have an inhibitory effect on progesterone and estrogen
production, because serum FSH levels higher than 5 ng/ml are commonly present. Only after ovulation
and before implantation, when the oocyte and cumulus cells are free floating within the oviduct and
not connected to the systemic blood supply, GDF9 could stimulate progesterone synthesis in the
surrounding cumulus cells (Elvin, et al., 1999a). Furthermore, expression of the inhibin a- and b-subunit
and thereby production of inhibin A and B are stimulated by GDF9 alone, while GDF9 enhances
FSH-induced production of inhibin A and inhibin B (Roh, et al., 2003). In this way, GDF9 is involved
in negative feedback regulation of FSH-release.
In the pre-ovulatory follicle, GDF9 plays an important role in the regulation of normal ovulation,
by stimulating cumulus expansion and regulating expression of several genes in the cumulus cells, like
hyaluran synthase 2, cyclooxygenase 2, urokinase plasminogen activator, LHR and steroidogenic
acute regulator protein (StAR) (Elvin, et al., 1999a, 1999b).
In summary, GDF9 plays an important role during folliculogenesis from primary follicle
development until ovulation.
Bone morphogenetic protein-15
Bone morphogenetic protein-15 (BMP15), a GDF9-related gene, is co-expressed with GDF9 in mouse
oocytes of primary and growing follicles, albeit with a lower expression level (Aaltonen, et al., 1999;
Jaatinen, et al., 1999; Otsuka, et al., 2000). Like GDF9, BMP15 signals by binding to BMPRII, and acts
on the granulosa cells and possibly also on the oocyte (Table 1.3) (Moore, et al., 2002; Vitt, et al.,
2002).
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which is the most important cyclin for entering S-phase, is normally expressed in GDF9 null mice.
Also p27kip1 and p21cip1, which bind to cyclin D2-cdk4/6 complexes and prevent their activation and
thus cell cycle progression, are expressed normally (Elvin, et al., 1999b). It is likely that GDF9 influences
other cell cycle regulators, which are necessary for normal cell division.
Interestingly, GDF9 is not only involved in growth of follicles but also in their survival and death.
In vitro culture studies of human primordial follicles revealed that GDF9 acts as a survival factor since
less atretic follicles were detected in ovarian tissue cultured with added GDF9 (Hreinsson, et al., 2002).
Furthermore, GDF9 is also necessary for apoptosis of granulosa cells as almost no apoptotic cells are
found in GDF9 null mice. Follicular structures do not disappear after the oocyte has degenerated, but
the granulosa cells form a steroidogenic cluster, which is positive for antral granulosa cell markers like
the inhibin a-subunit and aromatase and for periovulatory and luteal granulosa cell markers like LHR
and P450 side chain cleavage (P450scc). These results suggest that the expression of LHR and P450scc,
which are normally only expressed in corpora lutea (LHR and P450scc) or granulosa cells of 
pre-ovulatory follicles (LHR), are probably inhibited by the oocyte through GDF9 (Elvin, et al., 1999b).
The different effects of GDF9 on apoptosis, survival and proliferation could be explained by differences
in expression of transcription factors, co-activators or co-repressors, which result in differences in gene
transcription by GDF9.
Maturation of oocytes of type 3b follicles in GDF9 null mice is comparable to that of oocytes
found in antral follicles of heterozygote mice. Nevertheless, in vitro maturation of homozygous GDF9
knockout oocytes revealed that the majority of oocytes fail to complete meiotic maturation. This
discrepancy can be explained by a defect in communication between granulosa cells and oocyte.
Indeed, modified interactions between these cells were found using electron and fluorescence
microscopy. Although the follicles of GDF9 null mice stop growing at the early primary stage, the
oocytes continue to grow as can be seen by the changes in germinal vesicle chromatin patterns
(Carabatsos, et al., 1998).
GDF9 regulates mRNA expression of kit-ligand (KL) and inhibin a-subunit. GDF9 null mice
overexpress KL and this probably results in faster and larger growing oocytes compared to their wild-type
littermates (Dong, et al., 1996; Carabatsos, et al., 1998; Elvin, et al., 1999b). Follicles with dying
oocytes in GDF9 null mice express an even higher level of KL, but this expression disappears together
with the oocyte (Elvin, et al., 1999b). Like KL, the inhibin a-subunit also is expressed at a higher level
12
Chapter 1
in ovaries of GDF9 null mice (Elvin, et al., 1999b). The effect of GDF9 on KL and inhibin a-subunit
expression is dependent on the developmental stage of the follicle. GDF9 stimulates KL and inhibin
a-subunit expression in rat ovaries, which contain larger follicles than type 3b, in an in vitro culture
system (Hayashi, et al., 1999; Nilsson and Skinner, 2002; Roh, et al., 2003). The GDF9-related gene
BMP15 is not differentially expressed in GDF9 null mice ovaries and therefore abnormalities in these
ovaries are not caused by a changed expression of this gene (Yan, et al., 2001).
Theca cell recruitment also appears to be dependent on GDF9, since theca cell markers such as
17a-hydroxylase (P450c17), LHR and c-kit are not expressed in the stromal cells surrounding the
follicles in GDF9 mice (Elvin, et al., 1999b). In addition, treatment of immature rats with GDF9 results
in an increase of 17a-hydroxylase mRNA, a typical theca cell marker, in the stromal cells surrounding
the granulosa cells (Vitt, et al., 2000b). The effects of GDF9 on theca cells are indirect, because theca
cells do not express BMPRII, which is the type II receptor for GDF9 (Erickson and Shimasaki, 2003).
In antral follicles, GDF9 acts as an inhibitor of luteinization because it stimulates granulosa cell
proliferation and inhibits FSH-induced differentiation of granulosa cells. FSH-induced LHR expression
and production of estrogen and progesterone are inhibited by GDF9 in granulosa cells cultured in vitro
(Vitt, et al., 2000a). Interestingly, GDF9 alone stimulates estrogen synthesis in granulosa cell culture
of antral follicles and progesterone synthesis in granulosa cell culture of pre-ovulatory follicles (Elvin,
et al., 1999a; Vitt, et al., 2000a). Granulosa cells cultured in vitro can produce progesterone because
they express P450scc, which is not expressed in granulosa cells of pre-antral and antral follicles in vivo
(Elvin, et al., 1999b; Otsuka, et al., 2001b). However, the stimulatory effect on estrogen and progesterone
synthesis changes to inhibition when FSH (5 ng/ml) is present (Vitt, et al., 2000a). Therefore, during
folliculogenesis GDF9 would probably have an inhibitory effect on progesterone and estrogen
production, because serum FSH levels higher than 5 ng/ml are commonly present. Only after ovulation
and before implantation, when the oocyte and cumulus cells are free floating within the oviduct and
not connected to the systemic blood supply, GDF9 could stimulate progesterone synthesis in the
surrounding cumulus cells (Elvin, et al., 1999a). Furthermore, expression of the inhibin a- and b-subunit
and thereby production of inhibin A and B are stimulated by GDF9 alone, while GDF9 enhances
FSH-induced production of inhibin A and inhibin B (Roh, et al., 2003). In this way, GDF9 is involved
in negative feedback regulation of FSH-release.
In the pre-ovulatory follicle, GDF9 plays an important role in the regulation of normal ovulation,
by stimulating cumulus expansion and regulating expression of several genes in the cumulus cells, like
hyaluran synthase 2, cyclooxygenase 2, urokinase plasminogen activator, LHR and steroidogenic
acute regulator protein (StAR) (Elvin, et al., 1999a, 1999b).
In summary, GDF9 plays an important role during folliculogenesis from primary follicle
development until ovulation.
Bone morphogenetic protein-15
Bone morphogenetic protein-15 (BMP15), a GDF9-related gene, is co-expressed with GDF9 in mouse
oocytes of primary and growing follicles, albeit with a lower expression level (Aaltonen, et al., 1999;
Jaatinen, et al., 1999; Otsuka, et al., 2000). Like GDF9, BMP15 signals by binding to BMPRII, and acts
on the granulosa cells and possibly also on the oocyte (Table 1.3) (Moore, et al., 2002; Vitt, et al.,
2002).
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BMP15 construct of the Inverdale sheep (Liao, et al., 2003). This reduced GDF9 protein expression
could explain that the phenotype of homozygous Inverdale sheep is more similar to the phenotype of
GDF9 null mice than of the BMP15 null mice.
In conclusion, BMP15 is not necessary for primordial follicle recruitment in mice and stimulates
granulosa cell proliferation, inhibits FSH-induced progesterone, but not estrogen synthesis and
stimulates expression of KL. In this way, BMP15 inhibits luteinization of follicles. Furthermore, BMP15
is involved in ovulation. In sheep, homozygous mutations in the BMP15 gene result in a block in
folliculogenesis after the primary follicle stage. This block in folliculogenesis is probably caused by a
decreased GDF9 homodimer production in these mutants.
Bone Morphogenetic Protein-6
Bone morphogenetic protein-6 (BMP6) is a third TGFb family member expressed by oocytes. In contrast
to GDF9 and BMP15, BMP6 is also expressed in granulosa cells of secondary and tertiary follicles
(Erickson and Shimasaki, 2003). The type II receptor for BMP6 is BMPRII and this receptor is expressed
in the granulosa cells and oocytes (Table 1.3) (Ebisawa, et al., 1999; Erickson and Shimasaki, 2003).
The role of BMP6 is not clear, since BMP6 null female mice are fertile, have a normal littersize and
a normal reproductive life-span (Solloway, et al., 1998). The reason for the absence of a phenotype in
BMP6 null mice could be due to the expression in the ovary of related BMPs, which compensate for
the absence of the BMP6 (redundancy). Alternatively, it is possible that BMP6 evokes no biological
effects in the ovary in vivo.
However, in vitro studies revealed that BMP6 could influence granulosa cell function. FSH- and
forskolin-induced FSHR mRNA accumulation is inhibited by BMP6. In addition, FSH-induced
progesterone production is inhibited by BMP6 through inhibition of StAR and P450scc mRNA
expression. No influence of BMP6 was found on granulosa cell proliferation, on basal FSHR mRNA
expression, on FSH-induced aromatase expression or estrogen production. Since BMP6 does not inhibit
effects of 8-bromo-cAMP but inhibits effects of FSH and forskolin on progesterone production and
FSHR expression, it has been suggested that the underlying mechanisms involve the downregulation
of adenylate cyclase activity (Otsuka, et al., 2001a). This mechanism of action is different from that of
BMP15, which also inhibits progesterone secretion, but achieves this effect by inhibiting FSHR
mRNA expression (Otsuka, et al., 2001b).
In summary, BMP6 inhibits FSH-induced progesterone but not estrogen synthesis and this leads
to the hypothesis that BMP6, like BMP15, is an inhibitor of luteinization.
1.4.2 TGFb superfamily members expressed by theca cells
Theca cells are recruited from the interstitium of the ovary adjacent to the pre-antral follicle. The most
important function of theca cells is the production of androgens. The granulosa cells convert androgens
to estrogens, which are important for follicle development. At least three members of the TGFb
superfamily are expressed by the theca cells: bone morphogenetic proteins-3, -4 and -7. A summary of
the effects of TGFb family members expressed by the theca cells is given in Table 1.5 and Figure 1.1.
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Ovaries of BMP15 null mice contain all stages of follicular development, which shows that BMP15 is
not obligatory for primordial follicle recruitment or follicular development (Yan, et al., 2001). In
addition, we have found that ovaries of prepuberal and adult BMP15 null mice show a normal
number of growing follicles but a decrease in the primordial follicle stock, suggesting the involvement
of BMP15 in migration and/or proliferation of primordial germ cells, primordial follicle formation or
follicle survival (unpublished observations). Although early folliculogenesis is normal in the absence
of BMP15, in vitro studies showed a stimulatory effect of BMP15 on granulosa cell mitosis (Otsuka, et al.,
2000). Interestingly, this stimulation of granulosa cell proliferation by BMP15 is, at least partly, achieved
in cooperation with KL/c-kit-signaling. A c-kit neutralizing antibody inhibited BMP15 induced
proliferation of granulosa cells in a co-culture of granulosa cells and oocytes (Otsuka and Shimasaki,
2002). In addition, BMP15 stimulates expression of KL1 and KL2 mRNA, thereby forming a negative
feedback loop because BMP15 mRNA expression itself is inhibited by KL (Otsuka and Shimasaki, 2002).
Additionally, BMP15 inhibits FSHR mRNA expression in in vitro cultured granulosa cells and as
a consequence the FSH-induced expression of LHR, inhibin a-, bA-, bB-subunits, StAR, P450scc and
3b-hydroxysteroid dehydrogenase (3bHSD) but not aromatase. It is unclear why the aromatase
expression is not decreased after reduction of FSHR mRNA expression. However, the mRNA expression
of aromatase could be inhibited when no androstenedion was present in the culture medium.
Consistent with the BMP15 effects on mRNA expression of several steroidogenic enzymes, BMP15
inhibits the FSH-induced progesterone, but not estrogen synthesis when androstenedion is present
(Otsuka, et al., 2001b). If FSH-induced estrogen synthesis in vivo is inhibited by BMP15 needs to be
determined. However, the follicular fluid in dominant follicles contains a high concentration of
androstenedion, suggesting that BMP15 is unable to inhibit estrogen production in these follicles
(Otsuka, et al., 2000, 2001b). Thus, BMP15 inhibits luteinization of the follicle by stimulating granulosa
cell proliferation and by suppressing FSH-induced progesterone, but probably not estrogen production.
BMP15 does not seem to play an essential role in early folliculogenesis, but is important for
ovulation. A reduced number of ovulated oocytes was found in superovulated BMP15 null mice and
some oocytes remained trapped in follicles. The impaired ovulation and fertilization of oocytes in
BMP15 null mice could explain the reduced litter size in these homozygous knockout females (Yan,
et al., 2001). However, the reduced fertility in BMP15 null mice could not be completely explained by
impaired ovulation and fertilization, since also fewer litters per month are born (Yan, et al., 2001).
This suggests that BMP15 also has an effect on the length of the estrous cycle.
In sheep, it was found that normal BMP15 expression is obligatory for early follicular development.
Several breeds of sheep have a high incidence of twinning, indicating that often more than one follicle
is selected. Two of these breeds, the Inverdale (FecXI) and Hanna (FecXH) sheep have been found to
carry a naturally occurring inactivating mutation in the BMP15 gene. Loss of one normal gene copy
results in a lower BMP15 expression and a high incidence of twinning in these sheep. Homozygous
mutants are infertile since follicle development beyond the primary stage is impaired. In these
mutants, oocytes grow in the absence of granulosa cell proliferation until they cannot be supported
by the residual granulosa cells whereupon they degenerate (Galloway, et al., 2000). Recently, it was
shown that the phenotype of Inverdale sheep could be explained by the absence of GDF9 protein
rather than of BMP15. BMP15 and GDF9 can form heterodimers and the processing of GDF9
homodimers is severely impaired when GDF9 is expressed in a cell line together with the mutated
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BMP15 construct of the Inverdale sheep (Liao, et al., 2003). This reduced GDF9 protein expression
could explain that the phenotype of homozygous Inverdale sheep is more similar to the phenotype of
GDF9 null mice than of the BMP15 null mice.
In conclusion, BMP15 is not necessary for primordial follicle recruitment in mice and stimulates
granulosa cell proliferation, inhibits FSH-induced progesterone, but not estrogen synthesis and
stimulates expression of KL. In this way, BMP15 inhibits luteinization of follicles. Furthermore, BMP15
is involved in ovulation. In sheep, homozygous mutations in the BMP15 gene result in a block in
folliculogenesis after the primary follicle stage. This block in folliculogenesis is probably caused by a
decreased GDF9 homodimer production in these mutants.
Bone Morphogenetic Protein-6
Bone morphogenetic protein-6 (BMP6) is a third TGFb family member expressed by oocytes. In contrast
to GDF9 and BMP15, BMP6 is also expressed in granulosa cells of secondary and tertiary follicles
(Erickson and Shimasaki, 2003). The type II receptor for BMP6 is BMPRII and this receptor is expressed
in the granulosa cells and oocytes (Table 1.3) (Ebisawa, et al., 1999; Erickson and Shimasaki, 2003).
The role of BMP6 is not clear, since BMP6 null female mice are fertile, have a normal littersize and
a normal reproductive life-span (Solloway, et al., 1998). The reason for the absence of a phenotype in
BMP6 null mice could be due to the expression in the ovary of related BMPs, which compensate for
the absence of the BMP6 (redundancy). Alternatively, it is possible that BMP6 evokes no biological
effects in the ovary in vivo.
However, in vitro studies revealed that BMP6 could influence granulosa cell function. FSH- and
forskolin-induced FSHR mRNA accumulation is inhibited by BMP6. In addition, FSH-induced
progesterone production is inhibited by BMP6 through inhibition of StAR and P450scc mRNA
expression. No influence of BMP6 was found on granulosa cell proliferation, on basal FSHR mRNA
expression, on FSH-induced aromatase expression or estrogen production. Since BMP6 does not inhibit
effects of 8-bromo-cAMP but inhibits effects of FSH and forskolin on progesterone production and
FSHR expression, it has been suggested that the underlying mechanisms involve the downregulation
of adenylate cyclase activity (Otsuka, et al., 2001a). This mechanism of action is different from that of
BMP15, which also inhibits progesterone secretion, but achieves this effect by inhibiting FSHR
mRNA expression (Otsuka, et al., 2001b).
In summary, BMP6 inhibits FSH-induced progesterone but not estrogen synthesis and this leads
to the hypothesis that BMP6, like BMP15, is an inhibitor of luteinization.
1.4.2 TGFb superfamily members expressed by theca cells
Theca cells are recruited from the interstitium of the ovary adjacent to the pre-antral follicle. The most
important function of theca cells is the production of androgens. The granulosa cells convert androgens
to estrogens, which are important for follicle development. At least three members of the TGFb
superfamily are expressed by the theca cells: bone morphogenetic proteins-3, -4 and -7. A summary of
the effects of TGFb family members expressed by the theca cells is given in Table 1.5 and Figure 1.1.
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Ovaries of BMP15 null mice contain all stages of follicular development, which shows that BMP15 is
not obligatory for primordial follicle recruitment or follicular development (Yan, et al., 2001). In
addition, we have found that ovaries of prepuberal and adult BMP15 null mice show a normal
number of growing follicles but a decrease in the primordial follicle stock, suggesting the involvement
of BMP15 in migration and/or proliferation of primordial germ cells, primordial follicle formation or
follicle survival (unpublished observations). Although early folliculogenesis is normal in the absence
of BMP15, in vitro studies showed a stimulatory effect of BMP15 on granulosa cell mitosis (Otsuka, et al.,
2000). Interestingly, this stimulation of granulosa cell proliferation by BMP15 is, at least partly, achieved
in cooperation with KL/c-kit-signaling. A c-kit neutralizing antibody inhibited BMP15 induced
proliferation of granulosa cells in a co-culture of granulosa cells and oocytes (Otsuka and Shimasaki,
2002). In addition, BMP15 stimulates expression of KL1 and KL2 mRNA, thereby forming a negative
feedback loop because BMP15 mRNA expression itself is inhibited by KL (Otsuka and Shimasaki, 2002).
Additionally, BMP15 inhibits FSHR mRNA expression in in vitro cultured granulosa cells and as
a consequence the FSH-induced expression of LHR, inhibin a-, bA-, bB-subunits, StAR, P450scc and
3b-hydroxysteroid dehydrogenase (3bHSD) but not aromatase. It is unclear why the aromatase
expression is not decreased after reduction of FSHR mRNA expression. However, the mRNA expression
of aromatase could be inhibited when no androstenedion was present in the culture medium.
Consistent with the BMP15 effects on mRNA expression of several steroidogenic enzymes, BMP15
inhibits the FSH-induced progesterone, but not estrogen synthesis when androstenedion is present
(Otsuka, et al., 2001b). If FSH-induced estrogen synthesis in vivo is inhibited by BMP15 needs to be
determined. However, the follicular fluid in dominant follicles contains a high concentration of
androstenedion, suggesting that BMP15 is unable to inhibit estrogen production in these follicles
(Otsuka, et al., 2000, 2001b). Thus, BMP15 inhibits luteinization of the follicle by stimulating granulosa
cell proliferation and by suppressing FSH-induced progesterone, but probably not estrogen production.
BMP15 does not seem to play an essential role in early folliculogenesis, but is important for
ovulation. A reduced number of ovulated oocytes was found in superovulated BMP15 null mice and
some oocytes remained trapped in follicles. The impaired ovulation and fertilization of oocytes in
BMP15 null mice could explain the reduced litter size in these homozygous knockout females (Yan,
et al., 2001). However, the reduced fertility in BMP15 null mice could not be completely explained by
impaired ovulation and fertilization, since also fewer litters per month are born (Yan, et al., 2001).
This suggests that BMP15 also has an effect on the length of the estrous cycle.
In sheep, it was found that normal BMP15 expression is obligatory for early follicular development.
Several breeds of sheep have a high incidence of twinning, indicating that often more than one follicle
is selected. Two of these breeds, the Inverdale (FecXI) and Hanna (FecXH) sheep have been found to
carry a naturally occurring inactivating mutation in the BMP15 gene. Loss of one normal gene copy
results in a lower BMP15 expression and a high incidence of twinning in these sheep. Homozygous
mutants are infertile since follicle development beyond the primary stage is impaired. In these
mutants, oocytes grow in the absence of granulosa cell proliferation until they cannot be supported
by the residual granulosa cells whereupon they degenerate (Galloway, et al., 2000). Recently, it was
shown that the phenotype of Inverdale sheep could be explained by the absence of GDF9 protein
rather than of BMP15. BMP15 and GDF9 can form heterodimers and the processing of GDF9
homodimers is severely impaired when GDF9 is expressed in a cell line together with the mutated
14
Chapter 1
Bone Morphogenetic Protein-7
Similar to BMP4, bone morphogenetic protein-7 (BMP7) is expressed in theca cells of secondary and
tertiary follicles and it receptor (BMPRII) is expressed in the granulosa cells and oocytes (Table 1.3)
(ten Dijke, et al., 1994; Rosenzweig, et al., 1995; Shimasaki, et al., 1999; Erickson and Shimasaki, 2003).
Some BMP7 effects are similar to the effects of BMP4. Like BMP4, BMP7 inhibits FSH-induced
progesterone production and stimulates FSH-induced estrogen secretion (Shimasaki, et al., 1999).
These effects are achieved through inhibition of FSH-induced StAR expression and stimulation of
aromatase mRNA expression (Lee, et al., 2001). The inhibition of progesterone synthesis might
explain the reduced number of ovulated oocytes from ovaries treated with BMP7 (Lee, et al., 2001).
Like BMP4, BMP7 facilitates transition of primordial follicles to primary, pre-antral and antral follicles
in rats treated with BMP7 (Lee, et al., 2001). This stimulation of outgrowth of primordial follicles can
be explained by the increased growth of pre-antral follicles which produce factors that regulate primordial
follicle recruitment (Hirshfield, 1994). Furthermore, granulosa cell proliferation is stimulated in a dose
dependent manner by BMP7, independent of FSH (Lee, et al., 2001).
Thus, BMP7 has several effects throughout follicular development. At the start of follicular
development BMP7 facilitates primordial follicle outgrowth, and at the end of follicular development
it inhibits luteinization and ovulation.
1.4.3 TGFb superfamily members expressed by 
granulosa cells
Granulosa cells surround the oocyte and play an important role in the regulation of follicular
development. Granulosa cells are the most important cells through which FSH acts and regulates
folliculogenesis. At least five members of the TGFb superfamily are expressed by these granulosa cells:
bone morphogenetic protein-2, inhibins, activins, TGFb and the anti-Müllerian hormone. A summary
of the effect of TGFb family members expressed by the granulosa cells is given in Table 1.6 and Figure 1.1.
Bone Morphogenetic Protein-2
Bone morphogenetic protein-2 (BMP2) is expressed by granulosa cells from primary follicles onwards.
In addition, BMP2 is also expressed by theca cells, but at a lower level compared to the expression in
granulosa cells (Erickson and Shimasaki, 2003). BMP2 acts, like BMP4, on granulosa cells and
possibly also on oocytes as the type II receptor (BMPRII) for BMP2 is expressed there (Table 1.3)
(Koenig, et al., 1994; ten Dijke, et al., 1994; Yamaji, et al., 1994; Nohno, Mizunuma et al., 1999, 1995;
Shimasaki, et al., 1999; Erickson and Shimasaki, 2003).
BMP2 enhances FSH-stimulated estrogen production in granulosa cells of immature follicles,
without affecting inhibin A production or proliferation of the granulosa cells (Souza, et al., 2002).
Furthermore, BMP2 induces inhibin bB-subunit mRNA expression and inhibin B secretion by human
luteal granulosa cells and this effect is inhibited by hCG (Jaatinen, et al., 2002). This upregulation of
inhibin B and inhibin bB-subunit mRNA expression by BMP2 could be relevant in vivo since inhibin
B is the predominant form of inhibin in the pre-ovulatory follicle and its concentration in follicular
fluid is much higher than inhibin A (Groome, et al., 1996).
In conclusion, BMP2 stimulates differentiation of granulosa cells by enhancing the effect of FSH
on estrogen production and could be involved in regulation of expression of inhibin B protein and
inhibin bB-subunit RNA.
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Bone Morphogenetic Protein-3
Bone morphogenetic protein-3 and its related protein BMP3b (also called GDF10) are expressed by
theca cells of tertiary follicles (Erickson and Shimasaki, 2003). Furthermore, it has been reported that
human luteal-granulosa cells express BMP3 and that this expression is inhibited by human chorionic
gonadotropin (hCG) (Jaatinen, et al., 1996). These results suggest a role for BMP3 and BMP3b in late
follicular development.
Bone Morphogenetic Protein-4
Bone morphogenetic protein-4 (BMP4) is expressed by theca-interstitial cells from primary follicles
onwards, with increasing intensity when the follicles become larger (Shimasaki, et al., 1999; Erickson and
Shimasaki, 2003). The receptor for BMP4 is BMPRII and is expressed in the oocyte and granulosa
cells, which suggests that this factor acts on these two cell types (Table 1.3) (Koenig, et al., 1994; ten Dijke,
et al., 1994; Yamaji, et al., 1994; Nohno, et al., 1995; Shimasaki, et al., 1999; Erickson and Shimasaki, 2003).
In vitro culture of granulosa cells of antral follicles showed an inhibitory effect of BMP4 on FSH-
induced progesterone secretion and a stimulatory effect on FSH-induced estrogen secretion (Shimasaki,
et al., 1999; Mulsant, et al., 2001). In this way, BMP4 inhibits luteinization of antral follicles.
Recently, a stimulatory function of BMP4 on primordial follicle recruitment was discovered.
Neonatal rat ovaries cultured in the presence of BMP4 contained less primordial and more growing
follicles than the controls (Nilsson and Skinner, 2003). Furthermore, ovaries cultured in the presence
of a BMP4 neutralizing antibody were smaller than controls. This was caused by loss of oocytes and
primordial follicles, an increase in cellular apoptosis and loss of normal stromal ovarian tissue (Nilsson
and Skinner, 2003). These results suggest that BMP4 acts as a survival factor for both follicular and
non-follicular cell types in the neonatal ovary.
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Table 1.5: Overview of the effects on follicle development of TGFb family members expressed by theca cells. 
Effects on folliculgenesis of BMP2 and AMH, both expressed by theca- and granulosa cells, is described in Table 1.6.
Family Site of action: Effects: References:
member:
BMP3 theca cells • probably effects in late follicular Jaatinen et al., 1996
development
BMP4 oocyte • stimulates primordial follicle recruitment Nilsson and Skinner, 2003
granulosa cells • inhibits FSH-induced luteinization by Shimasaki et al., 1999; Mulsant et al., 2001
inhibiting FSH-induced progesterone but 
stimulating estrogen synthesis
• survival factor for follicular and Nilsson and Skinner, 2003
non-follicular ovarian cells
BMP7 oocyte • stimulates development from primordial Lee et al., 2001
to primary, pre-antral and antral follicles
granulosa cells • stimulates granulosa cell proliferation Lee et al., 2001
• inhibits FSH-induced luteinization by Shimasaki et al., 1999
inhibiting FSH-induced progesterone but 
stimulating estrogen synthesis
Bone Morphogenetic Protein-7
Similar to BMP4, bone morphogenetic protein-7 (BMP7) is expressed in theca cells of secondary and
tertiary follicles and it receptor (BMPRII) is expressed in the granulosa cells and oocytes (Table 1.3)
(ten Dijke, et al., 1994; Rosenzweig, et al., 1995; Shimasaki, et al., 1999; Erickson and Shimasaki, 2003).
Some BMP7 effects are similar to the effects of BMP4. Like BMP4, BMP7 inhibits FSH-induced
progesterone production and stimulates FSH-induced estrogen secretion (Shimasaki, et al., 1999).
These effects are achieved through inhibition of FSH-induced StAR expression and stimulation of
aromatase mRNA expression (Lee, et al., 2001). The inhibition of progesterone synthesis might
explain the reduced number of ovulated oocytes from ovaries treated with BMP7 (Lee, et al., 2001).
Like BMP4, BMP7 facilitates transition of primordial follicles to primary, pre-antral and antral follicles
in rats treated with BMP7 (Lee, et al., 2001). This stimulation of outgrowth of primordial follicles can
be explained by the increased growth of pre-antral follicles which produce factors that regulate primordial
follicle recruitment (Hirshfield, 1994). Furthermore, granulosa cell proliferation is stimulated in a dose
dependent manner by BMP7, independent of FSH (Lee, et al., 2001).
Thus, BMP7 has several effects throughout follicular development. At the start of follicular
development BMP7 facilitates primordial follicle outgrowth, and at the end of follicular development
it inhibits luteinization and ovulation.
1.4.3 TGFb superfamily members expressed by 
granulosa cells
Granulosa cells surround the oocyte and play an important role in the regulation of follicular
development. Granulosa cells are the most important cells through which FSH acts and regulates
folliculogenesis. At least five members of the TGFb superfamily are expressed by these granulosa cells:
bone morphogenetic protein-2, inhibins, activins, TGFb and the anti-Müllerian hormone. A summary
of the effect of TGFb family members expressed by the granulosa cells is given in Table 1.6 and Figure 1.1.
Bone Morphogenetic Protein-2
Bone morphogenetic protein-2 (BMP2) is expressed by granulosa cells from primary follicles onwards.
In addition, BMP2 is also expressed by theca cells, but at a lower level compared to the expression in
granulosa cells (Erickson and Shimasaki, 2003). BMP2 acts, like BMP4, on granulosa cells and
possibly also on oocytes as the type II receptor (BMPRII) for BMP2 is expressed there (Table 1.3)
(Koenig, et al., 1994; ten Dijke, et al., 1994; Yamaji, et al., 1994; Nohno, Mizunuma et al., 1999, 1995;
Shimasaki, et al., 1999; Erickson and Shimasaki, 2003).
BMP2 enhances FSH-stimulated estrogen production in granulosa cells of immature follicles,
without affecting inhibin A production or proliferation of the granulosa cells (Souza, et al., 2002).
Furthermore, BMP2 induces inhibin bB-subunit mRNA expression and inhibin B secretion by human
luteal granulosa cells and this effect is inhibited by hCG (Jaatinen, et al., 2002). This upregulation of
inhibin B and inhibin bB-subunit mRNA expression by BMP2 could be relevant in vivo since inhibin
B is the predominant form of inhibin in the pre-ovulatory follicle and its concentration in follicular
fluid is much higher than inhibin A (Groome, et al., 1996).
In conclusion, BMP2 stimulates differentiation of granulosa cells by enhancing the effect of FSH
on estrogen production and could be involved in regulation of expression of inhibin B protein and
inhibin bB-subunit RNA.
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Bone Morphogenetic Protein-3
Bone morphogenetic protein-3 and its related protein BMP3b (also called GDF10) are expressed by
theca cells of tertiary follicles (Erickson and Shimasaki, 2003). Furthermore, it has been reported that
human luteal-granulosa cells express BMP3 and that this expression is inhibited by human chorionic
gonadotropin (hCG) (Jaatinen, et al., 1996). These results suggest a role for BMP3 and BMP3b in late
follicular development.
Bone Morphogenetic Protein-4
Bone morphogenetic protein-4 (BMP4) is expressed by theca-interstitial cells from primary follicles
onwards, with increasing intensity when the follicles become larger (Shimasaki, et al., 1999; Erickson and
Shimasaki, 2003). The receptor for BMP4 is BMPRII and is expressed in the oocyte and granulosa
cells, which suggests that this factor acts on these two cell types (Table 1.3) (Koenig, et al., 1994; ten Dijke,
et al., 1994; Yamaji, et al., 1994; Nohno, et al., 1995; Shimasaki, et al., 1999; Erickson and Shimasaki, 2003).
In vitro culture of granulosa cells of antral follicles showed an inhibitory effect of BMP4 on FSH-
induced progesterone secretion and a stimulatory effect on FSH-induced estrogen secretion (Shimasaki,
et al., 1999; Mulsant, et al., 2001). In this way, BMP4 inhibits luteinization of antral follicles.
Recently, a stimulatory function of BMP4 on primordial follicle recruitment was discovered.
Neonatal rat ovaries cultured in the presence of BMP4 contained less primordial and more growing
follicles than the controls (Nilsson and Skinner, 2003). Furthermore, ovaries cultured in the presence
of a BMP4 neutralizing antibody were smaller than controls. This was caused by loss of oocytes and
primordial follicles, an increase in cellular apoptosis and loss of normal stromal ovarian tissue (Nilsson
and Skinner, 2003). These results suggest that BMP4 acts as a survival factor for both follicular and
non-follicular cell types in the neonatal ovary.
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Table 1.5: Overview of the effects on follicle development of TGFb family members expressed by theca cells. 
Effects on folliculgenesis of BMP2 and AMH, both expressed by theca- and granulosa cells, is described in Table 1.6.
Family Site of action: Effects: References:
member:
BMP3 theca cells • probably effects in late follicular Jaatinen et al., 1996
development
BMP4 oocyte • stimulates primordial follicle recruitment Nilsson and Skinner, 2003
granulosa cells • inhibits FSH-induced luteinization by Shimasaki et al., 1999; Mulsant et al., 2001
inhibiting FSH-induced progesterone but 
stimulating estrogen synthesis
• survival factor for follicular and Nilsson and Skinner, 2003
non-follicular ovarian cells
BMP7 oocyte • stimulates development from primordial Lee et al., 2001
to primary, pre-antral and antral follicles
granulosa cells • stimulates granulosa cell proliferation Lee et al., 2001
• inhibits FSH-induced luteinization by Shimasaki et al., 1999
inhibiting FSH-induced progesterone but 
stimulating estrogen synthesis
et al., 1988; Roberts, et al., 1993; Tebar, et al., 1997; van den Hurk and Van de Pavert, 2001; Pangas,
et al., 2002). As expected from the mRNA expression pattern, inhibin a-subunit protein is detected
in granulosa cells of primary to pre-ovulatory follicles while the inhibin bA- and bB-subunit proteins
are detected in granulosa cells of secondary and tertiary follicles (Meunier, et al., 1988). Furthermore,
activin A is detected in granulosa cells of pre-antral and antral follicles and in theca cells of small
antral follicles in porcine (van den Hurk and Van de Pavert, 2001). Activins signal through two receptors,
activin receptor type II (ActRII) and type IIB (ActRIIB). ActRII is expressed in oocytes of all follicle
types and in pre-antral and antral granulosa cells (Cameron, et al., 1994; van den Hurk and Van de
Pavert, 2001; Drummond, et al., 2002; Pangas, et al., 2002). ActRIIB is expressed by granulosa cells
and oocytes (Cameron, et al., 1994; Drummond, et al., 2002; Pangas, et al., 2002). These expression
patterns suggest that activins act on oocytes and granulosa cells (Table 1.3). Until now, no inhibin-specific
receptors have been identified. Betaglycan, a TGFb type III receptor, enhances the binding of inhibin
to the ActRII and the heteromerization of activin type I and type II receptors is inhibited. In this way,
the activin-opposing actions of inhibin could be explained (Lebrun and Vale, 1997; Martens, et al.,
1997; Lewis, et al., 2000).
No effect of activin or inhibin on primordial follicle recruitment has been described but an
important role was found in early follicle development. In vitro culture of granulosa cells obtained
from diethylstilbestrol (DES)-treated immature rats, inhibin production is stimulated by FSH and
activin enhances the sensitivity of pre-antral follicles for FSH. This effect is achieved by stimulating
FSHR mRNA expression in granulosa cells and preventing FSH-induced downregulation of FSHR
number (Hasegawa, et al., 1988; Xiao, et al., 1992; Nakamura, et al., 1993). In general, most actions
of inhibin are explained by its activin antagonizing effects (Lebrun and Vale, 1997; Martens, et al.,
1997). However, recently it was shown that inhibin also could antagonize signaling of BMPs by
binding to BMPRII (Wiater and Vale, 2003). Since BMPs play an important role in folliculogenesis,
actions of inhibins in the ovary could be more widespread.
FSH and activin are also involved in follicular structure formation. A monolayer of granulosa cells
and oocytes of primary follicles of immature rats cultured in vitro, forms follicle structures under the
influence of activin and FSH. Addition of LH to the culture medium induces dissociation of these
follicle-like structures, in a process resembling ovulation (Li, et al., 1995). Furthermore, there are
indications that activin, produced by secondary follicles, causes small pre-antral follicles to remain
dormant. A co-culture of small and larger pre-antral follicles caused an inhibition of growth of the
smaller follicles. Addition of follistatin to the culture medium resulted in an increase in diameter of
small and larger pre-antral follicles. This indicates that the growth inhibition of smaller follicles could
be caused by activin or BMPs (Mizunuma, et al., 1999).
Opposite effects of activin on granulosa cells of pre-antral follicles from immature and adult
animals cultured in vitro have been found. Activin A stimulates the proliferation of granulosa cells of
pre-antral follicles of immature rats and mice, measured by 3[H]thymidine uptake and follicle diameter.
Furthermore, FSH-stimulated growth of granulosa cells is enhanced by activin while inhibin has no
effect (Li, et al., 1995; Miro and Hillier, 1996; Yokota, et al., 1997; Liu, et al., 1998, 1999; Mizunuma,
et al., 1999). In contrast, in vitro growth of pre-antral follicles of adult mice is not stimulated by
activin and FSH-stimulated growth is inhibited (Yokota, et al., 1997; Liu, et al., 1999; Mizunuma, 
et al., 1999). 
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Inhibins and activins
Activins and inhibins are dimeric glycoproteins formed from the inhibin subunits a, bA and bB. The
inhibin a- together with the inhibin bA-subunit forms the inhibin A protein, while inhibin B consists
of an inhibin a- and an inhibin bB-subunit. Homo- and heterodimerization of the inhibin b-subunits
gives rise to three forms of activin, referred to as activin A (bA-bA), activin AB (bA-bB) and activin
B (bB-bB). Inhibins inhibit the secretion of FSH from the pituitary and FSH stimulates the inhibin
production by the ovary (Drummond, et al., 2000). In this way, inhibins are involved in the feedback
system between ovary and pituitary gland. Activins stimulate FSH secretion from the pituitary.
However, it is unlikely that activins produced in the ovaries are responsible for this effect, because in
the circulation activin is tightly bound to follistatin which neutralizes its biological activity (Woodruff,
1998). Instead, locally produced activin could be responsible for FSH secretion in the pituitary
(Besecke, et al., 1997). Activins and inhibins also directly influence folliculogenesis in the ovary, and these
effects will be described below.
Expression of the inhibin a-subunit is found in granulosa cells of primary, pre-antral and antral
follicles of several species (Meunier, et al., 1988; Tebar, et al., 1997; McNatty, et al., 1999; Pangas, 
et al., 2002). Expression of inhibin bA- and bB-subunits is detected in granulosa cells of pre-antral
and antral follicles and conflicting data were reported about their expression in theca cells (Meunier,
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Table 1.6: Overview of the effects on follicle development of TGFb family members expressed by granulosa
cells. Effects on folliculogenesis of BMP6, expressed in granulosa cells and oocytes, is described in Table 1.4.
Family Site of action: Effects: References:
member:
BMP2 granulosa cells • enhances FSH-induced estrogen production Souza et al., 2002
oocyte? • induces inhibin bB and inhibin B  Jaatinen et al., 2002
production in human luteal granulosa cells
inhibin granulosa cells • stimulates androgen production in theca cells Findlay, 1993; Hillier and Miro, 1993;
theca cells • antagonizes activin and possibly also BMPs Wiater and Vale, 2003
oocyte?
activin granulosa cells • induces together with FSH follicular structure
oocyte reorganisation of granulosa and oocytes in vitro Li et al., 1995
• activin produced by larger pre-antral follicles Mizunuma et al., 1999
inhibits growth of smaller pre-antral follicles in vitro
• immature animals: stimulates FSH sensitivity Hasegawa et al., 1988; Xiao et al.,
of follicles by stimulating FSH-induced FSHR 1992; Nakamura et al., 1993 
expression and inhibiting FSH-induced 
downregulation of FSHR 
• immature animals: activin stimulates granulosa LaPolt et al., 1989; Li et al., 1995; 
cell proliferation of pre-antral follicles and Miro and Hillier, 1996; 
inhibin and estradiol production Yokota et al.,1997; Liu et al., 1998, 
1999; Mizunuma et al., 1999
• adult animals: activin inhibits FSH-induced Yokota et al., 1997; 
estrogen, inhibin production and follicle growth Liu et al., 1998, 1999
• suppresses theca cell androgen production Findlay, 1993; Hillier and Miro, 1993
TGFb theca cells • stimulates follicular growth, inhibin and Roy and Kole, 1998; Liu et al., 1999;
oocyte? estradiol production of pre-antral follicles of Mizunuma et al., 1999
adult but not immature mice
AMH granulosa cells • inhibits primordial follicle recruitment Durlinger et al., 1999, 2002
• inhibits FSH sensitivity of pre-antral and Durlinger et al., 2001
antral follicles
et al., 1988; Roberts, et al., 1993; Tebar, et al., 1997; van den Hurk and Van de Pavert, 2001; Pangas,
et al., 2002). As expected from the mRNA expression pattern, inhibin a-subunit protein is detected
in granulosa cells of primary to pre-ovulatory follicles while the inhibin bA- and bB-subunit proteins
are detected in granulosa cells of secondary and tertiary follicles (Meunier, et al., 1988). Furthermore,
activin A is detected in granulosa cells of pre-antral and antral follicles and in theca cells of small
antral follicles in porcine (van den Hurk and Van de Pavert, 2001). Activins signal through two receptors,
activin receptor type II (ActRII) and type IIB (ActRIIB). ActRII is expressed in oocytes of all follicle
types and in pre-antral and antral granulosa cells (Cameron, et al., 1994; van den Hurk and Van de
Pavert, 2001; Drummond, et al., 2002; Pangas, et al., 2002). ActRIIB is expressed by granulosa cells
and oocytes (Cameron, et al., 1994; Drummond, et al., 2002; Pangas, et al., 2002). These expression
patterns suggest that activins act on oocytes and granulosa cells (Table 1.3). Until now, no inhibin-specific
receptors have been identified. Betaglycan, a TGFb type III receptor, enhances the binding of inhibin
to the ActRII and the heteromerization of activin type I and type II receptors is inhibited. In this way,
the activin-opposing actions of inhibin could be explained (Lebrun and Vale, 1997; Martens, et al.,
1997; Lewis, et al., 2000).
No effect of activin or inhibin on primordial follicle recruitment has been described but an
important role was found in early follicle development. In vitro culture of granulosa cells obtained
from diethylstilbestrol (DES)-treated immature rats, inhibin production is stimulated by FSH and
activin enhances the sensitivity of pre-antral follicles for FSH. This effect is achieved by stimulating
FSHR mRNA expression in granulosa cells and preventing FSH-induced downregulation of FSHR
number (Hasegawa, et al., 1988; Xiao, et al., 1992; Nakamura, et al., 1993). In general, most actions
of inhibin are explained by its activin antagonizing effects (Lebrun and Vale, 1997; Martens, et al.,
1997). However, recently it was shown that inhibin also could antagonize signaling of BMPs by
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Inhibins and activins
Activins and inhibins are dimeric glycoproteins formed from the inhibin subunits a, bA and bB. The
inhibin a- together with the inhibin bA-subunit forms the inhibin A protein, while inhibin B consists
of an inhibin a- and an inhibin bB-subunit. Homo- and heterodimerization of the inhibin b-subunits
gives rise to three forms of activin, referred to as activin A (bA-bA), activin AB (bA-bB) and activin
B (bB-bB). Inhibins inhibit the secretion of FSH from the pituitary and FSH stimulates the inhibin
production by the ovary (Drummond, et al., 2000). In this way, inhibins are involved in the feedback
system between ovary and pituitary gland. Activins stimulate FSH secretion from the pituitary.
However, it is unlikely that activins produced in the ovaries are responsible for this effect, because in
the circulation activin is tightly bound to follistatin which neutralizes its biological activity (Woodruff,
1998). Instead, locally produced activin could be responsible for FSH secretion in the pituitary
(Besecke, et al., 1997). Activins and inhibins also directly influence folliculogenesis in the ovary, and these
effects will be described below.
Expression of the inhibin a-subunit is found in granulosa cells of primary, pre-antral and antral
follicles of several species (Meunier, et al., 1988; Tebar, et al., 1997; McNatty, et al., 1999; Pangas, 
et al., 2002). Expression of inhibin bA- and bB-subunits is detected in granulosa cells of pre-antral
and antral follicles and conflicting data were reported about their expression in theca cells (Meunier,
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Table 1.6: Overview of the effects on follicle development of TGFb family members expressed by granulosa
cells. Effects on folliculogenesis of BMP6, expressed in granulosa cells and oocytes, is described in Table 1.4.
Family Site of action: Effects: References:
member:
BMP2 granulosa cells • enhances FSH-induced estrogen production Souza et al., 2002
oocyte? • induces inhibin bB and inhibin B  Jaatinen et al., 2002
production in human luteal granulosa cells
inhibin granulosa cells • stimulates androgen production in theca cells Findlay, 1993; Hillier and Miro, 1993;
theca cells • antagonizes activin and possibly also BMPs Wiater and Vale, 2003
oocyte?
activin granulosa cells • induces together with FSH follicular structure
oocyte reorganisation of granulosa and oocytes in vitro Li et al., 1995
• activin produced by larger pre-antral follicles Mizunuma et al., 1999
inhibits growth of smaller pre-antral follicles in vitro
• immature animals: stimulates FSH sensitivity Hasegawa et al., 1988; Xiao et al.,
of follicles by stimulating FSH-induced FSHR 1992; Nakamura et al., 1993 
expression and inhibiting FSH-induced 
downregulation of FSHR 
• immature animals: activin stimulates granulosa LaPolt et al., 1989; Li et al., 1995; 
cell proliferation of pre-antral follicles and Miro and Hillier, 1996; 
inhibin and estradiol production Yokota et al.,1997; Liu et al., 1998, 
1999; Mizunuma et al., 1999
• adult animals: activin inhibits FSH-induced Yokota et al., 1997; 
estrogen, inhibin production and follicle growth Liu et al., 1998, 1999
• suppresses theca cell androgen production Findlay, 1993; Hillier and Miro, 1993
TGFb theca cells • stimulates follicular growth, inhibin and Roy and Kole, 1998; Liu et al., 1999;
oocyte? estradiol production of pre-antral follicles of Mizunuma et al., 1999
adult but not immature mice
AMH granulosa cells • inhibits primordial follicle recruitment Durlinger et al., 1999, 2002
• inhibits FSH sensitivity of pre-antral and Durlinger et al., 2001
antral follicles
granulosa cells was inhibited by TGFb (Skinner, et al., 1987). Thus, although the expression pattern
of TGFb and its receptor suggests a role of TGFb in early folliculogenesis, the functional role of TGFb
still needs to be determined.
Anti-Müllerian Hormone
Anti-Müllerian hormone (AMH) is secreted by the testis during male sex differentiation and is
responsible for the regression of the Müllerian ducts, which form the anlagen of the oviduct, uterus
and the upper part of the vagina in females. In human girls, AMH is expressed after week 36 of gestation
(Rajpert-De Meyts, et al., 1999), while in mice AMH production starts in the days immediately
following birth (Chapter 3). In females, AMH is only expressed in the ovary and its mRNA and
protein are found in granulosa cells of small growing (i.e. pre-antral and small antral) non-atretic
follicles in rat and mouse (Ueno, et al., 1989; Hirobe, et al., 1992; Baarends, et al., 1995a and Chapter
3 of this thesis). The pregranulosa cells of primordial follicles do not express AMH, but when primordial
follicles are recruited into the growing pool, granulosa cells start to express AMH mRNA and protein
(Münsterberg and Lovell-Badge, 1991; Hirobe, et al., 1992; Taketo, et al., 1993; Baarends, et al., 1995a
and Chapter 3 of this thesis). The highest level of AMH expression is found in the granulosa cells of
large pre-antral and small antral follicles (Figure 1.2). Two studies have reported expression of AMH
in rat pre-ovulatory follicles (Ueno, et al., 1989; Hirobe, et al., 1994). However, these results were not
confirmed by other studies, which showed disappearance of AMH expression from antral stage
onward and its absence in pre-ovulatory follicles and corpora lutea (Figure 1.2) (Hirobe, et al., 1992;
Baarends, et al., 1995a; Durlinger, et al., 2002). In addition, AMH expression disappears when a follicle
becomes atretic (Hirobe, et al., 1992; Baarends, et al., 1995a; Durlinger, et al., 2002). AMH expression
is not found in theca cells, oocytes and interstitial cells of the ovary (Ueno, et al., 1989; Hirobe, et al.,
1992; Hirobe, et al., 1994; Baarends, et al., 1995a and Chapter 3 of this thesis).
Like other members of the TFGb family, AMH signals by binding to a type II transmembrane
serine/threonine (S/T) kinase receptor which forms a complex with and subsequently activates a type
I S/T kinase receptor by phosphorylation (see also Chapter 2). 
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Furthermore, activin stimulates production of inhibin and estradiol by pre-antral follicles of immature
but not of adult mice (Yokota, et al., 1997; Liu, et al., 1998, 1999). In addition, activin A stimulates
expression and biosynthesis of the inhibin a-subunit in cultured granulosa cells of immature rats
(LaPolt, et al., 1989). In vivo data showed an opposite effect from in vitro data. Inhibin stimulates growth
of follicles of immature rats in vivo and activin causes follicular atresia (Woodruff, et al., 1990), while
in vitro inhibin has no effect and activin stimulates follicular growth (Li, et al., 1995; Miro and Hillier,
1996; Yokota, et al., 1997; Liu, et al., 1998, 1999; Mizunuma, et al., 1999).
During follicular development, the effect of activin A on steroidogenesis changes. Basal steroidogenesis
in an undifferentiated granulosa cell culture from immature rats is not affected by activin, but the
FSH-induced estrogen and progesterone synthesis is enhanced. In differentiated and pre-ovulatory
granulosa cells activin stimulates basal as well as FSH-induced estrogen production. Basal progesterone
production is stimulated in differentiated and inhibited in pre-ovulatory granulosa cells by activin,
whereas FSH-induced progesterone synthesis is inhibited in both differentiated and pre-ovulatory
granulosa cell cultures (Hutchinson, et al., 1987; Miro, et al., 1991). These results show a role for
activin in modulating steroidogenesis during follicular development. In theca cells, inhibin enhances
LH-induced production of androgens, while activin suppresses this production (Findlay, 1993; Hillier
and Miro, 1993).
In conclusion, activin has multiple roles in pre-antral follicle development as it stimulates granulosa
cell proliferation in follicles of immature mice and rats, enhances FSH-responsiveness, inhibin and
estrogen production in granulosa cells and inhibits androgen production by theca cells. Furthermore,
activin is involved in follicle formation of pre-antral follicles. In addition, activin produced by larger
pre-antral follicles can inhibit growth of smaller pre-antral follicles. Inhibin stimulates LH-induced
androgen synthesis of theca cells and is an antagonist of activin- and possibly also BMP-action.
Transforming Growth Factor b
The expression pattern of transforming growth factor b (TGFb) and its receptors suggests a role for
TGFb in early folliculogenesis. Three isoforms of TGFb can be distinguished, TGFb1, 2 and 3. TGFb2
expression is found in monkey granulosa cells of non-growing follicles, while no expression is found
in small growing follicles (Gougeon and Busso, 2000). In the hamster, expression of TGFb2 also
declines after follicles have started to grow, although this drop occurs only after 2-3 layers of
granulosa cells have formed (Roy and Hughes, 1994). In contrast, no expression of TGFb1 is found
in non-growing and small growing monkey (Gougeon and Busso, 2000), rat (Teerds and Dorrington,
1992) or marmoset follicles (Wehrenberg, et al., 1998). In porcine and bovine follicles, the theca cells
seem to be the source of TGFb1 protein expression in antral follicles (Skinner, et al., 1987; May, et al.,
1996). TGFb receptor II is found in oocytes of primordial and primary follicles and a weak staining
is present in theca- but not granulosa cells (Qu, et al., 2000) while another group reported also
expression in granulosa cells (Table 1.3) (Roy and Kole, 1998). This TGFb receptor II expression 
in granulosa cells can be stimulated by EGF and FSH in human pre-antral follicle culture (Roy and
Kole, 1998).
TGFb stimulates follicle growth, inhibin and estradiol production in in vitro culture of pre-antral
follicles of adult (Liu, et al., 1999; Mizunuma, et al., 1999) but not in immature mouse (Liu, et al.,
1999) or human pre-antral follicles (Roy and Kole, 1998). In contrast, in vitro proliferation of bovine
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Figure 1.2: Immunohistochemical localization of AMH in Bouin-fixed ovaries of adult mice.
A. AMH protein is expressed in granulosa cells of small growing follicles, like primary (PY), pre-antral (PA)
and small antral (SA) follicles, but not in atretic follicles (At).
B. AMH protein expression disappears in larger antral follicles (A) and in atretic follicles (At).
granulosa cells was inhibited by TGFb (Skinner, et al., 1987). Thus, although the expression pattern
of TGFb and its receptor suggests a role of TGFb in early folliculogenesis, the functional role of TGFb
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and the upper part of the vagina in females. In human girls, AMH is expressed after week 36 of gestation
(Rajpert-De Meyts, et al., 1999), while in mice AMH production starts in the days immediately
following birth (Chapter 3). In females, AMH is only expressed in the ovary and its mRNA and
protein are found in granulosa cells of small growing (i.e. pre-antral and small antral) non-atretic
follicles in rat and mouse (Ueno, et al., 1989; Hirobe, et al., 1992; Baarends, et al., 1995a and Chapter
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Like other members of the TFGb family, AMH signals by binding to a type II transmembrane
serine/threonine (S/T) kinase receptor which forms a complex with and subsequently activates a type
I S/T kinase receptor by phosphorylation (see also Chapter 2). 
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Furthermore, activin stimulates production of inhibin and estradiol by pre-antral follicles of immature
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granulosa cells activin stimulates basal as well as FSH-induced estrogen production. Basal progesterone
production is stimulated in differentiated and inhibited in pre-ovulatory granulosa cells by activin,
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Figure 1.2: Immunohistochemical localization of AMH in Bouin-fixed ovaries of adult mice.
A. AMH protein is expressed in granulosa cells of small growing follicles, like primary (PY), pre-antral (PA)
and small antral (SA) follicles, but not in atretic follicles (At).
B. AMH protein expression disappears in larger antral follicles (A) and in atretic follicles (At).
The AMH-specific type II receptor (AMHRII) has been cloned and its mRNA expression is colocalized
with AMH in the granulosa cells (Baarends, et al., 1994; di Clemente, et al., 1994b). It is likely that the
AMHRII is also expressed in the pregranulosa cells of primordial follicles because ovarian expression
of AMHRII is already found during the fetal period and remains present after birth when the ovary mainly
contains primordial follicles (Baarends, et al., 1994; di Clemente, et al., 1994b, Chapter 5). In addition,
it has been suggested that AMHRII is also expressed in theca cells of pre-antral and small antral
follicles in rat ovaries (Table 1.3) (Ingraham, et al., 2000).
Although AMH null female mice did not show an obvious phenotype (Behringer, et al., 1994), a
more extensive study of the total follicle population in AMH null mice and their wild-type littermates
revealed that AMH has an effect on initial follicle development (Durlinger, et al., 1999). Ovaries of
prepubertal (25-day-old) and adult (4-month-old) AMH null mice contained more growing follicles
than ovaries of their wild-type littermates (Figure 1.3) (Durlinger, et al., 1999). In addition, ovaries of
AMH null adult mice contained less primordial follicles than control ovaries. These results indicate that
in the absence of AMH more primordial follicles are recruited into the growing pool. Interestingly,
heterozygous AMH null mice have a phenotype between those of wild-type and homozygous mice
(Figure 1.3). This AMH gene dose-dependency suggests that AMH production and secretion
depend on the intrinsic activity of the gene itself and is not under stringent feedback control
(Durlinger, et al., 1999).
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As a result of the absence of AMH, and thus the increased recruitment of primordial follicles, aged
13-month-old AMH null ovaries were almost completely depleted of their primordial follicles. As a
consequence, these ovaries hardly contained any growing follicles (Figure 1.3). This was reflected by
the fact that 56% of the AMH null females at 16-17 months of age had stopped ovulating compared
to only 18% of the aged wild-type females (Durlinger, et al., 2002). Thus, by inhibiting initial
recruitment AMH prevents early depletion of the follicle pool in the ovary. This hypothesis was
confirmed by in vitro studies (see Chapter 3).
Not only does AMH play a role in initial follicle recruitment, but AMH is also involved in the
regulation of selection of follicles for pre-ovulatory growth as shown by experiments in AMH null mice
(Durlinger, et al., 1999). The initial finding that led us to hypothesize that AMH might modulate the
FSH-sensitivity of follicles was that, despite lower FSH serum levels, ovaries of AMH null mice
contained more growing follicles compared to their wild-type littermates. In vitro culture of mouse
pre-antral follicles showed that AMH is able to inhibit FSH-stimulated growth of these follicles after
four and five days of culture. This was reflected by a decreased follicle diameter of follicles cultured in
the presence of AMH compared to controls. This growth inhibition is probably caused by a decrease
in the rate of granulosa cell proliferation (Durlinger, et al., 2001). In contrast, McGee et al. found a
stimulatory effect of AMH on the growth of in vitro cultured rat pre-antral follicles (2001). Although
in both studies pre-antral follicles were used, species difference and culture conditions (presence/
absence of serum and thus growth factors) may explain these opposite results (McGee, personal
communication).
The inhibitory effect of AMH on FSH-sensitivity was confirmed by in vivo studies using AMH null
mice. In the presence of low FSH serum levels, induced by GnRH-antagonist treatment, ovaries of AMH
null mice contained more growing follicles than the wild-type ovaries under the same experimental
conditions. Comparable results between wild-type and AMH null mice ovaries were found when FSH
serum levels were artificially increased (Durlinger, et al., 2001). Taken together, these studies show
that AMH inhibits selection of follicles for pre-ovulatory growth by decreasing their sensitivity for FSH.
In this way AMH is able to control the number of large pre-antral and small antral follicles that
continue to grow to the pre-ovulatory stage.
The usefulness of AMH as a new marker for female fertility was studied. Fertility in women is
determined by the ovarian reserve, which reflects both the quantity and quality of the ovarian follicle
pool. The decline of the ovarian reserve is called ovarian ageing. Besides aspects such as oocyte quality,
the number of primordial follicles that is left in the ovary is also an important parameter for ovarian
reserve (te Velde and Pearson, 2002). Although it is difficult to directly measure the size of the
primordial follicle stock in women, it appears that the number of growing follicles correlates with the
size of the primordial follicle stock from which they are recruited (Gougeon, et al., 1994; Scheffer, et al.,
1999). Therefore, a marker that reflects all follicles that have made the transition from the primordial
follicle pool to the growing pool may be a good indirect marker of the quantitative aspect of the
ovarian reserve. Since AMH is produced by growing follicles, the hypothesis whether AMH is a
candidate marker of ovarian reserve has been tested by measuring the AMH serum levels of 41 healthy 
normo-ovulatory women at two visits to the clinic with an average interval of 2.6 ± 1.7 years. AMH
serum levels significantly decreased between the two visits, and within each visit a negative correlation
was found between age and AMH levels (Figure 1.4A). In addition, the number of growing antral
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Figure 1.3: Follicle population in 25-day-old, 4-month-old and 13-month-old AMH(+/+), AMH(+/-) and AMH(-/-)
mice.
A. Primordial follicle population in ovaries of 25-day-old, 4-month-old and 13-month-old AMH(+/+),
AMH(+/-) and AMH(-/-) mice.
B. Non-atretic small growing follicle population in ovaries of 25-day-old, 4-month-old and 13-month-old
AMH(+/+), AMH(+/-) and AMH(-/-) mice. Data represent the mean ± SEM (n=4-5). An asterisk
indicates a statistically significant difference (P≤0.05). Data taken and adapted from: Durlinger A.L.L.,
Kramer P., Karels B., de Jong F.H., Uilenbroek J.Th.J., Grootegoed J.A. and Themmen A.P.N.; Control of
primordial follicle recruitment by Anti-Müllerian hormone in the mouse ovary; Endocrinology; Vol. 140;
No. 12; 5789-5796; 1999; copyright owner, The Endocrine Society.
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The AMH-specific type II receptor (AMHRII) has been cloned and its mRNA expression is colocalized
with AMH in the granulosa cells (Baarends, et al., 1994; di Clemente, et al., 1994b). It is likely that the
AMHRII is also expressed in the pregranulosa cells of primordial follicles because ovarian expression
of AMHRII is already found during the fetal period and remains present after birth when the ovary mainly
contains primordial follicles (Baarends, et al., 1994; di Clemente, et al., 1994b, Chapter 5). In addition,
it has been suggested that AMHRII is also expressed in theca cells of pre-antral and small antral
follicles in rat ovaries (Table 1.3) (Ingraham, et al., 2000).
Although AMH null female mice did not show an obvious phenotype (Behringer, et al., 1994), a
more extensive study of the total follicle population in AMH null mice and their wild-type littermates
revealed that AMH has an effect on initial follicle development (Durlinger, et al., 1999). Ovaries of
prepubertal (25-day-old) and adult (4-month-old) AMH null mice contained more growing follicles
than ovaries of their wild-type littermates (Figure 1.3) (Durlinger, et al., 1999). In addition, ovaries of
AMH null adult mice contained less primordial follicles than control ovaries. These results indicate that
in the absence of AMH more primordial follicles are recruited into the growing pool. Interestingly,
heterozygous AMH null mice have a phenotype between those of wild-type and homozygous mice
(Figure 1.3). This AMH gene dose-dependency suggests that AMH production and secretion
depend on the intrinsic activity of the gene itself and is not under stringent feedback control
(Durlinger, et al., 1999).
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indicates a statistically significant difference (P≤0.05). Data taken and adapted from: Durlinger A.L.L.,
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but also high AMH levels correlate with a poor response in IVF treatment. In patients with polycystic
ovary syndrome (PCOS), higher AMH serum levels were found than in normo-ovulatory women. In
these PCOS patients a higher number of immature oocytes was found after ovarian stimulation for
IVF treatment (Fallat, et al., 1997). Thus, AMH serum levels can give a prediction for the success of
oocyte retrieval during IVF treatment.
Although the serum level of AMH may not be the only marker of ovarian reserve, the relatively
small fluctuations in AMH serum levels during the menstrual cycle (Cook, et al., 2000) indicate that
a blood sample may be drawn at any moment during the menstrual cycle, to predict the ovarian
reserve. This further supports the advantage of the use of AMH as a marker for ovarian reserve over
antral follicle count using ultrasound.
1.5 AIM OF THIS STUDY
Age at menopause, and therefore also the age of infertility and the length of postmenopausal life, 
is determined by the efficiency by which the primordial follicle stock is utilized. Since AMH is
involved in the regulation of primordial follicle recruitment, this hormone is likely to play a role in
the determination of the onset of menopause. Therefore, it is important to understand the mechanisms
by which AMH mediates its effects. In this thesis, the mechanisms (signal transduction and regulated
genes) by which AMH exerts its effects in the ovary (inhibition of primordial follicle recruitment) are
investigated. Furthermore, expression of several growth factors, which are also involved in follicle
recruitment, has been investigated.
To understand the signaling mechanism, which might be used by AMH, Chapter 2 reviews the
TGFb superfamily signal transduction mechanisms.
AMH null mice ovaries contained less primordial and more growing follicles than their wild-type
littermates. These results suggest that AMH inhibits recruitment of primordial follicles. To examine
the ability of AMH to inhibit primordial follicle recruitment in vitro we used an ovary organ culture
system. The results of this study are described and discussed in Chapter 3.
In the Müllerian ducts, AMH signals through the AMHRII. In Chapter 4 we investigated if AMH
also signals through this receptor in the ovary by studying the ovarian phenotype inof AMHRII null mice.
The signaling pathway used by AMH in the ovary is unknown. Therefore, we identified the AMH-
signaling pathway and the expression and localization of candidate receptors and downstream
mediators for AMH signaling in the ovary (Chapter 5).
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follicles was counted using ultrasonography in the same women and FSH, inhibin B and estrogen
levels were determined. Of the serum levels measured, only those of AMH showed a strong correlation
with the number of antral follicles (Figure 1.4B) (de Vet, et al., 2002). These results indicate that
AMH, indeed, may be used as a marker for ovarian ageing.
The usefulness of AMH serum levels as a measure for the ovarian reserve was tested further in a
cohort of women undergoing in vitro fertilization (IVF) treatment. Hormonal parameters and antral
follicle count using transvaginal ultrasonography were determined on the third day of the menstrual
cycle in 119 IVF patients, not more than three months preceding the IVF treatment (van Rooij, et al.,
2002). The measured parameters were analyzed after division of the patients into two groups on the
basis of the number of oocytes retrieved after IVF treatment: normal responders (four or more retrieved
oocytes) and poor responders (less than four retrieved oocytes or cancellation of IVF treatment).
Ovaries of normally responding women contained significantly more growing antral follicles than
ovaries of women with a poor response to IVF treatment. In addition, AMH serum levels in these
poorly responding women were lower compared to those in normally responding women (Table 1.7).
Serum AMH levels correlated strongly with the antral follicle count, the number of follicles retrieved,
age, inhibin B and FSH (van Rooij, et al., 2002). In addition, logistic regression analysis used to predict
poor or normal response showed that both antral follicle count and AMH serum levels were equally
important for prediction, since the calculated areas under the receiver operating characteristic (ROC)
curve (ROCAUC) were 0.86 and 0.85, respectively (van Rooij, et al., 2002). The ROCAUC determines the
sensitivity of the diagnostic test and may vary between 0.5 (no discriminative power) to 1.0 (perfect
discrimination) (Harrell, et al., 1996). These data support the observations made in another study
where also a correlation was found between AMH serum levels and the number of retrieved oocytes
in women undergoing IVF treatment (Seifer, et al., 2002). However, not only low AMH serum levels
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Figure 1.4: Results of measurements of serum AMH at two different time points in 41 healthy normo-ovulatory
women, with an average time interval between two visits of 2.6 years ± 1.7 years.
The average age at visit 1 was 29 ± 4 years and at visit 2 32 ± 4 years. This figure shows the correlation
of AMH with age at the two visits (A) and of AMH with the number of antral follicles (B), with the AMH
level at visit 1 (closed circles, solid line) and visit 2 (open circles, dotted line) (de Vet, et al., 2002).
Reprinted by permission from the American Society for Reproductive Medicine (Fertility and Sterility,
2002; Vol 77; 357-362).
Table 1.7: Results of ovarian reserve test in IVF treated patients, divided in normal and poor responders. 
AMH levels are lower in poor responders than in normal responders. The number of antral follicles found at day 3 of the cycle
is higher in normal responders than in poor responders (van Rooij et al., 2002).
Variables: Total (n=119): Normal responders Poor responders p:
(n=84): (n=35):
Age (years) 33.8 (22.3-44.0) 33.8 (24.4-44.0) 36.3 (22.3-43.3) 0.09
AMH (mg/L) 0.9 (0.0-6.2) 1.4 (0.0-6.2) 0.2 (0.0-1.7) <0.001
Antral follicles (n) 8 (0-35) 11 (0-35) 4 (0-15) <0.001
Number of oocytes (n=96) 7 (1-28) 9 (4-28) 2 (1-3) not applicable
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Primordial follicle recruitment is regulated by several growth factors produced by growing follicles.
In Chapter 6 we studied the expression and localization of growth factors, involved in primordial follicle
recruitment. The results give more knowledge about the role in primordial follicle recruitment of several
growth factors produced by growing follicles.
To understand how AMH achieves its effect in the ovary, we initiated a search for AMH-regulated
genes in the ovary. Therefore we used the mouse granulosa cell line KK-1 and mouse neonatal ovary
culture. Chapter 7 describes the first results of this study.
In the general discussion the mechanisms by which AMH achieves its effects is discussed. In addition,
the role of AMH in follicle development compared to the role of systemic factors LH and FSH and
the clinical relevance of AMH are discussed.
Chapter 2
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2.1 INTRODUCTION
The transforming growth and differentiation factor b (TGFb) superfamily is the largest family of
growth and differentiation factors which is presently known. Family members have a broad range of
functions in mesenchymal-epithelial interactions, cell cycle regulation, lineage determination, 
cell differentiation, motility, adhesion and death. The TGFb superfamily can be divided in several
subfamilies, such as the TGFbs (TGFb1-5), activins (inhibina, bA-C, E) and bone morphogenetic
proteins (e.g. BMP1-15, GDF1-9). Furthermore, anti-Müllerian hormone (AMH) is a distant member
of the TGFb superfamily (Figure 2.1A) (Chang, et al., 2002). The important roles of several TGFb
superfamily members during folliculogenesis have been described in Chapter 1. This chapter describes
the characteristics of the TGFb superfamily members and the signaling mechanisms by which they
achieve their effects. In addition, the signaling mechanisms of AMH, a member of the TGFb superfamily
and the focus of this thesis, and AMH-regulated genes will be described in more detail.
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Figure 2.1: The TGFb superfamily of growth and differentiation factors. 
A. Similarity of amino acid sequences from mature proteins between the members of the TGFb
superfamily of growth and differentiation factors (Chang et al., Genetic analysis of the mammalian
transforming growth factor-beta superfamily. Copyright 2002, The Endocrine Society). 
B. Schematic representation of processing of TGFb superfamily members monomers. Family members
are produced as preproproteins. The preregion is the signal peptide. The mature protein is released
after cleavage from the proregion. 
C. Two-dimensional structure of the TGFb2 monomer. Amino-acids are indicated by their one-letter
code. The six conserved cysteine residues (Cys 15, 44, 48, 77, 78, 109 and 111) are reflected by
squares. Furthermore, the disulfide bonds formed by these cysteine residues are drawn. Cys 77 forms
the disulfide bond with the other monomer. Reprinted by permission from Nature (Schlunegger and
Grutter), Copyright 1992, Macmillan Publishers Ltd.
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and presenting it to the type II receptor (see Section 2.4). The type II and type I receptors share a
similar overall structure consisting of a N-terminal signal sequence, a short cysteine-rich extracellular
region (cysteine box), a single hydrophobic membrane-spanning domain and a cytoplasmic region
containing a kinase domain. Furthermore, the type II receptors contain a S/T-rich C-terminal tail,
which is absent in type I receptors. Another difference between type I and type II receptors is a highly
conserved region of 30 amino acids in the juxtamembrane region, named the GS box based on a
GSGSG motif. This GS box is found in the type I, but not in the type II receptors and contains five
clustered S/T residues which are essential for signaling (Massagué, 1992; Wrana, et al., 1994). 
Binding of TGFb family members to the type II receptor induces the formation of a hetero-
tetrameric complex containing two type II and two type I receptors (Figure 2.2) (Wrana, et al., 1994;
Heldin, et al., 1997; Kirsch, et al., 2000). The kinase domain of type II receptors is highly phosphorylated.
TGFb type II receptor (TbRII) studies showed that this phosphorylation of the kinase domain is
ligand-independent due to autophosphorylation and, possibly, due to the activity of other intracellular
kinases (Wrana, et al., 1994; Chen and Weinberg, 1995). After type I/type II receptor complex formation,
the constitutively active type II receptors phosphorylate the type I receptors at the GS box (Wrana, 
et al., 1994; Chen and Weinberg, 1995; Weis-Garcia and Massagué, 1996). For type I receptor activation,
at least two of the S/T residues in the GS box have to be phosphorylated (Wieser, et al., 1995). Next,
downstream intracellular substrates are phosphorylated by the type I receptor. Thus, the type I
receptors acts as a downstream substrate of the type II receptors and therefore determine the specificity
of downstream signals induced by ligands of the TGFb superfamily (Wrana, et al., 1994; Chen and
Weinberg, 1995). 
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2.2 CHARACTERISTICS OF TGFb FAMILY MEMBERS
TGFb family members are synthesized as large precursor proteins which are able to form homo- or
heterodimers. All precursor proteins contain a mono- or dibasic cleavage site located approximately
110 amino acids from the C-terminus. After cleavage, the biologically active dimeric C-terminal
protein (mature protein) and the N-terminal protein are formed (Figure 2.1B) (Gentry and Nash, 1990;
Massagué, 1990). For all members of the TGFb superfamily cleavage of the precursor protein is necessary
for biological activity, since the uncleaved protein is inactive (Gentry, et al., 1988). The N-terminal
fragment is involved in proper folding and secretion of the mature TGFb1 protein and it is suggested
that this is applicable to all TGFb superfamily members (Gray and Mason, 1990; Sha, et al., 1991).
Dissociation of this N-terminal domain from the mature protein is necessary for full biological activity
of this protein. This dissociation is a regulated process and provides a mechanism of controlling the
bioactivity of the protein (Gentry and Nash, 1990). This is shown by the TGFb protein where the
dimer of the N-terminal domain interacts with the mature hormone, thereby preventing binding of
TGFb to its receptor and thus biological activity (Gentry and Nash, 1990). AMH is the only known
TGFb family member where continuous association between the mature and N-terminal domain
after cleavage is necessary for full biological activity. The mature protein alone has a decreased bioactivity
in vitro and this bioactivity can be normalized by adding the N-terminal domain of AMH in the culture
medium. Presumably the N-terminal part of AMH stabilizes the proper conformation of this hormone
(Wilson, et al., 1993). Mutations in this N-terminal domain are found in persistent Müllerian duct
syndrome (PMDS) patients (see section 2.5), suggesting that these mutations result in an inactive
hormone in vivo (Imbeaud, et al., 1994).
The biologically active C-terminal domains of all family members share a high percentage of
homology (23-80%). Furthermore, the mature protein is characterized by a conserved motif of seven
cysteine residues (Wilson, et al., 1993), except in growth and differentiation factor (GDF) 9, GDF3
(McPherron and Lee, 1993) and bone morphogenic protein (BMP) 15 (Dube, et al., 1998), which
only contain six cysteine residues. Crystallography of transforming growth factor b2 (TGFb2) revealed
that the cysteines are involved in proper folding of the hormones. One cysteine forms a disulfide bond
between the two mature proteins. The other six cysteines are responsible for the intrachain folding
through the formation of disulfide bridges in a region known as the “cysteine knot” (Figure 2.1C)
(Daopin, et al., 1992; Schlunegger and Grutter, 1992).
2.3 SIGNALING OF TGFb FAMILY MEMBERS
2.3.1 Characteristics of serine/threonine kinase receptors
and signaling
Members of the TGFb superfamily mediate their actions by binding to serine/threonine (S/T) kinase
receptors. These receptors are divided in three types of S/T receptors based upon their relative
molecular weights of 55 kDa (type I), 80 kDa (type II) and 300 kDa (type III) found in binding studies
(Cheifetz, et al., 1987; Massagué, 1990, 1992). The type I and type II receptors bind the ligand and
mediate downstream signaling while the type III receptor modulates signaling by binding the ligand
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Figure 2.2: Signaling of TGFb family members through the TGFb/activin-like and BMP-like signaling pathway. 
TGFb and activin activate Smad2 and/or Smad3 after binding to their type II receptors (TbRII, ActRII or
ACTRIIB) which form a complex with ALK5 or ALK4. BMPs activate Smad1, Smad5 or Smad8 through a
receptor complex containing BMPRII and ALK2, ALK3 or ALK6. Upon activation of the receptor-specific
Smads (R-Smads), a complex with Smad4 is formed. This complex translocates to the nucleus and regulates
gene transcription. The inhibitory Smad6 and Smad7 antagonize signaling. Smad7 inhibits both signaling
pathways, whereas Smad6 preferentially inhibits BMP-like signaling. (Figure adapted from J.A. Visser.)
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Smad activation and signaling
The MH2 domain of receptor-specific Smads contains a conserved Ser-Ser-X-Ser motif which is
phosphorylated by the type I receptor (Macias-Silva, et al., 1996; Kretzschmar, et al., 1997; Souchelnytskyi,
et al., 1998). Phosphorylation of this motif disrupts the interaction between the MH1 and MH2 domains,
thereby activating the protein. The activated receptor-specific Smad forms a hetero-oligocomplex
with the common-mediator Smad4 and translocates to the nucleus where it regulates gene transcription
either through direct binding to specific DNA-sequences or through interaction with other DNA-binding
proteins (Baker and Harland, 1996; Lagna, et al., 1996; Liu, et al., 1996, 1997; Hata, et al., 1997;
Meersseman, et al., 1997; Wu, et al., 1997, 2001; Kawabata, et al., 1998; Lebrun, et al., 1999; Masuyama,
et al., 1999; Qin, et al., 2001, 2002). The MH1 domain acts as a negative regulator of Smad activation
since its interaction with the MH2 domain prevents binding of the non-phosphorylated receptor-specific
Smad to a common-mediator Smad. Furthermore, the MH1 domain is involved in maintaining a
cytoplasmic localization of non-activated receptor-specific Smads, because receptor-specific Smads
lacking the MH1 domain translocate to the nucleus without being phosphorylated (Baker and
Harland, 1996). 
Based upon which Smad is used by TGFb superfamily members, two main signaling pathways can
be distinguished. Smad2 and Smad3 are activated by TGFbs and activins through ALK4, ALK5 or
ALK7 (TGFb/activin-like signal pathway). On the other hand, Smad1, Smad5 and Smad8 are activated
by BMPs through ALK2, ALK3 and ALK6, referred to as the BMP-like signal pathway (Figure 2.2).
The only known exception is ALK1, a type I receptor for TGFb, which activates Smad1 instead of
Smad2 or Smad3. Activation of Smad1 by ALK1 is possible due to sequences in the kinase domain of
this receptor, which also can be found in ALK2 (Chen and Massagué, 1999). Furthermore, recently it
has been reported that GDF9 binds to the BMPRII while activating Smad2 (Vitt, et al., 2002; Kaivo-Oja,
et al., 2003; Roh, et al., 2003). Until now, the type I receptor involved in GDF9-signaling has not been
identified. However, these results suggest that type I receptors signaling in the BMP-like signaling
pathway can phosphorylate Smad2 or that GDF9 recruits a type I receptor from the TGFb-like
signaling pathway into a complex with BMPRII.
Inhibitory Smads
The signaling of TGFb family members through receptor-specific and common-mediator Smads is
antagonized by the inhibitory Smad6 and Smad7. Smad7 is a general inhibitor of TGFb/activin-like
and BMP-like signaling pathways (Hayashi, et al., 1997; Nakao, et al., 1997; Itoh, et al., 1998; Ishisaki,
et al., 1999; Hanyu, et al., 2001), while Smad6 preferentially inhibits the BMP-like signaling pathway
(Figure 2.2) (Hata, et al., 1998; Itoh, et al., 1998; Ishisaki, et al., 1999; Hanyu, et al., 2001).
The antagonistic effect of Smad6 and Smad7 on signaling is achieved by binding of these inhibitory
Smads to the activated type I receptor, in this way preventing recruitment and phosphorylation of
receptor-specific Smads (Hayashi, et al., 1997; Imamura, et al., 1997; Nakao, et al., 1997; Souchelnytskyi,
et al., 1998; Lebrun, et al., 1999; Hanyu, et al., 2001). However, Smad6 also blocks Smad-signaling by
forming a complex with the receptor-activated Smad1, thereby inhibiting the Smad1-Smad4 complex
formation (Hata, et al., 1998). In addition, Smad6 inhibits transcriptional activity of receptor-specific
Smads by interacting with transcription factors (Bai, et al., 2000).
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Until now, five type II en seven type I receptors have been identified in mammals. Table 2.1 shows an
overview of ligands and their receptors. TGFbs signal through the TGFb type II receptor (TbRII)
(Attisano, et al., 1993; Franzen, et al., 1993), while the activin type II receptors type II and type IIB
(ActRII and ActRIIB) are used by activins and BMPs (Attisano, et al., 1992, 1993; Yamashita, et al.,
1995). In contrast, the BMP type II receptor (BMPRII) specifically signals for BMPs (ten Dijke, et al.,
1994; Rosenzweig, et al., 1995; Yamashita, et al., 1995). The type II receptor for AMH (AMHRII) is
the fifth known type II receptor (Baarends, et al., 1994; di Clemente, et al., 1994b).
Based on similarities of the amino acid sequences, three different groups can be distinguished within
the seven type I receptors. Activin-receptor like kinase (ALK)4 (also termed ActRIB), -5 (also termed
TbRI) and –7 form one group. ALK4 signals for activins and nodal proteins which play an important
role in mesendoderm formation and left-right patterning during vertebrate development, whereas
ALK7 only signals for nodal (Attisano, et al., 1992, 1993; Franzen, et al., 1993; Reissmann, et al., 2001).
ALK5 serves as a type I receptor for TGFbs (Franzen, et al., 1993). The second group is formed by
ALK3 and ALK6 (also known as BMPRIA and BMPRIB respectively) which both are involved in BMP
and AMH-signaling (Koenig, et al., 1994; ten Dijke, et al., 1994; Gouédard, et al., 2000; Jamin, et al.,
2002). Finally, ALK1 and ALK2 form the third group of type I receptors. ALK2 (ActRIA) is a type I
receptor for BMPs and AMH (ten Dijke, et al., 1994; Rosenzweig, et al., 1995; Yamashita, et al., 1995;
Clarke, et al., 2001; Visser, et al., 2001), while ALK1 signals for TGFbs in endothelial cells (Chen and
Massagué, 1999; Oh, et al., 2000).
2.3.2 Downstream mediators of TGFb family signaling 
The major downstream signaling molecules in TGFb-signaling are the Smad proteins. These proteins
can be divided into three subclasses: receptor-specific Smads (Smad1, 2, 3, 5 and 8), common-partner
Smads (Smad4) or inhibitory Smads (Smad6 and 7). Receptor-specific and common-mediator Smad
proteins contain two regions of homology, the N-terminal Mad homology 1 (MH1) domain and the
C-terminal Mad homology domain 2 (MH2). The two domains are separated by a proline-rich region,
named the linker region. Inhibitory Smads only contain the MH2 domain and linker region (Heldin,
et al., 1997). 
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Table 2.1: Ligand-receptor combinations of the TGFb superfamily.
Ligand: Type II receptor: Type I receptor: References:
TGFbs TbRII ALK5 Attisano et al., 1993; Franzen et al., 1993;
ALK1 Chen and Massagué, 1999; Oh et al., 2000
activins ActRII ALK4 Attisano et al., 1992, 1993; Franzen et al., 1993;
ActRIIB (ALK2) Yamashita et al., 1995
nodal ActRIIB ALK4 Reissmann et al., 2001
ALK7
BMPs ActRII ALK2 Attisano et al., 1992, 1993; Koenig et al., 1994;
ActRIIB ALK3 ten Dijke et al., 1994; Rosenzweig et al., 1995;
BMPRII ALK6 Yamashita et al., 1995
AMH AMHRII ALK2 Baarends et al., 1994; di Clemente et al., 1994;
ALK3 Gouédard et al., 2000; Clarke et al., 2001; Visser et al., 2001;
ALK6 Jamin et al., 2002
Smad activation and signaling
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The antagonistic effect of Smad6 and Smad7 on signaling is achieved by binding of these inhibitory
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forming a complex with the receptor-activated Smad1, thereby inhibiting the Smad1-Smad4 complex
formation (Hata, et al., 1998). In addition, Smad6 inhibits transcriptional activity of receptor-specific
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Table 2.1: Ligand-receptor combinations of the TGFb superfamily.
Ligand: Type II receptor: Type I receptor: References:
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ALK6 Jamin et al., 2002
BMP1 is a metalloproteinase that cleaves free chordin and chordin bound to BMPs, thereby releasing
the BMPs (Piccolo, et al., 1997). 
The binding of ligand to the receptors is positively regulated by endoglin and betaglycan (also called
TGFb type III receptor). Both endoglin and betaglycan are membrane bound proteins which enhance
TGFb binding to the type II receptor by binding the ligand and presenting it to the type II receptor.
Endoglin may be a specific accessory protein for ALK1 because mutations in these genes result in similar
phenotypes. However, the ligand for endoglin and ALK1 may not have been identified yet, since only
a weak interaction of TGFb is found for these receptors (Massagué, 1998). 
At the receptor level, signaling is negatively regulated by binding of Smad6 and Smad7 to the type
I receptor, thereby preventing phosphorylation of Smad proteins (see section 2.3.2). Furthermore, Smad6
and Smad7 inhibit TGFb-signaling by inducing ubiquitination of the type I receptors. This is achieved
by binding of Smad6 and Smad7 to Smad ubiqitination regulatory factor 1 and 2 (Smurf1 and
Smurf2). This Smurf-Smad complex moves to the membrane and binds to the type I receptor, where
Smurf induces degradation of the type I receptor by ubiquitination of this receptor (Kavsak, et al.,
2000; Ebisawa, et al., 2001; Hanyu, et al., 2001). Interestingly, an antagonist of Smad6 has been
identified, which is called associated molecule with SH3 domain of a signal-transducing adaptor
molecule (AMSH). Its antagonistic effect is achieved by binding Smad6, thereby preventing Smad6 to
bind to the activated type I receptor (Itoh, et al., 2001) and regulates the inhibitory effect of Smad6.
Another protein which inhibits downstream signaling is BMP and activin membrane-bound
inhibitor (BAMBI). This protein has a high homology with the TGFb superfamily type I receptors but
lacks the intracellular kinase domain, which is necessary for type I receptor activation. Therefore,
BAMBI inhibits signaling of TGFb superfamily members by forming a complex with type I receptors
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Smad6 and Smad7 have an important role in the control of signaling of TGFb superfamily members.
Overexpression of these inhibitory Smads is found in cancer cells and expression level of Smad7 is a
prognostic marker in colorectal cancer (Kleeff, et al., 1999a, 1999b; Ozawa, et al., 2001; Boulay, et al.,
2003; Cerutti, et al., 2003). The expression of both inhibitory Smads is stimulated by TGFb superfamily
members and in this way a negative feedback loop is formed (Nakao, et al., 1997; Afrakhte, et al.,
1998; Ishisaki, et al., 1998, 1999; Itoh, et al., 1998; Takase, et al., 1998).
Other downstream mediators of TGFb superfamily signaling
In addition to the Smad proteins as downstream mediators, TGFb superfamily members may also
signal through other signaling pathways. The most important alternative signaling pathway is the
mitogen-activated protein kinase (MAPK) pathway, which is involved in cell proliferation and
differentiation (Mulder, 2000). TGFb can activate all three distinct groups of MAPKs, the extracellular
signal-regulated kinases (ERKs), c-JunN-terminal kinases/stress-activated protein kinases (JNKs/Sapks)
and p38 MAPK (Mulder, 2000), while BMPs can activate the p38 MAPK- and ERK-signaling pathway
(Gallea, et al., 2001; Goswami, et al., 2001; Lai and Cheng, 2002; Lee, et al., 2002). However, the exact
mechanism of activation of MAPKs by TGFb superfamily members remains unknown. Furthermore,
also signaling through trimeric guanine-nucleotide binding proteins (G-proteins) has been described
(Howe, et al., 1989; Kataoka, et al., 1993).
Recently, the b-catenin signaling pathway was identified as a signaling pathway through which
AMH, a member of the TGFb superfamily, mediates its effect. During Müllerian duct regression (see
section 2.5), b-catenin accumulates in the cytoplasm of mesenchymal cells which are exposed to
AMH (Allard, et al., 2000). Furthermore, it is suggested that b-catenin together with lymphoid enhancer
factor 1 (LEF1) may influence gene expression in the mesenchymal cells of the Müllerian ducts
(Allard, et al., 2000). However, the exact mechanism of the activation of b-catenin by AMH still needs
to be elucidated. 
2.4 MODULATION OF TGFb-SIGNALING
Signaling of TGFb superfamily members can be regulated, both positively and negatively, at several
levels. Regulation by Smad6 and Smad7 at the receptor level has already been described in section 2.3.2.
However, also binding of the ligand to its receptor can be regulated as well as signaling downstream
of the receptor (Figure 2.3).
Ligand binding of TGFb superfamily members to the receptor can be inhibited as well as facilitated.
Several antagonists of TGFb superfamily members, such as follistatin, noggin, chordin and members
of the DAN family (e.g. cerberus, drm/gremlin, dante) have been identified. These proteins achieve their
antagonistic effect by binding to the ligand, thereby preventing binding to the receptors. Follistatin
and follistatin-like protein are glycoproteins that bind activins and BMPs (de Winter, et al., 1996;
Iemura, et al., 1998; Tsuchida, et al., 2000). Noggin, chordin and DAN family members block interaction
of BMPs but not of TGFbs or activins to their receptor (Piccolo, et al., 1996, 1999; Zimmerman, et al.,
1996; Hsu, et al., 1998; Yokouchi, et al., 1999). Interestingly, the antagonistic effect of chordin can be
overcome by bone morphogenetic protein 1 (BMP1, also known as Xolloid in Xenopus). 
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Figure 2.3: Modulation of signaling by TGFb superfamily members.
Signaling can be modulated at three different levels. Binding of the ligand to the receptor is stimulated
by endoglin and betaglycan, while follistatin, noggin and DAN family members inhibit ligand-receptor
binding. The inhibitory effect of noggin can be antagonized by BMP1. Activation of the type I receptor
is inhibited by Smurf proteins, BAMBI and TRIP-1, TRAP-1, STRAP or PP2A. Furthermore, activation of
the receptor-specific Smads (R-Smads), which results in gene transcription regulation, can be modulated.
Smad6, Smad7, Smurf proteins and SARA inhibit activation of receptor specific Smads. AMSH
antagonizes the action of Smad6. In contrast, MAPK has shown to be involved in activation of R-Smads.
BMP1 is a metalloproteinase that cleaves free chordin and chordin bound to BMPs, thereby releasing
the BMPs (Piccolo, et al., 1997). 
The binding of ligand to the receptors is positively regulated by endoglin and betaglycan (also called
TGFb type III receptor). Both endoglin and betaglycan are membrane bound proteins which enhance
TGFb binding to the type II receptor by binding the ligand and presenting it to the type II receptor.
Endoglin may be a specific accessory protein for ALK1 because mutations in these genes result in similar
phenotypes. However, the ligand for endoglin and ALK1 may not have been identified yet, since only
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At the receptor level, signaling is negatively regulated by binding of Smad6 and Smad7 to the type
I receptor, thereby preventing phosphorylation of Smad proteins (see section 2.3.2). Furthermore, Smad6
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Figure 2.3: Modulation of signaling by TGFb superfamily members.
Signaling can be modulated at three different levels. Binding of the ligand to the receptor is stimulated
by endoglin and betaglycan, while follistatin, noggin and DAN family members inhibit ligand-receptor
binding. The inhibitory effect of noggin can be antagonized by BMP1. Activation of the type I receptor
is inhibited by Smurf proteins, BAMBI and TRIP-1, TRAP-1, STRAP or PP2A. Furthermore, activation of
the receptor-specific Smads (R-Smads), which results in gene transcription regulation, can be modulated.
Smad6, Smad7, Smurf proteins and SARA inhibit activation of receptor specific Smads. AMSH
antagonizes the action of Smad6. In contrast, MAPK has shown to be involved in activation of R-Smads.
PMDS is a rare form of male pseudohermaphrodism in which the Müllerian ducts have failed to regress.
Furthermore, male mice in which the AMHRII gene was disrupted, retain their Müllerian ducts,
similar to the AMH null mice (Behringer, et al., 1994; Mishina, et al., 1996). In addition, Müllerian
ducts regress in female mice which overexpress AMH during embryogenesis (Behringer, et al., 1990).
These in vivo data show that the AMHRII is the type II receptor for AMH in Müllerian duct regression.
Recent studies have shed a light on the identity of the AMH type I receptor(s) and its downstream
signaling components. Results of these studies are described below.
2.5.1 AMH-signaling in vitro
As described in section 2.3, two main signaling pathways can be distinguished for TGFb family members:
the TGFb/activin-like or BMP-like signaling pathway. Recently, it was found that also AMH signals
through the BMP-like signaling pathway (Visser, et al., 2001). In the mouse embryonic carcinoma cell
line P19, AMH stimulates the BMP-responsive mouse Tlx-2 promoter reporter but is unable to
activate the TGFb/activin-responsive A3-Luc promoter construct (Visser, et al., 2001). Similar results
were obtained by two other groups who found that AMH stimulates the BMP-responsive Xvent
promotor construct in P19 cells and not the TGFb/activin-responsive 3TP-Luc construct (Gouédard,
et al., 2000; Clarke, et al., 2001). The stimulation could only be achieved upon cotransfection of the
AMHRII but not with other type II receptors like BMPRII or ActRII. These in vitro data clearly show
that AMHRII is the only type II receptor through which AMH signals (Visser, et al., 2001). 
Three type I receptors ALK2, ALK3 and ALK6 have been identified as candidate AMH type I
receptors by several studies. Transfection of all type I receptors in P19 cells together with the Tlx2-Luc
reporter revealed that cotransfection of ALK2 enhanced AMH-signaling. Cotransfection of ALK6 only
showed a slight increase in AMH-signaling whereas ALK3 even had an inhibitory effect on AMH-signaling
(Visser, et al., 2001). 
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(except ALK2) and thereby preventing formation of active receptor complexes (Onichtchouk, et al., 1999).
In addition, several other receptor-interacting proteins have been found which negatively modulate
signaling of TGFb superfamily members, such as TGFb-receptor interacting protein 1 (TRIP-1),
TbRI-associated protein 1 (TRAP-1), serine/threonine kinase receptor-associated protein (STRAP)
and a regulatory subunit of protein phosphatase 2A (PP2A). However, little is known about their
mechanisms of action (reviewed by Massagué and Chen, 2000).
Downstream of the receptors, signaling is regulated by affecting the access of Smads to the receptor.
Smad anchor for receptor activation (SARA) binds receptor-specific Smad proteins and presents
these Smads to the activated receptor complex. In this way, phosphorylation of receptor-specific
Smads is increased, as was shown in cells overexpressing SARA (Tsukazaki, et al., 1998). In addition,
Smad levels in the cell are regulated by the ubiquitin ligases Smurf1 and Smurf2. Smurf1 interacts
preferentially with Smads which signal in the BMP-like signaling pathway (Smad1, 5 and 8), whereas
Smurf2 binds Smads signaling in the TGFb/activin-like signaling pathway (Smad2 and 3). Upon the
formation of the receptor-specific Smad/Smurf complex, Smad proteins are ubiquitinated and
degraded (Zhu, et al., 1999; Bonni, et al., 2001; Ebisawa, et al., 2001). Furthermore, it has been shown
that the MAPK pathway modulates TGFb-signaling at the level of Smad proteins. The Smad1 protein
contains four ERK consensus phosphorylation sites, which are necessary for activation of the SBE-Luc
promotor construct by TGFb (Mulder, 2000). 
2.5 AMH SIGNAL TRANSDUCTION
AMH plays an important role during folliculogenesis in the ovary, since it inhibits primordial follicle
recruitment and lowers the sensitivity of large pre-antral and antral follicles for FSH (see Chapter 1).
However, until recently little was known about the signaling pathway by which AMH achieves these
effects. The only identified mediator in AMH-signaling was the AMHRII (Baarends, et al., 1994; di
Clemente, et al., 1994b). Most knowledge about the AMH-signaling pathway was obtained by studying
Müllerian duct regression. 
The Müllerian ducts , the anlagen of the female genital tract, are formed during embryogenesis.
AMH, produced by the Sertoli cells in the fetal testis, causes the regression of the Müllerian ducts by
inducing apoptosis of the epithelial cells (Jost, 1947; Visser, et al., 1998; Roberts, et al., 1999; Allard,
et al., 2000). However, the AMHRII is expressed by the mesenchymal and not by the epithelial cells
of the Müllerian ducts (Baarends, et al., 1994; di Clemente, et al., 1994b), suggesting that AMH
induces a mesenchymal signal to the epithelial cells, which causes apoptosis in these cells. Indeed,
results of in vitro co-culture of mesenchymal and epithelial cells of Müllerian ducts suggest that AMH
stimulates the expression of a death factor or represses the expression of a survival factor in the
mesenchymal cells which, after being secreted, influences the survival of the epithelial cells (Figure 2.4)
(Roberts, et al., 1999).
Ultimate proof that the AMHRII is the true type II receptor for AMH, was obtained by the
identification of several mutations in AMHRII gene in persistent Müllerian duct syndrome (PMDS)
patients which phenotype is similar to mutations in the AMH gene (Knebelmann, et al., 1991; 
Carré-Eusèbe, et al., 1992; Imbeaud, et al., 1994, 1995, 1996). 
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Figure 2.4: AMH induces apoptosis of epithelial cells in Müllerian duct regression.
AMHRII is expressed by the mesenchymal cells of the Müllerian ducts. By stimulating the expression of a
death factor or by inhibiting the expression of a survival factor in the mesenchymal cells, apoptosis in
the epithelial cells is induced. (Figure adapted from Roberts et. al., Copyright 2002, The Company of
Biologists Ltd).
PMDS is a rare form of male pseudohermaphrodism in which the Müllerian ducts have failed to regress.
Furthermore, male mice in which the AMHRII gene was disrupted, retain their Müllerian ducts,
similar to the AMH null mice (Behringer, et al., 1994; Mishina, et al., 1996). In addition, Müllerian
ducts regress in female mice which overexpress AMH during embryogenesis (Behringer, et al., 1990).
These in vivo data show that the AMHRII is the type II receptor for AMH in Müllerian duct regression.
Recent studies have shed a light on the identity of the AMH type I receptor(s) and its downstream
signaling components. Results of these studies are described below.
2.5.1 AMH-signaling in vitro
As described in section 2.3, two main signaling pathways can be distinguished for TGFb family members:
the TGFb/activin-like or BMP-like signaling pathway. Recently, it was found that also AMH signals
through the BMP-like signaling pathway (Visser, et al., 2001). In the mouse embryonic carcinoma cell
line P19, AMH stimulates the BMP-responsive mouse Tlx-2 promoter reporter but is unable to
activate the TGFb/activin-responsive A3-Luc promoter construct (Visser, et al., 2001). Similar results
were obtained by two other groups who found that AMH stimulates the BMP-responsive Xvent
promotor construct in P19 cells and not the TGFb/activin-responsive 3TP-Luc construct (Gouédard,
et al., 2000; Clarke, et al., 2001). The stimulation could only be achieved upon cotransfection of the
AMHRII but not with other type II receptors like BMPRII or ActRII. These in vitro data clearly show
that AMHRII is the only type II receptor through which AMH signals (Visser, et al., 2001). 
Three type I receptors ALK2, ALK3 and ALK6 have been identified as candidate AMH type I
receptors by several studies. Transfection of all type I receptors in P19 cells together with the Tlx2-Luc
reporter revealed that cotransfection of ALK2 enhanced AMH-signaling. Cotransfection of ALK6 only
showed a slight increase in AMH-signaling whereas ALK3 even had an inhibitory effect on AMH-signaling
(Visser, et al., 2001). 
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(except ALK2) and thereby preventing formation of active receptor complexes (Onichtchouk, et al., 1999).
In addition, several other receptor-interacting proteins have been found which negatively modulate
signaling of TGFb superfamily members, such as TGFb-receptor interacting protein 1 (TRIP-1),
TbRI-associated protein 1 (TRAP-1), serine/threonine kinase receptor-associated protein (STRAP)
and a regulatory subunit of protein phosphatase 2A (PP2A). However, little is known about their
mechanisms of action (reviewed by Massagué and Chen, 2000).
Downstream of the receptors, signaling is regulated by affecting the access of Smads to the receptor.
Smad anchor for receptor activation (SARA) binds receptor-specific Smad proteins and presents
these Smads to the activated receptor complex. In this way, phosphorylation of receptor-specific
Smads is increased, as was shown in cells overexpressing SARA (Tsukazaki, et al., 1998). In addition,
Smad levels in the cell are regulated by the ubiquitin ligases Smurf1 and Smurf2. Smurf1 interacts
preferentially with Smads which signal in the BMP-like signaling pathway (Smad1, 5 and 8), whereas
Smurf2 binds Smads signaling in the TGFb/activin-like signaling pathway (Smad2 and 3). Upon the
formation of the receptor-specific Smad/Smurf complex, Smad proteins are ubiquitinated and
degraded (Zhu, et al., 1999; Bonni, et al., 2001; Ebisawa, et al., 2001). Furthermore, it has been shown
that the MAPK pathway modulates TGFb-signaling at the level of Smad proteins. The Smad1 protein
contains four ERK consensus phosphorylation sites, which are necessary for activation of the SBE-Luc
promotor construct by TGFb (Mulder, 2000). 
2.5 AMH SIGNAL TRANSDUCTION
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results of in vitro co-culture of mesenchymal and epithelial cells of Müllerian ducts suggest that AMH
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Figure 2.4: AMH induces apoptosis of epithelial cells in Müllerian duct regression.
AMHRII is expressed by the mesenchymal cells of the Müllerian ducts. By stimulating the expression of a
death factor or by inhibiting the expression of a survival factor in the mesenchymal cells, apoptosis in
the epithelial cells is induced. (Figure adapted from Roberts et. al., Copyright 2002, The Company of
Biologists Ltd).
to proceed normally up to the pre-ovulatory stage where the cumulus expansion is impaired, causing
the infertility of ALK6 null female mice (Yi, et al., 2001). In Booroola sheep, a naturally occurring mutation
in the kinase domain of the ALK6 gene was found, which results in an increased ovulation rate and
litter size (Davis, et al., 1982; Piper and Bindon, 1982; Souza, et al., 2001). The ALK6-mutation in Booroola
sheep causes a less active ALK6, resulting in a decreased signaling of BMPs (Fabre, et al., 2003). This
could explain the differences found in phenotype with the ALK6 null mice, which do not contain a
(partially) active ALK6 receptor. Ovaries of homozygous carriers of the Booroola mutation contain the
same number of antral and non-atretic follicles compared to non-carriers. However, the number of
pre-ovulatory follicles is increased. Furthermore, these pre-ovulatory follicles are smaller and contain
less granulosa cells than those in control animals (McNatty, et al., 1985). Thus, the mutation in the ALK6
gene mainly affects the pre-ovulatory follicles. Therefore, like the ALK6 null mice, this sheep model
does not suggest involvement of ALK6 in AMH-signaling, since AMH-effects are found on primordial
and small non-selected follicles.
The conclusion that ALK6 is not involved in Müllerian duct regression, was confirmed by urogenital
ridge culture. Tsuji and colleagues showed that treatment of female embryonic urogenital ridges with
AMH resulted in the regression of the Müllerian ducts (Tsuji, et al., 1992). Inhibition of the ALK6
expression by morpholino antisense ALK6 did not prevent the regression of the Müllerian ducts,
which shows that ALK6 expression is not necessary for this regression (Visser, et al., 2001). However,
the regression of the Müllerian ducts could be prevented using a morpholino antisense ALK2, suggesting
that ALK2 is involved in Müllerian duct regression and thus AMH-signaling (Visser, et al., 2001).
To circumvent embryonic lethality an ALK3 conditional knockout mouse has been developed.
This conditional knockout mouse was generated using the Cre-loxP system. An AMHRII-Cre mouse,
carrying the Cre gene under control of the AMHRII promoter, was crossbred to a mouse carrying the
ALK3 gene flanked by loxP sites (Jamin, et al., 2002). Thus, in the conditional knockout mice, cells
which express the AMHRII do not express ALK3 and this results in male mice with PMDS showing
that ALK3 is necessary in vivo for Müllerian duct regression (Jamin, et al., 2002). However, ALK3 is
not the only type I receptor through which Müllerian duct regression can be induced. When the ALK3
conditional knockout mouse is crossbred to a mice overexpressing AMH no PDMS is found anymore,
suggesting that another type I receptor may partially rescue the PMDS phenotype (Jamin, et al., 2003).
One candidate is ALK2, since this receptor is involved in Müllerian duct regression in vitro cultured
urogenital ridges (Visser, et al., 2001). 
In summary, the in vivo and in vitro data show that AMH may signal through ALK2 and ALK3,
but not through ALK6 in the Müllerian ducts. In the ovary, the AMH-signaling pathway still needs to
be determined. However, based on the ovarian phenotype in ALK6 null mice, it is unlikely that ALK6
is the type I receptor involved in AMH-signaling. Future studies should reveal the type I receptor(s)
for AMH in the ovary. 
2.5.3 Expression of type I receptors and Smads in 
AMH target tissue 
Involvement of candidate type I receptors and Smad proteins in AMH-signaling requires its expression
in AMH target tissue. AMHRII is expressed in the mesenchymal cells of the Müllerian ducts and in the
granulosa cells of healthy primary and pre-antral follicles in mouse and rat ovary (Baarends, et al., 1994;
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The preference for ALK2 in AMH-signaling was supported in a dominant-negative strategy in P19
cells. Increasing concentrations of dominant-negative ALK2 or ALK6 receptors, which cannot be
activated due to a truncated kinase domain, were transfected in P19 cells. Increasing amounts of
dominant-negative ALK2 inhibited AMH induced Tlx2-Luc activation, while the dominant-negative
ALK6 had no effect (Visser, et al., 2001). Similarly, the truncated ALK2, but not ALK3 or ALK6, was
able to inhibit AMH-signaling in P19 cells using the Tlx2-Luc promoter (Clarke, et al., 2001). These
results suggest that ALK2 could be a type I receptor involved in AMH-signaling.
However, also ALK6 has been suggested to be an AMH type I receptor. An AMH-dependent
interaction between AMHRII and ALK6 was observed in the CHO-3W cell line, whereas no interaction
between AMHRII and ALK2 or ALK3 was found. Furthermore, transfection of a dominant-negative
ALK6 in CHO-3W cells inhibited AMH-induced stimulation of the Xvent-Luc reporter (Gouédard,
et al., 2000) suggesting a role for ALK6 in AMH-signaling. However, a potential problem with
overexpression of type I receptors in cell lines is the formation of non-specific receptor interactions.
Indeed, overexpression of AMHRII results in ligand-independent interactions with all type I receptors
(Visser, 2003). The P19 cell line contains an endogenous type I receptor for AMH, since AMH can
activate the Tlx2-Luc reporter after transfection of AMHRII in these cells (Visser, et al., 2001).
Therefore, in order to determine whether ALK2 or ALK6 is a AMH type I receptor, these cells were
treated with antisense oligos for ALK2 or ALK6. In agreement with the results of the dominant-negative
type I receptor experiments in P19 cells, the morpholino antisense ALK2 oligomers completely
inhibited AMH-induced Tlx-2 promoter activity, whereas antisense ALK6 treatment had no effect
(Visser, et al., 2001). These results prove that ALK2, besides being a BMP type I receptor, also functions
as a AMH type I receptor in P19 cells. 
As described in section 2.3.2, BMP-like signaling is mediated through the downstream signaling
molecules Smad1, Smad5 and Smad8. Therefore, these Smads are also candidate downstream mediators
in AMH-signaling. Indeed, Smad1 and Smad5 augmented AMH-signaling in P19 cells and this
signaling was inhibited by dominant-negative Smad5. In contrast, Smad2, a TGFb/activin-like signaling
Smad, was unable to affect AMH-signaling in P19 cells (Visser, et al., 2001). Using the Gal4-Smad1
fusion protein with a Gal4-reporter construct, Clarke and colleagues showed that AMH-signaling can
be mediated through Smad1 (Clarke, et al., 2001). Furthermore, phosphorylation of Smad1 was shown
in Sertoli- and Leydig derived cell lines upon AMH exposure (Gouédard, et al., 2000). These results
show that Smad1 and Smad5 are AMH downstream mediators.
In conclusion, in vitro experiments have shown that AMH signals through the BMP-like but not
the TGFb/activin-like signaling pathway. In the next section experiments are described in which
AMH-signaling in vivo was investigated.
2.5.2 AMH-signaling in vivo
The ultimate proof for a role of the candidate type I receptors in AMH-signaling might be obtained
from knockout mice. Unfortunately, genetic disruption of most type I receptors results in early
embryonic lethality. Thus, no information in Müllerian duct regression or gonadal function could be
obtained from these mice. One exception is the ALK6 null mice, which are viable but display major
defects in the appendicular skeleton (Yi, et al., 2000). No abnormalities in Müllerian duct regression
in male ALK6 null mice are found (Clarke, et al., 2001). Furthermore, follicular development seems
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could explain the differences found in phenotype with the ALK6 null mice, which do not contain a
(partially) active ALK6 receptor. Ovaries of homozygous carriers of the Booroola mutation contain the
same number of antral and non-atretic follicles compared to non-carriers. However, the number of
pre-ovulatory follicles is increased. Furthermore, these pre-ovulatory follicles are smaller and contain
less granulosa cells than those in control animals (McNatty, et al., 1985). Thus, the mutation in the ALK6
gene mainly affects the pre-ovulatory follicles. Therefore, like the ALK6 null mice, this sheep model
does not suggest involvement of ALK6 in AMH-signaling, since AMH-effects are found on primordial
and small non-selected follicles.
The conclusion that ALK6 is not involved in Müllerian duct regression, was confirmed by urogenital
ridge culture. Tsuji and colleagues showed that treatment of female embryonic urogenital ridges with
AMH resulted in the regression of the Müllerian ducts (Tsuji, et al., 1992). Inhibition of the ALK6
expression by morpholino antisense ALK6 did not prevent the regression of the Müllerian ducts,
which shows that ALK6 expression is not necessary for this regression (Visser, et al., 2001). However,
the regression of the Müllerian ducts could be prevented using a morpholino antisense ALK2, suggesting
that ALK2 is involved in Müllerian duct regression and thus AMH-signaling (Visser, et al., 2001).
To circumvent embryonic lethality an ALK3 conditional knockout mouse has been developed.
This conditional knockout mouse was generated using the Cre-loxP system. An AMHRII-Cre mouse,
carrying the Cre gene under control of the AMHRII promoter, was crossbred to a mouse carrying the
ALK3 gene flanked by loxP sites (Jamin, et al., 2002). Thus, in the conditional knockout mice, cells
which express the AMHRII do not express ALK3 and this results in male mice with PMDS showing
that ALK3 is necessary in vivo for Müllerian duct regression (Jamin, et al., 2002). However, ALK3 is
not the only type I receptor through which Müllerian duct regression can be induced. When the ALK3
conditional knockout mouse is crossbred to a mice overexpressing AMH no PDMS is found anymore,
suggesting that another type I receptor may partially rescue the PMDS phenotype (Jamin, et al., 2003).
One candidate is ALK2, since this receptor is involved in Müllerian duct regression in vitro cultured
urogenital ridges (Visser, et al., 2001). 
In summary, the in vivo and in vitro data show that AMH may signal through ALK2 and ALK3,
but not through ALK6 in the Müllerian ducts. In the ovary, the AMH-signaling pathway still needs to
be determined. However, based on the ovarian phenotype in ALK6 null mice, it is unlikely that ALK6
is the type I receptor involved in AMH-signaling. Future studies should reveal the type I receptor(s)
for AMH in the ovary. 
2.5.3 Expression of type I receptors and Smads in 
AMH target tissue 
Involvement of candidate type I receptors and Smad proteins in AMH-signaling requires its expression
in AMH target tissue. AMHRII is expressed in the mesenchymal cells of the Müllerian ducts and in the
granulosa cells of healthy primary and pre-antral follicles in mouse and rat ovary (Baarends, et al., 1994;
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activated due to a truncated kinase domain, were transfected in P19 cells. Increasing amounts of
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Indeed, overexpression of AMHRII results in ligand-independent interactions with all type I receptors
(Visser, 2003). The P19 cell line contains an endogenous type I receptor for AMH, since AMH can
activate the Tlx2-Luc reporter after transfection of AMHRII in these cells (Visser, et al., 2001).
Therefore, in order to determine whether ALK2 or ALK6 is a AMH type I receptor, these cells were
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inhibited AMH-induced Tlx-2 promoter activity, whereas antisense ALK6 treatment had no effect
(Visser, et al., 2001). These results prove that ALK2, besides being a BMP type I receptor, also functions
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As described in section 2.3.2, BMP-like signaling is mediated through the downstream signaling
molecules Smad1, Smad5 and Smad8. Therefore, these Smads are also candidate downstream mediators
in AMH-signaling. Indeed, Smad1 and Smad5 augmented AMH-signaling in P19 cells and this
signaling was inhibited by dominant-negative Smad5. In contrast, Smad2, a TGFb/activin-like signaling
Smad, was unable to affect AMH-signaling in P19 cells (Visser, et al., 2001). Using the Gal4-Smad1
fusion protein with a Gal4-reporter construct, Clarke and colleagues showed that AMH-signaling can
be mediated through Smad1 (Clarke, et al., 2001). Furthermore, phosphorylation of Smad1 was shown
in Sertoli- and Leydig derived cell lines upon AMH exposure (Gouédard, et al., 2000). These results
show that Smad1 and Smad5 are AMH downstream mediators.
In conclusion, in vitro experiments have shown that AMH signals through the BMP-like but not
the TGFb/activin-like signaling pathway. In the next section experiments are described in which
AMH-signaling in vivo was investigated.
2.5.2 AMH-signaling in vivo
The ultimate proof for a role of the candidate type I receptors in AMH-signaling might be obtained
from knockout mice. Unfortunately, genetic disruption of most type I receptors results in early
embryonic lethality. Thus, no information in Müllerian duct regression or gonadal function could be
obtained from these mice. One exception is the ALK6 null mice, which are viable but display major
defects in the appendicular skeleton (Yi, et al., 2000). No abnormalities in Müllerian duct regression
in male ALK6 null mice are found (Clarke, et al., 2001). Furthermore, follicular development seems
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di Clemente, et al., 1994b). Furthermore, expression of AMHRII is found in theca cells of rat pre-antral
and small antral follicles (Ingraham, et al., 2000).
Initial studies mainly focused on expression patterns of AMH candidate type I receptors in the
Müllerian ducts. ALK2 and ALK6 are both expressed in the Müllerian ducts, however in different cell
types. In situ hybridizations showed ALK2 expression in the mesenchymal cells surrounding the
Müllerian ducts in mice and rats, thereby colocalizing with the AMHRII (He, et al., 1993; Clarke, 
et al., 2001; Visser, et al., 2001). In contrast, ALK6 mRNA expression is detected in the epithelial layer
and not in the mesenchymal cells of the Müllerian ducts (Dewulf, et al., 1995; Clarke, et al., 2001).
Furthermore, ALK2 is detected in male and female urogenital ridges and in fetal gonads of mice, while
ALK6 expression is absent in fetal gonads and is expressed at a lower level in the urogenital ridge
(Visser, et al., 2001). Thus, also based on the expression patterns in the Müllerian ducts, ALK2 is more
likely to be involved in AMH-signaling than ALK6. The expression pattern of ALK3 in the Müllerian
ducts still needs to be determined. However, based on the ALK3 conditional knockout mice, this receptor
is at least expressed by the mesenchymal cells in the Müllerian duct, which also express the AMHRII
(Jamin, et al., 2002).
In the ovary, ALK6 is expressed in oocytes of primordial and growing follicles and is highly
expressed in granulosa cells of antral follicles (Yi, et al., 2001; Erickson and Shimasaki, 2003). In
addition, a low expression of ALK6 is detected in theca cells (Erickson and Shimasaki, 2003). This
expression pattern differs from AMHRII, which is expressed in granulosa cells of healthy primary and
pre-antral follicles (Baarends, et al., 1995b) or in the theca cells of pre-antral and antral follicles
(Ingraham, et al., 2000). ALK3 is expressed in granulosa cells of primary follicles, secondary and
tertiary follicles, while oocytes of all follicles express this type I receptor. Furthermore, expression of
ALK3 in theca cells from pre-antral and larger follicles has been described (Erickson and Shimasaki,
2003, see also Chapter 5). Based on this expression pattern, ALK3 could mediate AMH-signaling,
since it is coexpressed with AMHRII. The expression pattern of the third BMP-like signaling type I
receptor, ALK2, still needs to be determined in the ovary (see Chapter 5).
The AMH downstream signaling proteins Smad1, Smad5 and Smad8 are expressed by the
mesenchymal cells of the Müllerian ducts, albeit that Smad5 is expressed at a lower level than Smad1
or Smad8 (Clarke, et al., 2001). Interestingly, a higher expression level of Smad8 mRNA was found in
mesenchymal cells of the Müllerian ducts in male compared to female mice fetuses, suggesting that
AMH may positively regulate its downstream signaling component (Clarke, et al., 2001). Thus, based
on the expression patterns, all three Smad proteins can be involved in AMH-signaling. The expression
patterns of the AMH receptor-specific Smad proteins in fetal and adult gonads still needs to be
determined.
In conclusion, the expression patterns of the type I receptors involved in the BMP-like signaling pathway,
suggest that ALK2 and ALK3 are strong candidate type I receptors for AMH-signaling. Involvement
of ALK6 in mediating the AMH signal cannot completely be excluded, but is less likely. These findings
are in agreement with observations from several in vitro and in vivo data. In addition, all three Smad
proteins involved in the BMP-like signaling pathway (Smad1, 5 and 8) are candidate downstream
mediators for AMH-signaling.
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ABSTRACT
Recruitment of primordial follicles is essential for female fertility, however, the exact mechanisms
regulating this process are largely unknown. Earlier studies using anti-Müllerian hormone-deficient
mice, suggested that anti-Müllerian hormone (AMH) is involved in the regulation of primordial follicle
recruitment. We tested this hypothesis in a neonatal ovary culture system, in which ovaries from 
2-day-old C57Bl/6J mice were cultured for 2 or 4 days in the absence or presence of AMH. Ovaries
from 2-day-old mice contain multiple primordial follicles, some naked oocytes, and no follicles at later
stages of development. We observed that in the cultured ovaries, either non-treated or AMH-treated,
follicular development progressed to the same extent as in in vivo ovaries of comparable age, confirming
the validity of our culture system. However, in the presence of AMH, cultured ovaries contained 40%
fewer growing follicles compared to control ovaries. A similar reduction was found after 4 days of
culture. Consistent with these findings, we noted lower inhibin a-subunit expression in AMH-treated
ovaries compared to untreated ovaries. In contrast, expression of AMHRII and the expression of oocyte
markers GDF9 and ZP3 were not influenced by AMH. 
Based on the results, we suggest that AMH inhibits initiation of primordial follicle growth and
therefore functions as an inhibitory growth factor in the ovary during these early stages of folliculogenesis.
INTRODUCTION
For female mammals, the finite number of primordial follicles available during reproductive life is
established during fetal development (human) (Peters, 1969) or just after birth (mouse, rat) (Peters,
1978; Ueno, et al., 1989). Factors involved in the initiation of primordial follicle growth, a process also
known as initial recruitment (McGee and Hsueh, 2000), have long remained unknown. Recently,
however, it was shown that stem cell factor (SCF, or kit-ligand) (Parrott and Skinner, 1999), growth
and differentiation factor 9 (GDF9) (Vitt, et al., 2000b), basic fibroblast growth factor (bFGF) (Nilsson,
et al., 2001) and nerve growth factor (NGF) (Dissen, et al., 2001) promote initiation of primordial
follicle growth. Also anti-Müllerian hormone (AMH) has been implicated in primordial follicle
recruitment from analysis of AMH null ovaries (Durlinger, et al., 1999). AMH is a member of the
transforming growth factor-b (TGFb) superfamily of growth and differentiation factors (Cate, et al.,
1986) and is responsible for Müllerian duct regression during male fetal development (Jost, 1947).
This ligand-receptor system is also found in the ovary with expression of both the AMH ligand and
its type II receptor (AMHRII) postnatally in granulosa cells of mainly non-atretic pre-antral and small
antral follicles (Hirobe, et al., 1992; Baarends, et al., 1995a). In addition, AMHRII is also expressed in
the prenatal ovary (Baarends, et al., 1994). Examination of ovarian follicles in AMH-deficient female
mice revealed lower numbers of primordial follicles and more growing follicles compared to wild-type
littermates. These findings led to the proposal that AMH inhibits primordial follicle recruitment
(Durlinger, et al., 1999).
In this study, we examined the ability of AMH to inhibit primordial follicle recruitment in cultured
neonatal mouse ovaries. To this end, we developed a neonatal ovary culture system, in which follicular
development progresses to the same extent as in in vivo ovaries of comparable age. In this system we
characterized primordial follicle recruitment by the determination of the number of primordial and
growing follicles in neonatal ovaries after 2 and 4 days of culture in the presence or absence of recombinant
AMH. The effects of AMH on primordial follicle recruitment was also investigated by assessing
AMHRII and inhibin a-subunit transcript expression and additional oocyte-specific markers, such as
growth and differentiation factor 9 (GDF9) and zona pellucida protein 3 (ZP3).
Collectively, results from these studies suggest that AMH is a potent inhibitor of primordial
follicle recruitment.
MATERIALS AND METHODS
AMH production
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ABSTRACT
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stages of development. We observed that in the cultured ovaries, either non-treated or AMH-treated,
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ovaries compared to untreated ovaries. In contrast, expression of AMHRII and the expression of oocyte
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INTRODUCTION
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recruitment from analysis of AMH null ovaries (Durlinger, et al., 1999). AMH is a member of the
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AMH. The effects of AMH on primordial follicle recruitment was also investigated by assessing
AMHRII and inhibin a-subunit transcript expression and additional oocyte-specific markers, such as
growth and differentiation factor 9 (GDF9) and zona pellucida protein 3 (ZP3).
Collectively, results from these studies suggest that AMH is a potent inhibitor of primordial
follicle recruitment.
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(0.4 mg/ml) and neomycin G418 (0.4 mg/ml). At a cell confluence of about 80-90%, the medium was
replaced by medium without FCS. 
43
AMH inhibits initiation of primordial follicle growth
The ovaries were cultured at 37C in a humidified atmosphere containing 5% CO2 for 2 or 4 days. Of each
pair of ovaries (derived from one animal) one ovary was cultured in medium containing concentrated
medium of wild-type HEK293 cells (control), while the other ovary was cultured in medium containing
concentrated medium of HEK293 cells producing rat AMH (800 U/ml).
After 2 days of culture the medium was removed and fresh medium was added. At the end of the
culture period, the ovaries were either fixed for 2 hours in Bouin’s fixative or snap frozen in liquid
nitrogen and stored at –80C. Ovaries of 2-, 4- and 6-day-old C57Bl/6J mice were used for comparison
of the development of follicles in the culture experiments, hereby focusing on the developmental stage
of the follicles. No comparison was made regarding the number of primordial and growing follicles
between cultured ovaries and freshly isolated ovaries of comparable age.
Ovarian histology and follicle counting
To investigate the development of ovarian follicles in the cultured ovaries and to compare it with follicle
development in vivo, fresh and cultured ovaries were fixed for 2 h in Bouin’s fixative, embedded in
paraffin after routine histological procedures, and 8 µm serial sections were mounted on slides and
stained with hematoxylin and eosin.
Primordial follicles are non-growing follicles and consist of an oocyte partially or completely
encapsulated by flattened squamous pregranulosa cells. Early primary follicles have initiated development
and contain at least one cuboidal (enlarged) granulosa cells (Pedersen and Peters, 1968). In addition,
primordial follicles and early primary follicles were distinguished by size: follicles with a mean diameter
≤ 20 µm were classified as primordial follicles, while follicles with a mean diameter > 20 µm were
classified as growing follicles (primary and secondary follicles). This borderline of 20 µm was established
in a pilot experiment. The mean diameter of the follicles was determined by measuring two perpendicular
diameters (van Cappellen, et al., 1989). All primordial follicles were counted in every second section,
while in every second section of the growing follicles only those in which the nucleus of the oocyte
was clearly visible were counted. We did not attempt to distinguish between non-atretic and atretic
follicles, since at this stage of follicle development, atresia is not apparent by histology. Both 2 and 4
day culture experiments were performed twice.
Immunohistochemistry of AMH and inhibin a-subunit 
To determine the onset of AMH and inhibin a-subunit protein expression in vivo and in cultured
neonatal mouse ovaries, immunohistochemistry was performed on freshly isolated 1- to 6-day-old
mouse ovaries and on 2-day-old mouse ovaries cultured for 2 or 4 days. Of every group, 4 ovaries
were examined, which were derived from 2 different animals.
The ovaries were fixed for 2 h in Bouin's fixative, embedded in paraffin and 8 µm sections were
made. Sections were mounted on slides coated with 3-aminopropyl triethoxysilane (Sigma). After
deparaffinisation, sections were quenched for 12 min in 3% H2O2 /methanol solution to block endogenous
peroxidase activity and transferred to PBS. For AMH immunohistochemistry, the sections were
microwaved for 3x5 min at 700 W in 0.01 M citric acid monohydrate buffer, pH 6.0 (Merck, Darmstadt,
Germany), cooled down to room temperature (RT) and subsequently rinsed in PBS. For AMH
immunohistochemistry the sections were preincubated with normal rabbit serum in 5% (w/v) BSA
(Dako, Glastrup, Denmark) for 15 min at RT, and for inhibin a-subunit immunohistochemistry 
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After 4 days the medium was collected and proteins with a molecular mass above 10 kDa were
concentrated approximately 35-fold using a Centriprep10 filter system (Millipore Corp., Bedford, MA).
The amount of AMH was measured by ELISA making use of the His-tag, with the Biorad TMB
Peroxidase ElA substrate kit (Biorad, Life Science Groups, Hercules, CA). The primary antibody, pentaHis
monoclonal antibody (raised in rabbit; Qiagen GmbH, Hilden, Germany), was used at 100 ng/ml.
The secondary antibody, a goat-anti-mouse IgG peroxidase conjugate (Sigma Chemical Co., St. Louis,
MO), was used at a 1:1000 dilution. The amount of AMH was calibrated using the same standard
preparation of His-tagged AMH in every ELISA and was expressed in arbitrary units. The concentrated
supernatant of wild-type HEK293 cells was used as control medium.
The presence or absence of AMH in the media used in the experiments was investigated by
Western blotting using a primary polyclonal antibody against AMH (raised in goat; C-20, Santa Cruz
Biotechnology, Santa Cruz, CA) at a 1:2000 dilution and a secondary peroxidase-conjugated 
mouse-anti-goat/sheep antibody (Sigma) at a dilution of 1:10000.
The AMH preparations (800 U/ml) were shown to be bioactive using a Müllerian duct regression
assay (Nachtigal and Ingraham, 1996; Ingraham, et al., 2000, data not shown).
Animals and ovary organ culture
C57Bl/6J female mice were used in all experiments described in this report. For the ovary organ culture
experiments ovaries of 2-day-old females were used, since these ovaries predominantly contain
primordial follicles, some naked oocytes and no growing follicles. Day of birth was denoted as day 1.
The animals were obtained from the Animal Facility (EDC) of the Faculty of Medicine and Health
Sciences of the Erasmus University Rotterdam and were kept under standard animal housing conditions
in accordance with the NIH guidelines for the Care and Use of Experimental Animals. Animals were
sacrificed by decapitation.
Ovaries of 2-day-old mice were either immediately fixed in Bouin's fixative for morphological
examination and follicle counting, or snap-frozen in liquid nitrogen for RNA isolation, or placed in
culture. An organ culture method was used as described by Cooke (Cooke, et al., 1987), which was
modified in our laboratory with the help of Dr. Judith Emmen (Emmen, et al., 2000). The ovaries,
together with some surrounding tissue, were removed from the abdomen under a dissection microscope.
The tissue was placed in watch-glasses containing phosphate-buffered saline (PBS). With the help of
two syringe needles the tissue surrounding the ovaries, including the capsule in which the ovary is
enclosed (peri-ovarian sac), was removed. Since large inter-animal variation in the number of follicles
per ovary was observed (see Results section), ovaries of each animal were matched and one was used
for control cultures and the other for treated cultures. Ovaries were cultured in a four-well culture
plate (Nunc plate, Applied Scientific, South San Francisco, CA). Each well contained 0.5 ml DMEM/F-12
medium with GLUTAMAX-I (Gibco) supplemented with 1% (v/v) charcoal-stripped fetal calf serum
(CS-FCS), insulin (10 µg/ml) and transferrin (10 µg/ml; Sigma). Penicillin (250 IU/ml), streptomycin
(0.25 mg/ml) and fungizone (3.1 µg/ml) (Bio Whitaker, Walkersville, MD) were added to the culture
medium to prevent bacterial contamination. No effect of the stripped FCS was found in the sensitive
fetal Müllerian duct regression assay, while by Western blotting no AMH could be detected in the
stripped CS-FCS. Each ovary was placed in a small droplet of medium (approximately 15 µl) on a piece
of 0.4 µm Millicel-CM filter (Millipore) of approximately 1 cm2, floating on the culture medium. 
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Mouse GDF9 DNA template (Laitinen, et al., 1998) was kindly donated by Dr. O. Ritvos (Helsinki).
This template was used to obtain a PCR fragment of 411 bp, containing a part of 293 bp of mouse
GDF9 construct and a part of pGEM-T vector containing the T7 polymerase site. The primers used
in this PCR reaction were primer 5'-CAGGGTTTTCCCAGTCAC-3', annealing to the sense sequence
2937-2954 located within the pGEM-T vector and primer 5'-CTG CCA TGG AAC ACT TGC TC-3',
annealing to the antisense sequence 490-471 located within the GDF9 construct. This PCR product
was used as template for the construction of a GDF9 [32P]-UTP-labeled anti-sense RNA probe. Mouse
AMHRII antisense probe was generated as described before (Visser, et al., 1998). The control
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA probe was synthesized using a construct
containing 163 bp AccI-Sau3AI fragment of the rat GAPDH cDNA.
RNase protection assays were performed on total RNA, extracted from fresh and cultured mouse
ovaries, as described by Baarends (1994). GAPDH was used as a control for RNA loading. The relative
amount of protected mRNA band was quantified through exposure of the gels to a phosphor screen
(Molecular Dynamics, B & L Systems, Zoetermeer, The Netherlands) and using Phosphor-Imager, and
Image Quant (Molecular Dynamics) as computer analysis software. The mRNA levels were normalized
to those for GAPDH mRNA and are expressed as a percentage of the mRNA level of 2-day-old
ovaries, which was considered 100%.
Two separate assays were performed, using RNA derived from two separate culture experiments.
In every assay, 5 µl of the RNA samples was hybridized with inhibin a-subunit and GAPDH probes,
and the remaining 5 µl with probes for AMHRII, GDF9, ZP3 and GAPDH. Total RNA of 30-day-old
mouse ovaries was used as a control.
Statistical analysis
Results are presented as the mean ± SEM. The data were evaluated for statistical differences by an
independent samples T-test using SPSS9.0 (SPSS, Inc., Chicago, IL) computer software. Differences were
considered significant at P ≤ 0.05.
RESULTS
AMH production
To ensure that no AMH is present in the concentrated control medium, and that AMH is present in
the concentrated medium of rat AMH-producing HEK293 cells, the concentrated media were examined
by Western blot analysis using an AMH antibody. Figure 3.1 shows the result of this analysis. There
is no AMH in lane 1, containing concentrated control medium, whereas two bands representing
AMH protein can be seen in lane 2 containing concentrated medium of rat AMH-producing HEK293
cells. The lower band is the monomeric form of mature AMH (12 kDa), while the top band is non-reduced
AMH dimer (24 kDa). The absence of larger bands indicates complete cleavage of the proform of AMH.
Culture medium from both control and AMH-treated cultures was also examined by Western
blot analysis to check for the presence of endogenous AMH and to make sure that the added rat AMH
is not degraded during the culture. No AMH was found in the control cultures, while non-degraded
AMH was present in the AMH-treated cultures (results not shown).
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the sections were preincubated with normal swine serum in 5% BSA (Dako) for 15 min at 37C. For
AMH immunohistochemistry the preincubation step was followed by incubation at 4C overnight
with primary polyclonal antibody against MIS (C-20; Santa Cruz), diluted 1:1000 in 5% BSA in PBS.
The antibody was raised against a peptide mapping at the carboxy terminus of human AMH, which
differs from the corresponding mouse sequence, by a single amino acid. For inhibin a-subunit
immunohistochemistry the preincubation step was followed by incubation at 37C for 30 min with
primary polyclonal antibody AS173-11, diluted 1:40 in 5% BSA in PBS. This primary polyclonal
antibody was raised against amino acids 37-55 of the rat inhibin pre-pro-a-subunit. After incubation,
the sections were rinsed in PBS and subsequently treated for 30 min at RT either with biotinylated
rabbit-anti-goat antibody (dilution: 1:400; Dako) for AMH immunohistochemistry or with biotinylated
swine-anti-rabbit antibody (dilution 1:400; Dako) for inhibin a-subunit immunohistochemistry.
Finally, a treatment with streptavidin-biotin-peroxidase complex (ABC; diluted 1:200 in PBS; Dako)
for 30 min at RT followed. Peroxidase activity was developed with 0.07% 3,3'-diaminobenzidine
tetrahydrochloride (DAB; Fluka, Basel, Switzerland) for 5-7 min. In each experiment control sections
were incubated with 5% BSA/PBS in the absence of the primary antibody (negative control).
Hematoxylin/eosin was used for counterstaining. Ovaries from 30-day-old mice, containing many
AMH and inhibin a-subunit positive follicles, were used as a positive control.
RNA isolation and RNase protection assay
Freshly isolated 2-, 4- and 6-day-old ovaries or 2-day-old ovaries that were cultured for 2 or 4 days in
the absence or presence of added AMH were snap frozen in liquid nitrogen and stored at -80C. Two
separate RNase protection assays were performed. In each assay different sets of total RNA were used.
For each assay total RNA was isolated from 20 ovaries per culture condition, 20 ovaries of 2-, 4- and
6-day-old mice and 5 ovaries of 30-day-old. Total RNA was isolated using Trizol Reagent (Gibco),
which is an improvement of the single-step RNA isolation method developed by Chomczynski and
Sacchi (1987). The isolated RNA was dissolved in 10 µl deionized H2O and stored by –80C.
Mouse zona pellucida protein 3 (ZP3) and mouse inhibin a-subunit DNA templates for in vitro
transcription were generated by RT-PCR. The RT-PCR reaction was carried out on 2.5 µg total RNA,
extracted from 30-day-old mouse ovaries, using random hexameres. A sample of the reverse transcription
reaction product was used in the PCR reaction. With the help of ZP3 primers 5’-GAC TTC CAC GGT
TGC CTT G-3’, annealing to nucleotide sequence 735-753 of the Zp3 gene (numbering according to
GenBank sequence), and 5’-GCA GTC CAG CCT TCC ACA G-3’, annealing to antisense sequence
1174-1156, a 440 bp fragment was generated. For the inhibin a-subunit PCR reaction primers 
5’-GCC ATC CCA ACA CAT ACG-3’, annealing to sense sequence 374-391, and 5’-GAA ACT GGG
AGG GTG TAC G-3’, annealing to antisense sequence 884-866, were used to generate a 511 bp
fragment. These fragments were inserted into the PCR2.1-TOPO vector. A fragment of 521 bp of the
PCR2.1-TOPO vector containing the ZP3 PCR product was removed from PCR2.1-TOPO vector by
cutting the plasmid with BamHI and XhoI, while a fragment of 538 bp containing inhibin a-subunit
PCR product was removed by cutting the PCR2.1-TOPO vector with EcoRI. Both fragments were
subsequently subcloned in pBluescript KS and used to generate a [32P]-UTP-labeled anti-sense RNA
probe.
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tetrahydrochloride (DAB; Fluka, Basel, Switzerland) for 5-7 min. In each experiment control sections
were incubated with 5% BSA/PBS in the absence of the primary antibody (negative control).
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RNA isolation and RNase protection assay
Freshly isolated 2-, 4- and 6-day-old ovaries or 2-day-old ovaries that were cultured for 2 or 4 days in
the absence or presence of added AMH were snap frozen in liquid nitrogen and stored at -80C. Two
separate RNase protection assays were performed. In each assay different sets of total RNA were used.
For each assay total RNA was isolated from 20 ovaries per culture condition, 20 ovaries of 2-, 4- and
6-day-old mice and 5 ovaries of 30-day-old. Total RNA was isolated using Trizol Reagent (Gibco),
which is an improvement of the single-step RNA isolation method developed by Chomczynski and
Sacchi (1987). The isolated RNA was dissolved in 10 µl deionized H2O and stored by –80C.
Mouse zona pellucida protein 3 (ZP3) and mouse inhibin a-subunit DNA templates for in vitro
transcription were generated by RT-PCR. The RT-PCR reaction was carried out on 2.5 µg total RNA,
extracted from 30-day-old mouse ovaries, using random hexameres. A sample of the reverse transcription
reaction product was used in the PCR reaction. With the help of ZP3 primers 5’-GAC TTC CAC GGT
TGC CTT G-3’, annealing to nucleotide sequence 735-753 of the Zp3 gene (numbering according to
GenBank sequence), and 5’-GCA GTC CAG CCT TCC ACA G-3’, annealing to antisense sequence
1174-1156, a 440 bp fragment was generated. For the inhibin a-subunit PCR reaction primers 
5’-GCC ATC CCA ACA CAT ACG-3’, annealing to sense sequence 374-391, and 5’-GAA ACT GGG
AGG GTG TAC G-3’, annealing to antisense sequence 884-866, were used to generate a 511 bp
fragment. These fragments were inserted into the PCR2.1-TOPO vector. A fragment of 521 bp of the
PCR2.1-TOPO vector containing the ZP3 PCR product was removed from PCR2.1-TOPO vector by
cutting the plasmid with BamHI and XhoI, while a fragment of 538 bp containing inhibin a-subunit
PCR product was removed by cutting the PCR2.1-TOPO vector with EcoRI. Both fragments were
subsequently subcloned in pBluescript KS and used to generate a [32P]-UTP-labeled anti-sense RNA
probe.
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AMH and inhibin a-subunit immunohistochemistry
To further evaluate the condition of the cultured ovaries and to determine the onset of AMH and
inhibin a-subunit protein expression in vivo, an immunohistochemical study was performed on freshly
isolated 1- to 6-day-old mouse ovaries, and in ovaries from 2-day-old mice cultured for 2 or 4 days.
In freshly isolated ovaries of 2-day-old mice, containing naked oocytes, primordial follicles 
or interstitial tissue no specific AMH protein expression was detected (Figure 3.3A). In vivo AMH
protein expression was first found in a few granulosa cells of the smallest primary follicles from 4-day-old
mice (Figure 3.3C), while in larger primary follicles all granulosa cells show AMH protein expression.
High AMH protein expression was found in the granulosa cells of primary and early secondary follicles
of 6-day-old mice (Figure 3.3E).
49
AMH inhibits initiation of primordial follicle growth
Ovary organ culture and ovarian morphology
The culture system was evaluated by comparing the morphology of 2-day-old ovaries cultured for 2 or
4 days with the morphology of in vivo ovaries of corresponding age, which were isolated from 4- and
6-day-old mice, respectively. This evaluation focussed on the developmental stage of the follicles,
while no comparison was made regarding the number of different stages of follicles.
Ovaries of 2-day-old mice, which were used for the ovary culture experiments, predominantly
contain primordial follicles, some naked oocytes and no growing follicles (Figure 3.2A). Histological
examination of the ovaries after 2 or 4 days of culture indicated that the culture conditions had no
pronounced detrimental effect on the ovarian tissue, i.e. almost no necrosis or apoptotic cells were
found (Figure 3.2B). After 2 days of culture the ovaries contained many primordial follicles but also
some primary follicles of different sizes (Figure 3.2D), while after 4 days of culture, the ovaries contained
in addition to primordial and many primary follicles also some early secondary follicles (Figure 3.2F).
Most primordial follicles were located in the cortical part of the ovary, while the primary and secondary
follicles (further referred to as growing follicles) were mostly found in the central part of the ovary
(Figure 3.2B). As a further validation of the culture system we compared ovaries of similar ages, i.e.
ovaries cultured for 2 or 4 days were compared with ovaries of 4- or 6-day-old mice respectively. The most
significant difference was a larger diameter of primary follicles in ovaries cultured for 2 days than
primary follicles in 4-day-old ovaries (Figure 3.2C), while follicle development in ovaries cultured for
4 days were not different from ovaries from 6-day-old mice (Figure 3.2E). It also seems if more
follicles reach the primary stage in ovaries cultured for 2 days than in 4-day-old ovaries. However, no
direct statements regarding the numbers can be made since no follicle counting was performed in the
freshly isolated ovaries.
The presence of AMH in the culture medium did not have detrimental effect on the tissue of the
cultured ovaries (results not shown).
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Figure 3.1: Western blot analysis of concentrated wild-type HEK293 and rat AMH-producing HEK293 cells.
No AMH protein expression is found in concentrated medium of wild-type HEK293 cells (lane 1), while
AMH protein is found in concentrated medium of rat AMH-producing HEK293 cells (lane 2). 
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Figure 3.2: Photomicrographs of cultured and non-cultured neonatal mouse ovaries.
A. Section of an ovary of a 2-day-old mouse. Many primordial follicles (pr) and some "naked" oocytes
(no) are present. Scale bar 20 µm.
B. Section of a 2-day-old mouse ovary cultured for 2 days. The present culture conditions had no detrimental
effect on tissue quality, since almost no necrotic and apoptotic cells were found. Most primordial
follicles are located in the cortex of the ovary, while the primary and secondary follicles are predominantly
found in the central part of the ovary. Scale bar 50 µm. 
C. Section of an ovary of a 4-day-old mouse. Many primordial (pr) and some primary (P) follicles are found.
Scale bar 20 µm.
D.Section of a 2-day-old mouse ovary cultured for 2 days. After 2 days of culture the ovaries contained
many primordial follicles (pr) and primary follicles (P) of different sizes. Scale bar 20 µm.
E. Section of an ovary of a 6-day-old mouse. Besides primordial (pr) and primary (P) follicles, also some
early secondary (S) follicles are present. Scale bar 20 µm.
F. Section of an ovary of a 2-day-old mouse cultured for 4 days. In addition to primordial (pr) and
primary (P) follicles, also some early secondary follicles (S) are found. Scale bar 20 µm. 
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Effect of AMH on initiation of primordial follicle growth
To determine the effect of AMH on the recruitment of primordial follicles, the numbers of primordial,
primary and secondary (growing) follicles were counted in ovaries cultured for 2 or 4 days in the absence
or presence of AMH.
In the ovarian culture experiment the effect of different culture conditions (+/- AMH) were tested
by comparing the number of primordial and growing follicles between ovaries derived from the same
animal (paired ovaries), since no large differences exist in the number of primordial follicles between
two ovaries derived from the same animal (results not shown). To optimize the contact between the
ovarian tissue and the culture medium the peri-ovarian sac was removed before the 2-day-old ovaries
were used in the ovarian culture experiments. To test whether the removal of the peri-ovarian sac has
any impact on the number of primordial follicles the number of primordial follicles was counted in
paired ovaries of two 2-day-old mice of which of one of the ovaries the peri-ovarian sac was removed.
Removal of the peri-ovarian sac resulted in the loss of primordial follicles since approximately 3000
(2982 ± 53) primordial follicles were found in 2-day-old ovaries with the peri-ovarian sac in place,
and about 1400 (1384 ± 37) after removal of the peri-ovarian sac.
After 2 or 4 days of culture no difference was found in the total number of follicles per cultured ovary,
when the ovaries were derived from the same female (results not shown). However, variation did occur
between cultured ovaries isolated from different animals. This inter-animal variation was mainly due
to a difference in the number of primordial follicles, ranging from 691 to 2281 primordial follicles per
ovary. Moreover, primordial follicles were also lost during the culture period, since significantly more
primordial follicles were found in the ovaries after 2 days of culture (1893 ± 104) than after 4 days of
culture (1401 ± 79).
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AMH inhibits initiation of primordial follicle growth
Cultured ovaries exhibited an identical AMH expression pattern compared to freshly isolated ovaries,
i.e. expression was found in granulosa cells of primary and secondary follicles. However, the expression
level of AMH was higher in the primary follicles of ovaries cultured for 2 days than that in freshly isolated
ovaries of 4-day-old animals (compare Figures 3.3C and 3G). No difference was found in AMH
protein expression level between freshly isolated 6-day-old ovaries and ovaries cultured for 4 days
(results not shown). The negative control showed that some background staining was found in the
oocytes and in the interstitium (Figure 3.3I).
The inhibin a-subunit protein expression pattern was identical to the AMH protein expression
both in vivo and in vitro (Figures 3.3B-J), although the inhibin a-subunit protein expression was
somewhat less abundant. Very low amount of background staining was found in the oocytes (Figure 3.3J).
The presence of AMH in the culture medium did not affect the expression of either AMH or
inhibin a-subunit (results not shown). 
Histological and immunohistochemical evaluation of cultured and freshly isolated ovaries of comparable
age revealed that follicle development in vivo and in vitro are similar and therefore our neonatal ovary
organ culture system was applied to examine the effect of AMH on the initiation of primordial follicle
recruitment.
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Figure 3.3: Immunohistochemical localization of AMH and inhibin a-subunit in freshly isolated (control) and
cultured neonatal C57Bl/6J mouse ovaries. (For a color version of this figure, see page 169.)
A-B. Section of a 2-day-old control mouse ovary. No AMH (A) and inhibin a-subunit (B) protein expression
is found in naked oocytes (no), primordial follicles (pr) and interstitial tissue (I). Scale bar 20 µm.
C-D. Section of a 4-day-old control mouse ovary. AMH protein expression (C) and inhibin a-subunit
protein expression (D) are found in several granulosa cells of early primary follicles. Scale bar 20 µm.
E-F. Section of a 6-day-old control mouse ovary. Abundant AMH protein expression (E) and inhibin a-
subunit protein expression (F) are found in granulosa cells of primary follicles (P) and early secondary
follicles (S). Scale bar 20 µm.
G-H. Section of a 2-day-old mouse ovary cultured for 2 days in the absence of added AMH. High AMH
protein expression (G) and inhibin a-subunit protein expression (H) are found in granulosa cells of
primary follicles (P). Scale bar 20 µm.
I-J. Section of a 4-day-old control mouse ovary. For AMH some background staining is found in the
interstitium (I) and the oocytes, while for inhibin a-subunit very low background staining is only
found in the oocytes (J). Scale bar 20 µm.
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Figure 3.3:
RNase protection assay
To investigate whether the decrease in number of growing follicles was reflected in the levels of
expression of mRNA for markers of follicle differentiation, the mRNA expression level for the granulosa
cell markers, inhibin a-subunit and AMHRII, and for the oocyte-specific markers, GDF9 and ZP3, in
freshly isolated 2-, 4- and 6-day-old ovaries and in cultured ovaries was examined using RNase protection
assay. Total RNA from 30-day-old mice was used as a control.
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AMH inhibits initiation of primordial follicle growth
The total numbers of primordial and growing follicles after 2 and 4 days of culture in the presence or
absence of AMH are shown in Table 3.1. After both 2 and 4 days of culture no effect of AMH on the
number of primordial follicles was found. However, significantly fewer growing follicles were found
in the AMH-treated ovaries compared to the control ovaries. After normalization to percentages, we
found that after 2 days of culture the number of growing follicles cultured in the presence of AMH
was approximately 59 ± 4% of the control (Figure 3.4A), while after 4 days of culture this was
approximately 66 ± 6% (Figure 3.4B).
After 2 days of culture, for both treatment groups, most growing follicles reached a diameter of
30 µm and some a diameter of 40 µm. After 4 days of culture, most growing follicles reached a diameter
of 40 µm and some a diameter of 50 µm. The presence of AMH did not affect the maximal diameter
reached by the follicles during the culture period.
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Table 3.1: The number of primordial and growing follicles after 2 and 4 days of culture in the absence or
presence of added AMH.
The numbers of follicles found in two independent experiments are pooled and shown as mean ± SEM (P<0.05). a indicates a
significant difference from the control. N is the number of ovaries examined.
Days of -/+ AMH # Primordial # Growing 
culture follicles follicles
2 (N=9) - AMH 1968 ± 82 81 ± 4
2 (N=9) + AMH 1808 ± 141 50 ± 2 a
4 (N=11) - AMH 1369 ± 148 153 ± 8
4 (N=11) + AMH 1434 ± 155 97 ± 8 a
Figure 3.4: Growing follicles as a percentage of the control in 2-day-old mouse ovaries cultured for 2 days (A) or
4 days (B) in the absence or presence of AMH.
The number of growing follicles found in ovaries cultured in the presence of AMH is shown as a
percentage of the control. N represents the number of ovaries that were investigated. Data represent
the mean ± SEM. The asterisks indicate a statistically significant difference (P ≤ 0.05).
2 days of culture 4 days of culture
A B
gr
ow
in
g 
fo
lli
cl
es
(%
 o
f 
co
nt
ro
l)
gr
ow
in
g 
fo
lli
cl
es
(%
 o
f 
co
nt
ro
l)
Figure 3.5: Effect of AMH on expression of GDF9, ZP3, AMHRII and inhibin a-subunit mRNAs.
A-B. Phosphor-Image analysis of a representative RNase protection assay for inhibin a-subunit and GAPDH
mRNA expression (A) and for ZP3, AMHRII, GDF9 and GAPDH mRNA expression (B) in neonatal
ovaries of 2-, 4- and 6-day-old control mice, and in 2-day-old ovaries cultured for 2 or 4 days in
the presence (+) or absence (-) of AMH. RNA from 30-day-old mice is used as a control. 
C. Quantification of inhibin a-subunit, ZP3, AMHRII and GDF9 mRNA levels in 2-, 4- and 6-day-old
control mouse ovaries, and in 2-day-old mouse ovaries cultured for 2 or 4 days in the absence or
presence of added AMH. All these mRNA levels were normalized to that of GAPDH mRNA. Values
are represented as a percentage of 2-day-old ovaries (considered 100%) and are the mean ± SEM
of two independent experiments. For every culture condition total RNA of 20 ovaries was pooled,
while total RNA of 20 ovaries of 2-, 4- and 6-day-old animals and of 5 ovaries of 30-day-old
animals were pooled. 
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RNase protection assay
To investigate whether the decrease in number of growing follicles was reflected in the levels of
expression of mRNA for markers of follicle differentiation, the mRNA expression level for the granulosa
cell markers, inhibin a-subunit and AMHRII, and for the oocyte-specific markers, GDF9 and ZP3, in
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assay. Total RNA from 30-day-old mice was used as a control.
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follicles which arise after 1 day of culture. Therefore, the effect of AMH found in the culture model
may be an underestimation of the actual effects.
To exclude the possibility that the lower number of growing follicles found in AMH-treated ovaries
is caused by an AMH-induced retardation of early primary follicle growth, we also looked at the maximal
mean diameter that was reached in control and AMH-treated ovaries. Since under both culture
conditions the growing follicles reached the same maximal diameter we conclude that AMH has no
effect on the pace of early primary follicle growth.
The inhibition of initiation of primordial follicle growth is probably due to a direct effect of AMH
on the primordial follicle. Using RNase protection assay we show that AMHRII mRNA expression,
essential for an effect of AMH, is present in ovaries of 2-day-old mice. In both mouse and rat, ovarian
AMHRII mRNA expression is even found before birth (our observations; Baarends, et al., 1994, 1995a).
In addition, in situ hybridization studies showed ovary-specific AMHRII expression in neonatal ovaries.
However, exact localization of the radio-active AMHRII probe to the pregranulosa cells was not possible
since this probe is best visualized using a microscope with darkfield whereby it is very difficult to
discern specific structures or cell types in neonatal ovaries (Baarends, et al., 1995a; A.L.L. Durlinger,
unpublished observations). At later stages of ovarian development, AMHRII expression is limited to
the granulosa cells of mainly non-atretic pre-antral and small antral follicles (Baarends, et al., 1995a;
A.L.L. Durlinger, unpublished observations), although recently AMHRII transcripts have also been
detected in the internal theca cell layer of pre-antral follicles (Ingraham, et al., 2000).
As soon as primordial follicle growth is initiated, as indicated by a change in appearance of the
pregranulosa cells, not only AMH, but also a-inhibin protein is produced by the granulosa cells of the
early primary follicles and the inhibitory effect of AMH on primordial follicle recruitment is reflected
by a decrease in a-inhibin, used as a marker of early follicle development. However a functional role
of a-inhibin produced by these primary follicles is unclear at the present. More insight in the role of
inhibin in early follicle development could come from detailed analysis of the follicle population of
inhibin-deficient females, before they develop ovarian tumors (Matzuk, et al., 1996).
The number of primordial follicles that start to grow within a certain time period was not dependent
on the total number of primordial follicles present in the ovary at the beginning of the culture experiment.
It appears that within a certain time period the same number of primordial follicles starts to grow,
irrespective of the size of the pool of primordial follicles. The same result was found in another in vitro
study in which prenatal and neonatal mouse ovaries were placed in culture (Byskov, et al., 1997;
Krarup et al., 1969) however, state that their in vivo study shows that the fraction of a pool of primordial
follicles that initiate growth does depend on the actual size of the pool primordial follicles (Krarup, 
et al., 1969). The discrepancy between our results and of Byskov et al. and the results of Krarup et al.
could be explained by the fact the ovarian culture experiments are in vitro studies, in which many
possible factors influencing the initiation of primordial follicle growth are eliminated, while Krarup
et al. performed an in vivo study.
Although the amount of AMH (800 U/ml) used in the herein described culture experiments caused
complete Müllerian duct regression in vitro (A.L.L. Durlinger, unpublished observations), the recruitment
of primordial follicles was not completely blocked. This observation is in accordance with the findings
in AMH-deficient females, in which not all primordial follicles initiated growth. Thus, AMH is not
the only regulator of initial recruitment. Indeed, the stimulatory effect of SCF (Parrott and Skinner, 1999),
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Phosphor-Image analysis of the RNase protection assay is shown in Figures 3.5A and 3.5B.
Quantitative analysis revealed that AMHRII mRNA expression is present in all ovaries examined and
does not change with age or under different culture conditions (Figure 3.5C). The mRNA expression
level of inhibin a-subunit increased from day 2 to day 6. In the ovaries cultured for 2 days in the presence
of AMH, a decrease in inhibin a-subunit expression level of 68% was found, compared to the ovaries
cultured in the absence of AMH. After 4 days of culture this decrease was 46% (Figure 3.5C).
In the freshly isolated ovaries an increase in the mRNA expression level from day 2 to day 6 was
found for both oocyte-specific markers (GDF9 and ZP3). No difference was found in mRNA expression
level between ovaries cultured in the presence or absence of added AMH, although a slight decrease
was found for ZP3 expression after 2 days of culture in the presence of AMH (Figure 3.5C).
DISCUSSION
In the mouse, primordial follicles are formed just after birth, and this pool of primordial follicles
constitutes the complete supply of ovarian follicles during reproductive life. Initiation of primordial
follicle growth occurs from the moment that these follicles arise in the ovary, although not all primordial
follicles start to grow at the same time and some will remain dormant for months in rodents (Peters,
1978; Ueno, et al., 1989) and even for years in the human (Peters, 1969). The factors that regulate this
initiation of primordial follicle growth are still largely unknown. Recently, it was shown in a culture
system for neonatal rat ovaries that SCF and bFGF can stimulate the recruitment of primordial
follicles (Parrott and Skinner, 1999; Nilsson, et al., 2001), while in vitro treatment with GDF9 enhances
the progression of primordial and primary rat follicles into small pre-antral follicles (Vitt, et al.,
2000b). Studying the follicle population of nerve growth factor (NGF)-deficient mice revealed that in
these mice fewer primary follicles were formed, whereas an almost normal complement of primordial
follicles existed, suggesting that NGF is important for the initiation of primordial follicle growth
(Dissen, et al., 2001). These are the first studies, which show that ovarian growth factors play an important
role in initiation of primordial follicle growth. In our study of ovaries from AMH-deficient females it
became evident that also AMH affects initiation of primordial follicle growth (Durlinger, et al., 1999).
In the present study, the effect of AMH on primordial follicle recruitment was tested using ovaries
from 2-day-old mice in a neonatal ovary organ culture system. Ovaries of 2-day-old mice provide a
useful system for the study of factors that influence the initiation of primordial follicle growth, since
they contain many primordial follicles, only few naked oocytes, and no growing follicles. In this
culture system, not all primordial follicles started to grow, but similar to observations in vivo (Byskov
and Lintern-Moore, 1973) and in another ovary culture system (Eppig and O'Brien, 1996), some of
the primordial follicles located in the central part of the ovary were the first to initiate growth.
After 2 and 4 days of culture, fewer growing follicles were found in ovaries cultured in the presence
of AMH than in the control ovaries, which indicates that AMH indeed inhibits initial recruitment. By
immunohistochemistry it was shown that AMH is already produced by early primary follicles,
making AMH a very early marker of ovarian follicle growth. This means that from postnatal day 4,
about one day after the first primary follicles are formed in mouse ovaries, these ovaries produce a
small amount of AMH. Also in the cultured ovaries endogenous AMH was found in the early primary
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follicles which arise after 1 day of culture. Therefore, the effect of AMH found in the culture model
may be an underestimation of the actual effects.
To exclude the possibility that the lower number of growing follicles found in AMH-treated ovaries
is caused by an AMH-induced retardation of early primary follicle growth, we also looked at the maximal
mean diameter that was reached in control and AMH-treated ovaries. Since under both culture
conditions the growing follicles reached the same maximal diameter we conclude that AMH has no
effect on the pace of early primary follicle growth.
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GDF9 (Vitt, et al., 2000b), bFGF (Nilsson, et al., 2001) and NGF (Dissen, et al., 2001) on the initiation
of primordial follicle growth show that activation of primordial follicle growth is under the influence
of both stimulatory and inhibitory regulation. It would be interesting to culture neonatal ovaries with
SCF, GDF9, bFGF or NGF in the presence of AMH to study the possible functional interactions on
initial recruitment. Indications for an interaction between SCF and GDF9 already exist, since SCF mRNA
expression is highly elevated in mice lacking GDF9, suggesting that GDF9 is one of the oocyte-secreted
factors that negatively regulate SCF expression (Elvin, et al., 1999b). Besides AMH, SCF, GDF9, bFGF
and NGF probably many other, as yet unidentified, factors are involved, whose role in initial recruitment
is still not established. Identification of receptors for hormones and growth factors expressed by either
the oocyte or the pregranulosa cells of primordial follicles will give more insight in the process of
initial recruitment.
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ABSTRACT
Anti-Müllerian hormone (AMH) is a member of the TGFb superfamily of growth and differentiation
factors. In the ovary, AMH is produced by granulosa cells of primary, pre-antral and small antral
follicles and inhibits recruitment of primordial follicles into the growing pool. Furthermore, AMH
decreases the sensitivity of large pre-antral and small antral follicles for FSH. These effects are thought
to be mediated through the AMH type II receptor (AMHRII). 
The function of the AMHRII in the ovary was studied using the AMHRII LacZ knock-in mice
(MRKI(-/-)). The ovaries of 4-month-old MRKI(-/-) mice contained an increased number of small
growing and atretic follicles. The number of primordial follicles in the ovary was decreased in the
MRKI(-/-) mice compared to wild-type (WT) mouse. These results are similar to the results obtained
from the ovaries of 4-month-old AMH null (AMH(-/-)) mice. However, the decrease of primordial
follicle numbers was more pronounced in the MRKI(-/-) than in the AMH(-/-) ovaries. The ovarian
phenotype of the MRKI(+/-) was similar to the WT, showing that one allele for the AMHRII is enough
for normal AMH-signaling in the ovary. In the MRKI(-/-) mice, the FSH level was decreased and
inhibin levels were increased compared to the WT, albeit not significant. 
We conclude that the AMHRII plays a role in primordial follicle recruitment. These effects can be
explained by the absence of AMH action. However, the decrease of the total number of follicles,
mainly caused by the decrease of primordial follicle numbers, in the 4-month-old MRKI ovaries, shows
an additional effect for the AMHRII in primordial follicle recruitment and/or follicle formation.
These additional effects could indicate a role of AMHRII in signaling through constitutive activity of
the AMHRII in absence of the ligand. Future studies of ovaries of neonatal and/or fetal mice should
reveal whether the absence of AMHRII is involved in decreased primordial follicle formation or is
responsible for increased recruitment of primordial follicles.
INTRODUCTION
Anti-Müllerian hormone (AMH), also called Müllerian-inhibiting substance (MIS), is a member of
the transforming growth factor b (TGFb) superfamily which is composed of several subfamilies, such
as the TGFbs (TGFb1-5), activins (inhibin a, bA-C,E) and bone morphogenetic proteins (e.g. BMP1-15,
GDF1-9). Members of this family play an important role in mesenchymal-epithelial interactions, cell
growth, extracellular matrix production and tissue remodeling (Massagué, 1998). Jost showed in 1947
that AMH expressed by the testis during male sex differentiation, is responsible for regression of the
Müllerian ducts, the anlagen of female genital tract (Jost, 1947). In the rodent ovary, AMH expression
is found in granulosa cells of primary, pre-antral and small antral follicles, but not of large antral, 
pre-ovulatory or atretic follicles (Chapter 3; Münsterberg and Lovell-Badge, 1991; Hirobe, et al., 1992;
Taketo, et al., 1993; Baarends, et al., 1995b; Durlinger, et al., 2002). AMH plays an important role in
follicle development, since it inhibits recruitment of primordial follicles and decreases the sensitivity
of large pre-antral and small antral follicles for FSH (Chapter 3; Durlinger, et al., 1999, 2001).
Like other members of the TGFb family, AMH signals by binding to a type II transmembrane
serine/threonine (S/T) kinase receptor which forms a complex with and then activates a type I S/T
kinase receptor by phosphorylation. The AMH-specific type II receptor (AMHRII) has been identified
(Baarends, et al., 1994; di Clemente, et al., 1994b) and its mRNA expression is colocalized with AMH
in the granulosa cells of healthy primary and pre-antral follicles (Baarends, et al., 1995b). It is likely
that the AMHRII is also expressed in the pregranulosa cells of primordial follicles because expression
of AMHRII is already found during the fetal period and remains present after birth when the ovary
mainly contains primordial follicles (Durlinger, et al., 2002; our unpublished data). In addition, it has
been suggested that AMHRII is also expressed in theca cells of pre-antral and small antral follicles in
rat ovaries (Ingraham, et al., 2000).
To study the function of AMHRII, AMHRII null mice were generated (Mishina, et al., 1996). Like
the AMH(-/-) mice, male AMHRII(-/-) mice suffered from persistent Müllerian duct syndrome (PMDS)
and showed Leydig cell hyperplasia in the testes (Behringer, et al., 1994; Mishina, et al., 1996).
Furthermore, no additional phenotype was observed in the AMH/AMHRII double mutant (Mishina,
et al., 1996). The phenocopy of the AMH(-/-) and AMHRII(-/-) mice suggests that AMH is the only
ligand for the AMHRII. However, the phenotype of the ovary of AMHRII(-/-) mice has not been
determined. Here, we studied the ovarian phenotype of mice where a LacZ reporter cassette was
introduced into the AMHRII gene (MIS-receptor knock-in mouse (MRKI)) (Arango, et al., 1999).
Like the AMHRII null mice, these mice do not express the AMHRII, as becomes clear from the fact
that in males the Müllerian ducts did not regress. Here, we report the phenotype of the ovaries of
these MRKI(-/-) and MRKI(+/-) mice and compared this with the ovarian phenotype of the AMH
null mice, in order to gain more information about the role of the AMHRII in the ovary.
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Statistical analysis
Results are presented as mean ± SEM. The data were analyzed for statistical differences by an independent
samples t-test or by one-way analysis of variance (ANOVA), followed by a Duncan’s new multiple range
test using SPSS, Inc9.0 (SPSS, Inc., Chicago, IL) computer software. Differences were considered to
be significant at P≤0.05.
RESULTS
Ovarian morphology and follicle counts
The follicle population in the ovaries of MRKI(-/-), MRKI(+/-) mice and their WT littermates was
determined. Ovaries of 4-month-old MRKI(-/-) mice contained follicles of all classes and corpora
lutea, suggesting an active estrous cycle (Figure 4.1). The numbers of healthy growing and atretic
growing follicles were increased over 2-fold in MRKI(-/-) ovaries compared to WT ovaries (Figure 4.2).
A decrease was detected in the number of primordial follicles, which resulted in a decrease of the total
number of follicles in the MRKI(-/-) ovaries compared to WT (Figure 4.2). The ovaries of MRKI(+/-)
ovaries showed a follicle population most similar to WT ovaries. A small number of large follicles was
detected in WT, MRKI(+/-) and MRKI(-/-) animals (results not shown). This was expected since the
mice were killed on the day of estrous when no large follicles have developed yet (Welschen and Rutte,
1971; Osman, 1985).
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MATERIALS AND METHODS
Animals 
MIS Receptor Knock-In (MRKI) mice were maintained under standard animal housing conditions in
accordance with NIH guidelines for the care and use of experimental animals and were housed in the
animal facility (EDC) of the Erasmus MC. For this study 4-month-old female MRKI(-/-) (n=6),
MRKI(+/-) (n=4) and their wild-type (WT) (n=2) siblings were used. Mice were sacrificed by decapitation
at the day of estrus, after which blood was collected. The stage of estrus cycle was determined by
microscopical examination of vaginal smears according to the criteria of Allen (1922). Body weight
was determined and blood was collected. Serum samples were stored at –20C until assayed for FSH
and inhibin A and inhibin B. The ovaries were isolated, weighed, fixed overnight in Bouin’s fixative,
embedded in paraffin and sectioned at 8 µm. In addition, the uterus was also isolated and weighed.
The genotype of the MRKI mice was determined using a PCR primerset for the wild-type and the
null allele. Wild-type allele PCR primers (forward primer: 5’-AGG TGG GTC AGA CCC AGA GCC-3’
and reverse primer 5’-GCA TGA CCT CCT TCC TGG ATT-3’) were used in a concentration of 
0.5 pmol/µl and the reaction was performed in 50 µl in a PCR buffer containing 1.2 mM DTT, 
50 mM KCl, 10 mM TrisHCl, 0.25 mM dNTP (Amersham Pharmacia Biotech, Roosendaal, The
Netherlands), 3.0 mM MgCl2 and 0.05 units/µl Supertaq (Sphearo Q, Leiden, The Netherlands). The
null allele was detected using LacZ primers (forward primer: 5’-GCA TCG AGC TGG GTA ATA AGG
GTT GGC AAT-3’ and reverse primer: 5’-GAC ACC AGA CCA ACT GGT AAT GGT AGC GAC-3’).
Null allele PCR primers were used in a concentration of 100 ng/µl and the reaction was performed in
50 µl in the amplitaq PCR buffer (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands)
containing 15 mM MgCl2, 0.25 mM dNTP (Amersham Pharmacia Biotech), and 1.5 U/µl amplitaq
(Applied Biosystems). The PCR reaction was performed using an annealing temperature of 65C and
35 PCR cycles. DNA for these PCRs was isolated as described by Durlinger (1999).
Ovarian histology and follicle counting
Serial 8 µm sections of one ovary were used for follicle counting. Follicle counts were performed as
described by Durlinger (1999). In summary, primordial follicles were counted in every second section,
while growing follicles were divided into two size classes, i.e. small and large follicles. The small follicle
class contains pre-antral and small antral follicles with a diameter smaller than 310 µm and the large
follicle class contains antral follicles with a diameter larger than 310 µm. The diameter was determined
by measuring two perpendicular diameters in the sections in which the nucleolus of the oocyte was
present. In addition, non-atretic and atretic follicles were counted separately. Furthermore, the number
of corpora lutea was determined.
Measurements of serum FSH, inhibin A and inhibin B
Serum FSH was determined by radioimmunoassay using rat FSH as a ligand and antibodies against
ovine FSH (Welschen, et al., 1975). All samples were measured in one assay. Serum inhibin A and
inhibin B were measured using kits purchased from Serotec Ltd (Oxford, UK) and the hormone
measurements were performed in one assay.
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Figure 4.1: Photomicrograph of a 4-month-old MRKI (-/-) mouse ovary. 
The ovary contains primary (PY), pre-antral (PA) and antral (A) follicles and corpora lutea (CL). In addition
also primordial follicles are present. However, they cannot be seen at this magnification. Magnification x 50.
Statistical analysis
Results are presented as mean ± SEM. The data were analyzed for statistical differences by an independent
samples t-test or by one-way analysis of variance (ANOVA), followed by a Duncan’s new multiple range
test using SPSS, Inc9.0 (SPSS, Inc., Chicago, IL) computer software. Differences were considered to
be significant at P≤0.05.
RESULTS
Ovarian morphology and follicle counts
The follicle population in the ovaries of MRKI(-/-), MRKI(+/-) mice and their WT littermates was
determined. Ovaries of 4-month-old MRKI(-/-) mice contained follicles of all classes and corpora
lutea, suggesting an active estrous cycle (Figure 4.1). The numbers of healthy growing and atretic
growing follicles were increased over 2-fold in MRKI(-/-) ovaries compared to WT ovaries (Figure 4.2).
A decrease was detected in the number of primordial follicles, which resulted in a decrease of the total
number of follicles in the MRKI(-/-) ovaries compared to WT (Figure 4.2). The ovaries of MRKI(+/-)
ovaries showed a follicle population most similar to WT ovaries. A small number of large follicles was
detected in WT, MRKI(+/-) and MRKI(-/-) animals (results not shown). This was expected since the
mice were killed on the day of estrous when no large follicles have developed yet (Welschen and Rutte,
1971; Osman, 1985).
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MATERIALS AND METHODS
Animals 
MIS Receptor Knock-In (MRKI) mice were maintained under standard animal housing conditions in
accordance with NIH guidelines for the care and use of experimental animals and were housed in the
animal facility (EDC) of the Erasmus MC. For this study 4-month-old female MRKI(-/-) (n=6),
MRKI(+/-) (n=4) and their wild-type (WT) (n=2) siblings were used. Mice were sacrificed by decapitation
at the day of estrus, after which blood was collected. The stage of estrus cycle was determined by
microscopical examination of vaginal smears according to the criteria of Allen (1922). Body weight
was determined and blood was collected. Serum samples were stored at –20C until assayed for FSH
and inhibin A and inhibin B. The ovaries were isolated, weighed, fixed overnight in Bouin’s fixative,
embedded in paraffin and sectioned at 8 µm. In addition, the uterus was also isolated and weighed.
The genotype of the MRKI mice was determined using a PCR primerset for the wild-type and the
null allele. Wild-type allele PCR primers (forward primer: 5’-AGG TGG GTC AGA CCC AGA GCC-3’
and reverse primer 5’-GCA TGA CCT CCT TCC TGG ATT-3’) were used in a concentration of 
0.5 pmol/µl and the reaction was performed in 50 µl in a PCR buffer containing 1.2 mM DTT, 
50 mM KCl, 10 mM TrisHCl, 0.25 mM dNTP (Amersham Pharmacia Biotech, Roosendaal, The
Netherlands), 3.0 mM MgCl2 and 0.05 units/µl Supertaq (Sphearo Q, Leiden, The Netherlands). The
null allele was detected using LacZ primers (forward primer: 5’-GCA TCG AGC TGG GTA ATA AGG
GTT GGC AAT-3’ and reverse primer: 5’-GAC ACC AGA CCA ACT GGT AAT GGT AGC GAC-3’).
Null allele PCR primers were used in a concentration of 100 ng/µl and the reaction was performed in
50 µl in the amplitaq PCR buffer (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands)
containing 15 mM MgCl2, 0.25 mM dNTP (Amersham Pharmacia Biotech), and 1.5 U/µl amplitaq
(Applied Biosystems). The PCR reaction was performed using an annealing temperature of 65C and
35 PCR cycles. DNA for these PCRs was isolated as described by Durlinger (1999).
Ovarian histology and follicle counting
Serial 8 µm sections of one ovary were used for follicle counting. Follicle counts were performed as
described by Durlinger (1999). In summary, primordial follicles were counted in every second section,
while growing follicles were divided into two size classes, i.e. small and large follicles. The small follicle
class contains pre-antral and small antral follicles with a diameter smaller than 310 µm and the large
follicle class contains antral follicles with a diameter larger than 310 µm. The diameter was determined
by measuring two perpendicular diameters in the sections in which the nucleolus of the oocyte was
present. In addition, non-atretic and atretic follicles were counted separately. Furthermore, the number
of corpora lutea was determined.
Measurements of serum FSH, inhibin A and inhibin B
Serum FSH was determined by radioimmunoassay using rat FSH as a ligand and antibodies against
ovine FSH (Welschen, et al., 1975). All samples were measured in one assay. Serum inhibin A and
inhibin B were measured using kits purchased from Serotec Ltd (Oxford, UK) and the hormone
measurements were performed in one assay.
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Figure 4.1: Photomicrograph of a 4-month-old MRKI (-/-) mouse ovary. 
The ovary contains primary (PY), pre-antral (PA) and antral (A) follicles and corpora lutea (CL). In addition
also primordial follicles are present. However, they cannot be seen at this magnification. Magnification x 50.
Measurements of serum FSH, inhibin A and inhibin B levels
Inhibin A and inhibin B levels were increased and FSH levels were decreased in the serum of MRKI(-/-)
females compared to WT (Table 4.2), albeit that the low number of WT animals (n=2) precluded
significant differences. 
DISCUSSION
AMH plays an important role in ovarian development since it inhibits primordial follicle recruitment
(Chapter 3; Durlinger, et al., 1999) and lowers the sensitivity of large pre-antral and small antral follicles
for FSH (Durlinger, et al., 2001). It is likely that AMH achieves these effects by binding to the AMHRII.
By studying the phenotype of the MRKI(-/-) and MRKI(+/-) mice ovaries, we sought to determine
the role of AMHRII in the ovary.
Studying the follicle population of 4-month-old MRKI(-/-) mice revealed an ovarian phenotype
similar to that of AMH(-/-) mice ovaries. Like the AMH(-/-) mice, MRKI(-/-) ovaries showed an
increased number of small growing and small atretic follicles and a decreased number of primordial
follicles compared to the WT. These results suggest an increased recruitment of primordial follicles
into the growing pool in the 4-month-old MRKI(-/-) ovary. The follicle population in MRKI(+/-)
mice ovaries was most similar to that in WT ovaries, suggesting that, although only one AMHRII
allele is present in the ovary, AMHRII-signaling is normal. The increase in the number of growing
follicles resulted in an increased ovarian weight of MRKI(-/-) ovaries compared to their controls,
albeit not significantly due to the small number (n=2) of control animals. 
The increase in the number of small growing follicles in ovaries of 4-month-old AMH(-/-) mice
resulted in an increase in immunoreactive serum inhibin and a decrease in serum FSH levels
(Durlinger, et al., 1999), since pre-antral mouse follicles produce inhibin A and inhibin B (O'Shaughnessy
and Gray, 1995; Smitz and Cortvrindt, 1998). The increase in inhibin production resulted in an increased
inhibition of FSH synthesis and release from the pituitary gland (de Jong, 1988). This decrease in FSH
synthesis subsequently caused a decreased estrogen production by the ovaries resulting in a 1.8-fold
(non-significant) decrease in uterine weight (Durlinger, et al., 1999). Similarly as in AMH(-/-) animals,
serum levels of inhibin A and inhibin B in MRKI(-/-) mice showed an increase followed by a decreased
FSH serum levels compared to the WT animals. The absence of significant difference might be
explained by the low number of WT animals, but also other explanations are possible. Determination
of estrus by vaginal smears is difficult and the large variation found between the serum FSH, inhibin
A and inhibin B levels of WT, MRKI(+/-) and MRKI(-/-) mice suggests that not all animals were
killed at estrus. Inhibin measurements in AMH(-/-) mice were performed using an assay which detects
levels of immunoreactive inhibin, while in the MRKI(-/-) mice inhibin A and inhibin B levels were
measured. Increase of the level of immunoreactive inhibin serum suggests an increase in inhibin A,
inhibin B and/or free inhibin a-subunits. Therefore, this method is less specific. 
The increased size of the small growing follicle population in MRKI(-/-) mice suggests that the
presence of one AMHRII allele in the ovary is sufficient for AMH-signaling, since the MRKI(+/-)
ovaries contained similar number of follicles compared to the WT animals. However, the inhibin A
and inhibin B serum levels seemed to be in between levels in the WT and MRKI(-/-) animals (Table 4.2).
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Weight of animals, ovaries and uterus
The increase in the number of small growing follicles in 4-month-old AMH(-/-) mice resulted in an
increase in ovarian weight (Durlinger, et al., 1999). Ovarian weight of 4-month-old MRKI(-/-) mice
was increased compared to WT animals, although no significant difference was found (Table 4.1).
Like in AMH(-/-) animals, the uterine weight (an estrogen-sensitive parameter) was decreased in
MRKI(-/-) mice compared to WT and MRKI(+/-) mice and no difference in body weight between the
three groups was detected. 
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Figure 4.2: Follicle population in 4-month-old WT, MRKI(+/-) and MRKI (-/-) mice ovaries.
From two WT, four MRKI(+/-) and six MRKI(-/-) animals the primordial, non-atretic small and atretic
small, non-atretic large and atretic large follicles were counted in a single ovary. The number of large
follicles was very low and not presented in this figure. Data represent the mean ± SEM. Asterisks
indicate a statistically significant difference (P≤0.05).
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Table 4.1: Weight of 4-months-old MRKI(+/+), MRKI(+/-) and MRKI(-/-) mice and their ovaries and uterus.
Values represent means ± SEM. No significant differences were measured.
WT MRKI(+/-) MRKI (-/-)
(n=2) (n=4) (n=6)
Animal weight (g) 21.8 ± 1.4 22.3 ± 0.2 22.1 ± 0.7
Ovary weight (mg) 4.1 ± 0.5 4.6 ± 0.5 6.3 ± 0.6
Uterine weight (mg) 83.0 ± 3.0 64.2 ± 6.8 63.8 ± 7.2
Table 4.2: Serum levels of inhibin A, inhibin B and FSH in 4-months-old WT, MRKI(+/-) and MRKI(-/-) mice.
Values represent the mean ± SEM. No significant differences were measured.
WT MRKI(+/-) MRKI(-/-)
(n=2) (n=4) (n=6)
Inhibin A (ng/l) 8.5 ± 6.5 20.8 ± 7.5 23.0 ± 12.1
Inhibin B (ng/l) 36.0 ± 18.0 49.3 ± 15.7 62.2 ± 9.2
FSH (ng/ml) 21.8 ± 2.1 10.5 ± 6.2 13.4 ± 4.3
all follicles primordial non-atretic atretic small
follicles small follicles follicles p≤0.05
Measurements of serum FSH, inhibin A and inhibin B levels
Inhibin A and inhibin B levels were increased and FSH levels were decreased in the serum of MRKI(-/-)
females compared to WT (Table 4.2), albeit that the low number of WT animals (n=2) precluded
significant differences. 
DISCUSSION
AMH plays an important role in ovarian development since it inhibits primordial follicle recruitment
(Chapter 3; Durlinger, et al., 1999) and lowers the sensitivity of large pre-antral and small antral follicles
for FSH (Durlinger, et al., 2001). It is likely that AMH achieves these effects by binding to the AMHRII.
By studying the phenotype of the MRKI(-/-) and MRKI(+/-) mice ovaries, we sought to determine
the role of AMHRII in the ovary.
Studying the follicle population of 4-month-old MRKI(-/-) mice revealed an ovarian phenotype
similar to that of AMH(-/-) mice ovaries. Like the AMH(-/-) mice, MRKI(-/-) ovaries showed an
increased number of small growing and small atretic follicles and a decreased number of primordial
follicles compared to the WT. These results suggest an increased recruitment of primordial follicles
into the growing pool in the 4-month-old MRKI(-/-) ovary. The follicle population in MRKI(+/-)
mice ovaries was most similar to that in WT ovaries, suggesting that, although only one AMHRII
allele is present in the ovary, AMHRII-signaling is normal. The increase in the number of growing
follicles resulted in an increased ovarian weight of MRKI(-/-) ovaries compared to their controls,
albeit not significantly due to the small number (n=2) of control animals. 
The increase in the number of small growing follicles in ovaries of 4-month-old AMH(-/-) mice
resulted in an increase in immunoreactive serum inhibin and a decrease in serum FSH levels
(Durlinger, et al., 1999), since pre-antral mouse follicles produce inhibin A and inhibin B (O'Shaughnessy
and Gray, 1995; Smitz and Cortvrindt, 1998). The increase in inhibin production resulted in an increased
inhibition of FSH synthesis and release from the pituitary gland (de Jong, 1988). This decrease in FSH
synthesis subsequently caused a decreased estrogen production by the ovaries resulting in a 1.8-fold
(non-significant) decrease in uterine weight (Durlinger, et al., 1999). Similarly as in AMH(-/-) animals,
serum levels of inhibin A and inhibin B in MRKI(-/-) mice showed an increase followed by a decreased
FSH serum levels compared to the WT animals. The absence of significant difference might be
explained by the low number of WT animals, but also other explanations are possible. Determination
of estrus by vaginal smears is difficult and the large variation found between the serum FSH, inhibin
A and inhibin B levels of WT, MRKI(+/-) and MRKI(-/-) mice suggests that not all animals were
killed at estrus. Inhibin measurements in AMH(-/-) mice were performed using an assay which detects
levels of immunoreactive inhibin, while in the MRKI(-/-) mice inhibin A and inhibin B levels were
measured. Increase of the level of immunoreactive inhibin serum suggests an increase in inhibin A,
inhibin B and/or free inhibin a-subunits. Therefore, this method is less specific. 
The increased size of the small growing follicle population in MRKI(-/-) mice suggests that the
presence of one AMHRII allele in the ovary is sufficient for AMH-signaling, since the MRKI(+/-)
ovaries contained similar number of follicles compared to the WT animals. However, the inhibin A
and inhibin B serum levels seemed to be in between levels in the WT and MRKI(-/-) animals (Table 4.2).
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Weight of animals, ovaries and uterus
The increase in the number of small growing follicles in 4-month-old AMH(-/-) mice resulted in an
increase in ovarian weight (Durlinger, et al., 1999). Ovarian weight of 4-month-old MRKI(-/-) mice
was increased compared to WT animals, although no significant difference was found (Table 4.1).
Like in AMH(-/-) animals, the uterine weight (an estrogen-sensitive parameter) was decreased in
MRKI(-/-) mice compared to WT and MRKI(+/-) mice and no difference in body weight between the
three groups was detected. 
62
Chapter 4
Figure 4.2: Follicle population in 4-month-old WT, MRKI(+/-) and MRKI (-/-) mice ovaries.
From two WT, four MRKI(+/-) and six MRKI(-/-) animals the primordial, non-atretic small and atretic
small, non-atretic large and atretic large follicles were counted in a single ovary. The number of large
follicles was very low and not presented in this figure. Data represent the mean ± SEM. Asterisks
indicate a statistically significant difference (P≤0.05).
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Table 4.1: Weight of 4-months-old MRKI(+/+), MRKI(+/-) and MRKI(-/-) mice and their ovaries and uterus.
Values represent means ± SEM. No significant differences were measured.
WT MRKI(+/-) MRKI (-/-)
(n=2) (n=4) (n=6)
Animal weight (g) 21.8 ± 1.4 22.3 ± 0.2 22.1 ± 0.7
Ovary weight (mg) 4.1 ± 0.5 4.6 ± 0.5 6.3 ± 0.6
Uterine weight (mg) 83.0 ± 3.0 64.2 ± 6.8 63.8 ± 7.2
Table 4.2: Serum levels of inhibin A, inhibin B and FSH in 4-months-old WT, MRKI(+/-) and MRKI(-/-) mice.
Values represent the mean ± SEM. No significant differences were measured.
WT MRKI(+/-) MRKI(-/-)
(n=2) (n=4) (n=6)
Inhibin A (ng/l) 8.5 ± 6.5 20.8 ± 7.5 23.0 ± 12.1
Inhibin B (ng/l) 36.0 ± 18.0 49.3 ± 15.7 62.2 ± 9.2
FSH (ng/ml) 21.8 ± 2.1 10.5 ± 6.2 13.4 ± 4.3
all follicles primordial non-atretic atretic small
follicles small follicles follicles p≤0.05
The difference found between AMH(-/-) and MRKI(-/-) ovaries might be explained by ligand-independent
activity of the AMHRII. Formation of ligand-independent receptor complexes is possible and has been
described for BMPRII and ALK3 and ALK6 (Gilboa, et al., 2000). Whether such receptor complexes
do signal in the absence of ligand in vivo is unclear, but in vitro cotransfection of BMPRII with ALK3
or ALK6 showed signaling capabilities of these complexes without ligand (Gilboa, et al., 2000). In addition,
cotransfection of ALK4 with ActRII or ActRIIB and ALK2 with ActRIIB resulted in ligand-independent
signaling (Wang, et al., 2003) and the AMHRII can form ligand-independent complexes with all type
I receptors, when these receptors are overexpressed in cells (Gouédard, et al., 2000; Visser, 2003).
Further research is necessary to show if the AMHRII is capable of forming ligand-independent complexes
with type I receptors in vivo and if these complexes are capable of signaling. On basis of these data,
we hypothesize that AMH-signaling in MRKI(-/-) ovaries is blocked completely while in AMH(-/-)
ovaries some ligand-independent signaling takes place. Therefore, the ovarian phenotype in MRKI(-/-)
mice is similar but more severe than in AMH(-/-) mice.
Another possible explanation for the differences found between AMH(-/-) and MRKI(-/-)
phenotypes may be caused by AMH and AMHRII acting independently of each other. All five known
type II receptors signaling for TGFb superfamily members bind more than one ligand, except
AMHRII which only binds AMH. AMH signals through the BMP-like signaling pathway (Gouédard,
et al., 2000; Clarke, et al., 2001; Visser, et al., 2001) and it can be suggested that some BMPs also signal
through the AMHRII. Oppositely, it can be suggested that AMH signals through another type II receptor.
However, there are no indications for AMH-signaling through another type II receptor or binding of
another ligand to the AMHRII.
An explanation for the decrease of the number of primordial follicles might also be explained by
a decrease in primordial follicle formation. Primordial follicles are formed from the germ cells and
the surrounding ovarian tissue the day after birth. Progenitors of the germ cells are the primordial
germ cells (PGCs), which are first found in E7.5 mice in the allantois (Tam and Snow, 1981; Ginsburg,
et al., 1990). At E13, the PGCs have migrated to the ovary and at that time, AMHRII expression is
detected in mouse urogenital ridges and gonads and its expression is found until birth (Visser, et al.,
2001). It would be interesting to know if the AMHRII is also expressed between E7.5 and E13, since
during that period the PGCs proliferate and migrate towards the ovary (Tam and Snow, 1981;
Ginsburg, et al., 1990). Involvement of AMHRII by ligand-independent signaling or signaling by
other ligands in this process might influence the number of PGCs and thus the number of primordial
follicles in the ovary in MRKI(-/-) mice. In addition, AMHRII could be involved in the formation of
primordial follicles on the day after birth. At that time, AMHRII is already expressed (Chapter 5) and
might be involved in follicle formation. 
In conclusion, the phenotype of the MRKI(-/-) ovaries can be explained by the absence of AMH-
signaling. The decreased primordial follicle population in 4-month-old MRKI(-/-) compared to the
AMH(-/-) mice ovaries might be explained by the absence of ligand-independent signaling of the
AMHRII in the MRKI(-/-) ovaries. Thus, the phenotype of the ovaries between AMH(-/-) and
MRKI(-/-) mice are similar.
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Furthermore, the FSH serum levels were similar to the levels found in MRKI(-/-) mice. However, the
variations in serum levels between animals and the small number of WT animals investigated, show
that more research is necessary before drawing any conclusions. Recently, it was described that AMH
stimulates the FSHb mRNA expression in pituitary gonadotropin-derived cell lines (Bédécarrats, 
et al., 2003). However, if AMH influences FSHb expression in vivo is uncertain since AMH serum levels
hardly change in females during the menstrual cycle (Cook, et al., 2000) and inhibins have a major
influence on FSH production and secretion (Drummond, et al., 2000).
The AMHRII is the only described type II receptor for AMH and therefore we hypothesized that
the phenotype of AMH(-/-) and MRKI(-/-) ovaries would be similar. To test this hypothesis, we compared
the follicle population in ovaries of AMH(-/-) and MRKI(-/-) mice in more detail (Figure 4.3). The
ovaries of WT siblings of AMH(-/-) and MRKI(-/-) mice contained similar numbers of primordial,
small growing and atretic follicles (results not shown). In addition, no difference in the follicle population
could be found between AMH(+/-) and MRKI(+/-) mice (results not shown). Also the number of
small growing follicles, atretic follicles (Figure 4.3) and corpora lutea (results not shown) in the
MRKI(-/-) mice and the AMH(-/-) mice were similar. However, the number of primordial follicles
was significantly decreased in MRKI(-/-) mice, suggesting an increased depletion of the primordial
follicle pool. The phenotype of the AMH(+/-) mice ovaries was intermediate between the WT and
AMH(-/-) mice. It was suggested that this AMH production and secretion is not under stringent
feedback control and that the lower concentration of AMH protein was the cause of the intermediate
phenotype (Durlinger, et al., 1999). In contrast, the MRKI(+/-) phenotype is similar to the WT,
suggesting that the expression of the AMHRII is more strictly regulated than the AMH expression.
That deletion of one receptor gene does not necessarily result in a phenotype is shown by the LH
receptor (LHR)(+/-) mice of which the phenotype is similar to that of the WT, while the LHR(-/-)
mice do show a phenotype (Zhang, et al., 2001). It is unlikely that differences in AMH-signaling in
the ovary would cause changes in expression of the AMHRII, since expression of the AMHRII is not
under control of AMH: AMH treatment of neonatal ovaries or the mouse granulosa cell line
KK1/AMHRII did not affect AMHRII mRNA expression (unpublished results).
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Figure 4.3: Follicle population in 4-month-old MRKI(-/-) and AMH(-/-) mouse ovaries.
Similar number of small growing and atretic follicles and a decreased number of primordial and total follicles
was found in MRKI(-/-) compared to AMH(-/-) female ovaries. Data represent the mean ± SEM (n=4-6).
Asterisks indicate a statistically significant difference (P≤0.05).
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The difference found between AMH(-/-) and MRKI(-/-) ovaries might be explained by ligand-independent
activity of the AMHRII. Formation of ligand-independent receptor complexes is possible and has been
described for BMPRII and ALK3 and ALK6 (Gilboa, et al., 2000). Whether such receptor complexes
do signal in the absence of ligand in vivo is unclear, but in vitro cotransfection of BMPRII with ALK3
or ALK6 showed signaling capabilities of these complexes without ligand (Gilboa, et al., 2000). In addition,
cotransfection of ALK4 with ActRII or ActRIIB and ALK2 with ActRIIB resulted in ligand-independent
signaling (Wang, et al., 2003) and the AMHRII can form ligand-independent complexes with all type
I receptors, when these receptors are overexpressed in cells (Gouédard, et al., 2000; Visser, 2003).
Further research is necessary to show if the AMHRII is capable of forming ligand-independent complexes
with type I receptors in vivo and if these complexes are capable of signaling. On basis of these data,
we hypothesize that AMH-signaling in MRKI(-/-) ovaries is blocked completely while in AMH(-/-)
ovaries some ligand-independent signaling takes place. Therefore, the ovarian phenotype in MRKI(-/-)
mice is similar but more severe than in AMH(-/-) mice.
Another possible explanation for the differences found between AMH(-/-) and MRKI(-/-)
phenotypes may be caused by AMH and AMHRII acting independently of each other. All five known
type II receptors signaling for TGFb superfamily members bind more than one ligand, except
AMHRII which only binds AMH. AMH signals through the BMP-like signaling pathway (Gouédard,
et al., 2000; Clarke, et al., 2001; Visser, et al., 2001) and it can be suggested that some BMPs also signal
through the AMHRII. Oppositely, it can be suggested that AMH signals through another type II receptor.
However, there are no indications for AMH-signaling through another type II receptor or binding of
another ligand to the AMHRII.
An explanation for the decrease of the number of primordial follicles might also be explained by
a decrease in primordial follicle formation. Primordial follicles are formed from the germ cells and
the surrounding ovarian tissue the day after birth. Progenitors of the germ cells are the primordial
germ cells (PGCs), which are first found in E7.5 mice in the allantois (Tam and Snow, 1981; Ginsburg,
et al., 1990). At E13, the PGCs have migrated to the ovary and at that time, AMHRII expression is
detected in mouse urogenital ridges and gonads and its expression is found until birth (Visser, et al.,
2001). It would be interesting to know if the AMHRII is also expressed between E7.5 and E13, since
during that period the PGCs proliferate and migrate towards the ovary (Tam and Snow, 1981;
Ginsburg, et al., 1990). Involvement of AMHRII by ligand-independent signaling or signaling by
other ligands in this process might influence the number of PGCs and thus the number of primordial
follicles in the ovary in MRKI(-/-) mice. In addition, AMHRII could be involved in the formation of
primordial follicles on the day after birth. At that time, AMHRII is already expressed (Chapter 5) and
might be involved in follicle formation. 
In conclusion, the phenotype of the MRKI(-/-) ovaries can be explained by the absence of AMH-
signaling. The decreased primordial follicle population in 4-month-old MRKI(-/-) compared to the
AMH(-/-) mice ovaries might be explained by the absence of ligand-independent signaling of the
AMHRII in the MRKI(-/-) ovaries. Thus, the phenotype of the ovaries between AMH(-/-) and
MRKI(-/-) mice are similar.
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Furthermore, the FSH serum levels were similar to the levels found in MRKI(-/-) mice. However, the
variations in serum levels between animals and the small number of WT animals investigated, show
that more research is necessary before drawing any conclusions. Recently, it was described that AMH
stimulates the FSHb mRNA expression in pituitary gonadotropin-derived cell lines (Bédécarrats, 
et al., 2003). However, if AMH influences FSHb expression in vivo is uncertain since AMH serum levels
hardly change in females during the menstrual cycle (Cook, et al., 2000) and inhibins have a major
influence on FSH production and secretion (Drummond, et al., 2000).
The AMHRII is the only described type II receptor for AMH and therefore we hypothesized that
the phenotype of AMH(-/-) and MRKI(-/-) ovaries would be similar. To test this hypothesis, we compared
the follicle population in ovaries of AMH(-/-) and MRKI(-/-) mice in more detail (Figure 4.3). The
ovaries of WT siblings of AMH(-/-) and MRKI(-/-) mice contained similar numbers of primordial,
small growing and atretic follicles (results not shown). In addition, no difference in the follicle population
could be found between AMH(+/-) and MRKI(+/-) mice (results not shown). Also the number of
small growing follicles, atretic follicles (Figure 4.3) and corpora lutea (results not shown) in the
MRKI(-/-) mice and the AMH(-/-) mice were similar. However, the number of primordial follicles
was significantly decreased in MRKI(-/-) mice, suggesting an increased depletion of the primordial
follicle pool. The phenotype of the AMH(+/-) mice ovaries was intermediate between the WT and
AMH(-/-) mice. It was suggested that this AMH production and secretion is not under stringent
feedback control and that the lower concentration of AMH protein was the cause of the intermediate
phenotype (Durlinger, et al., 1999). In contrast, the MRKI(+/-) phenotype is similar to the WT,
suggesting that the expression of the AMHRII is more strictly regulated than the AMH expression.
That deletion of one receptor gene does not necessarily result in a phenotype is shown by the LH
receptor (LHR)(+/-) mice of which the phenotype is similar to that of the WT, while the LHR(-/-)
mice do show a phenotype (Zhang, et al., 2001). It is unlikely that differences in AMH-signaling in
the ovary would cause changes in expression of the AMHRII, since expression of the AMHRII is not
under control of AMH: AMH treatment of neonatal ovaries or the mouse granulosa cell line
KK1/AMHRII did not affect AMHRII mRNA expression (unpublished results).
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Figure 4.3: Follicle population in 4-month-old MRKI(-/-) and AMH(-/-) mouse ovaries.
Similar number of small growing and atretic follicles and a decreased number of primordial and total follicles
was found in MRKI(-/-) compared to AMH(-/-) female ovaries. Data represent the mean ± SEM (n=4-6).
Asterisks indicate a statistically significant difference (P≤0.05).
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ABSTRACT
Anti-Müllerian hormone (AMH) is a member of the TGFb superfamily which regulates follicle
development at two regulatory points. It inhibits the recruitment of primordial follicles into the growing
pool and decreases the sensitivity of large pre-antral and antral follicles to follicle stimulating hormone
(FSH). Thus, AMH plays an important role in determining the number of growing follicles in the
ovary. However, the signaling mechanism by which AMH mediates its effect in the ovary is unknown.
In the Müllerian ducts, AMH signals through its specific AMH type II receptor (AMHRII) and the
type I receptors ALK2, ALK3 and ALK6 have been implicated.
Here, we have investigated the AMH signaling pathway in the ovary. We found that AMH signals
through a BMP-like signaling pathway in the mouse granulosa cell line KK-1. In agreement with this,
AMH stimulation results in the phosphorylation of Smad1 and not Smad2.
In addition, we determined the expression level and localization of AMH-signaling mediators in
the ovary. All candidate type I receptors and downstream Smad proteins are expressed in the ovary albeit
at different levels. ALK2 mRNA expression was found in all cell types of the ovary, including the granulosa
cells. Interestingly, AMH stimulates the expression of the receptor-specific Smad8 and the inhibitory
Smad6 and Smad7 in both cultured neonatal ovaries and KK-1 cells stably expressing the AMHRII.
In conclusion, AMH signals through the BMP-like signaling pathway in the ovary and stimulates
an intracellular negative feedback loop formed by upregulation of Smad6 and Smad7 expression. All
candidate type I receptors and Smads are expressed in the ovary and therefore can be involved in
AMH-signaling.
INTRODUCTION
The ovary provides an environment where oocytes differentiate, mature and are selected for ovulation
and fertilization. Primordial follicles form the resting pool of follicles and development of the primordial
follicle to a pre-ovulatory follicle is under tight control of several intra-ovarian factors, such as members
of the transforming growth factor b (TGFb) superfamily of growth- and differentiation factors (such
as AMH, GDF9, BMP15, inhibin, activin) and systemic factors, like the pituitary-produced gonadotropins
follicle stimulating hormone (FSH) and luteinizing hormone (LH). Two important sites of regulation
during follicular development can be distinguished: recruitment of primordial follicles into the
growing pool and selection of large pre-antral and antral follicles for further growth to the pre-
ovulatory stage (McGee and Hsueh, 2000). Every primordial follicle that has entered the growing pool
will grow to the pre-ovulatory stage or be removed through the process of atresia.
Previously, we have found that anti-Müllerian hormone (AMH), a member of the TGFb
superfamily, is involved at both regulatory sites. Recruitment of primordial follicles is inhibited by
AMH, as was shown by the phenotype of AMH null mice. Ovaries of adult homozygous AMH null
mice contained less primordial and more growing follicles than control ovaries (Durlinger, et al.,
1999). This AMH effect was confirmed by culturing neonatal ovaries in the presence of AMH
(Chapter 3). By inhibiting primordial follicle recruitment, AMH prevents early depletion of the follicle
pool in the ovary and partially determines the size of the pool of growing follicles in the ovary. At selection,
AMH decreases the sensitivity of large pre-antral and antral follicles to FSH thereby controlling
the number of follicles that are selected to grow to the pre-ovulatory stage (Durlinger, et al., 2001).
Interestingly, the importance of AMH in the regulation of the growing pool is illustrated by the
expression pattern of AMH. AMH is expressed in granulosa cells immediately after recruitment of the
follicle and expression disappears after the follicle has been selected for growth to the pre-ovulatory
phase (Chapter 3). However, the mechanisms by which AMH inhibits primordial follicle recruitment
and decreases the sensitivity of large pre-antral and small antral follicles for FSH are unknown.
Members of the TGFb superfamily signal by binding to transmembrane serine/threonine (S/T)
kinase type I and II receptors (reviewed by Miyazono, et al., 2001). When ligands have formed a complex
with the type II receptor and the type I receptor, the type I receptor is phosphorylated at the GS-box.
Subsequently, the receptor-specific Smads (R-Smads) are phosphorylated by the type I receptor. The
phosphorylated R-Smads form a complex with the common Smad4 and this complex translocates to
the nucleus where it regulates gene transcription (reviewed by Miyazono, et al., 2001). Based on the
identity of the Smads that are used for downstream signaling, two main signaling pathways can be
distinguished. Smad2 and Smad3 are phosphorylated in the TGFb/activin-like signaling pathway
while in the BMP-like signaling pathway Smad1, Smad5 and Smad8 are activated (reviewed by Miyazono,
et al., 2001). The inhibitory Smads (I-Smads), Smad6 and Smad7, prevent phosphorylation of the 
R-Smads and in this way can block signaling of TGFb superfamily members. Smad7 functions as a
common I-Smad and inhibits both BMP- and TGFb/activin-like signaling whereas Smad6 preferentially
inhibits signaling of the BMP-like signaling pathway (Itoh, et al., 1998; Ishisaki, et al., 1999; Hanyu,
et al., 2001). Expression of these I-Smads is induced by TGFb/activin- or BMP-like signaling, thereby
providing an intracellular negative feedback mechanism for signaling by TGFb family members (Nakao,
et al., 1997; Takase, et al., 1998).
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The Netherlands) and stored at –80C. Cryosections of 5 µm were cut using a cryostat (Leica, Rijswijk,
The Netherlands), mounted on Superfrost®plus glass slides (Menzel, Omnilabo International BV,
Breda, The Netherlands) and stored at –80C until use.
AMH production and purification
Medium containing His6-tagged rat AMH was collected from stably transfected HEK293 cells as described
previously (Durlinger, et al., 2001). AMH was purified from this medium using the NiNTA superflow
Ni-column (Qiagen, Westburg, Leusden, The Netherlands). Subsequently, AMH was eluted from this
column using Hanks Balanced Salt Solution (HBSS) (Gibco BRL, Invitrogen, Breda, The Netherlands)
containing 250 nM imidazole (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) and collected
in siliconized tubes (Biozym, Landgraaf, The Netherlands) in the presence of 0.1% BSA. Next, a PD10
column (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) was used to remove the
imidazole. Control medium was obtained by purifying Ni-column elution buffer over a PD10 column.
Samples were stored at -20C.
Cell culture
The mouse granulosa cell line KK-1 (a kind gift of Dr. I. Huhtaniemi) was cultured in DMEM/F12 (Gibco)
containing 10% FCS and penicillin (400 IU/ml) and streptomycin (0.4 mg/ml). For AMH-induced
luciferase assays, KK-1 cells were seeded at 20% confluency in 24 wells plates (NUNC, VWR International
BV, Amsterdam, The Netherlands) and transfected with the 3TP-luc or BRE2-Luc reporter (150 ng/well)
and the indicated receptor expression vector (20 ng/well) using Fugene 6 transfection reagent (Roche
Diagnostics Nederland B.V., Almere, The Netherlands). Twenty-four hours after transfection, cells
were cultured for 2 hours in medium containing 0.2% FCS followed by 16 hours treatment with
AMH (33 ng/ml). Luciferase was measured using the Steady-Glo® Luciferase Assay (Promega, Leiden,
The Netherlands) in the TOPCOUNT (Packard, Applied Biosystems, Nieuwekerk a/d IJssel, The
Netherlands) luminometer. In all transfections, b-galactosidase expression plasmid (pSV40-bgal)
served as internal control to normalize for transfection efficiency. Plasmids containing rat AMHRII,
BMPRII, ActRIIB and TbRII and empty expression vectors were described previously (Visser, et al.,
2001). The BRE2-Luc plasmid was a kind gift of Dr. P. ten Dijke.
For AMH-induced gene expression experiments, KK-1 cells stably expressing the AMHRII were
generated. These KK-1/AMHRII cells were cultured in DMEM/F12 in 10% FCS, penicillin (400 IU/ml)
and streptomycin (0.4 mg/ml). At a cell confluency of 80%, cells were cultured for 2 hours in 0.2%
FCS, followed by a 24 hour treatment with AMH (33 ng/ml). Next, cells were washed with PBS and
stored at -20C in RNA-Bee (Campro Scientific, Veenendaal, The Netherlands). 
Smad activation experiments and Western blot analysis
KK-1 cells were transiently transfected with Flag-tagged Smad constructs using Fugene 6 transfection
reagent. Twenty-four hours after transfection, cells were starved overnight in low serum medium
(0.2% FCS), followed by incubation with ligand for 1 hour. Next, cells were washed once with cold
PBS and lysed in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100)
containing phosphatase and protease inhibitors (Sigma). Equal amounts of protein were separated on
SDS-PAGE, transferred to nitrocellulose membranes, and subjected to immunoblotting with aPS1 or
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For AMH, the specific type II receptor (AMHRII) has been identified and cloned (Baarends, et al.,
1994; di Clemente, et al., 1994b). Recently, more knowledge about other components of the AMH-
signaling pathway has been obtained. It was found that AMH signals through the BMP-like signaling
pathway in non-ovarian cells (Gouédard, et al., 2000; Clarke, et al., 2001; Visser, et al., 2001). The type I
receptors ALK2, ALK3 and ALK6 are candidate receptors involved in AMH-signaling. Dominant-negative
and antisense approaches in cell lines showed that ALK2 is necessary for AMH-signaling (Clarke, 
et al., 2001; Visser, et al., 2001). In addition, Müllerian duct regression is inhibited by antisense ALK2
(Visser, et al., 2001). ALK3 also plays a role in AMH-signaling, as indicated by the presence of
persistent Müllerian ducts in conditional ALK3 null mice (Jamin, et al., 2002). Interestingly, when
conditional ALK3 null mice are crossbred with mice overexpressing AMH, Müllerian duct regression
occurs normally (Jamin, et al., 2003). This suggests that, in the presence of high AMH levels, receptor(s)
different from ALK3 can act as AMH type I receptor, at least in the process of Müllerian duct regression.
Furthermore, the involvement of ALK6 in AMH-signaling was suggested, based on the observation
that AMH-induced a ligand-dependent AMHRII/ALK6 receptor complex (Gouédard, et al., 2000).
However, the ALK6 null mouse model (Clarke, et al., 2001), the expression pattern of ALK6 in the
Müllerian ducts (Dewulf, et al., 1995; Clarke, et al., 2001) and in vitro experiments in which the role
of ALK6 in AMH-signaling is investigated (Clarke, et al., 2001; Visser, et al., 2001) suggest that ALK6 is
not involved in AMH-signaling in Müllerian duct regression, although a role for ALK6 in AMH-signaling
in the ovary cannot be ruled out yet.
To determine whether AMH signals through a similar mechanism in the ovary, we have studied
the function of its signaling components in this organ. Using the mouse granulosa cell line KK-1, we
determined the pathway through which AMH signals in ovarian cells. Moreover, candidate type I
receptors for AMH must be co-expressed with AMHRII in ovarian cells. Therefore, we have determined
the expression pattern of AMHRII and candidate type I receptors in developing postnatal ovaries. In
addition, we measured mRNA expression of candidate AMH-signaling components in these ovaries.
We concluded that ALK2 is a candidate type I receptor for AMH in the ovary, since it was expressed
by granulosa cells of all follicle types. In addition, we show that AMH stimulates expression of the
inhibitory Smad6 and Smad7, thereby forming an intracellular negative feedback loop.
MATERIALS AND METHODS
Animals 
Mice were obtained from the Animal Facility (EDC) of the Erasmus MC. Mice were maintained
under standard animal housing conditions in accordance with NIH guidelines for the care and use of
experimental animals. Ovaries were isolated at 2, 6, 12, 18 and 25 days of age, snap frozen in liquid
nitrogen and stored at -80C. Ovaries of 2-day-old AMH null mice were cultured under similar conditions
as previously described (Chapter 3), using purified rat AMH (533 ng/ml). AMH null mouse genotype
was determines as described by Durlinger et al. (1999).
For in situ hybridizations, ovaries of 18-day-old mice were fixed in 4% paraformaldehyde (PFA)
at room temperature for 3 hours and subsequently incubated overnight at 4C in 30% sucrose dissolved
in phosphate-buffered saline (PBS). Next, ovaries were embedded in Tissue Tek (Bayer BV, Mijdrecht,
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200 or 100 nM of FAM-TAMRA probe (Eurogentec, Maastricht, The Netherlands), 4mM MgCl2, 0.2 mM
dNTPs (Amersham Pharmacia Biotech), 1.25 U AmplitaqGold in sample buffer A (Applied Biosystems)
in a volume of 50 ml. Samples were heated for 2 minutes at 50C, 10 minutes at 95C and amplified for
40 cycles of 15 seconds at 95C and 60 seconds at 60C (Meijerink et. al., 2001). These PCR conditions
were also used to determine the expression of AMH-signaling components in KK-1 cells. Measurements
using SYBRgreen (Applied Biosystems) were performed with 20 ng of total RNA in the presence of
300 nM primers (Invitrogen) in a total volume of 25 µl using the same amplification conditions. 
b-actin levels were used as a internal control to correct for differences in reverse transcriptase efficiency.
Primers and probes were developed using the Oligo 6.22 computer software (Molecular Biology
Insights Inc., Cascade, USA) and are listed in Table 5.1. All primers and probe combination functioned
at an efficiency of 100%. 
Statistical analysis
Results are presented as mean ± SD or SEM. The data were analyzed for statistical differences by a
dependent samples t-test or by one-way analysis of variance (ANOVA), followed by a Duncan’s new
multiple range test using SPSS, Inc9.0 (SPSS, Inc., Chicago, IL) computer software. Differences were
considered to be significant at P≤0.05.
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aPS2 antibodies (kind gift of Dr. A. Moustakas). Total Smad levels were detected with an a-Flag M2
monoclonal antibody (Sigma). Proteins were visualized by enhanced chemoluminescence (ECL,
Amersham).
In situ hybridization
To detect expression of AMHRII and ALK2 mRNA in the ovary, in situ hybridizations were performed.
The AMHRII and ALK2 templates to generate sense and antisense DIG-labeled transcripts for in situ
hybridization were described previously (Visser, et al., 1998, 2001). Probes were labeled using the DIG
RNA labeling kit (Sp6/T7) (Roche), purified using Sephadex G-50 column (Amersham Pharmacia
Biotech) and tested for labeling efficiency by Northern blotting. 
Cryostat sections were air dried, fixed in 4% PFA on ice for 5 min and washed with PBS.
Subsequently, sections were treated for 15 min at room temperature with proteinase K (1 µg/ml in 10 mM
TrisHCl, pH 7.6) and postfixed in 4% PFA for 5 min at 4C. Slides were washed in PBS and non-specific
binding was blocked by treatment of the slides with 0.1 M triethanolamine and acetic anhydride. Slides
were washed with PBS and dehydrated. Probes (sense and antisense) were heated for 1 min at 85C
and added to the hybridization buffer (50% formamide, 1xDenhardt’s solution, 5mM EDTA, 10%
dextransulphate, 500 µg/ml tRNA, 10 mM TrisHCl (pH 8.0), 300 mM NaCl, 10 mM NaH2PO4), which
was also preheated at 85C. The hybridization mix was added to the slides and incubated overnight at
55C in a humidified chamber. Next, slides were washed with 4xSSC/50% formalin, 2xSCC and treated
with RNAse A (20 µg/ml) at 37C for 30 min to remove none hybridized probe. Next, slides were washed
with 0.2% SCC and incubated in 100 mM TrisHCl (pH 7.6), 150 mM NaCl (TN-buffer). Non-specific
binding of the anti-DIG antibody was blocked using Antibody diluent (Cell Marque, ITK Diagnostics
BV, Uithoorn, The Netherlands) for 30 min at room temperature. Slides were incubated overnight at
4C with an 1:1000 dilution of the anti-DIG antibody (Roche) in TN buffer. The next day, signal was
detected using NBT-BCIP (Roche). The staining reaction was stopped with 2mM TrisHCl (pH=7.6),
10 mM EDTA and rinsed with water. 
RNA isolation, cDNA synthesis and real-time PCR
RNA was isolated from ovaries and KK-1 cells using RNA-Bee according to the manufacturer’s protocol
(Campro Scientific). Additionally, 1 µg of RNase-free glycogen was added before RNA precipitation
(Roche Diagnostics). Genomic DNA was removed by RNase-free DNAse (Stratagene, Amsterdam,
The Netherlands) treatment for one hour at 37C in a buffer (40 mM TrisHCl, 6 mM MgCl2, 2 mM CaCl2)
also containing the RNAse inhibitor RNAsin (Promega). 
Total mRNA was measured using Ribogreen™ RNA Quantitation Kit (Molecular Probes, Leiden,
The Netherlands). cDNA was synthesized using a mix of random nucleotide hexamers (Roche
Diagnostics) and 200 nM oligo dT (Promega). The 25 µl RT buffer contained 8 U/µl mmLV (Promega),
0.2 mM dNTP (Amersham Pharmacia Biotech) and 1 U/µl RNAsin (Promega). All samples were checked
for the presence of genomic DNA in a RT minus reaction, measuring b-actin using SYBRgreen reagent.
If genomic DNA was present, a second DNAse-treatment of the RNA was performed.
Quantitative real-time PCR amplification reactions were performed using an Applied Biosystems
Sequence Detector 7700. For measurements with a FAM-TAMRA probe, 40 ng of total mRNA was
amplified in duplicate in the presence of 300 nM primers (Invitrogen, Breda, The Netherlands), 
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Table 5.1.Oligonucleotide primer sequences used to measure gene expression in KK-1/AMHRII cells and 
postnatal ovaries. 
A. Oligonucleotide primers and FAM-TAMRA probe sequences used to amplify AMHRII, ALK2, ALK3, ALK6, Smad1, Smad5,
Smad6, Smad7, Smad8 and b-actin cDNA with quantitative real-time PCR in postnatal ovaries and KK-1 cells. In addition,
Smad8 primers and probes were used to measure Smad8 expression in AMH-treated KK-1/AMHRII cells and neonatal
ovaries cultured with AMH. 
B. Oligonucleotide primer sequences used to amplify Smad6, Smad7 and b-actin cDNA using SYBRgreen quantitative real-
time PCR in KK-1/AMHRII cells treated with AMH and neonatal ovaries cultured with AMH. SYBRgreen was used because
of the lack of neonatal ovary cDNA. Less cDNA is necessary to perform quantitative real-time PCR with SYBRgreen than
with FAM-TAMRA probes.
A. Product size 
Gene: Primers: Probe: (bp):
AMHRII 5’-CTC TGG CGC TAC TAC TGT G-3’ 5’-AGA TCC TGA GCC GCT GTT CC-3’ 257
5’-TGT CAG CCG TGC TTC T-3’
ALK2 5’-GCC CAT TTG CAC ATA GAG-3’ 5’-TGG TGA AGA AGA ATG GAC AGT GCT-3’ 273
5’-AAA GGC CCA AAT ATC GAC-3’
ALK3 5’-CAT TTC CAG CCC TAC ATC-3’ 5’-ATG AGG ACA TGC GTG AGG TTG T-3’ 206
5’-CTG TTC CAG CGG TTA GAC-3’
ALK6 5’-GAC GGC CCT GAG AGT TA-3’ 5’-ACG TCA GAT ACT TGT GGA CAG AGC A-3’ 145
5’-CAC TGG GCA GTA GGC TAA-3’
Smad1 5’-CGG CTG CAA ATG TAG ACT A-3’ 5’-TCC TTC TGT TCG CAA ATC AAC TG-3’ 302
5’-TTG GAA ATC AAA GCC TAT GT-3’
Smad5 5’-TCT GGC TCA GTC AGT CAA C-3’ 5’-AGT ACC ACC GAC AGG ACG TCA C-3’ 218
5’-CAG AAG AAA TGG GGT TCA-3’
Smad6 5’-CCC CAT CTT CGT CAA CT-3’ 5’-CCG GGT TAC TCC ATC AAG GTG-3’ 223
5’-GCA GGA GGT GAT GAA CTG -3’
Smad7 5’-ACT GGA CAA CCC GGA-3’ 5’-TGT TGG TGC ACA AAG TGT TCC C-3’ 95
5’-GCA GGC TGT AGG CTT TC-3’
Smad8 5’-GTA CCA AGA CAC AGC GAG TA-3’ 5’-CGC CAC CTA CCC TGA CTC TTT-3’ 242
5’-CGG AAG TCT GAG TGT TGA TA-3’
b-actin 5’-CTA CGA GGG CTA TGC TCT C-3’ 5’-ACC GAG CGT GGC TAC AGC TT-3’ 283
5’-CTC AGG GCA TCG GAA-3’
200 or 100 nM of FAM-TAMRA probe (Eurogentec, Maastricht, The Netherlands), 4mM MgCl2, 0.2 mM
dNTPs (Amersham Pharmacia Biotech), 1.25 U AmplitaqGold in sample buffer A (Applied Biosystems)
in a volume of 50 ml. Samples were heated for 2 minutes at 50C, 10 minutes at 95C and amplified for
40 cycles of 15 seconds at 95C and 60 seconds at 60C (Meijerink et. al., 2001). These PCR conditions
were also used to determine the expression of AMH-signaling components in KK-1 cells. Measurements
using SYBRgreen (Applied Biosystems) were performed with 20 ng of total RNA in the presence of
300 nM primers (Invitrogen) in a total volume of 25 µl using the same amplification conditions. 
b-actin levels were used as a internal control to correct for differences in reverse transcriptase efficiency.
Primers and probes were developed using the Oligo 6.22 computer software (Molecular Biology
Insights Inc., Cascade, USA) and are listed in Table 5.1. All primers and probe combination functioned
at an efficiency of 100%. 
Statistical analysis
Results are presented as mean ± SD or SEM. The data were analyzed for statistical differences by a
dependent samples t-test or by one-way analysis of variance (ANOVA), followed by a Duncan’s new
multiple range test using SPSS, Inc9.0 (SPSS, Inc., Chicago, IL) computer software. Differences were
considered to be significant at P≤0.05.
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aPS2 antibodies (kind gift of Dr. A. Moustakas). Total Smad levels were detected with an a-Flag M2
monoclonal antibody (Sigma). Proteins were visualized by enhanced chemoluminescence (ECL,
Amersham).
In situ hybridization
To detect expression of AMHRII and ALK2 mRNA in the ovary, in situ hybridizations were performed.
The AMHRII and ALK2 templates to generate sense and antisense DIG-labeled transcripts for in situ
hybridization were described previously (Visser, et al., 1998, 2001). Probes were labeled using the DIG
RNA labeling kit (Sp6/T7) (Roche), purified using Sephadex G-50 column (Amersham Pharmacia
Biotech) and tested for labeling efficiency by Northern blotting. 
Cryostat sections were air dried, fixed in 4% PFA on ice for 5 min and washed with PBS.
Subsequently, sections were treated for 15 min at room temperature with proteinase K (1 µg/ml in 10 mM
TrisHCl, pH 7.6) and postfixed in 4% PFA for 5 min at 4C. Slides were washed in PBS and non-specific
binding was blocked by treatment of the slides with 0.1 M triethanolamine and acetic anhydride. Slides
were washed with PBS and dehydrated. Probes (sense and antisense) were heated for 1 min at 85C
and added to the hybridization buffer (50% formamide, 1xDenhardt’s solution, 5mM EDTA, 10%
dextransulphate, 500 µg/ml tRNA, 10 mM TrisHCl (pH 8.0), 300 mM NaCl, 10 mM NaH2PO4), which
was also preheated at 85C. The hybridization mix was added to the slides and incubated overnight at
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with RNAse A (20 µg/ml) at 37C for 30 min to remove none hybridized probe. Next, slides were washed
with 0.2% SCC and incubated in 100 mM TrisHCl (pH 7.6), 150 mM NaCl (TN-buffer). Non-specific
binding of the anti-DIG antibody was blocked using Antibody diluent (Cell Marque, ITK Diagnostics
BV, Uithoorn, The Netherlands) for 30 min at room temperature. Slides were incubated overnight at
4C with an 1:1000 dilution of the anti-DIG antibody (Roche) in TN buffer. The next day, signal was
detected using NBT-BCIP (Roche). The staining reaction was stopped with 2mM TrisHCl (pH=7.6),
10 mM EDTA and rinsed with water. 
RNA isolation, cDNA synthesis and real-time PCR
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The Netherlands) treatment for one hour at 37C in a buffer (40 mM TrisHCl, 6 mM MgCl2, 2 mM CaCl2)
also containing the RNAse inhibitor RNAsin (Promega). 
Total mRNA was measured using Ribogreen™ RNA Quantitation Kit (Molecular Probes, Leiden,
The Netherlands). cDNA was synthesized using a mix of random nucleotide hexamers (Roche
Diagnostics) and 200 nM oligo dT (Promega). The 25 µl RT buffer contained 8 U/µl mmLV (Promega),
0.2 mM dNTP (Amersham Pharmacia Biotech) and 1 U/µl RNAsin (Promega). All samples were checked
for the presence of genomic DNA in a RT minus reaction, measuring b-actin using SYBRgreen reagent.
If genomic DNA was present, a second DNAse-treatment of the RNA was performed.
Quantitative real-time PCR amplification reactions were performed using an Applied Biosystems
Sequence Detector 7700. For measurements with a FAM-TAMRA probe, 40 ng of total mRNA was
amplified in duplicate in the presence of 300 nM primers (Invitrogen, Breda, The Netherlands), 
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Table 5.1.Oligonucleotide primer sequences used to measure gene expression in KK-1/AMHRII cells and 
postnatal ovaries. 
A. Oligonucleotide primers and FAM-TAMRA probe sequences used to amplify AMHRII, ALK2, ALK3, ALK6, Smad1, Smad5,
Smad6, Smad7, Smad8 and b-actin cDNA with quantitative real-time PCR in postnatal ovaries and KK-1 cells. In addition,
Smad8 primers and probes were used to measure Smad8 expression in AMH-treated KK-1/AMHRII cells and neonatal
ovaries cultured with AMH. 
B. Oligonucleotide primer sequences used to amplify Smad6, Smad7 and b-actin cDNA using SYBRgreen quantitative real-
time PCR in KK-1/AMHRII cells treated with AMH and neonatal ovaries cultured with AMH. SYBRgreen was used because
of the lack of neonatal ovary cDNA. Less cDNA is necessary to perform quantitative real-time PCR with SYBRgreen than
with FAM-TAMRA probes.
A. Product size 
Gene: Primers: Probe: (bp):
AMHRII 5’-CTC TGG CGC TAC TAC TGT G-3’ 5’-AGA TCC TGA GCC GCT GTT CC-3’ 257
5’-TGT CAG CCG TGC TTC T-3’
ALK2 5’-GCC CAT TTG CAC ATA GAG-3’ 5’-TGG TGA AGA AGA ATG GAC AGT GCT-3’ 273
5’-AAA GGC CCA AAT ATC GAC-3’
ALK3 5’-CAT TTC CAG CCC TAC ATC-3’ 5’-ATG AGG ACA TGC GTG AGG TTG T-3’ 206
5’-CTG TTC CAG CGG TTA GAC-3’
ALK6 5’-GAC GGC CCT GAG AGT TA-3’ 5’-ACG TCA GAT ACT TGT GGA CAG AGC A-3’ 145
5’-CAC TGG GCA GTA GGC TAA-3’
Smad1 5’-CGG CTG CAA ATG TAG ACT A-3’ 5’-TCC TTC TGT TCG CAA ATC AAC TG-3’ 302
5’-TTG GAA ATC AAA GCC TAT GT-3’
Smad5 5’-TCT GGC TCA GTC AGT CAA C-3’ 5’-AGT ACC ACC GAC AGG ACG TCA C-3’ 218
5’-CAG AAG AAA TGG GGT TCA-3’
Smad6 5’-CCC CAT CTT CGT CAA CT-3’ 5’-CCG GGT TAC TCC ATC AAG GTG-3’ 223
5’-GCA GGA GGT GAT GAA CTG -3’
Smad7 5’-ACT GGA CAA CCC GGA-3’ 5’-TGT TGG TGC ACA AAG TGT TCC C-3’ 95
5’-GCA GGC TGT AGG CTT TC-3’
Smad8 5’-GTA CCA AGA CAC AGC GAG TA-3’ 5’-CGC CAC CTA CCC TGA CTC TTT-3’ 242
5’-CGG AAG TCT GAG TGT TGA TA-3’
b-actin 5’-CTA CGA GGG CTA TGC TCT C-3’ 5’-ACC GAG CGT GGC TAC AGC TT-3’ 283
5’-CTC AGG GCA TCG GAA-3’
AMH-induced activation of the BMP-responsive BRE2-Luc reporter, AMH treatment resulted in
phosphorylation of Smad1, but not Smad2 (Figure 5.2). In conclusion, these results indicate that AMH
signals through a BMP-like signaling pathway in an ovary-derived cell line.
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RESULTS
AMH induces a BMP-like response in granulosa cells
We have investigated whether AMH-signaling in the ovary is mediated through the BMP-like signaling
pathway. KK-1 cells, a granulosa cell line derived from gonadal tumors from transgenic mice expressing
the Simian virus 40 T-antigens driven by the mouse inhibin a-subunit promoter (Kananen, et al.,
1995), were transiently transfected with either the TGFb/activin-responsive 3TP-Luc reporter or the
BMP-responsive BRE2-Luc reporter. AMH treatment of KK-1 cells resulted in an activation of the
BMP-responsive reporter only upon cotransfection with the AMHRII. AMH-signaling specifically
requires the presence of AMHRII as none of the other type II receptors could activate the BRE2-Luc
reporter in presence of AMH (Figure 5.1). In agreement with previous studies, AMH was unable to
activate the TGFb/activin-responsive reporter in KK-1 cells (Figure 5.1). 
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Table 5.1.
B. Product size
Gene: Forward primer: Reverse primer: (bp):
Smad6 5’-CCC CAT CTT CGT CAA CT-3’ 5’-CGC TCA AAG TCG AAC AC-3’ 105
Smad7 5’-CTC CAG GAC GCT GTT G-3’ 5’-TGC ATG AAC TCG TGG TC-3’ 108
b-actin 5’-CTA CGA GGG CTA TGC TCT-3’ 5’-TCG TTG CCA ATA GTG ATG-3’ 264
Figure 5.1: AMH signals through a BMP-like signaling pathway in KK-1 cells.
KK-1 cells were transiently transfected with a TGFb/activin-responsive (3TP-Luc) or BMP-responsive
(BRE2-Luc) reporter gene together with the indicated type II receptors or the empty expression vector
pRK5. Cells were incubated overnight in the presence of control medium (control, open bars) or purified
AMH (closed bars). The relative luciferase activity was measured in cell lysates and normalized to 
b-galactosidase activity. Data are given as mean ± SD of triplicates in one experiment and are
representative for at least three independent experiments. 
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We next determined which Smad proteins were activated in response to AMH using phospho-specific
Smad antibodies. These antibodies recognize the phosphorylated C-terminal serines of the Smad proteins
but not the unphosphorylated proteins (Persson, et al., 1998). KK-1 cells were transiently transfected
with Smad1 or Smad2 and stimulated with AMH or TGFb for 1 hour. As expected, TGFb induced
phosphorylation of Smad2 (Figure 5.2) but not Smad1 (results not shown). In agreement with the
Expression of members of the AMH-signaling pathway in
KK-1 cells and mouse ovaries
AMH signals through the BMP-like signaling pathway and therefore Smad1, Smad5, Smad8, the type
I receptors ALK2, ALK3, ALK6 and the inhibitory Smad6 and Smad7 are candidate components of
the AMH-signaling pathway. To determine which of the AMH-signaling components are present in
KK-1 cells, RT-PCR analysis was performed. RNAse protection assay showed the almost complete
absence of AMH and AMHRII in these cells (results not shown), which is in agreement with the lack
of activation of the BMP-responsive reporter when the AMHRII was not cotransfected. All three
candidate type I receptors were expressed in KK-1 cells (Figure 5.3). ALK6 was expressed at lower
levels, which was supported by quantitative real-time PCR experiments (results not shown).
Furthermore, KK-1 cells expressed all receptor-specific Smads (Smad1, Smad5 and Smad8) and the
inhibitory Smad6 and Smad7. Thus, all candidate members of AMH-signaling pathway are expressed
in the KK-1 cell line.
Figure 5.2: AMH induces Smad1 phosphorylation.
KK-1/AMHRII cells were transiently transfected with Flag-tagged Smad1 or Smad2 and stimulated with
AMH or TGFb. Phosphorylation of Smad proteins was detected with aPS1 or aPS2 antibodies. Total
Smad proteins were detected with a a-Flag M2 antibody.
Figure 5.3: mRNA expression of members of AMH-signaling in KK-1 cells.
Expression of ALK2 (273 bp), ALK3 (206 bp), ALK6 (145 bp), Smad1 (302 bp), Smad5 (218 bp), Smad8
(242 bp), Smad6 (223 bp) and Smad7 (95 bp) was determined in KK-1 cells under quantitative real-time
PCR conditions after separation on a 1.5% agarose gel.
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AMH-induced activation of the BMP-responsive BRE2-Luc reporter, AMH treatment resulted in
phosphorylation of Smad1, but not Smad2 (Figure 5.2). In conclusion, these results indicate that AMH
signals through a BMP-like signaling pathway in an ovary-derived cell line.
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RESULTS
AMH induces a BMP-like response in granulosa cells
We have investigated whether AMH-signaling in the ovary is mediated through the BMP-like signaling
pathway. KK-1 cells, a granulosa cell line derived from gonadal tumors from transgenic mice expressing
the Simian virus 40 T-antigens driven by the mouse inhibin a-subunit promoter (Kananen, et al.,
1995), were transiently transfected with either the TGFb/activin-responsive 3TP-Luc reporter or the
BMP-responsive BRE2-Luc reporter. AMH treatment of KK-1 cells resulted in an activation of the
BMP-responsive reporter only upon cotransfection with the AMHRII. AMH-signaling specifically
requires the presence of AMHRII as none of the other type II receptors could activate the BRE2-Luc
reporter in presence of AMH (Figure 5.1). In agreement with previous studies, AMH was unable to
activate the TGFb/activin-responsive reporter in KK-1 cells (Figure 5.1). 
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Table 5.1.
B. Product size
Gene: Forward primer: Reverse primer: (bp):
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Figure 5.1: AMH signals through a BMP-like signaling pathway in KK-1 cells.
KK-1 cells were transiently transfected with a TGFb/activin-responsive (3TP-Luc) or BMP-responsive
(BRE2-Luc) reporter gene together with the indicated type II receptors or the empty expression vector
pRK5. Cells were incubated overnight in the presence of control medium (control, open bars) or purified
AMH (closed bars). The relative luciferase activity was measured in cell lysates and normalized to 
b-galactosidase activity. Data are given as mean ± SD of triplicates in one experiment and are
representative for at least three independent experiments. 
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We next determined which Smad proteins were activated in response to AMH using phospho-specific
Smad antibodies. These antibodies recognize the phosphorylated C-terminal serines of the Smad proteins
but not the unphosphorylated proteins (Persson, et al., 1998). KK-1 cells were transiently transfected
with Smad1 or Smad2 and stimulated with AMH or TGFb for 1 hour. As expected, TGFb induced
phosphorylation of Smad2 (Figure 5.2) but not Smad1 (results not shown). In agreement with the
Expression of members of the AMH-signaling pathway in
KK-1 cells and mouse ovaries
AMH signals through the BMP-like signaling pathway and therefore Smad1, Smad5, Smad8, the type
I receptors ALK2, ALK3, ALK6 and the inhibitory Smad6 and Smad7 are candidate components of
the AMH-signaling pathway. To determine which of the AMH-signaling components are present in
KK-1 cells, RT-PCR analysis was performed. RNAse protection assay showed the almost complete
absence of AMH and AMHRII in these cells (results not shown), which is in agreement with the lack
of activation of the BMP-responsive reporter when the AMHRII was not cotransfected. All three
candidate type I receptors were expressed in KK-1 cells (Figure 5.3). ALK6 was expressed at lower
levels, which was supported by quantitative real-time PCR experiments (results not shown).
Furthermore, KK-1 cells expressed all receptor-specific Smads (Smad1, Smad5 and Smad8) and the
inhibitory Smad6 and Smad7. Thus, all candidate members of AMH-signaling pathway are expressed
in the KK-1 cell line.
Figure 5.2: AMH induces Smad1 phosphorylation.
KK-1/AMHRII cells were transiently transfected with Flag-tagged Smad1 or Smad2 and stimulated with
AMH or TGFb. Phosphorylation of Smad proteins was detected with aPS1 or aPS2 antibodies. Total
Smad proteins were detected with a a-Flag M2 antibody.
Figure 5.3: mRNA expression of members of AMH-signaling in KK-1 cells.
Expression of ALK2 (273 bp), ALK3 (206 bp), ALK6 (145 bp), Smad1 (302 bp), Smad5 (218 bp), Smad8
(242 bp), Smad6 (223 bp) and Smad7 (95 bp) was determined in KK-1 cells under quantitative real-time
PCR conditions after separation on a 1.5% agarose gel.
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development in the first 25 days. ALK3 expression levels remained constant during all timepoints
studied. In contrast, ALK6 mRNA expression increased from day 2 to day 18 (6-fold) and an even
stronger increase of expression was observed from day 18 to day 25.
Of the three possibly receptor-specific Smads involved, Smad1 and Smad5 were most abundantly
expressed at constant levels during follicular development. In contrast, Smad8 expression could hardly
be detected at any stage of ovarian development although a significant increase (8-fold) in expression
was observed from day 18 to day 25. In addition, constant mRNA expression levels of the inhibitory
Smads (Smad6 and Smad7) were found between day 2 and day 18. Like for Smad8, an increase in
expression of Smad6 and Smad7 was found in 25-day-old ovaries (Figure 5.4). 
Localization of expression of members of 
the AMH-signaling pathway in the ovary
To be involved in AMH-signaling, type I receptors should be colocalized with the AMHRII. Therefore,
we performed in situ hybridizations of AMHRII and ALK2 to determine localization of expression in
the ovary. The AMHRII mRNA was expressed in granulosa cells of growing follicles (Figure 5.5 A-E).
Expression was first detected in granulosa cells of primary follicles (Figure 5.5C), AMHRII mRNA
was highly expressed in granulosa cells of pre-antral follicles (Figure 5.5D) and disappeared in large
pre-antral and antral follicles (Figure 5.5D). No expression was detected in oocytes, theca or
interstitial cells (Figure 5.5A, C and D) or in the sense slides (Figure 5.5B and E). 
Expression of ALK2 mRNA was detected in granulosa, theca and interstitial cells but not in the
oocytes (Figure 5.5F-J). Staining levels of ALK2 mRNA were similar in the granulosa and theca cells
of all follicle types and in interstitial cells (Figure 5.5F, H and I). ALK2 mRNA staining was absent in
the control sections (Figure 5.5G and J). 
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To determine which type I receptor and Smad proteins are involved in AMH-signaling in the ovary,
we measured the mRNA expression of candidate signaling components in differently aged postnatal
ovaries of wild-type mice (Figure 5.4). Each time point reflects a different stage of follicle differentiation.
Primordial follicles are the only follicles found in ovaries of 2-day-old mice, whereas at day 6 ovaries
also contain primary follicles. In 12-day-old ovaries pre-antral follicles are present and antral follicles
are first found in ovaries of 18-day-old mice. All antral and large pre-antral follicles have become
atretic in ovaries of 25-day-old mice.
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Figure 5.4. Expression levels of different candidate components of AMH-signaling in mouse ovaries.
Expression was measured in ovaries of 2-,6-, 12-, 18- and 25-day-old wild-type mice by quantitative
real-time PCR with FAM-TAMRA probes. Expression of all genes has been corrected for b-actin
expression. Open bars represent AMHRII, black bars represent the type I receptors, hatched bars the 
R-Smads and gray bars the inhibitory Smads. 
Data represent means ± SEM. a, b, c, d, e indicate a significant difference from day 2, 6, 12, 18 and 25
respectively (P≤0.05). For each age 3 independent pools of ovaries were measured.
Note the difference in scale of the Y-axes of the different graphs.
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AMHRII mRNA was abundantly expressed in 2-day-old ovaries, but its expression decreased from
day 2 to day 6. From day 6 onward, AMHRII expression increased until day 25. All candidate type I
receptors were expressed in the postnatal ovary, albeit at different levels. ALK2 was expressed at a
lower level, compared to ALK3 or ALK6, but showed a 3-fold increase in expression during ovarian
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Figure 5.5: In situ hybridization of AMHRII and ALK2 in 18-day-old mouse ovaries.
AMHRII mRNA is detected in granulosa cells of growing follicles (A, C, D) and not in the control slides
(B-E). It is present in primary (PY) and small pre-antral (SPA) follicles and expression decreases in
granulosa cells of large pre-antral (LPA) and antral (AF) follicles. ALK2 mRNA is detected in granulosa,
theca and interstitial cells (F, H, I) and not in the control slides (G, J). No difference in expression level
can be determined between granulosa and theca cells in primary, pre-antral, antral follicles and the
surrounding interstitium.
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development in the first 25 days. ALK3 expression levels remained constant during all timepoints
studied. In contrast, ALK6 mRNA expression increased from day 2 to day 18 (6-fold) and an even
stronger increase of expression was observed from day 18 to day 25.
Of the three possibly receptor-specific Smads involved, Smad1 and Smad5 were most abundantly
expressed at constant levels during follicular development. In contrast, Smad8 expression could hardly
be detected at any stage of ovarian development although a significant increase (8-fold) in expression
was observed from day 18 to day 25. In addition, constant mRNA expression levels of the inhibitory
Smads (Smad6 and Smad7) were found between day 2 and day 18. Like for Smad8, an increase in
expression of Smad6 and Smad7 was found in 25-day-old ovaries (Figure 5.4). 
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interstitial cells (Figure 5.5A, C and D) or in the sense slides (Figure 5.5B and E). 
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To determine which type I receptor and Smad proteins are involved in AMH-signaling in the ovary,
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ovaries of wild-type mice (Figure 5.4). Each time point reflects a different stage of follicle differentiation.
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Figure 5.4. Expression levels of different candidate components of AMH-signaling in mouse ovaries.
Expression was measured in ovaries of 2-,6-, 12-, 18- and 25-day-old wild-type mice by quantitative
real-time PCR with FAM-TAMRA probes. Expression of all genes has been corrected for b-actin
expression. Open bars represent AMHRII, black bars represent the type I receptors, hatched bars the 
R-Smads and gray bars the inhibitory Smads. 
Data represent means ± SEM. a, b, c, d, e indicate a significant difference from day 2, 6, 12, 18 and 25
respectively (P≤0.05). For each age 3 independent pools of ovaries were measured.
Note the difference in scale of the Y-axes of the different graphs.
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Figure 5.5: In situ hybridization of AMHRII and ALK2 in 18-day-old mouse ovaries.
AMHRII mRNA is detected in granulosa cells of growing follicles (A, C, D) and not in the control slides
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strongly induced the expression of Smad6 (14-fold), the apparent stimulation of Smad7 expression
(2-fold), was not significant (p=0.08) (Figure 5.6). In a timecourse experiment, we found that the
upregulation of the inhibitory Smads was a rapid event, since the expression was already increased after
6 hours (results not shown). In addition, we found that AMH, similar to the results in the KK-1/AMHRII
cells significantly upregulated Smad6 and Smad7 in cultured neonatal ovaries (Figure 5.6).
In a previous study (Clarke, et al., 2001) it was found that Smad8 showed a sex-specific expression
pattern in the Müllerian ducts, with Smad8 being expressed at a higher level in male versus female
Müllerian ducts. This suggests that AMH may regulate Smad8 expression in the Müllerian ducts.
Therefore, we determined whether Smad8 expression is regulated by AMH in the ovary. Indeed,
AMH stimulation of KK-1/AMHRII cells and neonatal ovaries results in a strong upregulation of the
hardly expressed Smad8 (10-fold respectively 37-fold) (Figure 5.6). Similar to the upregulation of
Smad6 and Smad7, the upregulation of Smad8 is a rapid effect (results not shown).
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AMH regulates its downstream signaling components
To have a further indication of AMH action in the ovary, we determined whether AMH influences
the expression of the inhibitory Smads in the ovary, since several TGFb family members stimulate the
expression of these Smads. KK-1/AMHRII cells were cultured for 24 hours in the absence or presence
of AMH and expression of Smad6 and Smad7 was determined using SYBRgreen reagent. AMH
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Figure 5.6: AMH regulates expression of inhibitory Smad6 and Smad7 and of the receptor-specific Smad8.
Expression of Smad6, Smad7 (p=0.08) and Smad8 is upregulated by AMH in KK-1/AMHRII cells treated
for 24 hours. In addition, an increase in Smad6, Smad7 and Smad8 (p=0.1) mRNA expression was also
found in neonatal AMH null ovaries cultured for 24 hours in presence of AMH. For each treatment
(control or AMH), five independent pools of KK-1/AMHRII and three independent pools of neonatal
ovaries were measured. All data are presented as mean ± SEM.
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DISCUSSION
The development of a primordial follicle to the pre-ovulatory follicle stage is a tightly regulated
process in which intra-ovarian factors as well as systemic factors LH and FSH play an important role.
AMH, a member of the TGFb superfamily, plays an important role in this process, since AMH
inhibits the recruitment of primordial follicles into the growing pool and decreases the sensitivity of
large pre-antral and small antral follicles for FSH (Durlinger, et al., 1999, 2001). Like all members of
the TGFb superfamily, AMH signals through serine/threonine kinase type I and type II receptors
which phosphorylate the downstream Smad proteins. Based upon the Smad which is used by TGFb
superfamily members, two main signaling pathways can be distinguished. Smad2 and Smad3 are activated
by TGFbs and activins through ALK4, ALK5 or ALK7 (TGFb/activin-like signaling pathway). On the
other hand, Smad1, Smad5 and Smad8 are activated by BMPs through ALK2, ALK3 and ALK6, referred
to as the BMP-like signaling pathway. The type II receptor for AMH has been identified (Baarends, 
et al., 1994; di Clemente, et al., 1994b) and the type I receptors ALK2, ALK3 and ALK6 have been
suggested as the type I receptors for AMH. Here, we show that in the KK-1 granulosa cell line, AMH
signals through the BMP-like signaling pathway since AMH in the presence of the AMHRII could
activate the BMP-responsive BRE2-Luc reporter and not the TGFb/activin-responsive 3TP-Luc
reporter. In addition, AMH phosphorylates Smad1 but not Smad2 in KK-1 cells. The presence of the
AMHRII is obligatory for AMH-signaling, since no other type II receptor could mediate AMH-signaling.
These results are in agreement with earlier reports which showed that AMH signals through the BMP-like
signaling pathway in non-ovarian fetal cell lines and Müllerian ducts (Gouédard, et al., 2000; Clarke,
et al., 2001; Visser, et al., 2001). 
To investigate which candidate type I receptors and Smads can be involved in AMH-signaling in
the ovary, we measured mRNA expression levels of AMHRII, ALK2, ALK3, ALK6, Smad1, Smad5 and
Smad8 in ovaries of mice of various ages, which contain different follicle populations. In addition, we
determined the localization of expression of AMHRII and ALK2 by in situ hybridization. The in situ
hybridization experiments for ALK3 and ALK6 are ongoing. The AMHRII is like AMH (Durlinger, et al.,
2002 and Chapter 6 of this thesis) expressed in granulosa cells of primary and pre-antral follicles and
expression decreases in large pre-antral follicles. Surprisingly, AMHRII mRNA expression in the ovary
does not increase during the first 18 days of life when the granulosa cell number increases enormously.
In situ hybridizations of fetal rat ovaries showed ubiquitous expression of AMHRII in these ovaries
(Baarends, et al., 1994). In 18-day-old mouse ovaries AMHRII mRNA is selectively expressed by the
granulosa cells of growing follicles. Therefore, the decrease in AMHRII mRNA from 2-day-old to 
6-day-old ovaries suggests a rearrangement from ubiquitous to specific expression of the AMHRII in
the ovary. The mRNA expression pattern of AMHRII in postnatal mouse ovaries suggests expression
of AMHRII in primordial follicles, explaining the effect of AMH on primordial follicle recruitment.
Unfortunately, the histology of the in situ hybridization does not allow the identification of primordial
follicles and therefore we were not able to determine if primordial follicles express AMHRII mRNA.
In situ hybridization revealed that ALK2 is ubiquitously expressed in the ovary. Expression was
detected in granulosa, theca and interstitial cells of the ovary and quantitative real-time PCR showed
that ALK2 mRNA levels increase only slightly during the first 25 days of life. These results show that
in granulosa cells ALK2 mRNA expression is colocalized with AMH and AMHRII mRNA, allowing a
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role for ALK2 in AMH-signaling in the ovary. Previous studies reported an overall ALK2 expression
in neonatal rat ovaries with high expression in the oocytes (He, et al., 1993). However, since the probes
for this study contained the highly homologous kinase domain, cross-reactivity with other type I receptors
could explain the discrepancy between the results.
In situ hybridization on ovaries of adult cycling rats showed ALK3 expression in oocytes, granulosa
and theca cells of all follicles (Erickson and Shimasaki, 2003). These observations correlate with our
results which showed a constant level of ALK3 mRNA in developing ovaries. In contrast, ALK6
mRNA levels increased from 12-day-old to 25-day-old ovaries, suggesting mRNA expression in
granulosa cells of growing follicles since the number of granulosa cells strongly increases during this
period. Indeed, ALK6 mRNA was strongly expressed in granulosa cells of growing follicles in adult rat
ovaries (Erickson and Shimasaki, 2003). Thus, from these studies and from the present study it may
be concluded that on basis of their expression pattern, each of the candidate type I receptors might
be involved in AMH-signaling. Further studies, such as organ and/or cell specific knockouts, are
necessary to determine exactly which type I receptor is involved in AMH-signaling in the ovary.
Levels of Smad1 and Smad5 mRNA expression did not change during the first 25 days of ovarian
development, while Smad8 mRNA expression increased in 25-day-old ovaries, suggesting a role of
Smad8 in atresia: the number of atretic follicles increases dramatically from 18-day-old to 25-day-old
ovaries. Interestingly, Smad8 mRNA expression levels in the mesenchymal cells surrounding the
Müllerian ducts is much higher in males compared to females whereas no difference in expression
level could be detected for Smad1 or Smad5, suggesting regulation of Smad8 by AMH (Clarke, et al.,
2001). Indeed, in cultured neonatal ovaries and in KK-1/AMHRII cells AMH stimulated Smad8, but
not Smad1 or Smad5 (results not shown) mRNA expression. These results suggest a role for Smad8
in AMH-signaling. However, the significance of these observations should be investigated in more
detail since the expression level of Smad8 compared to that of Smad1 and Smad5 is very low.
The signaling of TGFb family members through receptor-specific and common-mediator Smads
is antagonized by the inhibitory Smad6 and Smad7. Smad7 is a general inhibitor of TGFb/activin-like
and BMP-like signaling pathways (Hayashi, et al., 1997; Nakao, et al., 1997; Itoh, et al., 1998; Ishisaki,
et al., 1999; Hanyu, et al., 2001), while Smad6 preferentially inhibits the BMP-like signaling pathway
(Hata, et al., 1998; Itoh, et al., 1998; Ishisaki, et al., 1999; Hanyu, et al., 2001). The expression of both
inhibitory Smads can be stimulated by TGFb family members and in this way a negative feedback
mechanism is formed (Afrakhte, et al., 1998; Takase, et al., 1998; Ishisaki, et al., 1999). In addition, Clarke
and colleagues found an increased Smad6 mRNA expression level in male Müllerian ducts, suggesting
that AMH upregulates Smad6 mRNA expression. Indeed, in two different Leydig cell lines AMH
increased expression of Smad6 and to a lesser extent Smad7 mRNA (Clarke, et al., 2001). In agreement
with these observations, we found stimulation of Smad6 and Smad7 mRNA expression by AMH in
neonatal ovaries and in the granulosa cell line KK-1/AMHRII. No increase in Smad6 and Smad7 mRNA
was detected in 2-day-old to 18-day-old ovaries in vivo, a time-period when AMH levels increase strongly.
However, Smad6 and Smad7 expression is probably ubiquitous and in vivo expression of these inhibitory
Smads is regulated by several members of the TGFb superfamily which may counteract the effect of AMH.
In conclusion, AMH signals through the BMP-like signaling pathway All candidate type I receptors
and Smad proteins are present in the ovary, necessitating further studies on their relative contribution
to the AMH-signaling pathway. ALK6 seems to play a more important role in larger pre-antral and
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antral follicles. The role of Smad8 in AMH-signaling is very interesting since its low expression is
regulated by AMH, this needs further investigation. Like other members of the TGFb superfamily,
AMH upregulates expression of the inhibitory Smads, Smad6 and Smad7, forming a negative
feedback loop.
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ABSTRACT
Follicle recruitment is an important process in the regulation of the primordial follicle stock depletion
in the ovary. Since the exhaustion of the follicle stock results in menopause and infertility, the
understanding of the regulation of primordial follicle recruitment is of great importance. Several
growth factors, such as anti-Müllerian hormone (AMH), activins, inhibins, growth and differentiation
factor 9 (GDF9), bone morphogenetic protein-15 (BMP15), kit-ligand (KL), basic fibroblast growth
factor (bFGF) and nerve growth factor (NGF) have been suggested to be involved in the regulation of
primordial follicle recruitment. We have localized these proteins and have measured expression of
their mRNAs in postnatal ovaries of mice of several ages, in which different follicle types were present.
In this way, more knowledge about their role in follicle recruitment was obtained.
This study shows that AMH, activins, inhibins, GDF9, BMP15 and KL could be involved in
regulation of primordial follicle recruitment, while an involvement of bFGF and NGF is less likely.
INTRODUCTION
Menopause is a major milestone in the aging process in women and starts after the last menstrual cycle.
The cessation of ovarian function, which is caused by the exhaustion of the follicle stock in the ovaries,
causes the almost complete absence of secretion of female sex hormones. Postmenopausal life is
related with an increased risk of several diseases, like osteoporosis, cardiac failure and cognitive decline
(Gibaldi, 1997; Mijatovic, et al., 1999; Kesslak, 2002). Furthermore, menopause is correlated with the
age at which infertility occurs, since it is preceded by a premenopausal period of 15-20 years during
which fertility decreases, culminating in complete infertility approximately 10 years before menopause
(te Velde, et al., 1998). In view of the association of early infertility and female health problems associated
with menopause, it is important to understand the processes involved in the depletion of the resting
stock of primordial follicles. This limited supply of follicles is formed during fetal life and cannot be
replenished at any time afterwards. Loss of the primordial follicle stock occurs through atresia and
through recruitment of primordial follicles into the pool of growing follicles (Gougeon, et al., 1994;
Gougeon, 1996). It has been hypothesized that this recruitment is regulated by factors expressed by
the growing follicles in the ovary (Hirshfield, 1994). In order to understand the process of primordial
follicle recruitment it is therefore important to identify factors that are expressed by these growing
follicles. Also growth factors which are involved in follicle development could be involved in regulation
of primordial follicle recruitment: by influencing follicle growth and development they influence the
growth factors secreted by the follicles.
Several members of the transforming growth factor b (TGFb) superfamily have been implicated
to be involved in the regulation of follicle recruitment. This is the largest known family of growth and
differentiation factors and can be divided in several subfamilies, such as the TGFbs (TGFb1-5), the
activins (A, B, C, E), inhibins (A, B) and the bone morphogenetic proteins (e.g. BMP1-15, GDF1-9).
In addition, anti-Müllerian hormone (AMH) is a distant member of the TGFb superfamily (Massagué,
1998). Family members have a broad range of functions during development and in adult life, including
cell cycle regulation and cell differentiation, but also in the regulation of follicular development (see
also Chapter 1). Interestingly, several members of the TGFb superfamily like AMH, inhibins, activins,
growth and differentiation factor 9 (GDF9) and bone morphogenetic protein-15 (BMP15) could play
an important role in the regulation of early follicle development. AMH inhibits recruitment of
primordial follicles in vivo (Durlinger, et al., 1999) and in vitro (Chapter 3 of this thesis). Furthermore,
FSH-stimulated growth of pre-antral follicles in vitro is inhibited by AMH (Durlinger, et al., 2001).
Activin plays a role in the regulation of follicle development as has been shown in in vitro co-cultures
of large and small pre-antral follicles. Activin, produced by larger pre-antral follicles, inhibits the
growth of smaller pre-antral follicles in vitro (Mizunuma, et al., 1999). However, the effect of activin
on pre-antral follicles is controversial since in immature animals activin stimulates pre-antral follicle
growth while in mature animals the opposite effect has been described (Yokota, et al., 1997; Liu, et al.,
1998, 1999). Inhibin is known for its antagonistic actions on effects of activin. Furthermore, it was
described recently that inhibin also can antagonize BMP action and therefore the action of inhibin
could be more widespread than thought until recently (Wiater and Vale, 2003). The oocyte-expressed
GDF9 stimulates growth of small follicles, as illustrated by a block in follicle development from primary
follicles onward in GDF9 null mice (Dong, et al., 1996). 
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Follicle recruitment is an important process in the regulation of the primordial follicle stock depletion
in the ovary. Since the exhaustion of the follicle stock results in menopause and infertility, the
understanding of the regulation of primordial follicle recruitment is of great importance. Several
growth factors, such as anti-Müllerian hormone (AMH), activins, inhibins, growth and differentiation
factor 9 (GDF9), bone morphogenetic protein-15 (BMP15), kit-ligand (KL), basic fibroblast growth
factor (bFGF) and nerve growth factor (NGF) have been suggested to be involved in the regulation of
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also Chapter 1). Interestingly, several members of the TGFb superfamily like AMH, inhibins, activins,
growth and differentiation factor 9 (GDF9) and bone morphogenetic protein-15 (BMP15) could play
an important role in the regulation of early follicle development. AMH inhibits recruitment of
primordial follicles in vivo (Durlinger, et al., 1999) and in vitro (Chapter 3 of this thesis). Furthermore,
FSH-stimulated growth of pre-antral follicles in vitro is inhibited by AMH (Durlinger, et al., 2001).
Activin plays a role in the regulation of follicle development as has been shown in in vitro co-cultures
of large and small pre-antral follicles. Activin, produced by larger pre-antral follicles, inhibits the
growth of smaller pre-antral follicles in vitro (Mizunuma, et al., 1999). However, the effect of activin
on pre-antral follicles is controversial since in immature animals activin stimulates pre-antral follicle
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1998, 1999). Inhibin is known for its antagonistic actions on effects of activin. Furthermore, it was
described recently that inhibin also can antagonize BMP action and therefore the action of inhibin
could be more widespread than thought until recently (Wiater and Vale, 2003). The oocyte-expressed
GDF9 stimulates growth of small follicles, as illustrated by a block in follicle development from primary
follicles onward in GDF9 null mice (Dong, et al., 1996). 
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Antibodies
The AMH 7/2A antibody was raised against a synthetic peptide VPTAYAGKLLISLSEERISAHHVPN
MVATECG corresponding to the C-terminus of the mature AMH protein. This human peptide sequence
differs from the mouse sequence in one amino acid. In addition, the commercially available antibody
MIS C-20 was used (Santa Cruz Technologies, cat# sc-6886, Santa Cruz, CA, USA). To detect expression
of the inhibin a-subunit, the R1 antibody was used. This antibody recognizes free inhibin a-subunits,
but also inhibin A and inhibin B (Groome, et al., 1990; Arora, et al., 1997). Using the E4 antibody,
inhibin bA-subunit was detected. This antibody recognizes inhibin A, activin A and activin AB (Groome
and Lawrence, 1991; Arora, et al., 1997). Detection of the inhibin bB-subunit was performed with the
C5 antibody (Groome, et al., 1996). The C5 antibody recognizes inhibin bB-subunit and therefore
also inhibin B, activin AB and activin B. For GDF9 two different monoclonal antibodies were used:
GDF9 70 and GDF9 2/4B. GDF9 70 was raised against the synthetic peptide CVPAKYSPLSVLTIE
PDGSIAYKEYEDMIATKC, corresponding to the C-terminal domain of the mature human GDF9
sequence. Between human and mouse sequences of this peptide amino acids at two positions are
different. GDF9 2/4B was raised against the synthetic peptide GQETVSSELKKPLGPC, corresponding
to the N-terminal domain of the mature human GDF9 sequence. This sequence differs at 7 amino
acids between mouse and human GDF9. All above mentioned antibodies were used in biotinylated
form. NGF protein expression was detected using the rabbit polyclonal antibody H20 (Santa Cruz
Biotechnologies cat#: sc-548). Finally, the FGF-2 147 rabbit polyclonal antibody (Santa Cruz
Biotechnologies cat#: sc-79) was used to detect bFGF expression. A biotinylated secondary goat anti-rabbit
antibody (Dako, Glastrup, Denmark) was used to detect localization of bFGF and NGF.
Immunohistochemistry for the MIS C-20 antibody was performed as described in Chapter 3. Because
the AMH 7/2A, GDF9 70, GDF9 2/4B, R1, E4 and C5 antibodies were biotinylated, no use of a secondary
antibody was necessary for these antibodies.
Immunohistochemistry
The localization of AMH, GDF9, NGF, bFGF and the inhibin a-, inhibin bA- and inhibin bB-subunits
was studied by immunohistochemistry on ovaries of 2-, 6-, 12-, 18- and 25-day-old mouse ovaries. 
Sections were mounted on slides coated with 3-aminopropyltriethoxysilane (Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands). After deparaffinisation, sections were quenched for 20
min in 3% H2O2 /methanol solution to block endogenous peroxidase activity, washed with water and
transferred to phosphate-buffered saline (PBS). The sections were microwaved for 3x5 min (AMH
and GDF9 immunohistochemistry) or 2x10 min (inhibin a-, bA- and bB-subunits, NGF and bFGF
immunohistochemistry) at 700 W in 0.01 M citric acid monohydrate buffer, pH 6.0 (Merck, Darmstadt,
Germany), cooled down to room temperature (RT) and rinsed in PBS. For NGF and bFGF
immunohistochemistry the sections were preincubated with normal goat serum (1:10 dilution in PBS)
(Dako) for 15 min at RT. For bFGF, NGF, GDF9 and inhibin bB-subunit immunohistochemistry,
endogenous biotin, biotin receptors, and avidin binding sites present in the tissues were blocked using
the Avidin/biotin blocking kit (Brunschwig, Vector, Amsterdam, The Netherlands) according to 
the manufacturer’s protocol. Sections were incubated at 4C overnight (AMH, GDF9, inhibin a- and 
bA-subunits, bFGF, NGF) or during 6 hours (inhibin bB-subunit) with primary antibodies against
the different proteins. The antibodies were diluted in 5% BSA in PBS for AMH (MIS C-20: 0.4 ng/µl,
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BMP15, which is also expressed in oocytes, stimulates granulosa cell mitosis of pre-antral follicles and
inhibits FSH-induced differentiation in vitro (Otsuka, et al., 2000, 2001b; Otsuka and Shimasaki,
2002). These data indicate that TGFb family members may play a role in the regulation of follicle
growth and development. If these growth factors influence follicle growth and development they may
also be involved in regulation of primordial follicle recruitment.
Besides TGFb family members other growth factors, such as kit-ligand (KL), basic fibroblast
growth factor (bFGF) and nerve growth factor (NGF), are also involved in primordial follicle recruitment
and/or early follicle development. Naturally occurring mutations in the KL gene result in impaired
primordial follicle recruitment and a block in follicle growth and development after the primary follicle
stage (Huang, et al., 1993). In vivo and in vitro studies showed that KL is required for primordial
follicle recruitment (Yoshida, et al., 1997; Parrott and Skinner, 1999). A similar stimulatory effect of
bFGF on primordial follicle recruitment was found (Nilsson, et al., 2001). Furthermore, granulosa cell
proliferation is stimulated by bFGF, showing involvement of bFGF in early follicular development
(Gospodarowicz and Bialecki, 1979). Another growth factor, which might be involved in regulation
of primordial follicle recruitment, is NGF. Ovaries of NGF null mice contain less growing follicles
than their wild-type littermates (Dissen, et al., 2001). In addition, follicle differentiation is stimulated
by NGF through an increase in FSH receptor (FSHR) expression. The impaired growth of small follicles
in NGF null mice can be explained by the decrease in FSHR mRNA (Romero, et al., 2002). These
results suggest a role for KL, bFGF and NGF in the regulation of primordial follicle recruitment.
If the growing follicle pool secretes growth factors which are involved in regulation of primordial
follicle recruitment, mRNA encoding these growth factors should be expressed by growing follicles.
Therefore, we measured the mRNA expression level of growth factors during ovarian development
and determined the ovarian protein expression pattern. 
MATERIALS AND METHODS
Animals 
Mice were obtained from the animal facility (EDC) of the Erasmus MC and were maintained under
standard animal housing conditions in accordance with NIH guidelines for the care and use of
experimental animals. Ovaries were isolated from C57Bl6/6J wild-type mice at 1 to 10 days of age,
then every other day until day 22 of age and at 25 days of age. Ovaries were fixed for 3 hours (day 1
to 12) or overnight (day 14 to 25) in Bouin’s fixative, embedded in paraffin and sectioned at 5 µm. Based
on the follicle population present at different ages, 2, 6, 12, 18 and 25-day-old ovaries were selected
for further research. Ovaries were snap frozen in liquid nitrogen and stored at -80C, or collected and
fixed for 3 hours (day 2, 6 and 12) or overnight (day 18 and 25) in Bouin’s fixative for AMH, inhibin
a-subunit and inhibin bA-subunit immunohistochemistry or in 3.7% formaldehyde for GDF9, bFGF,
NGF and inhibin-bB subunit immunohistochemistry. Subsequently, the ovaries were embedded in
paraffin and 5 µm sections were cut.
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in NGF null mice can be explained by the decrease in FSHR mRNA (Romero, et al., 2002). These
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Therefore, we measured the mRNA expression level of growth factors during ovarian development
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Mice were obtained from the animal facility (EDC) of the Erasmus MC and were maintained under
standard animal housing conditions in accordance with NIH guidelines for the care and use of
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Statistical analysis
Results are presented as mean ± SEM. Data were analyzed for statistical differences by one-way
analysis of variance (ANOVA), followed by Duncan’s new multiple range test using SPSS, Inc9.0 (SPSS,
Inc., Chicago, IL, USA) computer software. Differences were considered to be significant at P≤0.05.
RESULTS
Selection of ovaries
The follicle population was characterized in ovaries collected from two mice, starting the day of birth
(=day 1) until day 10, then every 2 days until day 22 and day 25. Based on the age on which a new
follicle class was found, five different ages were selected for detailed analysis (Figure 6.1). Ovaries of
2-day-old mice only contained primordial follicles, whereas on day 6 also primary follicles were
present. In 12-day-old ovaries also pre-antral follicles were present and antral follicles were found first
in ovaries of 18-day-old mice. All antral and large pre-antral follicles had become atretic in ovaries of
25-day-old mice. The criteria for atresia were the presence of picnotic nuclei in the granulosa cells
and/or degeneration of the nucleus of the oocyte (Byskov, 1974; Osman, 1985). These five time points
were subsequently used to determine the expression of AMH, inhibin a-, bA-, and bB-subunits,
GDF9, BMP15, KL, bFGF and NGF. 
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AMH 7/2A: 15 ng/µl), GDF9 (GDF9 70: 5.3 ng/µl, GDF 2/4B: 10 ng/µl), inhibin a-subunit (day 2-18
ovaries: 10 ng/µl, day 25 ovaries: 20 ng/µl), inhibin bA-subunit (day 2-12 ovaries: 10 ng/µl, day 18-
25 ovaries: 20 ng/µl) and inhibin bB-subunit (day 2 ovaries: 1 ng/µl, day 6-25 ovaries 5 ng/µl). NGF
(0.4 ng/µl) and bFGF (0.4 ng/µl) antibodies were diluted in 1.5% normal goat serum in PBS. After
incubation, the sections were rinsed in PBS and the bFGF and NGF sections were subsequently
treated for 30 min at RT with the biotinylated goat anti-rabbit antibody (dilution: 1:200 in 6% normal
goat serum in PBS, Brunschwig, Vector). Next, sections incubated with the various antibodies were
treated with streptavidin-biotin-peroxidase complex (ABC; diluted 1:200 in PBS; Dako) for 30 min at
RT. They were washed three times with PBS and the peroxidase activity was developed with 0.07%
3,3'-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich) for seven minutes. Finally, all sections
were counterstained with hematoxylin. The sections incubated with antibodies against inhibin a-,
bA-, bB-subunits, bFGF and NGF were added for 4 seconds in 0.2% NH4OH and washed with water
to increase the blue color of the tissue. 
Negative control sections for immunohistochemistry of AMH, GDF9 and inhibin a-, bA- and
bB-subunits were incubated with 5% BSA/PBS followed by treatment with the streptavidin-biotin-
peroxidase complex. NGF and bFGF control sections were incubated with peptide-primary antibody
complexes, according to the manufacturer’s protocol. 
RNA isolation and preparation
RNA isolation, cDNA synthesis and development of primers and probes for quantitative real-time
PCR were performed as described in Chapter 5. For each age group, three separately pooled groups
of ovaries (n=20-40) were used. The primers and probes for the quantitative real-time PCR of AMH,
KL, GDF9, BMP15, bFGF, NGF and the inhibin a-, bA- and bB-subunits are shown in Table 6.1.
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Table 6.1: Oligonucleotide primers and probe sequences used to amplify AMH, GDF9, BMP15, inhibin a-,
inhibin bA- and inhibin bB-subunits, NGF, kit-ligand, bFGF and b-actin mRNAs in the different aged ovaries.
Gene: Primers: Probe: Product size (bp):
AMH 5’-GCT GCT GCT GCT AAA GG-3’ 5’-CTC ATC CCG GAG ACC TAC CAA-3’ 227
5’-GCG GAT TAC GGT CAG AC-3’
GDF9 5’-TGC TGT GGG CCT TAG A-3’ 5’-CGA GTG CAG TGT CCG TAG GTG TA-3’ 168
5’-TTG GTT TAT GGC AAC GA-3’
BMP15 5’-CCG GAC CAA GCA CTT AC-3’ 5’-AAA GCC TTC TCC CAT GTC TAA AGC-3’ 136
5’-GCG AAG AAC ACT CCG TC-3’
Inhibin a 5’-TGC ACA GGA CCT CTG AAC CA-3’ 5’-TGA CTT CAG CCC AGC TGT GGT TCC A-3’ 269
5’-TGA TAG CAC CAG AAG ATC TAG CA-3’
Inhibin bA 5’-ACC TCG GAG ATC ATC ACC TTT G-3’ 5’-CTG ACA GGT CAC TGC CTT CCT TGG AAA TCT-3’ 126
5’-GAC TTT CAG GAA GAG CCA CAC TTC T-3’
Inhibin bB 5’-ACC CAC ACA GGC GAA-3’ 5’-AAG GCC AGC GGA TCA GTT TT-3’ 306
5’-GCA GGC CAC TCG AAG-3’
NGF 5’-TGA AGC CCA CTG GAC TAA-3’ 5’-AAT AGC TGC CCG AGT GAC AGG-3’ 246
5’-CTG TTG AAA GGG ATT GTA CC-3’
Kit-ligand 5'-GAA AAG CGG TCG TGC-3' 5’-CCA ATT TGT AAA AAC GAT AAC CCG-3’ 278
5'-GCC AAT TTC ACA ATA TCA TTC-3'
bFGF 5’-GCA CTT GGC CTC TCT TTA CGT GA-3’ 5’-CAT CCA AGC CTC GGC TCG GTG TCT A-3’ 320
5’-CAC AGA AGT GGC GCA TAC CTC A-3’
b-actin 5’-CTA CGA GGG CTA TGC TCT C-3’ 5’-ACC GAG CGT GGC TAC AGC TT-3’ 283
5’-CTC AGG GCA TCG GAA-3’
Figure 6.1: Follicle types found in postnatal ovaries.
Ovaries of 2-day-old mice only contain primordial follicles, which consist of an oocyte (O) surrounded by
pre-granulosa cells (pGC). In addition to the primordial follicles, also primary follicles can be found in an
ovary of a 6-day-old mouse. Oocytes of primary follicles have an increased diameter compared to primordial
follicles and the granulosa cells (GC) have become cuboidal. Pre-antral follicles are first detected in 12-day-old
ovaries and contain multiple layers of granulosa cells. The appearance of an antrum (An) is the characteristic
of an antral follicle, which also contains granulosa (GC) and theca cells (TC). These follicles can be found
in 18-day-old ovaries. Ovaries of 25-day-old mice contain atretic follicles (At) which can be recognized
by several picnotic granulosa cells. Magnification x 400 for all photographs.
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treated for 30 min at RT with the biotinylated goat anti-rabbit antibody (dilution: 1:200 in 6% normal
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3,3'-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich) for seven minutes. Finally, all sections
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peroxidase complex. NGF and bFGF control sections were incubated with peptide-primary antibody
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inhibin bA- and inhibin bB-subunits, NGF, kit-ligand, bFGF and b-actin mRNAs in the different aged ovaries.
Gene: Primers: Probe: Product size (bp):
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Inhibin a 5’-TGC ACA GGA CCT CTG AAC CA-3’ 5’-TGA CTT CAG CCC AGC TGT GGT TCC A-3’ 269
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Inhibin bA 5’-ACC TCG GAG ATC ATC ACC TTT G-3’ 5’-CTG ACA GGT CAC TGC CTT CCT TGG AAA TCT-3’ 126
5’-GAC TTT CAG GAA GAG CCA CAC TTC T-3’
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5’-CTG TTG AAA GGG ATT GTA CC-3’
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b-actin 5’-CTA CGA GGG CTA TGC TCT C-3’ 5’-ACC GAG CGT GGC TAC AGC TT-3’ 283
5’-CTC AGG GCA TCG GAA-3’
Figure 6.1: Follicle types found in postnatal ovaries.
Ovaries of 2-day-old mice only contain primordial follicles, which consist of an oocyte (O) surrounded by
pre-granulosa cells (pGC). In addition to the primordial follicles, also primary follicles can be found in an
ovary of a 6-day-old mouse. Oocytes of primary follicles have an increased diameter compared to primordial
follicles and the granulosa cells (GC) have become cuboidal. Pre-antral follicles are first detected in 12-day-old
ovaries and contain multiple layers of granulosa cells. The appearance of an antrum (An) is the characteristic
of an antral follicle, which also contains granulosa (GC) and theca cells (TC). These follicles can be found
in 18-day-old ovaries. Ovaries of 25-day-old mice contain atretic follicles (At) which can be recognized
by several picnotic granulosa cells. Magnification x 400 for all photographs.
pre-antral follicles. Expression disappeared in antral or atretic follicles. Similar patterns were found
with the two antibodies for detecting AMH (Figure 6.2). Inhibin a-subunit protein expression could
be detected in granulosa cells of all growing and/or atretic follicles in ovaries from day 6 onward
(Figure 6.3). Inhibin bB-subunit protein expression was first detected in ovaries of 12-day-old mice,
while first expression of the inhibin bA-subunit protein was detected in 18-day-old ovaries. Inhibin
bA- and bB-subunit proteins were detected in granulosa cells of large pre-antral, antral and atretic
follicles (Figure 6.3). Expression of the GDF9 protein was first detected in the oocytes of primary
follicles in 6-day-old ovaries and subsequently in all different growing and atretic follicles (Figure
6.4). No expression was detected in primordial follicles. Two GDF9 antibodies were used and some
differences in expression level could be recognized. In 6-day-old ovaries, similar staining levels were
found with the two GDF9 antibodies, while in 12-, 18-, and 25-day-old ovaries the staining with the
GDF9 2/4B antibody was higher compared to that by the GDF9 70 antibody. Interestingly, the GDF9
70 antibody showed an increased staining in larger and atretic follicle oocytes of 25-day-old ovaries.
All control slides for AMH, GDF9, inhibin a-, bA- and bB-subunits immunohistochemistry were
negative (results not shown). 
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Immunolocalization of growth factors
Ovaries of 2-day-old mice contained only primordial follicles and immunoreactivity of TGFb family
members could be detected in these ovaries. AMH immunoreactivity could be detected first in granulosa
cells of primary follicles in 6-day-old ovaries (Figure 6.2) and at later ages also in granulosa cells of
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Figure 6.2: Immunohistochemical localization of AMH in postnatal C57Bl/6J mouse ovaries of different ages. 
(For a color version of this figure, see page 170.) Magnification x 100.
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Figure 6.3: Immunohistochemical localization of inhibin a-, bA- and bB-subunits in postnatal C57Bl/6J mouse
ovaries of different ages. (For a color version of this figure, see page 171.)
Histology of the inhibin bB-subunits differs from the inhibin a and bA-subunit immunohistochemistry
due to fixation differences (formaldehyde vs. bouin). Magnification x 100.
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Immunohistochemistry for NGF and bFGF revealed that these factors were not expressed by specific
ovarian cell types. Expression could be found in oocytes, granulosa, theca and interstitial cells in the
ovary at all ages (Figure 6.5). The expression level for bFGF in the different cell types varied during
ovarian development. In 2- and 6-day-old ovaries the strongest bFGF expression was detected in
oocytes and granulosa cells, while in 18- and 25-day-old ovaries interstitial cells showed the strongest
bFGF staining (Figure 6.6). At every age, NGF expression was strongest in granulosa cells and oocytes
of primordial to antral and atretic follicles while a lower staining was found in interstitial and theca
cells. This expression was specific since the control slides, in which the peptide complex was added,
no expression of bFGF or NGF could be detected (Figure 6.5).
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Figure 6.4: Immunohistochemical localization of GDF9 in postnatal C57Bl/6J mouse ovaries of different ages. 
(For a color version of this figure, see page 172.)
Magnification x 100.
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Figure 6.5: Immunohistochemical localization of bFGF and NGF in postnatal C57Bl/6J mouse ovaries of different
ages. (For a color version of this figure, see page 173.) Magnification x 100.
bFGF NGF
day 2
day 6
GDF9 70 GDF9 2/4B
day 2
day 6
day 12
Immunohistochemistry for NGF and bFGF revealed that these factors were not expressed by specific
ovarian cell types. Expression could be found in oocytes, granulosa, theca and interstitial cells in the
ovary at all ages (Figure 6.5). The expression level for bFGF in the different cell types varied during
ovarian development. In 2- and 6-day-old ovaries the strongest bFGF expression was detected in
oocytes and granulosa cells, while in 18- and 25-day-old ovaries interstitial cells showed the strongest
bFGF staining (Figure 6.6). At every age, NGF expression was strongest in granulosa cells and oocytes
of primordial to antral and atretic follicles while a lower staining was found in interstitial and theca
cells. This expression was specific since the control slides, in which the peptide complex was added,
no expression of bFGF or NGF could be detected (Figure 6.5).
93
Growth factors and primordial follicle recruitment
92
Chapter 6
GDF9 70 GDF9 2/4B
day 18
day 25
Figure 6.3 Figure 6.4:
Figure 6.4: Immunohistochemical localization of GDF9 in postnatal C57Bl/6J mouse ovaries of different ages. 
(For a color version of this figure, see page 172.)
Magnification x 100.
inhibin a inhibin bA inhibin bB
day 18
day 25
Figure 6.5: Immunohistochemical localization of bFGF and NGF in postnatal C57Bl/6J mouse ovaries of different
ages. (For a color version of this figure, see page 173.) Magnification x 100.
bFGF NGF
day 2
day 6
GDF9 70 GDF9 2/4B
day 2
day 6
day 12
94
Chapter 6
Expression of growth factors in the ovary
The mRNA expression patterns of nine growth factors in postnatal ovaries of various ages are shown
in Figure 6.7. The patterns of AMH and the inhibin a-, bA- and bB-subunits were very similar during
the first 25 days of life, only the level of expression was different. For all tested TGFb family members,
mRNA expression could hardly be found in 2-day-old ovaries but expression increased from day 2 to 25
(Figure 6.7A). The inhibin a-subunit was the highest expressed TGFb superfamily member and its
expression was approximately 1000 times higher than that of inhibin bB-subunit mRNA. GDF9 and
BMP15 showed a similar mRNA expression pattern. Expression was low in 2-day-old ovaries and
increased until day 18, where the expression level was maximal and significantly higher than at the
other days. NGF and bFGF mRNA expression levels were very low compared to the expression levels
of the other growth factors in the ovary (Figure 6.7B). No age-dependent change in mRNA expression
levels of KL and NGF could be detected in ovaries from 2- to 25-day-old mice (Figure 6.7B). The mRNA
expression pattern of bFGF was significantly increased at day 18 and 25 compared to expression in
the younger animals. 
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Figure 6.5
Figure 6.6: bFGF protein is expressed in the interstitial cells surrounding primordial follicles in an 18-day-old
mouse ovary. (For a color version of this figure, see page 174.) Magnification x 200.
Figure 6.7: Expression levels of growth factors in postnatal ovaries of different ages.
A. mRNA expression patterns of the TGFb superfamily members inhibin a-, bA-, bB-subunits, AMH,
GDF9 and BMP15.
B. mRNA expression patterns of KL, NGF and bFGF. Data represent the mean ± SEM for three pools of
ovaries at every age. a, b, c, d, e indicate a significant difference from day 2, 6, 12, 18 and 25
respectively (P≤0.05). Note the difference in scale of the Y-axis among the different graphs.
ex
pr
es
si
on
/ 
b
-a
ct
in
AMH
2 6 12 18 25
0
50
100
150
200
250
c d e d e
a d
a b e
a b c d
Inhibin a Inhibin bA Inhibin bB20
15
10
5
0
2500
2000
1500
1000
500
0
15000
10000
5000
0
ex
pr
es
si
on
/ 
b
-a
ct
in
d e c d e
c d e
a b e
a b e
a b c d
d e
e
a b e
a b c d
d e
a b c e
d e
d e
a b c d
2 6 12 18 252 6 12 18 252 6 12 18 25
A
age (days after birth)
GDF9 BMP15
6000
8000
0
4000
2000
6000
8000
0
4000
2000
a c d e
b c d e
a b d e
a b c d
a b c e
c d e c d e
a b d
a b c e
a b d
2 6 12 18 25 2 6 12 18 25
ex
pr
es
si
on
/ 
b
-a
ct
in
KL
2 6 12 18 25
0
50
100
150
200
250
B
age (days after birth)
0
2
4
6
8 NGF
2
4
6
8
2 6 12 18 25
bFGF
0
2
4
6
8
d e d e d e
a b c a b c
2 6 12 18 25
94
Chapter 6
Expression of growth factors in the ovary
The mRNA expression patterns of nine growth factors in postnatal ovaries of various ages are shown
in Figure 6.7. The patterns of AMH and the inhibin a-, bA- and bB-subunits were very similar during
the first 25 days of life, only the level of expression was different. For all tested TGFb family members,
mRNA expression could hardly be found in 2-day-old ovaries but expression increased from day 2 to 25
(Figure 6.7A). The inhibin a-subunit was the highest expressed TGFb superfamily member and its
expression was approximately 1000 times higher than that of inhibin bB-subunit mRNA. GDF9 and
BMP15 showed a similar mRNA expression pattern. Expression was low in 2-day-old ovaries and
increased until day 18, where the expression level was maximal and significantly higher than at the
other days. NGF and bFGF mRNA expression levels were very low compared to the expression levels
of the other growth factors in the ovary (Figure 6.7B). No age-dependent change in mRNA expression
levels of KL and NGF could be detected in ovaries from 2- to 25-day-old mice (Figure 6.7B). The mRNA
expression pattern of bFGF was significantly increased at day 18 and 25 compared to expression in
the younger animals. 
95
Growth factors and primordial follicle recruitment
bFGF NGF
day 12
day 18
day 25
day 25
negative
control
Figure 6.5
Figure 6.6: bFGF protein is expressed in the interstitial cells surrounding primordial follicles in an 18-day-old
mouse ovary. (For a color version of this figure, see page 174.) Magnification x 200.
Figure 6.7: Expression levels of growth factors in postnatal ovaries of different ages.
A. mRNA expression patterns of the TGFb superfamily members inhibin a-, bA-, bB-subunits, AMH,
GDF9 and BMP15.
B. mRNA expression patterns of KL, NGF and bFGF. Data represent the mean ± SEM for three pools of
ovaries at every age. a, b, c, d, e indicate a significant difference from day 2, 6, 12, 18 and 25
respectively (P≤0.05). Note the difference in scale of the Y-axis among the different graphs.
ex
pr
es
si
on
/ 
b
-a
ct
in
AMH
2 6 12 18 25
0
50
100
150
200
250
c d e d e
a d
a b e
a b c d
Inhibin a Inhibin bA Inhibin bB20
15
10
5
0
2500
2000
1500
1000
500
0
15000
10000
5000
0
ex
pr
es
si
on
/ 
b
-a
ct
in
d e c d e
c d e
a b e
a b e
a b c d
d e
e
a b e
a b c d
d e
a b c e
d e
d e
a b c d
2 6 12 18 252 6 12 18 252 6 12 18 25
A
age (days after birth)
GDF9 BMP15
6000
8000
0
4000
2000
6000
8000
0
4000
2000
a c d e
b c d e
a b d e
a b c d
a b c e
c d e c d e
a b d
a b c e
a b d
2 6 12 18 25 2 6 12 18 25
ex
pr
es
si
on
/ 
b
-a
ct
in
KL
2 6 12 18 25
0
50
100
150
200
250
B
age (days after birth)
0
2
4
6
8 NGF
2
4
6
8
2 6 12 18 25
bFGF
0
2
4
6
8
d e d e d e
a b c a b c
2 6 12 18 25
does not reveal if follicles produce activins or inhibins because the b-subunit antibodies used cannot
distinguish between inhibins and activins containing the subunit against which the antibodies have
been raised. Interestingly, inhibin a-subunit protein is expressed earlier in granulosa cells than the
inhibin bA- and bB-subunits proteins. No effect of the inhibin a-subunit itself has been described,
and therefore it is questionable if the inhibin a-subunit produced by the primary follicles already has
an effect on follicle growth and development or primordial follicle recruitment. 
In contrast to the expression pattern of TGFb superfamily members in granulosa cells, the
mRNA expression of the oocyte-expressed family members GDF9 and BMP15 is highest in 18-day-old
ovaries. These mRNA expression patterns suggest that GDF9 and BMP15 mRNA are expressed
strongest in large pre-antral and antral follicles. We found an increase in GDF9 protein expression in
pre-antral follicles compared to primary follicles in ovaries of 12-, 18- and 25-day-old mice using two
different GDF9 monoclonal antibodies, whereas we did not detect any difference in GDF9 protein
staining between pre-antral or antral follicles in 18-day-old mouse ovaries. Immunohistochemistry
with a polyclonal GDF9 antibody in rat ovaries showed even a decreased staining in oocytes of antral
follicles (Jaatinen, et al., 1999). The GDF9 mRNA expression data together with the AMH, inhibin 
a-, bA- and bB-subunit mRNA expression data suggest an increase in the number of growing follicles
in 18-day-old ovaries. A complication is that in 25-day-old ovaries the GDF9 70 antibody, but not the
GDF9 2/4B antibody, showed an increased staining in oocytes of large pre-antral and antral follicles.
This increase in staining is probably not caused by an increased GDF9 protein expression but by a
cross-reactivity with BMP15 protein. The peptide used to raise the GDF9 70 antibody shows a 61%
homology with the BMP15 amino acid sequence, while the peptide against which the GDF9 2/4B
antibody was raised shows no homology with BMP15. Furthermore, almost all follicles with an
increased GDF9 70 antibody staining showed histological hallmarks of atresia. Therefore, it is possible
that in atretic follicles, where proteins become degraded, the GDF9 70 antibody also recognizes
degraded BMP15. 
The TGFb superfamily members studied in this chapter are specifically expressed by oocytes
or granulosa cells. Since it is hypothesized (Hirshfield, 1994) that the growing follicle pool is involved
in the regulation of the outgrowth of primordial follicles, these family members could be involved in
regulation of this process. In contrast, bFGF and NGF are expressed by all cell types in the ovary,
including the interstitial cells. Therefore, these growth factors may have a facilitating but not a
regulatory role in primordial follicle recruitment. Indeed, Romero and colleagues showed a facilitating
role of NGF in follicle differentiation by its stimulatory effect on FSH receptor mRNA expression
(Romero, et al., 2002). The protein expression of bFGF by interstitial cells surrounding primordial
follicles (Figure 6.7) does not exclude a facilitating role for this growth factor in primordial follicle
recruitment. Both NGF and bFGF mRNA are expressed at low levels in the ovary during the first 
25 days of life. In contrast, both proteins show a general but specific staining in the ovary. The high
staining of NGF in granulosa cells of growing follicles does not correlate with the absence of such an
increase in mRNA expression during the first 18 days of life. A short half-life of mRNA of these
proteins could explain the discrepancy between mRNA and protein levels. Therefore, studies about
the mRNA and protein stability of bFGF and NGF should be performed to confirm the
immunohistochemistry and real-time PCR data.
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DISCUSSION
Knowledge about the regulation of primordial follicle recruitment is important for the understanding
of the rate of depletion of the primordial follicle pool. An inverse correlation between the number of
primordial follicles in the ovary and the rate at which they were recruited into the growing pool has
been found (Hirshfield, 1994). This resulted in a constant number of antral follicles present in ovaries.
This result strongly suggests a feedback mechanism between growing follicles and the resting follicle
pool. Recently, several growth factors, including TGFb superfamily members, have been identified to
play a role in the regulation of primordial follicle recruitment. Here we determined the protein expression
pattern and quantified mRNA expression of growth factors in mouse ovaries at different ages in order
to gain more knowledge about their role in primordial follicle recruitment.
Several members of the TGFb superfamily might play a role in follicle growth and development
(see also Chapter 1). Here, we studied the expression of AMH, inhibin a-, bA- and bB-subunits, GDF9
and BMP15 mRNA expression and protein localization in postnatal ovaries. AMH and the three
inhibin subunits are specifically expressed by the granulosa cells while GDF9 expression is only found
in oocytes and these expression patterns are in agreement with results of other studies (Meunier, et al.,
1988; Tebar, et al., 1997; Aaltonen, et al., 1999; Elvin, et al., 1999a; Hayashi, et al., 1999; Jaatinen, et al.,
1999; Durlinger, et al., 2002). No immunohistochemistry for BMP15 was performed because no
antibody for BMP15 is yet available. However, in situ hybridization showed BMP15 mRNA expression
in oocytes of growing follicles (Aaltonen, et al., 1999; Jaatinen, et al., 1999; Otsuka, et al., 2000). This
specific expression of TGFb superfamily members by oocytes or granulosa cells of growing follicles
might enable these proteins to regulate follicle development and/or primordial follicle recruitment.
Interestingly, the mRNA expression levels of the oocyte-expressed factors are relatively high compared
to the granulosa cell-expressed TGFb family members, suggesting an important role of these oocyte
factors in follicle development and/or primordial follicle recruitment.
Ovarian expression of mRNA of all granulosa cell-expressed TGFb superfamily members increases
during the first 25 days of life. For AMH, this result is unexpected since AMH protein was not detected
in granulosa cells of antral and atretic follicles of which the number is increased in 18- and 25-day-old
mice ovaries. The AMH mRNA expression pattern suggests that 25-day-old ovaries contain an
increased number of small growing follicles or that AMH mRNA expression in smaller healthy
follicles is increased in 25-day-old compared to 18-day-old ovaries, since the mRNA expression levels
are corrected for the expression of b-actin and thus for the number of cells present in the ovary.
Highest expression of inhibin a-, bA- and bB-subunit mRNA is found in 25-day-old ovaries. Inhibin
a- and bA-subunit mRNA expression is stimulated by FSH in rat granulosa cell cultures (LaPolt, et
al., 1989, 1990) and FSH stimulates inhibin protein production in immature mouse and rat ovary
culture (Yokota, et al., 1997; Drummond, et al., 2000). Since FSH serum levels decrease after day 18
in mice (Halpin, et al., 1986) the increase in mRNA levels of inhibin a- and bA-subunits was not
expected in the 25-day-old ovaries. One explanation for the discrepancy in increased inhibin subunit
levels in 25-day-old ovaries might be that the ovary has become more sensitive for FSH due to an
increased expression of the FSH receptor mRNA and protein. In the rat postnatal ovary, levels of FSH
receptor mRNA and protein increases during postnatal ovarian development (White and Ojeda,
1981; Sokka and Huhtaniemi, 1990; Dunkel, et al., 1994; Drummond, et al., 1996). The present study
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during the first 25 days of life. For AMH, this result is unexpected since AMH protein was not detected
in granulosa cells of antral and atretic follicles of which the number is increased in 18- and 25-day-old
mice ovaries. The AMH mRNA expression pattern suggests that 25-day-old ovaries contain an
increased number of small growing follicles or that AMH mRNA expression in smaller healthy
follicles is increased in 25-day-old compared to 18-day-old ovaries, since the mRNA expression levels
are corrected for the expression of b-actin and thus for the number of cells present in the ovary.
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a- and bA-subunit mRNA expression is stimulated by FSH in rat granulosa cell cultures (LaPolt, et
al., 1989, 1990) and FSH stimulates inhibin protein production in immature mouse and rat ovary
culture (Yokota, et al., 1997; Drummond, et al., 2000). Since FSH serum levels decrease after day 18
in mice (Halpin, et al., 1986) the increase in mRNA levels of inhibin a- and bA-subunits was not
expected in the 25-day-old ovaries. One explanation for the discrepancy in increased inhibin subunit
levels in 25-day-old ovaries might be that the ovary has become more sensitive for FSH due to an
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KL is required for primordial follicle recruitment since the absence of KL blocks outgrowth of follicles
(Yoshida, et al., 1997; Parrott and Skinner, 1999). Several reports showed an increase in expression of
KL from primordial to the pre-antral stage using in situ hybridization and immunohistochemistry
(Manova, et al., 1993; Motro and Bernstein, 1993). After antrum formation, KL expression in granulosa
cells surrounding the oocyte disappears and continues only in the outer granulosa cell layer of the
follicle (Manova, et al., 1993). This expression pattern resulted in a decrease of mRNA from the day
of birth until the age of 8 days, whereafter the mRNA expression increased again (Manova, et al.,
1993). In contrast, we did not find a significant increase in KL mRNA expression during the first 25 days
of life although the expression of KL in 18-day-old ovaries was 1.5-fold increased compared to 2-day-old
ovaries. Measuring mRNA levels of KL using SYBRgreen and a different primerset showed similar
results (results not shown). One explanation for not finding a significant decrease in KL mRNA levels,
might be that KL mRNA is also expressed in primordial follicles since 2-day-old ovaries only contain
primordial follicles and express KL mRNA. Also in situ hybridization on postnatal mouse ovaries
suggested expression of KL in primordial follicles (Manova, et al., 1993) and KL protein expression is
reported in primordial follicles in monkey (Gougeon and Busso, 2000) and sheep (Tisdall, et al.,
1999) ovaries. Because primordial follicles form the largest group of follicles in the postnatal ovary, a
small increase in KL expression in pre-antral follicles could be too small to result in a significant
increase in KL mRNA expression in the total ovary. No immunohistochemistry on postnatal ovaries
was performed yet, since KL mRNA and protein expression in (postnatal) ovaries of several species
was already described in detail by several other groups (Manova, et al., 1993; Motro and Bernstein,
1993; Tisdall, et al., 1999; Gougeon and Busso, 2000). However, the results of this study show the
importance of studying KL expression in postnatal mouse ovaries, focussing on the expression of KL
in primordial follicles.
In conclusion, the results presented in this chapter show that AMH, GDF9, BMP15, inhibin/
activin subunits and KL are specifically expressed by granulosa cells or oocytes in growing follicles and
therefore may be involved in regulating the feedback signal to the primordial follicle pool. In contrast,
NGF and bFGF are expressed by all cell types present in the ovary and therefore these growth factors
probably may have a facilitating rather than a regulatory effect on primordial follicle recruitment. 
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ABSTRACT
Anti-Müllerian hormone (AMH) is a member of the TGFb superfamily of growth and differentiation
factors and is responsible for regression of the Müllerian ducts during male sexual development. In
addition, AMH plays an important role in ovarian function since it inhibits primordial follicle
recruitment and decreases the FSH-sensitivity of large pre-antral and small antral follicles. However,
the molecular mechanisms by which AMH achieves these effects are largely unknown.
To understand the downstream effects of AMH we aimed to identify AMH-regulated genes.
Neonatal mouse ovaries were cultured for 24 hours in the absence and presence of AMH and gene
expression differences were analyzed using the Atlas™ mouse cDNA expression array. In addition, mouse
KK-1/AMHRII granulosa cells were treated with AMH for 24 hours and a genome-wide search was
performed using the Agilent mouse development oligo microarray. 
This study identified eight upregulated and three downregulated genes, of which four genes can
also be regulated by TGFb and/or BMPs. Quantitative real-time PCR experiments should validate
AMH-regulation of the identified genes. The importance of validation of differentially expressed genes
obtained by Atlas array is illustrated: all identified genes turned out to be false positives. In addition, we
report limitations of the Agilent mouse development oligo microarray caused by variations in dye labeling.
INTRODUCTION
Anti-Müllerian hormone (AMH) is a member of the TGFb superfamily of growth and differentiation
factors which include also inhibins, activins, bone morphogenetic proteins (BMPs) and growth and
differentiation factors (GDFs) (Massagué and Chen, 2000). In 1947 it was shown by Jost that during male
sex differentiation AMH produced by the testis is responsible for regression of the Müllerian ducts,
the anlagen of female genital tract (Jost, 1947). In the testis, both Leydig and Sertoli cells are AMH
target cells, since both cell types express the AMH type II receptor (AMHRII) (Baarends, et al., 1994;
di Clemente, et al., 1994b; Racine, et al., 1998; Lee, et al., 1999; Teixeira, et al., 1999). Male mice,
overexpressing AMH, have impaired Leydig cell function (Behringer, et al., 1990; Lyet, et al., 1995;
Racine, et al., 1998). Furthermore, AMH and AMHRII null mice incidentally show Leydig cell hyperplasia
(Behringer, et al., 1994; Mishina, et al., 1996). During the spermatogenic cycle, both AMH and AMHRII
are differentially expressed by Sertoli cells with the highest expression at stage VII, suggesting a role
for AMH in spermatogenesis (Baarends, et al., 1995a). In female mice and rats, AMH is expressed
postnatally in the ovaries in granulosa cells of small growing (i.e. pre-antral and small antral) non-atretic
follicles in rat and mouse (Chapter 3; Ueno, et al., 1989; Münsterberg and Lovell-Badge, 1991; Hirobe,
et al., 1992; Baarends, et al., 1995b). In the ovary, AMH inhibits outgrowth of primordial follicles
(Chapter 3, Durlinger, et al., 1999) and decreases the sensitivity of pre-antral and small antral follicles
for FSH (Durlinger, et al., 2001). Although the physiological effects of AMH in the Müllerian ducts, testis
and ovary have been described, little is known about the exact molecular mechanism by which AMH
establishes these effects. Few AMH-regulated genes have been identified (Table 7.1); these genes play
a role in apoptosis, cell cycle, steroidogenesis, BMP/AMH-signaling pathway or in the regulation of
effects of gonadotropins.
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Table 7.1: AMH-regulated genes found in Müllerian ducts, ovary, testis or breast cancer tissue.
Gene: Group: Up (+) or down (-)
regulation: Tissue: References:
MMP2 Apoptosis + Müllerian ducts Roberts et al., 2002
IEX-1S Apoptosis/NFkB-signaling + Breast Segev et al., 2000, 2001
Cyp17 Steroidogenesis - Testis Racine et al., 1998; Teixeira et al., 1999
Cyp11A Steroidogenesis - Testis Racine et al., 1998
∆5-3b-HSD Steroidogenesis - Testis Racine et al., 1998
Cyp19 Steroidogenesis - Ovary, testis di Clemente et al., 1994; Rouiller-Fabre et al., 1998
Smad6 BMP/AMH-signaling + Müllerian ducts, ovary, testis Clarke et al., 2001, Chapter 5 of this thesis
Smad7 BMP/AMH-signaling + Ovary, testis Clarke et al., 2001, Chapter 5 of this thesis
Smad8 BMP/AMH-signaling + Müllerian ducts, ovary Clarke et al., 2001, Chapter 5 of this thesis
LHR Gonadotrophin receptor - Ovary di Clemente et al., 1994; Racine et al., 1998
p16 Cell cycle + Ovary Ha et al., 2000
Two AMH-regulated genes are involved in apoptosis: matrix metalloproteinase 2 (MMP2) and IEX-IS.
During Müllerian duct regression, epithelial cells become apoptotic after they become detached from
the basement membrane (Roberts, et al., 1999; Allard, et al., 2000). This suggests a role for MMPs
since these enzymes are involved in degradation of extracellular matrix and cell surface proteins (Vu and
Werb, 2000). 
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MATERIALS AND METHODS
Animals
Mice were obtained from the animal facility (EDC) of the Erasmus MC. The mice were maintained
under standard animal housing conditions in accordance with NIH guidelines for the care and use of
experimental animals. The AMH null mouse genotype was determined as described by Durlinger et al.
(1999).
Ovary and cell culture
Ovaries of 2-day-old wild-type and AMH null mice were cultured for 24 hours in the presence of purified
AMH (267 ng/ml) or control medium. Culture conditions were as described previously (Chapter 3).
Rat His6-tagged AMH was purified from conditioned medium of stably transfected cells as described
previously (Durlinger, et al., 2001, Chapter 5 of this thesis). After culture ovaries were snap-frozen in
liquid nitrogen and stored at –80C. 
The KK-1/AMHRII cell line (Chapter 5 of this thesis) was cultured in DMEM/F12 with 10% FCS,
penicillin (400 IU/ml) and streptomycin (0.4 mg/ml). At a cell confluency of 80%, cells were further
cultured for 2 hours in 2% FCS, followed by a 24 hour treatment with AMH (33 ng/ml). Next, cells
were washed with PBS and stored at -20C in RNA-Bee (Campro Scientific, Veenendaal, The Netherlands). 
RNA isolation of cultured ovaries and of KK-1/AMHRII cells using RNA-Bee was performed as
described in Chapter 5. Gene expression differences were analyzed using the Agilent mouse development
oligo microarray.
Hybridization on Atlas™ mouse cDNA 
expression array filters
Neonatal ovary cultures were used to search for AMH-regulated genes using the Atlas™ mouse cDNA
expression array filters. After RNA isolation, the presence/absence of genomic DNA in the RNA
samples was tested using a 40 cycle PCR on the mouse L1-repeat gene (forward primer: 5’-GAG ATT
ACC AGA TGG CGA AAG-3’ and reverse primer 5’-GCC GAT GTT CTC TAT GGA ATC-3’). For
the 50 ml PCR reaction, 0.5 pmol/ml primers were used in a PCR buffer containing 1.2 mM DTT, 
50 mM KCl, 10 mM TrisHCl, 0.25 mM dNTP (Amersham Pharmacia Biotech, Roosendaal, The
Netherlands), 1.5 mM MgCl2 and 0.05 units/ml Supertaq (Sphearo-Q, Leiden, The Netherlands). The
PCR reaction mixtures were preheated at 95C for 5 minutes followed by 40 PCR cycles (30 seconds
denaturation at 94C, 45 seconds annealing at 60C, 30 seconds extension at 72C) and a final extension
step of 10 minutes at 72C. The products were separated by electrophoresis on a 1.5% agarose gel. If a
product was found, the DNAse treatment was repeated. 
cDNA was made from total RNA using a mixture of array gene-specific primers and was labeled
with 32P-dATP. Probe synthesis, labeling, purification and hybridization to the filters was performed
following the instructions of the manufacturer (Clontech, USA). The filters were exposed to a
phosphorimaging screen at room temperature and scanned using the PhosphorImager (Molecular
Dynamics, Sunnyvale, USA). The results were analyzed using BD AtlasImage™ Software 2.7. 
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Indeed, MMP2 is necessary for Müllerian duct regression and its expression is under control of AMH
(Roberts, et al., 2002). The second AMH-regulated gene involved in regulation of apoptosis is the
NFkB-regulated gene IEX-IS. In the breast tumor cell line T47D, AMH induces growth inhibition and
apoptosis and it was suggested that this is mediated through the NFkB-signaling cascade (Segev, et al.,
2000) since the mRNA levels of the IEX-IS gene are upregulated after 1 hour of AMH stimulation
(Segev, et al., 2000, 2001). Involvement of the IEX-1S in apoptosis is supported by the fact that expression
of this gene by itself induces apoptosis in T47D cells (Segev, et al., 2000). However, if AMH signals
through the NFkB-signaling pathway still needs to be proven.
Four steroidogenic enzymes are known to be regulated by AMH: P450 17a-hydroxylase/C17-20
lyase (Cyp17), cytochrome P450 cholesterol side-chain cleavage (P450SCC, Cyp11A), D5-3b-hydroxysteroid
dehydrogenase (D5-3b-HSD) and aromatase (Cyp19). AMH suppresses testosterone serum levels by
inhibiting the expression of several steroidogenic enzymes. This is mainly caused by a decreased
expression of Cyp17, the enzyme that catalyzes the conversion of progesterone to androstenedione
(Racine, et al., 1998; Teixeira, et al., 1999). In addition, also mRNA expression of Cyp11A and D5-3b-HSD
is decreased (Racine, et al., 1998). Cyp19 is another steroidogenic enzyme of which expression is inhibited
by AMH. A decreased FSH-stimulated Cyp19 mRNA expression was found in cultured immature rat
granulosa cells treated with AMH (di Clemente, et al., 1994a). Furthermore, AMH inhibits Cyp19
expression in cultured Sertoli cells (Rouiller-Fabre, et al., 1998).
The candidate downstream mediators of AMH-signaling (Smad1, -5 and -8) are all expressed in
the mesenchyme cells surrounding the Müllerian ducts. Interestingly, the Smad8 mRNA expression
level is much higher in males compared to females while no difference in expression level could be
detected for Smad1 or Smad5 (Clarke, et al., 2001). Indeed, AMH stimulates the expression of Smad8
in cultured neonatal ovaries and in the mouse granulosa cell line KK-1/AMHRII (Chapter 5). In addition,
Smad6 mRNA expression is also upregulated in mesenchymal cells of the male Müllerian duct.
Expression of Smad6 and also Smad7, another inhibitory Smad, is regulated by AMH in neonatal
ovaries, the KK-1/AMHRII cell line (Chapter 5) and in Leydig cell lines (Clarke, et al., 2001). 
Another AMH-regulated gene is the LH receptor (LHR). AMH inhibits the FSH-induced expression
of the LHR in cultured rat and porcine granulosa cells (di Clemente, et al., 1994a). However, this
inhibition is only achieved in vitro and not in vivo, since LHR expression is normal in mice overexpressing
AMH (Racine, et al., 1998). AMH inhibits cell cycle progression in the human ovarian cancer cell line
OVCAR8 by upregulating p16 protein expression which inhibits cell cycle progression by binding to
cyclin dependent kinase 4 (cdk4) and cdk6 (Sherr, 1995; Ha, et al., 2000). This upregulation of p16
protein is probably achieved by an increase in translation of p16 mRNA, since no change in p16
mRNA level was found (Ha, et al., 2000).
In conclusion, several AMH-regulated genes in different AMH target tissues have been described.
However, it is not clear if these genes are responsible for the effects of AMH on primordial follicle
recruitment and/or inhibition of FSH-sensitivity of large pre-antral and small antral follicles. To
identify AMH-regulated genes, which are involved in these processes in the ovary, we cultured
neonatal ovaries and KK-1/AMHRII mouse granulosa cells in the presence and absence of AMH.
Differences in gene expression were studied using the Atlas™ mouse cDNA expression array and the
Agilent mouse development oligo microarray.
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RESULTS
Identification of AMH-regulated genes using the Atlas™
mouse cDNA expression array filters
Previously, we have shown that neonatal ovaries are sensitive to AMH (Chapter 3). Therefore, to
screen for AMH-regulated genes in the ovary, neonatal ovaries were cultured for 24 hours in the
absence or presence of AMH. Using the Atlas Array expression system, which contains 588 different
mouse genes, AMH-induced differences in gene expression were studied (Figure 7.1). Using the BD
AtlasImage™ Software 2.7 four up- and three downregulated genes were identified (Table 7.3). 
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Hybridization on Agilent mouse development 
oligo microarray
The response of the KK-1/AMHRII cells to AMH was checked by determining the expression of
Smad6 (forward primer 5’-CCC CAT CTT CGT CAA CT-3’ and reverse primer 5’-CGC TCA AAG
TCG AAC AC-3’) and Smad7 (forward primer 5’-CTC CAG GAC GCT GTT G-3’ and reverse primer
5’-TGC ATG AAC TCG TGG TC-3’) using quantitative real-time PCR (as described in Chapter 5).
Genomic DNA present in the RNA samples used to hybridize the Agilent mouse development
oligo microarray was removed using the SV Total RNA Isolation system (Promega, Leiden, The
Netherlands). In addition, the quality of RNA was tested using the Lab-on-a-chip 2100 Bioanalyzer
(Agilent) performed according to the protocol of the manufacturer by ServiceXS (Leiden, The
Netherlands).
The Cy5/Cy3 labeling of RNA and the hybridization on the Agilent mouse development oligo
microarray were performed by Service XS, according to the protocols of the manufacturer of Agilent
Fluorescent Direct label kit and Agilent Oligonucleotide microarray hybridization (Agilent Technologies,
USA). Hybridization was performed in duplicate with a reverse dye labeling (dye-swap) to check for
preferential dye incorporation. The data were analyzed using the Agilent Feature Extraction software.
Genes were considered to be significantly up- or downregulated if in one array the Cy3/Cy5 and in
the other array the Cy5/Cy3 ratio was equal to or larger than 1.5, if the signal level was above
background (=average signal of negative controls + 2xSD) (Wang, et al., 2001) and when the p-value
was lower than 10-3.
cDNA synthesis and quantitative real-time PCR
AMH-regulated genes identified by the Atlas™ mouse cDNA expression array filters were re-examined
using quantitative real-time PCR. RNA samples were first tested for the presence of genomic DNA in
a RT minus reaction, measuring b-actin (primers see Table 7.2) using SYBRgreen reagent as described
in Chapter 5. Subsequently, cDNA synthesis and quantitative real-time PCR using SYBRgreen were
performed as described in Chapter 5. Primers used are shown in Table 7.2.
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Table 7.2: Oligonucleotide primer sequences used to validate gene expression differences found with the
Atlas™ mouse cDNA expression array filters. 
Gene: Forward primer: Reverse primer: Product size (bp):
RelA 5’-AAG CCT TCC CGA AGT G-3’ 5’-CCT CCG AAA GCG AGA T-3’ 112
Frizzled 3 5’-AAA CAG AGT TCG GAT TGA GA-3’ 5’-AAG AGT GGC ACA AGG TAG AG-3’ 109
Cathepsin L 5’-GTG GGC TAT GGC TAT GAA-3’ 5’-TCA TTA CCG CTA CCC ATC-3’ 181
Integrin a6 5’-GAA GCC GAT TCG TCT AAA-3’ 5’-TTC CCA GCG ATT GAA TAG-3’ 225
b-actin 5’-CTA CGA GGG CTA TGC TCT-3’ 5’-TCG TTG CCA ATA GTG ATG-3’ 264
Table 7.3: AMH-regulated genes obtained using the Atlas™ mouse cDNA expression array. 
Wild-type neonatal mouse ovaries were cultured for 24 hours in the absence or presence of AMH. 
Gene: Group: ratio 
(+AMH/-AMH):
Glutathione S-transferase mu 2 (GSTM2); GST5-5 Detoxification 0.3
Integrin alpha 6 (ITGA6) Extracellular matrix 0.4
Frizzled homolog 3 (FZD3; FZ3) Wnt-signaling 0.5
Cathepsin L (CTSL); major excreted protein (MEP) Protease 1.7
Transcription termination factor 1 (TTF1) Transcription factor 2.1
RelA proto-oncogene; NF-kappa-B transcription factor p65 subunit (NF-kB p65) NFkB-signaling 2.3
Special AT-rich sequence-binding protein 1 (SATB1) Transcription factor 2.5
Figure 7.1: cDNA expression profile of 2-day-old neonatal ovary culture of wild-type mice cultured for 24 hours in
the absence or presence of AMH.
Membranes were hybridized under identical conditions with 5 mg total 32P-labeled cDNA. Differentially
expressed genes were identified using BD AtlasImage™ Software 2.7 and are marked by numbers:
1=RelA, 2=cathepsin L, 3=frizzled 3 and 4=integrin a6.
RESULTS
Identification of AMH-regulated genes using the Atlas™
mouse cDNA expression array filters
Previously, we have shown that neonatal ovaries are sensitive to AMH (Chapter 3). Therefore, to
screen for AMH-regulated genes in the ovary, neonatal ovaries were cultured for 24 hours in the
absence or presence of AMH. Using the Atlas Array expression system, which contains 588 different
mouse genes, AMH-induced differences in gene expression were studied (Figure 7.1). Using the BD
AtlasImage™ Software 2.7 four up- and three downregulated genes were identified (Table 7.3). 
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Hybridization on Agilent mouse development 
oligo microarray
The response of the KK-1/AMHRII cells to AMH was checked by determining the expression of
Smad6 (forward primer 5’-CCC CAT CTT CGT CAA CT-3’ and reverse primer 5’-CGC TCA AAG
TCG AAC AC-3’) and Smad7 (forward primer 5’-CTC CAG GAC GCT GTT G-3’ and reverse primer
5’-TGC ATG AAC TCG TGG TC-3’) using quantitative real-time PCR (as described in Chapter 5).
Genomic DNA present in the RNA samples used to hybridize the Agilent mouse development
oligo microarray was removed using the SV Total RNA Isolation system (Promega, Leiden, The
Netherlands). In addition, the quality of RNA was tested using the Lab-on-a-chip 2100 Bioanalyzer
(Agilent) performed according to the protocol of the manufacturer by ServiceXS (Leiden, The
Netherlands).
The Cy5/Cy3 labeling of RNA and the hybridization on the Agilent mouse development oligo
microarray were performed by Service XS, according to the protocols of the manufacturer of Agilent
Fluorescent Direct label kit and Agilent Oligonucleotide microarray hybridization (Agilent Technologies,
USA). Hybridization was performed in duplicate with a reverse dye labeling (dye-swap) to check for
preferential dye incorporation. The data were analyzed using the Agilent Feature Extraction software.
Genes were considered to be significantly up- or downregulated if in one array the Cy3/Cy5 and in
the other array the Cy5/Cy3 ratio was equal to or larger than 1.5, if the signal level was above
background (=average signal of negative controls + 2xSD) (Wang, et al., 2001) and when the p-value
was lower than 10-3.
cDNA synthesis and quantitative real-time PCR
AMH-regulated genes identified by the Atlas™ mouse cDNA expression array filters were re-examined
using quantitative real-time PCR. RNA samples were first tested for the presence of genomic DNA in
a RT minus reaction, measuring b-actin (primers see Table 7.2) using SYBRgreen reagent as described
in Chapter 5. Subsequently, cDNA synthesis and quantitative real-time PCR using SYBRgreen were
performed as described in Chapter 5. Primers used are shown in Table 7.2.
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Table 7.2: Oligonucleotide primer sequences used to validate gene expression differences found with the
Atlas™ mouse cDNA expression array filters. 
Gene: Forward primer: Reverse primer: Product size (bp):
RelA 5’-AAG CCT TCC CGA AGT G-3’ 5’-CCT CCG AAA GCG AGA T-3’ 112
Frizzled 3 5’-AAA CAG AGT TCG GAT TGA GA-3’ 5’-AAG AGT GGC ACA AGG TAG AG-3’ 109
Cathepsin L 5’-GTG GGC TAT GGC TAT GAA-3’ 5’-TCA TTA CCG CTA CCC ATC-3’ 181
Integrin a6 5’-GAA GCC GAT TCG TCT AAA-3’ 5’-TTC CCA GCG ATT GAA TAG-3’ 225
b-actin 5’-CTA CGA GGG CTA TGC TCT-3’ 5’-TCG TTG CCA ATA GTG ATG-3’ 264
Table 7.3: AMH-regulated genes obtained using the Atlas™ mouse cDNA expression array. 
Wild-type neonatal mouse ovaries were cultured for 24 hours in the absence or presence of AMH. 
Gene: Group: ratio 
(+AMH/-AMH):
Glutathione S-transferase mu 2 (GSTM2); GST5-5 Detoxification 0.3
Integrin alpha 6 (ITGA6) Extracellular matrix 0.4
Frizzled homolog 3 (FZD3; FZ3) Wnt-signaling 0.5
Cathepsin L (CTSL); major excreted protein (MEP) Protease 1.7
Transcription termination factor 1 (TTF1) Transcription factor 2.1
RelA proto-oncogene; NF-kappa-B transcription factor p65 subunit (NF-kB p65) NFkB-signaling 2.3
Special AT-rich sequence-binding protein 1 (SATB1) Transcription factor 2.5
Figure 7.1: cDNA expression profile of 2-day-old neonatal ovary culture of wild-type mice cultured for 24 hours in
the absence or presence of AMH.
Membranes were hybridized under identical conditions with 5 mg total 32P-labeled cDNA. Differentially
expressed genes were identified using BD AtlasImage™ Software 2.7 and are marked by numbers:
1=RelA, 2=cathepsin L, 3=frizzled 3 and 4=integrin a6.
Of the 20,000 genes present on the Agilent array, the Cy3 and Cy5 signal levels of almost 89% (about
18,000 genes) were above background levels on both arrays (=average signal of negative controls + 2xSD)
and had a p-value smaller than 10-3. However, only eight upregulated and three downregulated genes were
identified (Table 7.4) and they are in the process of being validated using quantitative real-time PCR. 
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We focussed on RelA, cathepsin L, integrin a6 and frizzled3 since in the literature a connection of
these genes with AMH can be found and/or a role in follicular development has been described.
Quantitative real-time PCR was performed to confirm the AMH-induced differential expression of
these genes. However, none of these four genes was found to be differentially regulated using this
technique neither in neonatal ovaries nor in KK-1/AMHRII cells (Figure 7.2).
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Figure 7.2: Validation of AMH-regulated gene expression in 2-day-old neonatal AMH null ovaries (A) and in 
KK-1/AMHRII cells (B).
Gene expression of RelA, cathepsin L, frizzled3 and integrin a6 was measured by quantitative real-time
PCR using SYBRgreen. Gene expression was corrected for b-actin and fold induction was determined as
ratio of gene expression +AMH/-AMH. The bars represent the mean fold induction and the spots
represent the fold induction of the two independent experiments.
Identification of AMH-regulated genes using the Agilent
mouse oligo microarray
Because the Atlas array did not yield any AMH-regulated genes, we decided to perform a genome-wide
screen using the Agilent developmental oligo array. This glass-slide based array contains over 20,000
mouse genes and ESTs. For this expression analysis, KK-1/AMHRII cells were stimulated with AMH
for 24 hours. As described in Chapter 5, we found that Smad6 and Smad7 gene expression is upregulated
in KK-1/AMHRII cells after 24 hours of culture in the presence of AMH. To test the quality of the
response of the KK-1/AMHRII cells to AMH, the expression of Smad6 and Smad7 was measured
before using this RNA to hybridize to the Agilent array. Indeed, expression of Smad6 and Smad7 was
stimulated about 18- and 4-fold respectively by AMH and the RNA samples were subsequently used.
Table 7.4: Candidate AMH-regulated genes obtained using the Agilent mouse development oligo microarray. 
KK-1/AMHRII cells were cultured for 24 hours in the absence or presence of AMH. The p-value respresents the
significance of the log(Cy5signal/Cy3signal) per feature after dye normalization (Agilent Technologies, USA).
Gene: Abbreviation: Group: Ratio p-value
(+AMH/-AMH)
array 1: array 2: array 1: array 2:
Ribosomal protein L24 Rpl24 Ribosomal protein 0.6 0.6 1.1*10-4 7.6*10-7
Neuronal precursor cell expressed, Nedd9 Ubiquitin-proteosome 0.6 0.7 3.5*10-4 1.3*10-5
developmentally down-regulated gene 9 pathway
Transferrin receptor Trfr Iron uptake 0.6 0.6 1.2*10-4 2.0*10-4
Tumor necrosis factor, alpha-induced protein 3 Tnfaip3 NFkB-signaling 1.6 1.6 4.9*10-5 8.0*10-5
Crystallin alpha B Cryab Heat shock protein 1.6 1.9 2.0*10-7 3.4*10-5
CD24a antigen/heat stable antigen Differentiation marker 1.7 1.6 1.2*10-4 1.7*10-5
Procollagen C-endopeptidase enhancer 2 Pcolce2 Protease 1.7 1.7 5.0*10-6 7.1*10-6
Unknown EST, similar to Homo sapiens clone EST 2.0 1.7 3.4*10-5 1.7*10-7
RP11-349E11 from 7p14-15
Unknown EST, similar to Homo sapiens clone EST 2.2 2.5 3.1*10-10 1.1*10-8
RP11-337C18 on chromosome 1,
Latexin Lxn Enzyme inhibitor 3.5 1.9 9.1*10-8 1.3*10-17
Inhibitor of DNA binding 2 Id2 Transcription factor 5.5 2.7 1.9*10-13 9.3*10-24
DISCUSSION
Two different types of arrays were used in the search for AMH-regulated genes. Using the Atlas mouse
cDNA expression array, four upregulated and three downregulated genes were identified in wild-type
neonatal ovaries stimulated with AMH in vitro (Table 7.3). Based on the literature, four of these genes
were selected for validation. RelA (NFkB) has been shown to be involved in the AMH-induced growth
inhibition in two breast tumor cell lines and in a mammary epithelial cell line (Segev, et al., 2000, 2001).
This growth inhibition was associated with an increase in RelA activity (Segev, et al., 2000, 2001).
Cathepsin L, a lysosomal cysteine protease member of the papain family (Kirschke, et al., 1998), has been
suggested to be important for tissue remodeling and cell migration (Ishidoh and Kominami, 1998).
Interestingly, cathepsin L has been implicated in folliculogenesis, since cathepsin L expression in
granulosa cells of pre-ovulatory follicles is important for ovulation (Robker, et al., 2000). However, to
ensure that cathepsin L is an AMH-regulated gene in vivo further research is needed, since AMH is not
expressed in pre-ovulatory follicles where cathepsin L is expressed. In the testis, cathepsin L is differentially
expressed in Sertoli cells during the various stages of spermatogenesis. Interestingly, its expression is
highest during stage VI and VII of the seminiferous epithelium, when also AMHRII expression is highest
in Sertoli cells (Zabludoff, et al., 2001). Laminin degradation is associated with cathepsin L expression
and laminin a5 expression in basement membrane of embryonic testicular chords disappears when
Sertoli cells start expressing AMH (Frojdman, et al., 1999; Zabludoff, et al., 2001). 
Of the 20,000 genes present on the Agilent array, the Cy3 and Cy5 signal levels of almost 89% (about
18,000 genes) were above background levels on both arrays (=average signal of negative controls + 2xSD)
and had a p-value smaller than 10-3. However, only eight upregulated and three downregulated genes were
identified (Table 7.4) and they are in the process of being validated using quantitative real-time PCR. 
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We focussed on RelA, cathepsin L, integrin a6 and frizzled3 since in the literature a connection of
these genes with AMH can be found and/or a role in follicular development has been described.
Quantitative real-time PCR was performed to confirm the AMH-induced differential expression of
these genes. However, none of these four genes was found to be differentially regulated using this
technique neither in neonatal ovaries nor in KK-1/AMHRII cells (Figure 7.2).
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Figure 7.2: Validation of AMH-regulated gene expression in 2-day-old neonatal AMH null ovaries (A) and in 
KK-1/AMHRII cells (B).
Gene expression of RelA, cathepsin L, frizzled3 and integrin a6 was measured by quantitative real-time
PCR using SYBRgreen. Gene expression was corrected for b-actin and fold induction was determined as
ratio of gene expression +AMH/-AMH. The bars represent the mean fold induction and the spots
represent the fold induction of the two independent experiments.
Identification of AMH-regulated genes using the Agilent
mouse oligo microarray
Because the Atlas array did not yield any AMH-regulated genes, we decided to perform a genome-wide
screen using the Agilent developmental oligo array. This glass-slide based array contains over 20,000
mouse genes and ESTs. For this expression analysis, KK-1/AMHRII cells were stimulated with AMH
for 24 hours. As described in Chapter 5, we found that Smad6 and Smad7 gene expression is upregulated
in KK-1/AMHRII cells after 24 hours of culture in the presence of AMH. To test the quality of the
response of the KK-1/AMHRII cells to AMH, the expression of Smad6 and Smad7 was measured
before using this RNA to hybridize to the Agilent array. Indeed, expression of Smad6 and Smad7 was
stimulated about 18- and 4-fold respectively by AMH and the RNA samples were subsequently used.
Table 7.4: Candidate AMH-regulated genes obtained using the Agilent mouse development oligo microarray. 
KK-1/AMHRII cells were cultured for 24 hours in the absence or presence of AMH. The p-value respresents the
significance of the log(Cy5signal/Cy3signal) per feature after dye normalization (Agilent Technologies, USA).
Gene: Abbreviation: Group: Ratio p-value
(+AMH/-AMH)
array 1: array 2: array 1: array 2:
Ribosomal protein L24 Rpl24 Ribosomal protein 0.6 0.6 1.1*10-4 7.6*10-7
Neuronal precursor cell expressed, Nedd9 Ubiquitin-proteosome 0.6 0.7 3.5*10-4 1.3*10-5
developmentally down-regulated gene 9 pathway
Transferrin receptor Trfr Iron uptake 0.6 0.6 1.2*10-4 2.0*10-4
Tumor necrosis factor, alpha-induced protein 3 Tnfaip3 NFkB-signaling 1.6 1.6 4.9*10-5 8.0*10-5
Crystallin alpha B Cryab Heat shock protein 1.6 1.9 2.0*10-7 3.4*10-5
CD24a antigen/heat stable antigen Differentiation marker 1.7 1.6 1.2*10-4 1.7*10-5
Procollagen C-endopeptidase enhancer 2 Pcolce2 Protease 1.7 1.7 5.0*10-6 7.1*10-6
Unknown EST, similar to Homo sapiens clone EST 2.0 1.7 3.4*10-5 1.7*10-7
RP11-349E11 from 7p14-15
Unknown EST, similar to Homo sapiens clone EST 2.2 2.5 3.1*10-10 1.1*10-8
RP11-337C18 on chromosome 1,
Latexin Lxn Enzyme inhibitor 3.5 1.9 9.1*10-8 1.3*10-17
Inhibitor of DNA binding 2 Id2 Transcription factor 5.5 2.7 1.9*10-13 9.3*10-24
DISCUSSION
Two different types of arrays were used in the search for AMH-regulated genes. Using the Atlas mouse
cDNA expression array, four upregulated and three downregulated genes were identified in wild-type
neonatal ovaries stimulated with AMH in vitro (Table 7.3). Based on the literature, four of these genes
were selected for validation. RelA (NFkB) has been shown to be involved in the AMH-induced growth
inhibition in two breast tumor cell lines and in a mammary epithelial cell line (Segev, et al., 2000, 2001).
This growth inhibition was associated with an increase in RelA activity (Segev, et al., 2000, 2001).
Cathepsin L, a lysosomal cysteine protease member of the papain family (Kirschke, et al., 1998), has been
suggested to be important for tissue remodeling and cell migration (Ishidoh and Kominami, 1998).
Interestingly, cathepsin L has been implicated in folliculogenesis, since cathepsin L expression in
granulosa cells of pre-ovulatory follicles is important for ovulation (Robker, et al., 2000). However, to
ensure that cathepsin L is an AMH-regulated gene in vivo further research is needed, since AMH is not
expressed in pre-ovulatory follicles where cathepsin L is expressed. In the testis, cathepsin L is differentially
expressed in Sertoli cells during the various stages of spermatogenesis. Interestingly, its expression is
highest during stage VI and VII of the seminiferous epithelium, when also AMHRII expression is highest
in Sertoli cells (Zabludoff, et al., 2001). Laminin degradation is associated with cathepsin L expression
and laminin a5 expression in basement membrane of embryonic testicular chords disappears when
Sertoli cells start expressing AMH (Frojdman, et al., 1999; Zabludoff, et al., 2001). 
genes which are differentially expressed by AMH. Thus, the small number of apparently AMH-regulated
genes found in the KK-1/AMHRII cell line using the Agilent array might be caused by the variation
in labeling. Another explanation for the small number of identified genes could be the use of the 
KK-1/AMHRII cell line. AMH is involved in follicle development in primary and pre-antral follicles.
The KK-1/AMHRII cells are derived from granulosa cell tumors and may have lost the granulosa cells
characteristics of pre-antral follicles.
Some of the identified candidate genes are members of families of proteins or have related functions:
iron uptake (Trfr), ubiquination (Nedd9), members of NFkB-signaling (Tnfaip3), transcription factors
(Id2), heat shock proteins (Cryab), differentiation markers (CD24a antigen), enzyme inhibitors (Lxn),
proteases (Pcolce2) and ribosomal proteins (Rpl24) (see also Table 7.4). Also two ESTs were identified.
The transferrin receptor (Trfr) is a very interesting candidate AMH-regulated gene since this receptor
is necessary in the cell cycle because of its role in iron uptake (Neckers and Cossman, 1983),
suggesting that downregulation of this receptor by AMH could inhibit granulosa cell proliferation. In
addition, an inhibitory effect of transferrin is reported on differentiation of in vitro cultured granulosa
cells by inhibiting FSH-induced aromatase activity (Li, et al., 1991) and inhibin and progesterone
production (Yu and Findlay, 1991; Kawano, et al., 1995). AMH is known to inhibit aromatase activity
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The receptor for laminin is the integrin receptor a6b1 or a6b4 (Burgeson, et al., 1994). This receptor
is involved in adhesion of cells to the extracellular matrix and is a modulator of growth, development and
differentiation. Integrin a6 is also involved in development and sex differentiation of the mouse ovary
(Frojdman and Pelliniemi, 1995) and in luteinization of human granulosa cells during the
periovulatory phase (Fujiwara, et al., 1998). Finally, frizzled3 is a member of the frizzled receptor
family that mediates Wnt-signaling. Wnt family members are involved in many processes including
sex differentiation. For example Wnt-4 is involved in embryonic ovarian development and Wnt-7a is
necessary for AMHRII expression in the Müllerian ducts (Parr and McMahon, 1998; Vainio, et al.,
1999). Wnt binding to frizzled leads to accumulation of b-catenin. Accumulation of b-catenin is found
in Müllerian ducts upon AMH exposure (Allard, et al., 2000). However, none of these four genes was
differentially expressed in AMH null neonatal ovary culture or KK-1/AMHRII cells in the validation
experiment using quantitative real-time PCR, underlining the necessity to validate candidate
regulated genes by an alternative quantitative method. The failure to identify AMH-regulated genes
was caused by technical problems (high and varying background levels) and due to the limited
number of genes present on these filter arrays. 
Thus a more extensive study was necessary to identify AMH-regulated genes, which are potentially
involved in the regulation of recruitment of primordial follicles and in regulation of FSH-sensitivity
of pre-antral and antral follicles. KK-1/AMHRII cells were stimulated with AMH for 24 hours and a
genome wide screen was performed using the Agilent mouse oligo microarray representing over
20,000 mouse genes. The low number of identified AMH-regulated genes, eight upregulated and
three downregulated genes, is not caused by a lack of response of the cell culture since in the same
samples Smad6 and Smad7 were found to be stimulated by AMH. Unfortunately, Smad6 and Smad7
were not present on the Agilent array and could not be used to check the quality of the procedure. 
A major problem of the Agilent array seemed to be the variation of dye-incorporation. The Agilent
array was performed in duplicate, using the same batch of RNA, where in one experiment RNA from
cells treated with AMH was labeled with Cy3 and in the other experiment with Cy5 and the untreated
cells were labeled in reverse. When the ratios of Cy3/Cy5 from the genes with a signal above background
are plotted in a graph, a negative slope would be expected since genes should have an inversed
Cy3/Cy5 ratio in array 1 compared to array 2 if the dye labeling would be similar. However, a positive
slope was found when the ratios of genes expressed above background in both arrays were plotted
(Figure 7.3). Quadrant I contains the genes which have incorporated more Cy3 than Cy5 while
quadrant III contains genes which have incorporated more Cy5 than Cy3. AMH-induced genes are
highlighted by triangles in quadrant IV, while AMH-downregulated genes are highlighted by triangles
in quadrant II. The Cy3/Cy5 ratios of these genes are inversed between both arrays and this Cy3/Cy5
or Cy5/Cy3 ratio is equal to or larger than 1.5-fold. Differences in labeling between the two array
experiments might explain the small number of identified genes (Figure 7.3). The large number of
genes in quadrant I and III suggest that many genes preferentially incorporate the Cy3 or the Cy5 dye.
Indeed, two Agilent arrays hybridized with the same RNA sample (self-self hybridization experiments)
showed a preferential dye labeling in about 10% of the expressed genes (data kindly provided by 
Dr. J. T. den Dunnen, Leiden University Medical Centre). However, only a small overlap (0.4%) of
the genes which preferentially incorporated the Cy3 or the Cy5 dye in both arrays was found,
indicating variation in dye labeling between experiments. The variation in dye labeling can mask
Figure 7.3: Logarithmic plot of the Cy3/Cy5 ratio of reverse dye labeling of two arrays.
In array 1, cDNA of KK-1/AMHRII cells treated with AMH was labeled Cy3, while in array 2 this cDNA
was labeled with Cy5. Preferentially incorporated genes can be found in quadrant I and III, causing a
positive correlation between the ratios of the two arrays. AMH-upregulated genes are highlighted by
triangles in quadrant I and have a Cy3/Cy5 ratio above 1.5 in array 1 and below 0.67 in array 2. AMH-
downregulated genes are highlighted by triangles in quadrant II and have a Cy3/Cy5 ratio below 0.67 in
array 1 and above 1.5 in array 2. Only genes with signals above background are plotted in this graph.
genes which are differentially expressed by AMH. Thus, the small number of apparently AMH-regulated
genes found in the KK-1/AMHRII cell line using the Agilent array might be caused by the variation
in labeling. Another explanation for the small number of identified genes could be the use of the 
KK-1/AMHRII cell line. AMH is involved in follicle development in primary and pre-antral follicles.
The KK-1/AMHRII cells are derived from granulosa cell tumors and may have lost the granulosa cells
characteristics of pre-antral follicles.
Some of the identified candidate genes are members of families of proteins or have related functions:
iron uptake (Trfr), ubiquination (Nedd9), members of NFkB-signaling (Tnfaip3), transcription factors
(Id2), heat shock proteins (Cryab), differentiation markers (CD24a antigen), enzyme inhibitors (Lxn),
proteases (Pcolce2) and ribosomal proteins (Rpl24) (see also Table 7.4). Also two ESTs were identified.
The transferrin receptor (Trfr) is a very interesting candidate AMH-regulated gene since this receptor
is necessary in the cell cycle because of its role in iron uptake (Neckers and Cossman, 1983),
suggesting that downregulation of this receptor by AMH could inhibit granulosa cell proliferation. In
addition, an inhibitory effect of transferrin is reported on differentiation of in vitro cultured granulosa
cells by inhibiting FSH-induced aromatase activity (Li, et al., 1991) and inhibin and progesterone
production (Yu and Findlay, 1991; Kawano, et al., 1995). AMH is known to inhibit aromatase activity
109
Search for AMH-regulated genes
108
Chapter 7
The receptor for laminin is the integrin receptor a6b1 or a6b4 (Burgeson, et al., 1994). This receptor
is involved in adhesion of cells to the extracellular matrix and is a modulator of growth, development and
differentiation. Integrin a6 is also involved in development and sex differentiation of the mouse ovary
(Frojdman and Pelliniemi, 1995) and in luteinization of human granulosa cells during the
periovulatory phase (Fujiwara, et al., 1998). Finally, frizzled3 is a member of the frizzled receptor
family that mediates Wnt-signaling. Wnt family members are involved in many processes including
sex differentiation. For example Wnt-4 is involved in embryonic ovarian development and Wnt-7a is
necessary for AMHRII expression in the Müllerian ducts (Parr and McMahon, 1998; Vainio, et al.,
1999). Wnt binding to frizzled leads to accumulation of b-catenin. Accumulation of b-catenin is found
in Müllerian ducts upon AMH exposure (Allard, et al., 2000). However, none of these four genes was
differentially expressed in AMH null neonatal ovary culture or KK-1/AMHRII cells in the validation
experiment using quantitative real-time PCR, underlining the necessity to validate candidate
regulated genes by an alternative quantitative method. The failure to identify AMH-regulated genes
was caused by technical problems (high and varying background levels) and due to the limited
number of genes present on these filter arrays. 
Thus a more extensive study was necessary to identify AMH-regulated genes, which are potentially
involved in the regulation of recruitment of primordial follicles and in regulation of FSH-sensitivity
of pre-antral and antral follicles. KK-1/AMHRII cells were stimulated with AMH for 24 hours and a
genome wide screen was performed using the Agilent mouse oligo microarray representing over
20,000 mouse genes. The low number of identified AMH-regulated genes, eight upregulated and
three downregulated genes, is not caused by a lack of response of the cell culture since in the same
samples Smad6 and Smad7 were found to be stimulated by AMH. Unfortunately, Smad6 and Smad7
were not present on the Agilent array and could not be used to check the quality of the procedure. 
A major problem of the Agilent array seemed to be the variation of dye-incorporation. The Agilent
array was performed in duplicate, using the same batch of RNA, where in one experiment RNA from
cells treated with AMH was labeled with Cy3 and in the other experiment with Cy5 and the untreated
cells were labeled in reverse. When the ratios of Cy3/Cy5 from the genes with a signal above background
are plotted in a graph, a negative slope would be expected since genes should have an inversed
Cy3/Cy5 ratio in array 1 compared to array 2 if the dye labeling would be similar. However, a positive
slope was found when the ratios of genes expressed above background in both arrays were plotted
(Figure 7.3). Quadrant I contains the genes which have incorporated more Cy3 than Cy5 while
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Figure 7.3: Logarithmic plot of the Cy3/Cy5 ratio of reverse dye labeling of two arrays.
In array 1, cDNA of KK-1/AMHRII cells treated with AMH was labeled Cy3, while in array 2 this cDNA
was labeled with Cy5. Preferentially incorporated genes can be found in quadrant I and III, causing a
positive correlation between the ratios of the two arrays. AMH-upregulated genes are highlighted by
triangles in quadrant I and have a Cy3/Cy5 ratio above 1.5 in array 1 and below 0.67 in array 2. AMH-
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1987; Cross and Cambier, 1990; Ruegemer, et al., 1990) and stimulates expression of Cryab 
(Welge-Lussen, et al., 2000). Regulation of gene expression by the both TGFb/activin-like and BMP-
like signaling pathways suggests that Smad4 or other signaling pathways (like MAPK) are involved.
In conclusion, using the Agilent array we identified 11 candidate AMH-regulated genes. This low
number of AMH-regulated genes may be caused by the preferential dye-incorporation of many genes.
The identified AMH-regulated genes should be validated by quantitative real-time PCR.
Confirmation of identified genes using an array is important as shown by the Atlas™ mouse cDNA
expression array where all identified AMH-regulated genes were false positives.
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and FSH-sensitivity of large pre-antral and antral follicles and therefore it is unexpected that a
receptor which also could achieve these effects is downregulated by AMH. 
Nedd proteins are ubiquitin-like proteins (Yeh, et al., 2000) and Nedd9 is expressed in KK-1/AMHRII
granulosa cells and oocytes (EST K0232A09-3 from the NIA mouse unfertilized egg cDNA library).
Downregulation of Nedd9 by AMH could be important since a family member Nedd8 is involved in
ubiquination of steroid receptors (Fan, et al., 2002) and the inhibitor of NFkB-signaling IkBa (Tanaka,
et al., 2001). Interestingly, AMH induces expression of the NFkB regulated gene IEX-1S in breast tumor
cell lines (Segev, et al., 2000, 2001). However, whether also Nedd9 is involved in ubiquitination of
NkBa should be determined. In addition, also the AMH-upregulated gene tumor necrosis factor
alpha-induced protein 3 (Tnfaip3) is involved in the NFkB-signaling pathway (Baltathakis, et al., 2001).
If regulation of Tnfaip3 by AMH can be confirmed by quantitative real-time PCR, a role of the 
NFkB-signaling downstream of AMH-signaling would be probable. 
Inhibitors of DNA binding or differentiation, referred to as Id proteins, antagonize the effect of
helix-loop-helix transcription factors which play a role in cell growth, differentiation and tumorigenesis
(Norton, et al., 1998). Id2 expression is associated with dedifferentiation of cells (Coppe, et al., 2003)
and Id2 is therefore interesting as an AMH-upregulated gene, since inhibition of FSH-sensitivity of
pre-antral follicles by AMH is a measure of inhibition of differentiation of granulosa cells. Another
protein that could inhibit differentiation is the AMH-upregulated gene Cd24a. This gene encodes the
murine differentiation marker heat stable antigen (HSA) in hematopoietic cell lineages, which is
generally highly expressed in immature precursor cells and low in differentiated cells (Bruce, et al.,
1981; Linton, et al., 1989). However, little is known about the function of Cd24a and it is unknown
what the role of this gene in the ovary is. Also nothing is known about the role in the ovary of the
candidate AMH-regulated gene Cryab, a heat shock protein expressed by lenticular tissues of the eye,
but also heart, brain kidney, placenta, lung and striated muscle (Iwaki, et al., 1990; Kato, et al., 1991;
Flugel, et al., 1993). 
Procollagen C-endopeptidase enhancer (Pcolce2) specifically binds to procollagen C-propeptides,
thereby facilitating cleavage by procollagen C-proteinases into collagen (Ricard-Blum, et al., 2002).
Collagen is the most important extracellular matrix component and could be important in maintaining
the follicle structure. In addition, Pcolce2 functions as a tissue inhibitor of metalloproteinases
(TIMPs) when the netrin-like domain of this protein is released after proteolysis (Kessler, et al., 1990;
Banyai and Patthy, 1999; Mott, et al., 2000). BMP-signaling can be stimulated by Pcolce2 since the
CUB domains bind to BMP1 thereby enhancing its activity and stimulating the release of BMPs
bound to chordin (Hulmes et al., 1997). Another candidate AMH-regulated gene is latexin, a carboxy
peptidase A inhibitor (Balint, et al., 2003). A function for this protein in the ovary is unknown.
AMH signals through the BMP-like signaling pathway (Gouédard, et al., 2000; Clarke, et al., 2001;
Visser, et al., 2001, Chapter 5 of this thesis). Like the AMH-regulated genes identified using the
Agilent array, BMP-regulation has been described for factors involved in cell cycle, transcription
factors, heat shock proteins, factors involved in extracellular matrix and Id-proteins (Balint, et al.,
2003) and the candidate AMH-regulated genes Id2 (Hollnagel, et al., 1999; Balint, et al., 2003) and
latexin (Balint, et al., 2003) have been described to be regulated by BMPs. In addition to regulation
of expression by BMPs, Id2 mRNA expression is also under control of TGFb (Hacker, et al., 2003;
Sugai, et al., 2003). Furthermore, TGFb inhibits expression of the transferrin receptor (Smeland, et al.,
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8.1 INTRODUCTION
Female reproduction is dependent on successful development of a primordial follicle into a pre-ovulatory
follicle. In women, the limited primordial follicle pool is formed during fetal life, whereafter this pool
is gradually depleted since no new primordial follicles can be formed (for review see Chapter 1).
Depletion of this follicle pool is associated with decreased fertility, followed by infertility and ends in
menopause, which is associated with increased risk for several health problems (osteoporosis,
cardiovascular disease). Recruitment of primordial follicles into the growing pool is an important
regulatory checkpoint in primordial follicle stock exhaustion. The rate of primordial follicle recruitment
is determined by growth factors, including members of the TGFb superfamily, which are produced
by the growing follicles. These growing follicles can develop into a pre-ovulatory follicle or undergo
atresia. Thus, for understanding the regulation of primordial stock depletion, follicular development
and atresia are important processes to investigate.
Anti-Müllerian hormone (AMH), a member of the TGFb superfamily, is produced by the granulosa
cells of small growing follicles in the ovary and inhibits recruitment of primordial follicles. The major
objective of this thesis was to obtain more insight in the role of AMH and the molecular mechanisms
by which AMH achieves this effect. We studied the effect of AMH on primordial follicle recruitment
in neonatal ovaries, investigated the AMH-signaling pathway and searched for AMH-regulated genes.
In this Chapter, the mechanisms by which AMH could achieve its specific effects is discussed. In addition,
the role of AMH in follicle development compared to the role of the systemic factors LH and FSH and
the clinical relevance of AMH are discussed.
8.2 MODULATION OF TGFb SUPERFAMILY SIGNALING
The TGFb superfamily is the largest known family of growth- and differentiation factors and presently
consists of 35 family members (Chang, et al., 2002). All members of the TGFb family signal through
serine/threonine (S/T) kinase type II and type I receptors (for a review see Chapter 2). The signaling
mechanisms of the TGFb superfamily members has intriguing properties since only five type II and
seven type I receptors have sofar been identified in mammals. Combinations of a ligand with different
type II and type I receptors can generate ligand- and cell-specific effects. After activation of the receptors,
receptor-specific Smads are activated. However, different ligands may activate the same downstream
Smads. In addition, one ligand can mediate different effects in different cell types. Therefore, the
question arises how so many different ligands can generate so many cell-specific signals through a
relatively limited system of transduction molecules. This section discusses the mechanisms of modulation
of signaling of TGFb family members at the level of the ligand, of the receptor and further downstream
which are involved in transducing the specific signal for the TGFb family members and which also
could be involved in achieving specific effects of AMH.
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In addition, BMP2/7 and BMP2/6 heterodimers are more potent in the alkaline phosphatase induction
assay as well as in inducing cartilage and bone in an in vivo assay compared to their homodimers
(Israel, et al., 1996). Recently, also the heteromeric protein BMP15/GDF9 has been identified by
immunoprecipitation and immunoblotting. However the biological effect of this heterodimer is unknown
(Liao, et al., 2003). The best known heterodimers are inhibin A, inhibin B and activin AB, which are
formed by a combination of inhibin a- and inhibin bA-subunits, inhibin a- and inhibin bB-subunits
and inhibin bA- and inhibin bB-subunits respectively. Inhibins antagonize the biological effects of
activins and BMPs. Thus, the effects of TGFb superfamily members can be regulated by the secretion
of homo- and heterodimers, since differences in biological effects and potency are described between
the homo- and heterodimers. 
For AMH, the formation of heterodimers has not been reported yet, but it cannot be excluded. In
principle, all TGFb family members, expressed in the same cell types (granulosa cells of primary or
pre-antral follicles) and at the same time as AMH, are candidates for heteromerization with AMH.
One possible candidate for AMH heteromerization is the inhibin a-subunit, since both AMH and
inhibin a-subunit are expressed in granulosa cells of primary and pre-antral follicles (Chapter 6).
Furthermore, inhibin bA- and inhibin bB-subunits, which form heteromeric complexes with the
inhibin a-subunit, are not expressed in these cells until the follicle has developed into a large pre-antral
follicle. Thus, the inhibin a-subunit is expressed without being able to form a known dimer (Chapter 6).
Therefore, it is possible that the inhibin a-subunit forms a dimer with another TGFb superfamily member,
for example AMH. Since antibodies against AMH and inhibin a-subunit are available, it would be
interesting to investigate the existence of this dimer in follicle fluid and serum.
TGFb superfamily members are synthesized as precursors and cleavage of these proteins is necessary
to obtain biological activity of the mature growth factor (for a review see Chapter 2)(Gentry, et al.,
1988); this is also true for AMH (Pepinsky, et al., 1988; Kurian, et al., 1995). After cleavage, the N-
terminal peptide and the mature protein dissociate. This is necessary for full bio-activity of the mature
protein (Gentry and Nash, 1990) with the exception of AMH which is the only known TGFb family
member where continuous association between the mature and the N-terminal domain is necessary
for full biological activity (Wilson, et al., 1993). The precise function of this N-terminal domain in
AMH-signaling is unknown. However, a role as a docking protein can be suggested, based on the
function of the N-terminal domain of TGFb. The N-terminal domain of TGFb, named latency
associate peptide (LAP), can bind to the latency binding protein (LTBP) which localizes TGFb to the
extracellular matrix, generating a reservoir of TGFb at the cell membrane of certain cells (reviewed
by Khalil, 1999). TGFb is released from this complex by the proteolytic enzyme plasmin, which removes
LAP from the complex, thereby releasing TGFb. Sofar, no AMH-docking proteins have been described.
Another mechanism for cell-specific signaling of TGFb superfamily members is modulation of the
availability of TGFb superfamily members by extracellular proteins, which prevent binding of the ligand
to their receptors (Table 8.1 and Figure 8.1), antagonists (Figure 8.1) or by accessory receptors which
inhibit or facilitate ligand binding to their receptors (Figure 8.1). Several ligand-binding proteins of
the TGFb superfamily have been identified. BMP action is inhibited by sclerostin (Winkler, et al.,
2003), noggin (Zimmerman, et al., 1996), chordin (Blader, et al., 1997), and the DAN family members
Dan (Stanley, et al., 1998), gremlin (Hsu, et al., 1998), and cerebrus (Bouwmeester, et al., 1996; Piccolo,
et al., 1996, 1999; Yokouchi, et al., 1999). 
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General Discussion
8.2.1 Ligand
Signaling of TGFb superfamily members can be regulated, both positively and negatively, at the level
of the ligand. Formation of homo- or heterodimers determines the presence of a ligand with a certain
biological effect and/or potency. The availability of the ligand for binding to its receptor can be regulated
by docking proteins which can bind to the ligand, other extracellular proteins, antagonists and accessory
receptors present on the membrane. This section will discuss these sites of modulation of TGFb
superfamily signaling at the level of the ligand (Figure 8.1).
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Figure 8.1: Sites of modulation of signaling of TGFb superfamily members.
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Figure 8.1: Sites of modulation of signaling of TGFb superfamily members.
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biological effects and/or biological potency compared to homodimers. The heterodimer TGFb1.2, 
a combination of TGFb1 and TGFb2, binds more efficiently to the type II and I receptors than
TGFb2 but less efficiently than TGFb1 (Cheifetz, et al., 1988). In addition, the biological potency of
the TGFb1.2 heterodimer as measured by cell proliferation lies in between the potencies of TGFb1
and TGFb2 homodimers. Thus, the TGFb heterodimer has a similar biological effect compared to the
homodimers, but its potency is different. Several BMP heterodimers has also been described, but in
contrast to TGFb the biological effects of the BMP heterodimers are different from those of the
homodimers. The BMP4/7 and BMP2/7 heterodimers induce ventral mesoderm in Xenopus animal
caps, whereas BMP2, BMP4 and BMP7 do not (Suzuki, et al., 1997; Nishimatsu and Thomsen, 1998).
Another protein which inhibits downstream signaling is BMP and activin membrane-bound inhibitor
(BAMBI). This protein has a high homology with the TGFb superfamily type I receptors but lacks the
intracellular kinase domain, which is necessary for type I receptor activation. BAMBI can interacts
with all type I receptors (except ALK2) and the presence of BAMBI in a receptor complex with type
II receptors prevents downstream signaling for TGFb, activins and BMPs (Onichtchouk, et al., 1999).
No data about a role of the accessory receptors betaglycan or BAMBI in AMH-signaling are available.
However, it would be interesting to investigate the role of these accessory proteins in AMH-signaling.
Inhibin and betaglycan are expressed in the ovary (Findlay, et al., 2001) and it might be possible that
betaglycan together with inhibin can antagonize AMH-signaling by preventing binding of AMH to
the AMHRII, similar to the inhibition of BMP-signaling by this proteins. In addition, a modulating
role of BAMBI in AMH-signaling is possible since AMH signals through ALK3 (Jamin, et al., 2002).  
In conclusion, signaling of TGFb superfamily members can be modulated at ligand level by
heteromerization, antagonists and accessory proteins and this could contribute to ligand specific
effects. Thus, although not much is known yet about modulation of AMH-signaling at the level of the
ligand, many sites of modulation are possible.
8.2.2 Receptor
TGFb superfamily members signal through binding to serine/threonine (S/T) kinase type II and type I
receptors. Five type II (TbRII, ActRII, ActRIIB, BMPRII, AMHRII) and seven type I receptors (ALK1-7)
have been identified in mammals (for a review see Chapter 2). Binding of TGFb family members to
the type II receptor induces the formation of a hetero-tetrameric complex containing two type II and
two type I receptors (Wrana, et al., 1994; Heldin, et al., 1997; Kirsch, et al., 2000). The combination
of the ligand with type II and type I receptors is responsible for a ligand-specific signal into the cell.
In addition, some receptor-interacting proteins have been described which might influence type I
receptor activity. This section describes the modulation of signaling at the level of the receptor by
which AMH-signaling might be influenced.
Five type II receptors are known and most of these receptors signal for more than one ligand. 
So can several BMPs bind to the BMPRII or ActRII receptors (ten Dijke, et al., 1994; Rosenzweig, et al.,
1995; Yamashita, et al., 1995). In contrast, AMH is the only described ligand for the AMHRII, and
mice lacking AMH (Behringer, et al., 1994) or the AMHRII (Mishina, et al., 1996; Arango, et al., 1999)
show absence of Müllerian duct regression. Furthermore, the phenotypes of the testis in AMH null
and AMHRII null mice are similar, showing the production of functional sperm and hyperplasia of
Leydig cells (Behringer, et al., 1994; Mishina, et al., 1996). In contrast, the ovarian phenotype of the
AMH null and MRKI(-/-) mice are not completely identical (Chapter 4), since a larger decrease of the
number of primordial follicles is found in ovaries of MRKI(-/-) mice than in AMH(-/-) mice. This
difference in ovarian phenotype might be explained by ligand-independent AMHRII-signaling.
Furthermore, it is likely that AMH only signals through the AMHRII and not through other type II
receptors. This is shown by transfection experiments, where AMH only signals through AMHRII and
not through TbRII, ActRIIB or BMPRII (Chapter 5).
Ligands can signal through more than one of the seven type I receptors as is shown for BMPs (ten
Dijke, et al., 1994; Ebisawa, et al., 1999), activins (Attisano, et al., 1993) and TGFbs (Franzen, et al.,
1993; Oh, et al., 2000). 
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In addition, follistatin (de Winter, et al., 1996; Fainsod, et al., 1997; Iemura, et al., 1998) and follistatin-
like protein (Tsuchida, et al., 2000) inhibit the actions of BMPs and activins. That these extracellular
binding proteins can have an important role in regulating normal signaling of their ligands is shown
by sclerostin. Sclerosteosis is a human disease typified by high bone mass due to the loss of sclerostin
expression (Winkler, et al., 2003). Furthermore, overexpression of sclerostin by transgenic mice,
resulted in low bone mass and decreased bone strength through reduction of osteoblast activity caused
by decreased BMP-signaling (Winkler, et al., 2003). Sofar, no effect of any of these extracellular
ligand-binding proteins on AMH-signaling have been investigated. However, follistatin might be a
possible candidate, since this protein is expressed in the ovary by granulosa cells of growing follicles
and plays a role in follicle development. Mice overexpressing follistatin show a block in folliculogenesis,
caused by blocking the activity of activin and possibly also GDF9 (Guo, et al., 1998). However, whether
recruitment of primordial follicles is influenced by follistatin, and thus a role of follistatin in 
AMH-signaling, is unknown and needs further research.
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Table 8.1: Extracellular binding proteins for TGFb superfamily members.
Extracellular protein: Binds: Reference:
Sclerotin BMPs Winkler et al., 2003
Noggin BMPs Zimmerman et al., 1996
Chordin BMPs Blader et al., 1997
Dan BMPs Stanley et al., 1998
Gremlin BMPs Hsu et al., 1998
Cerebrus BMPs, activins Bouwmeester et al., 1996; Piccolo et al., 1996, 1999; Hsu et al., 1998;
Yokouchi et al., 1999
Follistatin activins, BMPs de Winter et al., 1996; Fainsod et al., 1997; Iemura et al., 1998
Follistatin-like protein activins, BMPs Tsuchida et al., 2000
Alternatively, ligand binding to the receptor can be inhibited by competitive binding of antagonists
to the receptor. Inhibins are known for their antagonizing effect on activin signaling by direct binding
of inhibin to ActRII and ActRIIB, thereby preventing activin binding (Attisano, et al., 1992; Martens,
et al., 1997). No reports have been published in which inhibin binding to the AMHRII is described.
However, it can be suggested that inhibin may inhibit AMH signaling by binding to betaglycan (see
next section).
As described above, binding of TGFb superfamily members to their receptors can be modulated
by extracellularly localized antagonists. In addition, ligand binding can also be positively or negatively
modulated by accessory receptors expressed at the membrane. In this section, this will be illustrated
by the role of betaglycan and BAMBI in TGFb superfamily members signaling. Betaglycan stimulates
TGFb signaling by binding of TGFb and thereby facilitating TGFb binding to the type II receptor.
Although all three TGFb forms are bound by betaglycan, the effect on signaling is most evident for
TGFb2 since this TGFb shows the lowest affinity for the TbRII (reviewed by Massagué, 1998). Besides
binding of TGFb, betaglycan also binds inhibin (Lewis, et al., 2000). Binding of inhibin to betaglycan
increases the affinity of inhibin for ActRII and ActRIIB, resulting in an inhibition of activin signaling
through these receptors (Lewis, et al., 2000; Chapman, et al., 2002). Recently, it was reported that
inhibin by binding to betaglycan also can form a complex with BMPRII and antagonize BMP-signaling
(Wiater and Vale, 2003). Thus, betaglycan facilitates TGFb-signaling, but inhibits, by facilitation of
inhibins action, activin and BMP-signaling.
Another protein which inhibits downstream signaling is BMP and activin membrane-bound inhibitor
(BAMBI). This protein has a high homology with the TGFb superfamily type I receptors but lacks the
intracellular kinase domain, which is necessary for type I receptor activation. BAMBI can interacts
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role of BAMBI in AMH-signaling is possible since AMH signals through ALK3 (Jamin, et al., 2002).  
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effects. Thus, although not much is known yet about modulation of AMH-signaling at the level of the
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(Wiater and Vale, 2003). Thus, betaglycan facilitates TGFb-signaling, but inhibits, by facilitation of
inhibins action, activin and BMP-signaling.
Müllerian duct regression (Jamin, et al., 2002). However, crossbreeding of the ALK3 conditional
mutant mice with transgene mice that overexpress AMH rescues the regression of the Müllerian ducts
(Jamin, et al., 2003). These results indicate involvement of ALK3 in AMH-signaling in the Müllerian
ducts, which can be mediated by another type I receptor if AMH is highly expressed. This other type
I receptor is probably ALK2 since the absence of ALK2 expression prevents Müllerian duct regression
(Visser, et al., 2001). It can be suggested that ALK2 and ALK3 form heteromeric complexes since both
receptors are necessary for Müllerian duct regression.
To test which type I receptors are involved in AMH-signaling in the ovary, several approaches are
applicable. We have transfected plasmids containing dominant-negative type I receptors into KK-1 cells.
However this approach was not successful since too large amounts of plasmid had to be used causing
non-specific side-effects. To avoid transfection problems, silencing of genes with morpholinos or small
interfering RNA might be a more successful approach. The use of antisense oligos (morpholinos) has
proven its value in the Müllerian duct system (Visser, et al., 2001) and might be successful in ovarian
cell lines. Another approach for the identification of type I receptors involved in AMH-signaling is
the generation of mice lacking the expression of a type I receptor. This approach is complicated since
ALK2 null (Mishina, et al., 1999) and ALK3 null (Mishina, et al., 1995) mice die before birth. The
ALK6 null mouse is viable but does not show Müllerian duct regression, suggesting that ALK6 is not
necessary for this AMH-induced event (Yi, et al., 2000; Clarke, et al., 2001). The ovarian function in
these ALK6 null mice is aberrant, as shown by irregular estrus cycles and cumulus expansion resulting in
the absence of fertilization in vivo (Yi, et al., 2001). This ovarian phenotype shows that the interpretation
of type I receptor knockout and also conditional knockout mouse models like for ALK3 (Jamin, et al.,
2002) is complicated since these receptors are involved in signaling pathways of several ligands. Therefore,
it will be difficult to link the observed phenotypes to the absence of AMH-signaling. Identification of
type I receptors involved in AMH-signaling could be achieved using immunoprecipitation of AMHRII
and type I receptors. However, this technique was not very successful since it AMHRII in overexpressing
systems bind to all type I receptors (unpublished results J.A. Visser). Fluorescence resonance energy
transfer (FRET) analysis might be a useful technique in the search for AMH-induced receptor interactions.
Through labeling of AMHRII with a donor fluorophore and the different type I receptors with an
acceptor fluorophore, AMH-induced receptor type II and type I association may be shown since the
energy of the excited donor fluorophore is transmitted to the acceptor fluorophore when these
fluorophores are in near proximity (reviewed by Sekar and Periasamy, 2003). FRET analysis would be
a new approach for the study of combinations of TGFb superfamily receptors.
Receptor signaling can be modulated within the cell by proteins which bind to these receptors
(Table 8.2). Smad6 and Smad7 antagonize signaling by TGFb superfamily members by binding to the
type I receptors, thereby preventing binding of receptor-specific Smads (Hayashi, et al., 1997; Imamura,
et al., 1997; Nakao, et al., 1997; Souchelnytskyi, et al., 1998; Lebrun, et al., 1999; Hanyu, et al., 2001).
Less well described receptor binding proteins are BMP receptor associated molecule (BRAM) which
binds to ALK3 (Kurozumi, et al., 1998) and the Smad1 antagonistic effector (SANE) which binds to
ALK3 and ALK6, thereby preventing Smad1 phosphorylation (Raju, et al., 2003). Since these receptor
binding proteins can bind to ALK3 or ALK6, they may be involved in modulating AMH-signaling.
However, more research is necessary at the effects of these interactions.
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The affinity for the type I receptor can be dependent on the cell line, shown by BMP6, which binds
strongly to ALK2 but weakly to ALK3 in mouse undifferentiated mesenchymal cells (C2C12), while a
strong binding to ALK6 and a weak binding to ALK2 and ALK3 were found in rat osteoprogenitor
cells (ROB-C26 cells) (Ebisawa, et al., 1999). Furthermore, signaling of a ligand through two different
type I receptors can result in a synergistic effect. The alkaline phosphatase activity and the type I
receptor-induced transcriptional activity is synergistically induced by a combination of signaling
through ALK2 and ALK3 or ALK2 and ALK6 (Aoki, et al., 2001). The combination of signaling through
two different type I receptors might activate the downstream signaling pathways more efficiently than
signaling through one type I receptor. These results show that cell-specific effects may be achieved
through expression of different type I receptors in different cell types.
The receptor complex through which TGFb superfamily members signal contains two type II and
two type I receptors. In endothelial cells, TGFb can mediate its signal through two receptor complexes
containing TbRII/ALK5 or TbRII/ALK1/ALK5 (Goumans, et al., 2002, 2003). Signaling through the
TbRII/ALK5 receptor complex results in inhibition of migration and proliferation of the endothelial
cells, while signaling through the TbRII/ALK1/ALK5 receptor complex stimulates these processes. 
In addition, different genes are induced by the two receptor complexes (Goumans, et al., 2002). It appeared
that ALK1 is a negative mediator of TbRII/ALK5-signaling and that endothelial cells can regulate
TGFb-induced responses by expression of ALK1 (Goumans, et al., 2003). In addition, heteromeric
ALK3/ALK6 complexes are found and formation of these complexes can be induced by BMP2 (Gilboa,
et al., 2000). However, whether these ALK3/ALK6 complexes are functional needs to be determined.
Candidate type I receptors for AMH-signaling are ALK2, ALK3 and ALK6 (Gouédard, et al., 2000;
Clarke, et al., 2001; Visser, et al., 2001) and all three type I receptors are expressed in the ovary
(Chapter 5, Erickson and Shimasaki, 2003). Dominant-negative and antisense approaches in cell lines
showed that ALK2 is necessary for AMH-signaling (Clarke, et al., 2001; Visser, et al., 2001). In addition,
Müllerian duct regression is inhibited by antisense ALK2 (Visser, et al., 2001). ALK3 also plays a role
in AMH-signaling, as indicated by the presence of persistent Müllerian ducts in conditional ALK3 null
mice (Jamin, et al., 2002). Furthermore, the involvement of ALK6 in AMH-signaling was suggested,
based on the observation that AMH-induced a ligand-dependent AMHRII/ALK6 receptor complex
(Gouédard, et al., 2000). However, the ALK6 null mouse model (Clarke, et al., 2001), the expression
pattern of ALK6 in the Müllerian ducts (Dewulf, et al., 1995; Clarke, et al., 2001) and in vitro
experiments in which the role of ALK6 in AMH-signaling was investigated (Clarke, et al., 2001; Visser,
et al., 2001) suggest that ALK6 is not involved in AMH-signaling in Müllerian duct regression, whereas
a role for ALK6 in AMH-signaling in the ovary cannot be ruled out yet.
AMH has several effects on follicles in the ovary: it inhibits primordial follicle recruitment
(Chapter 3, Durlinger, et al., 1999) and decreases the sensitivity for FSH in large pre-antral and small
antral follicles (Durlinger, et al., 2001). It can be suggested that AMH achieves these different effects
by signaling through different receptor complexes. An indication for this hypothesis is that AMH
stimulates MMP2 expression in the Müllerian ducts (Roberts, et al., 2002) but not in KK-1 cells (our
unpublished observations). However, this difference may also be explained by varying expression of
transcription factors and/or signaling through different signaling pathways. In addition, AMH-signaling
might be mediated by a receptor complex containing two different type I receptors. The strongest
indication for this hypothesis is given by the ALK3 conditional mutant mice, which do not show
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by Smad6 (Hata, et al., 1998) and the inhibitory action of Smad6 can be prevented by the SH3 domain
of STAM (AMSH) (Itoh, et al., 2001) or enhanced by Tob (Yoshida, et al., 2003). In addition, several
transcription factors have been described to form a complex with the receptor-specific Smad-Smad4
complex, thereby enhancing or inhibiting gene transcription (For review see Zwijsen, et al., 2003).
Thus, downstream BMP-signaling can be modulated by several proteins. Since these proteins bind Smad1,
5 and/or 8, they could also be involved in modulating AMH-signaling, although more research is necessary
to obtain data which show involvement of these proteins. 
Not only the Smad-signaling pathway will mediate BMP signals but also the MAPK and possibly
the Wnt/b-catenin signaling pathways are involved in BMP and AMH-signaling. The differential
activation of these signaling pathways by AMH and the different BMPs may result in ligand-specific
effects in the cells. The MAPK-signaling pathway plays an important role in mediating BMP-signaling.
Three MAPK cascades have been identified: the extracellular signal regulated kinases (ERKs), p38-MAPK,
and the c-Jun N-terminal kinases (JNKs) and all three signaling pathways might be involved in 
BMP-signaling. A mutation in the BMPRII showed that MAPK-signaling is induced by another part
of the receptor than the Smad-signaling pathway showing the activation of the MAPK-pathway is
independent of the Smad-signaling pathway (Rudarakanchana, et al., 2002). Erk1 and Erk2 are involved
in BMP15-induced proliferation of granulosa cells, since an inhibitor of these MAPK inhibits this
BMP15-induced effect (Moore, et al., 2002). MAPK-signaling by BMP is cell type dependent since
BMP4 inhibits neuronal induction in Xenopus ectoderm by inhibition of Erk2 and p38 signaling
(Uzgare, et al., 1998; Goswami, et al., 2001), whereas it stimulates phosphorylation of Erk1/2 and 
p38-MAPK in an osteoblast-like cell line (Kozawa, et al., 2002). Likewise, BMP2 induces Erk- (Gallea,
et al., 2001) and p38- (Gallea, et al., 2001; Lee, et al., 2002) signaling in osteoblast differentiation. Recently,
it was shown that also JNK can be activated by BMP2 in an osteoblast cell line through induction of
protein kinase D (Lemonnier, et al., 2003) and BMP7 inhibits IL1b-induced JNK activation (Lee, et al.,
2003). Thus, all three MAPK-signaling pathways can be involved in mediating BMP- and therefore
probably also AMH-signaling.
A role for the MAPK-signaling pathway in AMH-signaling was suggested by studies on Müllerian
duct regression. Apoptotic cells in the Müllerian ducts show a decreased expression of JNK and p38
proteins. When the expression of JNK and p38 was restored by treating the cells with diethylstilbestrol
(DES), apoptosis in the Müllerian ducts was inhibited, suggesting a role of these signaling pathways
in this AMH-regulated process (Teng, 2001). 
Recently, a connection between the Wnt/b-catenin and the BMP-signaling pathway was reported
(Hussein, et al., 2003; Soshnikova, et al., 2003). Wnt members are involved in developmental processes,
cell proliferation, differentiation and survival (Wodarz and Nusse, 1998; Eastman and Grosscheldl,
1999; Huelsken and Birchmeier, 2001). After binding of Wnt molecules to their receptors, b-catenin
is stabilized, which interacts with Lef transcription factors and regulates gene expression (Behrens, et al.,
1996; Eastman and Grosscheldl, 1999; van de Wetering, et al., 2002). In apical ectodermal ridge formation,
b-catenin action is influenced by ALK3, showing involvement of the BMP-signaling pathway (Soshnikova,
et al., 2003). Also in the Müllerian ducts it has been suggested that AMH signals through or interacts
with the Wnt/b-catenin pathway since AMH-signaling results in an accumulation of b-catenin and Lef1
(Allard, et al., 2000). However, whether AMH signals through the Wnt/b-catenin pathway or influences
this pathway by for example downregulated genes, needs to be determined.
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In conclusion, specificity of AMH-signaling can be obtained by the type II receptor and the type I
receptors used. AMH signals through a specific type II receptor and uses probably three different type
I receptors. Furthermore, receptor binding proteins can influence type I receptor activity. 
8.2.3 Downstream signaling
After binding to the receptor complex, TGFb superfamily members activate downstream signaling
pathways. Two main Smad-signaling pathways are activated by TGFb superfamily members: the
TGFb/activin-like or the BMP-like signaling pathway (Figure 8.1). Smad2 and Smad3 are activated
by TGFbs and activins through the type I receptors ALK4, ALK5 and ALK7, which form a receptor
complex with TbRII, ActRII or ActRIIB (TGFb/activin-like signal pathway). On the other hand,
Smad1, Smad5 and Smad8 are activated by BMPs through the type I receptors ALK2, ALK3 and
ALK6, which form a complex with BMPRII, ActRII or ActRIIB (BMP-like signaling pathway). Crossovers
between these two main signaling pathways have also been described. TGFb signals in most cells
through TbRII and ALK5 resulting in phosphorylation of Smad2 and Smad3. In endothelial cells, also
signaling through TbRII and a ALK1/ALK5 receptor complex has been described which results in
phosphorylation of Smad1 and Smad5 (Goumans, et al., 2002, 2003). In addition, GDF9 binds to the
BMPRII and an unidentified type I receptor. Unexpectedly, not Smad1 but Smad2 is phosphorylated
after GDF9 binding (Kaivo-Oja, et al., 2003; Roh, et al., 2003), suggesting that ALK4 or ALK5 are
involved in the GDF9/BMPRII complex. 
AMH signals through the BMP-like signaling pathway in non-ovarian tissues (Gouédard, et al., 2000;
Clarke, et al., 2001; Visser, et al., 2001). In this thesis, we show that also in the ovary AMH signals
through the BMP-like signaling pathway, since in the granulosa cell line KK-1 only the BMP-responsive
and not the TGFb-responsive promoter can be activated (Chapter 5). In agreement with this result,
AMH treatment of KK-1 cells causes Smad1 but not Smad2 phosphorylation (Chapter 5). Therefore,
in this section the focus is on modulation of the BMP-like signaling pathway. Binding of BMPs or
AMH to their receptors results in activation of Smad1, Smad5 or Smad8. An important question is
how the ligands can generate their specific signal. Although this question cannot be completely answered,
downstream signaling can be modulated by Smad-interacting proteins or by alternative pathways.
After BMPs have been bound to their receptors and have activated the Smad proteins, their
signaling can be modulated by several interacting repressors and/or activators that are present in the
cytoplasm or nucleus and can bind to the receptor-specific Smads, the common Smad4 and the
inhibitory Smads. For example, the receptor-specific Smad–Smad4 complex formation can be inhibited
Table 8.2: Receptor binding proteins involved in BMP-signaling.
Protein: Interacts with: Effect: Reference:
Smad6 ALK2, ALK3, ALK6 Inhibitor, antagonizes BMP-like signaling, Imamura et al., 1997; Ishisaki et al., 1999;
by inhibiting receptor-specific Smad activation Lebrun et al., 1999
Smad7 All type I receptors Inhibitor, antagonizes BMP-like and Hayashi et al., 1997; Nakao et al., 1997; 
TGFb/activin-like signaling, Souchelnytskyi et al., 1998; Ishisaki et al.,
by inhibiting receptor-specific Smad activation 1999; Lebrun et al., 1999; Hanyu et al., 2001
BRAM ALK3 Unknown Kurozumi et al., 1998
SANE ALK3, ALK6 Antagonizes BMP signaling by binding to Raju et al., 2003
receptor and preventing Smad1 activation
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effects in the cells. The MAPK-signaling pathway plays an important role in mediating BMP-signaling.
Three MAPK cascades have been identified: the extracellular signal regulated kinases (ERKs), p38-MAPK,
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(DES), apoptosis in the Müllerian ducts was inhibited, suggesting a role of these signaling pathways
in this AMH-regulated process (Teng, 2001). 
Recently, a connection between the Wnt/b-catenin and the BMP-signaling pathway was reported
(Hussein, et al., 2003; Soshnikova, et al., 2003). Wnt members are involved in developmental processes,
cell proliferation, differentiation and survival (Wodarz and Nusse, 1998; Eastman and Grosscheldl,
1999; Huelsken and Birchmeier, 2001). After binding of Wnt molecules to their receptors, b-catenin
is stabilized, which interacts with Lef transcription factors and regulates gene expression (Behrens, et al.,
1996; Eastman and Grosscheldl, 1999; van de Wetering, et al., 2002). In apical ectodermal ridge formation,
b-catenin action is influenced by ALK3, showing involvement of the BMP-signaling pathway (Soshnikova,
et al., 2003). Also in the Müllerian ducts it has been suggested that AMH signals through or interacts
with the Wnt/b-catenin pathway since AMH-signaling results in an accumulation of b-catenin and Lef1
(Allard, et al., 2000). However, whether AMH signals through the Wnt/b-catenin pathway or influences
this pathway by for example downregulated genes, needs to be determined.
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In conclusion, specificity of AMH-signaling can be obtained by the type II receptor and the type I
receptors used. AMH signals through a specific type II receptor and uses probably three different type
I receptors. Furthermore, receptor binding proteins can influence type I receptor activity. 
8.2.3 Downstream signaling
After binding to the receptor complex, TGFb superfamily members activate downstream signaling
pathways. Two main Smad-signaling pathways are activated by TGFb superfamily members: the
TGFb/activin-like or the BMP-like signaling pathway (Figure 8.1). Smad2 and Smad3 are activated
by TGFbs and activins through the type I receptors ALK4, ALK5 and ALK7, which form a receptor
complex with TbRII, ActRII or ActRIIB (TGFb/activin-like signal pathway). On the other hand,
Smad1, Smad5 and Smad8 are activated by BMPs through the type I receptors ALK2, ALK3 and
ALK6, which form a complex with BMPRII, ActRII or ActRIIB (BMP-like signaling pathway). Crossovers
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through TbRII and ALK5 resulting in phosphorylation of Smad2 and Smad3. In endothelial cells, also
signaling through TbRII and a ALK1/ALK5 receptor complex has been described which results in
phosphorylation of Smad1 and Smad5 (Goumans, et al., 2002, 2003). In addition, GDF9 binds to the
BMPRII and an unidentified type I receptor. Unexpectedly, not Smad1 but Smad2 is phosphorylated
after GDF9 binding (Kaivo-Oja, et al., 2003; Roh, et al., 2003), suggesting that ALK4 or ALK5 are
involved in the GDF9/BMPRII complex. 
AMH signals through the BMP-like signaling pathway in non-ovarian tissues (Gouédard, et al., 2000;
Clarke, et al., 2001; Visser, et al., 2001). In this thesis, we show that also in the ovary AMH signals
through the BMP-like signaling pathway, since in the granulosa cell line KK-1 only the BMP-responsive
and not the TGFb-responsive promoter can be activated (Chapter 5). In agreement with this result,
AMH treatment of KK-1 cells causes Smad1 but not Smad2 phosphorylation (Chapter 5). Therefore,
in this section the focus is on modulation of the BMP-like signaling pathway. Binding of BMPs or
AMH to their receptors results in activation of Smad1, Smad5 or Smad8. An important question is
how the ligands can generate their specific signal. Although this question cannot be completely answered,
downstream signaling can be modulated by Smad-interacting proteins or by alternative pathways.
After BMPs have been bound to their receptors and have activated the Smad proteins, their
signaling can be modulated by several interacting repressors and/or activators that are present in the
cytoplasm or nucleus and can bind to the receptor-specific Smads, the common Smad4 and the
inhibitory Smads. For example, the receptor-specific Smad–Smad4 complex formation can be inhibited
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receptor and preventing Smad1 activation
Also the TGFb superfamily members GDF9 (Hayashi, et al., 1999), activin A (only follicles from
immature but not from adult mice) (Liu, et al., 1999; Mizunuma, et al., 1999) and TGFb (follicles of
adult but not immature mice) (Liu, et al., 1999; Mizunuma, et al., 1999) have been described to
stimulate pre-antral follicle growth.
Markers for increase in follicle development are estrogen and inhibin production by the follicles.
LH and FSH together are involved in stimulation of the estrogen production, since LH stimulates the
production of androgens by theca cells while FSH stimulates the conversion of androgens into estrogens
by the granulosa cells. Also TGFb superfamily members can stimulate pre-antral follicle development.
Activin A stimulates the development of cultured pre-antral follicles from immature but not from
adult mice as shown by an increase in inhibin and estrogen production (Liu, et al., 1999; Mizunuma,
et al., 1999). TGFb stimulates inhibin and estrogen production in adult but not immature follicles
(Liu, et al., 1999; Mizunuma, et al., 1999). In addition, a stimulatory effect on pre-antral follicle
development of GDF9 has been found, since an increase in inhibin a-subunit mRNA expression was
detected after treatment with this oocyte factor (Hayashi, et al., 1999). Besides stimulation of growth
and development of immature pre-antral follicles, activin is involved in regulation of pre-antral follicle
growth of adult mice since activin production by large pre-antral follicles keep small pre-antral follicles
dormant (Mizunuma, et al., 1999). In conclusion, follicle development until the point of selection is
regulated by several TGFb superfamily members, while the gonadotropins LH and FSH have a
subordinate role.
In rodents, large pre-antral follicles become selected for further growth towards the pre-ovulatory
stage by FSH. Follicle growth and development from the point of selection is dominantly regulated
by FSH and LH, while the TGFb superfamily members play a less important role. The importance of
FSH in this process is clearly shown by the FSHb null (Kumar, et al., 1997) and FSHR null (Dierich,
et al., 1998) mice of which the ovaries do not contain any antral follicle. The sensitivity of follicles to
FSH is inhibited by AMH, thereby decreasing the number of follicles selected for pre-ovulatory
growth (Durlinger, et al., 2001). Follicle development becomes dependent on LH after formation of
the antrum as shown in the LHR null mice of which the ovaries do not contain pre-ovulatory follicles
(Zhang, et al., 2001). FSH stimulates antral follicle growth by stimulating granulosa cell proliferation.
In addition, antrum formation is induced by FSH, a process which is enhanced by LH. During the last
phase of follicle development, LH is involved in successful maturation of the follicles and is essential
for ovulation. 
8.3.2 Modulation of FSH action by TGFb superfamily 
members
As described above, both FSH and TGFb superfamily members are involved in follicle development.
Interestingly, FSH action is modulated by several TGFb superfamily members (Table 8.3). The 
FSH-induced growth of pre-antral follicles is e.g. inhibited by AMH (Durlinger, et al., 2001) and
activin (Yokota, et al., 1997; Liu, et al., 1999; Mizunuma, et al., 1999), but enhanced by GDF9
(Hayashi, et al., 1999) and TGFb (both in adult and immature mice pre-antral follicles) (Liu, et al.,
1999; Mizunuma, et al., 1999). In addition, the FSH-stimulated differentiation of follicles, measured
by increasing inhibin a mRNA expression is enhanced by GDF9 (Hayashi, et al., 1999) which suggests
that GDF9 in addition to FSH stimulates follicle development. 
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8.3 TGFb SUPERFAMILY MEMBERS VERSUS FSH/LH 
IN FOLLICULOGENESIS
During follicle development, two important sites of regulation can be recognized: recruitment and
selection (see Figure 1.1). At recruitment, primordial follicles enter the growth phase from the dormant
follicle pool. The oocyte diameter starts to increase, the granulosa cells become cuboidal and start to
proliferate and the primordial follicle develops into a primary follicle. When more than one layer of
granulosa cells have been formed the follicle is called pre-antral (for review see Chapter 1). After
formation of the antrum, the follicle is named antral follicle. At selection, large pre-antral follicles in
mice and rats and antral follicles in human are selected for growth until the pre-ovulatory stage. Only
those follicles that have become sensitive enough for FSH will be rescued from atresia (McGee and
Hsueh, 2000).
8.3.1 Follicle development
Follicle development is regulated by the gonadotropins LH and FSH, which are produced by the pituitary.
In the literature, these two hormones are described as the most important for follicle development.
However, the ovary produces several growth factors belonging to the TGFb superfamily, like BMP2,
BMP3, BMP4, BMP6, BMP7, BMP15, GDF9, AMH, TGFb, activins and inhibins which can also be very
important for follicle development (for review see Chapter 1, Figure 1.1). That ovarian factors can have
a dominant role in follicle development is shown by the FSHb/AMH deficient mice in which the
ovaries, like the ovaries of AMH null mice, contain more growing and less primordial follicles
compared to wild-type mice ovaries (Durlinger, et al., 2001). In contrast, the ovaries of FSHb null
mice show similar numbers of primordial and growing follicles compared to ovaries of wild-type mice.
Although both gonadotropins and TGFb superfamily members are important for follicle development,
their roles are distinct. In this section, the effects of the gonadotropins and several members of the
TGFb superfamily on follicle development and the interaction between these two groups of hormones
and growth factors are discussed. 
TGFb superfamily members are involved in follicle development from recruitment of the primordial
follicles until ovulation of the oocyte. AMH inhibits recruitment of primordial follicles into the
growing pool as shown by the AMH null mice (Durlinger, et al., 1999) and neonatal ovary cultures
(Chapter 3), while BMP4 stimulates primordial follicle recruitment in neonatal ovary cultures (Nilsson
and Skinner, 2003). Gonadotropins are not obligatory for primordial follicle recruitment, since
growing follicles are found in FSHb null, FSHR null and LHR null mice (Kumar, et al., 1997; Dierich,
et al., 1998; Zhang, et al., 2001). In addition, primordial follicle recruitment cannot be directly stimulated
by FSH or LH since these primordial follicles do not express the receptors for these gonadotropins (for
review see Chapter 1)(Rannikki, et al., 1995; Teerds and Dorrington, 1995; O'Shaughnessy, et al., 1996,
1997; Oktay, et al., 1997).
After recruitment, primary follicle development requires GDF9 since follicle development is blocked
at the primary follicle stage in GDF9 null mice (Dong, et al., 1996). First effects of LH and FSH on
follicle growth and development have been described on pre-antral follicles, which growth is stimulated
by LH (for review see Chapter 1)(Cortvrindt, et al., 1998; Wu, et al., 2000) and FSH (for review see
Chapter 1)(Yokota, et al., 1997; Mizunuma, et al., 1999; Gutierrez, et al., 2000). 
Also the TGFb superfamily members GDF9 (Hayashi, et al., 1999), activin A (only follicles from
immature but not from adult mice) (Liu, et al., 1999; Mizunuma, et al., 1999) and TGFb (follicles of
adult but not immature mice) (Liu, et al., 1999; Mizunuma, et al., 1999) have been described to
stimulate pre-antral follicle growth.
Markers for increase in follicle development are estrogen and inhibin production by the follicles.
LH and FSH together are involved in stimulation of the estrogen production, since LH stimulates the
production of androgens by theca cells while FSH stimulates the conversion of androgens into estrogens
by the granulosa cells. Also TGFb superfamily members can stimulate pre-antral follicle development.
Activin A stimulates the development of cultured pre-antral follicles from immature but not from
adult mice as shown by an increase in inhibin and estrogen production (Liu, et al., 1999; Mizunuma,
et al., 1999). TGFb stimulates inhibin and estrogen production in adult but not immature follicles
(Liu, et al., 1999; Mizunuma, et al., 1999). In addition, a stimulatory effect on pre-antral follicle
development of GDF9 has been found, since an increase in inhibin a-subunit mRNA expression was
detected after treatment with this oocyte factor (Hayashi, et al., 1999). Besides stimulation of growth
and development of immature pre-antral follicles, activin is involved in regulation of pre-antral follicle
growth of adult mice since activin production by large pre-antral follicles keep small pre-antral follicles
dormant (Mizunuma, et al., 1999). In conclusion, follicle development until the point of selection is
regulated by several TGFb superfamily members, while the gonadotropins LH and FSH have a
subordinate role.
In rodents, large pre-antral follicles become selected for further growth towards the pre-ovulatory
stage by FSH. Follicle growth and development from the point of selection is dominantly regulated
by FSH and LH, while the TGFb superfamily members play a less important role. The importance of
FSH in this process is clearly shown by the FSHb null (Kumar, et al., 1997) and FSHR null (Dierich,
et al., 1998) mice of which the ovaries do not contain any antral follicle. The sensitivity of follicles to
FSH is inhibited by AMH, thereby decreasing the number of follicles selected for pre-ovulatory
growth (Durlinger, et al., 2001). Follicle development becomes dependent on LH after formation of
the antrum as shown in the LHR null mice of which the ovaries do not contain pre-ovulatory follicles
(Zhang, et al., 2001). FSH stimulates antral follicle growth by stimulating granulosa cell proliferation.
In addition, antrum formation is induced by FSH, a process which is enhanced by LH. During the last
phase of follicle development, LH is involved in successful maturation of the follicles and is essential
for ovulation. 
8.3.2 Modulation of FSH action by TGFb superfamily 
members
As described above, both FSH and TGFb superfamily members are involved in follicle development.
Interestingly, FSH action is modulated by several TGFb superfamily members (Table 8.3). The 
FSH-induced growth of pre-antral follicles is e.g. inhibited by AMH (Durlinger, et al., 2001) and
activin (Yokota, et al., 1997; Liu, et al., 1999; Mizunuma, et al., 1999), but enhanced by GDF9
(Hayashi, et al., 1999) and TGFb (both in adult and immature mice pre-antral follicles) (Liu, et al.,
1999; Mizunuma, et al., 1999). In addition, the FSH-stimulated differentiation of follicles, measured
by increasing inhibin a mRNA expression is enhanced by GDF9 (Hayashi, et al., 1999) which suggests
that GDF9 in addition to FSH stimulates follicle development. 
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follicle pool. The oocyte diameter starts to increase, the granulosa cells become cuboidal and start to
proliferate and the primordial follicle develops into a primary follicle. When more than one layer of
granulosa cells have been formed the follicle is called pre-antral (for review see Chapter 1). After
formation of the antrum, the follicle is named antral follicle. At selection, large pre-antral follicles in
mice and rats and antral follicles in human are selected for growth until the pre-ovulatory stage. Only
those follicles that have become sensitive enough for FSH will be rescued from atresia (McGee and
Hsueh, 2000).
8.3.1 Follicle development
Follicle development is regulated by the gonadotropins LH and FSH, which are produced by the pituitary.
In the literature, these two hormones are described as the most important for follicle development.
However, the ovary produces several growth factors belonging to the TGFb superfamily, like BMP2,
BMP3, BMP4, BMP6, BMP7, BMP15, GDF9, AMH, TGFb, activins and inhibins which can also be very
important for follicle development (for review see Chapter 1, Figure 1.1). That ovarian factors can have
a dominant role in follicle development is shown by the FSHb/AMH deficient mice in which the
ovaries, like the ovaries of AMH null mice, contain more growing and less primordial follicles
compared to wild-type mice ovaries (Durlinger, et al., 2001). In contrast, the ovaries of FSHb null
mice show similar numbers of primordial and growing follicles compared to ovaries of wild-type mice.
Although both gonadotropins and TGFb superfamily members are important for follicle development,
their roles are distinct. In this section, the effects of the gonadotropins and several members of the
TGFb superfamily on follicle development and the interaction between these two groups of hormones
and growth factors are discussed. 
TGFb superfamily members are involved in follicle development from recruitment of the primordial
follicles until ovulation of the oocyte. AMH inhibits recruitment of primordial follicles into the
growing pool as shown by the AMH null mice (Durlinger, et al., 1999) and neonatal ovary cultures
(Chapter 3), while BMP4 stimulates primordial follicle recruitment in neonatal ovary cultures (Nilsson
and Skinner, 2003). Gonadotropins are not obligatory for primordial follicle recruitment, since
growing follicles are found in FSHb null, FSHR null and LHR null mice (Kumar, et al., 1997; Dierich,
et al., 1998; Zhang, et al., 2001). In addition, primordial follicle recruitment cannot be directly stimulated
by FSH or LH since these primordial follicles do not express the receptors for these gonadotropins (for
review see Chapter 1)(Rannikki, et al., 1995; Teerds and Dorrington, 1995; O'Shaughnessy, et al., 1996,
1997; Oktay, et al., 1997).
After recruitment, primary follicle development requires GDF9 since follicle development is blocked
at the primary follicle stage in GDF9 null mice (Dong, et al., 1996). First effects of LH and FSH on
follicle growth and development have been described on pre-antral follicles, which growth is stimulated
by LH (for review see Chapter 1)(Cortvrindt, et al., 1998; Wu, et al., 2000) and FSH (for review see
Chapter 1)(Yokota, et al., 1997; Mizunuma, et al., 1999; Gutierrez, et al., 2000). 
8.4 AMH AND THE CLINIC
Interestingly, in ovaries of the mouse (Chapter 3, Münsterberg and Lovell-Badge, 1991; Taketo, et al.,
1993; Durlinger, et al., 2002), the rat (Hirobe, et al., 1994; Baarends, et al., 1995b) as well as the human
(Weenen, et al., 2004), expression of AMH is found in granulosa cells of follicles immediately after
primordial follicle recruitment and expression is continued during follicle growth until the point of
selection. Thus, AMH is expressed in follicles that grow independently of FSH stimulation (for review
see Chapter 1). This is reflected by the absence of large AMH serum fluctuations in female serum levels
during the menstrual cycle (Cook, et al., 2000). Many studies have been performed to investigate the
correlation of AMH serum levels with ovarian function and in this section these studies are discussed. 
Throughout life, the primordial stock decreases and when a women has reached the menopause,
the primordial follicle pool is almost depleted (for review see Chapter 1)(Baker, 1963). The decrease
of the primordial follicle stock in the ovary is called ovarian aging. However, ovarian aging is difficult
to measure since the size of the primordial follicle stock in women is difficult to determine. However,
it appears that the number of growing follicles is correlated to the size of the primordial follicle stock
from which they are recruited (Gougeon, et al., 1994; Scheffer, et al., 1999). Since AMH is produced by
the growing follicles, the hypothesis that AMH might be a candidate marker of ovarian reserve was tested.
Indeed, a negative correlation was found between age and AMH levels (de Vet, et al., 2002). In addition,
AMH serum levels showed a strong correlation with the number of growing antral follicles. 
This correlation was stronger than the correlation of the number of growing antral follicles with FSH
or inhibin B serum levels (de Vet, et al., 2002; Fanchin, et al., 2003). In line with these results, AMH
serum levels are undetectable after menopause (Lee, et al., 1996; de Vet, et al., 2002). Thus, AMH
correlates with the number of growing follicles present in the ovary and ovarian aging.
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FSH stimulated estrogen production in pre-antral follicles of adult mice is inhibited by activin
(Yokota, et al., 1997; Liu, et al., 1999; Mizunuma, et al., 1999). In antral and pre-ovulatory follicles,
FSH induces differentiation as shown by increased LHR expression and estrogen and progesterone
production and these effects are all inhibited by GDF9 (Vitt, et al., 2000a). In addition, FSH-induced
antral follicle growth is inhibited by AMH (Durlinger, et al., 2001). Thus, these experiments show a
differentiating effect of FSH on follicle development while TGFb superfamily members mainly have
an FSH-inhibitory effect.
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Table 8.3: Modulation of effects of FSH action by TGFb family members during follicle development.
Follicle type: Effect on: FSH effect: FSH effect positively (+) or negatively (-) 
modulated by TGFb family member:
Pre-antral Growth + GDF9 +
Activin (immature mice) +
AMH -
Inhibin production + GDF9 +
Estrogen production + Activin (mature mice ) -
Antral Growth + AMH -
Pre-ovulatory Estrogen production + GDF9 -
Progesterone production + GDF9 -
LHR expression + GDF9 -
Many experiments have been performed to study the effects of TGFb superfamily members on FSH
regulation of granulosa cell cultures of immature rats (Table 8.4). Since granulosa cells luteinize when
cultured in the presence of FSH (Thanki and Channing, 1976), the exact developmental stage of cultured
granulosa cells is unclear and therefore discussed separately from the follicle culture experiments.
FSH-induced estrogen production is stimulated by BMP4, BMP7 and activin (Xiao, et al., 1992; Shimasaki,
et al., 1999). The inhibin production, a measurement for follicle differentiation (also measured by
inhibin a-, bA- or bB-subunit mRNA transcription) is inhibited by several TGFb superfamily members
(Xiao, et al., 1992; Otsuka, et al., 2001a, 2001b). Progesterone production and LHR expression are
signs of luteinization of the granulosa cells. Both LHR expression and progesterone production are
stimulated by FSH and inhibited by TGFb superfamily members, causing the inhibition of luteinization
by these TGFb superfamily members (Xiao, et al., 1992; di Clemente, et al., 1994a; Elvin, et al., 1999a;
Shimasaki, et al., 1999; Otsuka, et al., 2001a). A discrepancy is found concerning the regulation of FSHR
mRNA expression by FSH, since stimulation and inhibition of FSHR mRNA by FSH has been described.
In both experiments, the FSH effect was inhibited by TGFb superfamily members (Xiao, et al., 1992;
Otsuka, et al., 2001a, 2001b).
Together these results show that FSH and LH are the driving forces of follicle development from
selection to ovulation while TGFb superfamily members have a dominant role in follicle development
until selection but also are involved in follicle development after this regulatory point. In addition,
ovarian factors modulate actions of FSH on follicle development: in general they inhibit FSH-induced
differentiation.
Table 8.4: FSH effects modulated by members of the TGFb superfamily in granulosa cell culture.
FSH effect: TGFb family member modulation: References:
Stimulates estrogen synthesis Stimulated by BMP4, BMP7, Xiao et al., 1992; Shimasaki et al., 1999
activin (granulosa cells of follicles 
of immature mice) 
Stimulates inhibin production Stimulated by activin (granulosa cells Xiao et al., 1992
of follicles of immature mice)
Stimulates inhibin a mRNA Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
expression
Stimulates inhibin bA mRNA Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
Stimulates inhibin bB mRNA Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
Stimulates progesterone production Inhibited by GDF9, BMP15, BMP6, Elvin et al., 1999; Shimasaki et al., 1999; 
BMP4, BMP7 Otsuka et al., 2001a
Stimulated by activin (granulosa cells Xiao et al., 1992; Shimasaki et al., 1999
of follicles of immature mice)
Stimulates LHR expression Inhibited by GDF9, AMH, BMP6 di Clemente et al., 1994; Elvin eet al., 1999; 
Otsuka et al., 2001a
Stimulates FSHR expression Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
Inhibits FSHR expression Inhibited by activin (granulosa cells Xiao et al., 1992
of follicles of immature mice)
8.4 AMH AND THE CLINIC
Interestingly, in ovaries of the mouse (Chapter 3, Münsterberg and Lovell-Badge, 1991; Taketo, et al.,
1993; Durlinger, et al., 2002), the rat (Hirobe, et al., 1994; Baarends, et al., 1995b) as well as the human
(Weenen, et al., 2004), expression of AMH is found in granulosa cells of follicles immediately after
primordial follicle recruitment and expression is continued during follicle growth until the point of
selection. Thus, AMH is expressed in follicles that grow independently of FSH stimulation (for review
see Chapter 1). This is reflected by the absence of large AMH serum fluctuations in female serum levels
during the menstrual cycle (Cook, et al., 2000). Many studies have been performed to investigate the
correlation of AMH serum levels with ovarian function and in this section these studies are discussed. 
Throughout life, the primordial stock decreases and when a women has reached the menopause,
the primordial follicle pool is almost depleted (for review see Chapter 1)(Baker, 1963). The decrease
of the primordial follicle stock in the ovary is called ovarian aging. However, ovarian aging is difficult
to measure since the size of the primordial follicle stock in women is difficult to determine. However,
it appears that the number of growing follicles is correlated to the size of the primordial follicle stock
from which they are recruited (Gougeon, et al., 1994; Scheffer, et al., 1999). Since AMH is produced by
the growing follicles, the hypothesis that AMH might be a candidate marker of ovarian reserve was tested.
Indeed, a negative correlation was found between age and AMH levels (de Vet, et al., 2002). In addition,
AMH serum levels showed a strong correlation with the number of growing antral follicles. 
This correlation was stronger than the correlation of the number of growing antral follicles with FSH
or inhibin B serum levels (de Vet, et al., 2002; Fanchin, et al., 2003). In line with these results, AMH
serum levels are undetectable after menopause (Lee, et al., 1996; de Vet, et al., 2002). Thus, AMH
correlates with the number of growing follicles present in the ovary and ovarian aging.
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FSH stimulated estrogen production in pre-antral follicles of adult mice is inhibited by activin
(Yokota, et al., 1997; Liu, et al., 1999; Mizunuma, et al., 1999). In antral and pre-ovulatory follicles,
FSH induces differentiation as shown by increased LHR expression and estrogen and progesterone
production and these effects are all inhibited by GDF9 (Vitt, et al., 2000a). In addition, FSH-induced
antral follicle growth is inhibited by AMH (Durlinger, et al., 2001). Thus, these experiments show a
differentiating effect of FSH on follicle development while TGFb superfamily members mainly have
an FSH-inhibitory effect.
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Table 8.3: Modulation of effects of FSH action by TGFb family members during follicle development.
Follicle type: Effect on: FSH effect: FSH effect positively (+) or negatively (-) 
modulated by TGFb family member:
Pre-antral Growth + GDF9 +
Activin (immature mice) +
AMH -
Inhibin production + GDF9 +
Estrogen production + Activin (mature mice ) -
Antral Growth + AMH -
Pre-ovulatory Estrogen production + GDF9 -
Progesterone production + GDF9 -
LHR expression + GDF9 -
Many experiments have been performed to study the effects of TGFb superfamily members on FSH
regulation of granulosa cell cultures of immature rats (Table 8.4). Since granulosa cells luteinize when
cultured in the presence of FSH (Thanki and Channing, 1976), the exact developmental stage of cultured
granulosa cells is unclear and therefore discussed separately from the follicle culture experiments.
FSH-induced estrogen production is stimulated by BMP4, BMP7 and activin (Xiao, et al., 1992; Shimasaki,
et al., 1999). The inhibin production, a measurement for follicle differentiation (also measured by
inhibin a-, bA- or bB-subunit mRNA transcription) is inhibited by several TGFb superfamily members
(Xiao, et al., 1992; Otsuka, et al., 2001a, 2001b). Progesterone production and LHR expression are
signs of luteinization of the granulosa cells. Both LHR expression and progesterone production are
stimulated by FSH and inhibited by TGFb superfamily members, causing the inhibition of luteinization
by these TGFb superfamily members (Xiao, et al., 1992; di Clemente, et al., 1994a; Elvin, et al., 1999a;
Shimasaki, et al., 1999; Otsuka, et al., 2001a). A discrepancy is found concerning the regulation of FSHR
mRNA expression by FSH, since stimulation and inhibition of FSHR mRNA by FSH has been described.
In both experiments, the FSH effect was inhibited by TGFb superfamily members (Xiao, et al., 1992;
Otsuka, et al., 2001a, 2001b).
Together these results show that FSH and LH are the driving forces of follicle development from
selection to ovulation while TGFb superfamily members have a dominant role in follicle development
until selection but also are involved in follicle development after this regulatory point. In addition,
ovarian factors modulate actions of FSH on follicle development: in general they inhibit FSH-induced
differentiation.
Table 8.4: FSH effects modulated by members of the TGFb superfamily in granulosa cell culture.
FSH effect: TGFb family member modulation: References:
Stimulates estrogen synthesis Stimulated by BMP4, BMP7, Xiao et al., 1992; Shimasaki et al., 1999
activin (granulosa cells of follicles 
of immature mice) 
Stimulates inhibin production Stimulated by activin (granulosa cells Xiao et al., 1992
of follicles of immature mice)
Stimulates inhibin a mRNA Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
expression
Stimulates inhibin bA mRNA Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
Stimulates inhibin bB mRNA Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
Stimulates progesterone production Inhibited by GDF9, BMP15, BMP6, Elvin et al., 1999; Shimasaki et al., 1999; 
BMP4, BMP7 Otsuka et al., 2001a
Stimulated by activin (granulosa cells Xiao et al., 1992; Shimasaki et al., 1999
of follicles of immature mice)
Stimulates LHR expression Inhibited by GDF9, AMH, BMP6 di Clemente et al., 1994; Elvin eet al., 1999; 
Otsuka et al., 2001a
Stimulates FSHR expression Inhibited by BMP6, BMP15 Otsuka et al., 2001a, 2001b
Inhibits FSHR expression Inhibited by activin (granulosa cells Xiao et al., 1992
of follicles of immature mice)
Fertility in women is determined by the ovarian reserve, which represents both the quantity and
quality of the ovarian follicle pool. Besides aspects such as oocyte quality, the number of primordial
follicles that are left in the ovary is also an important parameter for ovarian reserve (te Velde and
Pearson, 2002). Therefore, a marker that reflects all follicles that have made the transition from the
primordial follicle pool to the growing pool may be a good indirect marker of the quantitative aspects
of the ovarian reserve. Indeed, low AMH serum levels were associated with a decreased response to
ovarian stimulation for IVF (Seifer, et al., 2002; van Rooij, et al., 2002). Although AMH serum levels
may not be the only marker of ovarian reserve, the relatively small fluctuations in AMH serum level
during the menstrual cycle (Cook, et al., 2000) indicate that a predictive blood sample may be drawn
at any moment during the menstrual cycle, which further supports the advantage of the use of AMH
as a marker of ovarian reserve over antral follicle count using ultrasound. An interesting new field of
research is the role of AMH during follicle development of an individual follicle. The immature female
gametes in the ovarian cortex can be cryopreserved (Gosden, 2000), for example for females undergoing
cancer treatment. At this moment, it is still impossible to mature these primordial follicles to a 
pre-ovulatory follicle in vitro. However, the in vitro culture of follicles is still under development.
AMH is expressed by granulosa cells of growing follicles until selection and AMH production by these
follicles might give an indication of developmental stage of the follicle. During the in vitro maturation
of follicles different concentrations of FSH, LH and growth factors might be needed, and AMH may be
an excellent marker of follicle developmental stage to indicate successful maturation of follicles.
AMH serum levels may also give an indication of abnormal ovarian function. In patients with
polycystic ovary syndrome (PCOS), much higher AMH serum levels were found than in normo-ovulatory
women (Fallat, et al., 1997; Cook, et al., 2002; Laven, et al., 2004). In these PCOS patients a higher number
of immature oocytes was found after ovarian stimulation for IVF treatment (Fallat, et al., 1997).
Furthermore, increased serum levels of AMH are found in most women with granulosa cell tumors
(Gustafson, et al., 1992; Lane, et al., 1999; Long, et al., 2000; Rey, et al., 2000).
In conclusion, AMH is a good marker for ovarian function. Decreasing AMH serum levels show a
decrease in ovarian reserve, with poor prognosis for good results in IVF. In addition, an increased
AMH serum level is an indication for PCOS and can be used to detect the presence of granulosa cell
tumors.
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SUMMARY
Menopause, the end of menstrual cycling, is a major milestone in the aging process in women. 
The cessation of ovarian function is accompanied by the almost complete absence of female sex
steroid hormone secretion by the ovaries in postmenopausal life. Consequently, before and after the
menopausal transition very different physiological hormonal regimens prevail, which have a major
impact on healthy aging of women and their quality of life. After menopause, due to the loss of
exposure to protective female sex steroid hormones, women have an increased risk for different
health problems (such as osteoporosis, cardiovascular diseases and a decreased cognitive function).
In addition, the age at menopause is associated with the age at which infertility starts. Approximately,
20 years before menopause female fertility starts to decrease, culminating through sub-fertility into
complete infertility 10 years before menopause. Since the age at menopause affects the length of the
postmenopausal period and the age of infertility, it is of utmost importance to understand the process
leading to menopause. Menopause is caused by the exhaustion of the follicle stock in the ovaries. 
The limited supply of primordial follicles is formed during fetal life and cannot be replenished
afterwards. The number of primordial follicles decreases by outgrowth of follicles or by atresia.
Studies on the anti-Müllerian hormone (AMH) null mice showed that AMH inhibits the outgrowth
of primordial follicles and thereby inhibits the exhaustion of follicles in the ovary.
This thesis focuses on the role of AMH in the ovary and investigates through which molecular
mechanisms these effects are achieved.
In the General Introduction (Chapter 1), the process of follicle development from primordial to 
pre-ovulatory follicle is described. This process is regulated by follicle-stimulating hormone (FSH)
and luteinizing hormone (LH), produced by the pituitary, but also by several intra-ovarian factors.
One important family of growth- and differentiation factors which plays a role in follicle development
is the transforming growth factor b (TGFb) superfamily, to which also AMH belongs. The involvement
of several TGFb family members in follicle development is described and the emphasis is on the
known effects of AMH on follicle development and the clinical relevance of these findings.
AMH is a member of the TGFb superfamily and family members signal through a receptor complex
consisting of a type II and a type I transmembrane serine/threonine kinase receptor. The production
of TGFb superfamily members, the mechanism of receptor activation and downstream signaling are
described in Chapter 2.
The inhibitory effect of AMH on primordial follicle recruitment was investigated in an in vitro
study in which 2-day-old neonatal wild-type ovaries were cultured in the absence or presence of AMH
(Chapter 3). The ovaries of 2-day-old mice contain only primordial and no growing follicles, and
therefore provide a good model for studying the effect of AMH on primordial follicle recruitment. After
2 or 4 days of culture of the neonatal ovaries, less growing follicles were found in the ovaries cultured in
the presence of AMH compared to ovaries cultured in the absence of AMH. Furthermore, the mRNA
levels of the inhibin a-subunit, expressed by early growing follicles detected by immunohistochemistry,
was lower in the ovaries cultured in the presence of AMH. No effect on mRNA levels of the AMH type II
receptor (AMHRII) or the oocyte markers zona pellucida protein 3 (ZP3) and growth and differentiation
factor 9 (GDF9) was detected after culturing ovaries in the presence of AMH.
147
Summary
Summary
SUMMARY
Menopause, the end of menstrual cycling, is a major milestone in the aging process in women. 
The cessation of ovarian function is accompanied by the almost complete absence of female sex
steroid hormone secretion by the ovaries in postmenopausal life. Consequently, before and after the
menopausal transition very different physiological hormonal regimens prevail, which have a major
impact on healthy aging of women and their quality of life. After menopause, due to the loss of
exposure to protective female sex steroid hormones, women have an increased risk for different
health problems (such as osteoporosis, cardiovascular diseases and a decreased cognitive function).
In addition, the age at menopause is associated with the age at which infertility starts. Approximately,
20 years before menopause female fertility starts to decrease, culminating through sub-fertility into
complete infertility 10 years before menopause. Since the age at menopause affects the length of the
postmenopausal period and the age of infertility, it is of utmost importance to understand the process
leading to menopause. Menopause is caused by the exhaustion of the follicle stock in the ovaries. 
The limited supply of primordial follicles is formed during fetal life and cannot be replenished
afterwards. The number of primordial follicles decreases by outgrowth of follicles or by atresia.
Studies on the anti-Müllerian hormone (AMH) null mice showed that AMH inhibits the outgrowth
of primordial follicles and thereby inhibits the exhaustion of follicles in the ovary.
This thesis focuses on the role of AMH in the ovary and investigates through which molecular
mechanisms these effects are achieved.
In the General Introduction (Chapter 1), the process of follicle development from primordial to 
pre-ovulatory follicle is described. This process is regulated by follicle-stimulating hormone (FSH)
and luteinizing hormone (LH), produced by the pituitary, but also by several intra-ovarian factors.
One important family of growth- and differentiation factors which plays a role in follicle development
is the transforming growth factor b (TGFb) superfamily, to which also AMH belongs. The involvement
of several TGFb family members in follicle development is described and the emphasis is on the
known effects of AMH on follicle development and the clinical relevance of these findings.
AMH is a member of the TGFb superfamily and family members signal through a receptor complex
consisting of a type II and a type I transmembrane serine/threonine kinase receptor. The production
of TGFb superfamily members, the mechanism of receptor activation and downstream signaling are
described in Chapter 2.
The inhibitory effect of AMH on primordial follicle recruitment was investigated in an in vitro
study in which 2-day-old neonatal wild-type ovaries were cultured in the absence or presence of AMH
(Chapter 3). The ovaries of 2-day-old mice contain only primordial and no growing follicles, and
therefore provide a good model for studying the effect of AMH on primordial follicle recruitment. After
2 or 4 days of culture of the neonatal ovaries, less growing follicles were found in the ovaries cultured in
the presence of AMH compared to ovaries cultured in the absence of AMH. Furthermore, the mRNA
levels of the inhibin a-subunit, expressed by early growing follicles detected by immunohistochemistry,
was lower in the ovaries cultured in the presence of AMH. No effect on mRNA levels of the AMH type II
receptor (AMHRII) or the oocyte markers zona pellucida protein 3 (ZP3) and growth and differentiation
factor 9 (GDF9) was detected after culturing ovaries in the presence of AMH.
147
Summary
Summary
AMH inhibits recruitment of primordial follicles and decreases the sensitivity of large pre-antral and
small antral follicles for FSH. However, the molecular mechanisms by which AMH achieves these effects
are largely unknown. To understand the downstream effects of AMH we aimed to identify AMH-regulated
genes (Chapter 7). We cultured neonatal mouse ovaries and the mouse granulosa cell line KK-1/AMHRII
for 24 hours in the absence or presence of AMH. To identify gene expression differences in neonatal
ovaries we used the Atlas™ mouse cDNA expression array and to identify gene expression differences
in KK-1/AMHRII cells we used the Agilent mouse development oligo microarray. Differences in gene
expression found on the arrays were validated using quantitative real-time PCR. The genes identified
from neonatal ovary culture and the Atlas™ mouse cDNA expression array could not be confirmed
by quantitative real-time PCR. Validation of the genes identified from the KK-1/AMHRII and the Agilent
mouse development oligo microarray is ongoing.
The General Discussion (Chapter 8) summarizes the mechanisms by which AMH could achieve
its specific effects. In addition, the role of AMH in follicle development compared to the role of the
systemic factors LH and FSH and the clinical relevance of AMH are discussed.
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AMH signals through a receptor complex containing type II and type I serine/threonine kinase
receptors. The AMH type II receptor (AMHRII) is responsible for AMH-signaling in the Müllerian
ducts, since the absence of the receptor results in the absence of Müllerian duct regression. To investigate
if this AMHRII is also responsible for AMH-signaling in the ovary, we studied the follicle population
of ovaries of 4-month-old mice lacking expression of the AMHRII, the MIS receptor knock-in (MRKI)
mice (Chapter 4). Similar to the results found in the AMH null mice ovaries, ovaries of MRKI(-/-) mice
contained more growing and less primordial follicles than their wild-type littermates. The increased
number of growing follicles was accompanied by increased inhibin A and inhibin B and decreased FSH
serum levels, albeit that these differences were not significant due to the small number of wild-type
mice investigated. The number of total and primordial follicles in the MRKI(-/-) mice ovaries was
smaller compared to the AMH(-/-) ovaries, suggesting an increased recruitment of primordial follicles.
This increased recruitment is probably caused by the absence of ligand-independent activity of the
AMHRII in the MRKI(-/-) mice ovaries. These experiments show that AMH signals through the
AMHRII in the ovary.
Two main signaling pathways can be distinguished for TGFb superfamily members: the BMP-like
and TGFb/activin-like signaling pathway. In Chapter 5, we investigated through which signaling pathway
AMH transduces its signal in the ovary. In addition, we studied if AMH can regulate its own signaling
by changing gene expression of its receptors or downstream signaling mediators. Using the mouse
granulosa cell line KK-1, we showed that AMH signals through the BMP-like signaling pathway. The
different candidate type I receptors and receptor-specific and inhibitory Smads are expressed by ovaries
of postnatal ovaries, showing possible involvement in primordial follicle recruitment. The AMHRII
and one of the candidate type I receptors, ALK2, are expressed by granulosa cells of pre-antral and
antral follicles, shown by in situ hybridization. In addition, we showed by quantitative real-time PCR
that AMH upregulates the mRNA expression of the inhibitory Smad6 and Smad7, showing an intracellular
negative feedback mechanism. Furthermore, AMH upregulates the expression of the receptor-specific
Smad8. However, the importance of this finding needs further research since the expression of Smad8
is very low.
Primordial follicle recruitment is under control of the growing follicle pool. To identify the importance
of several intra-ovarian growth factors in this process, we studied the mRNA expression and protein
localization in postnatal ovaries. The age of the ovaries was selected on basis of the presence of different
follicle types. Ovaries of 2-day-old mice only contained primordial follicles, whereas on day 6 also
primary follicles were present. In 12-day-old ovaries pre-antral follicles first appeared and antral
follicles were found first in ovaries of 18-day-old mice. All antral and large pre-antral follicles had become
atretic in ovaries of 25-day-old mice. At these five different ovarian ages the protein localization and
mRNA expression levels were determined of growth factors which are or could be involved in
primordial follicle recruitment. Granulosa cells of small growing follicles expressed AMH, activins,
inhibins and kit-ligand, while growth and differentiating factor 9 (GDF9) and bone morphogenetic
protein 15 (BMP15) were expressed by the oocytes of small growing follicles. Therefore, these growth
factors could be involved in primordial follicle recruitment. However, the intra-ovarian growth
factors basic fibroblast growth factor (bFGF) and nerve growth factor  (NGF) were expressed by oocytes,
granulosa, theca and interstitial cells. Since these growth factors are so generally expressed, it is unlikely
that bFGF and NGF play a regulatory role in primordial follicle recruitment. 
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Menopauze is een mijlpaal in het verouderingsproces van vrouwen en de postmenopausale periode
begint na de laatste menstruele cyclus. De achteruitgang van de ovariële functie veroorzaakt de bijna
complete afwezigheid van afgifte van vrouwelijke geslachtshormonen door de ovaria. Na de menopauze
hebben vrouwen een verhoogde kans op verscheidene gezondheidsproblemen zoals osteoporose,
veranderingen in cognitieve functies (bijv. de ziekte van Alzheimer) en cardiovasculaire ziekten. Aan de
andere kant is er een verband tussen de leeftijd waarop een vrouw in de menopauze komt en de leeftijd
waarop zij onvruchtbaar wordt. Circa twintig jaar voor de menopauze begint de vruchtbaarheid af te
nemen en 10 jaar voor de menopauze is de vrouw volledig onvruchtbaar. In het licht van mogelijk vroege
onvruchtbaarheid en de gezondheidsproblemen geassocieerd met de menopauze is het van groot belang
om de processen die een rol spelen bij het ontstaan van de menopauze te begrijpen.
De menopauze wordt veroorzaakt door de uitputting van de follikelvoorraad in de ovaria. 
De gelimiteerde voorraad primordiale follikels wordt gevormd tijdens de foetale ontwikkeling en kan
later niet meer aangevuld worden. Na de vorming van de primordiale follikelvoorraad, neemt het aantal
primordiale follikels af door uitgroei of door sterfte van deze follikels. Studies aan muizen die geen
anti-Müllerse gang hormoon (AMH) eiwit kunnen maken, hebben laten zien dat AMH de uitgroei van
de primordiale follikels remt en daarmee de uitputting van de voorraad follikels in de ovaria tegengaat.
Dit proefschrift richt zich op de functie van AMH in het ovarium en onderzoekt door welke
moleculaire werkingsmechanismen de effecten van AMH worden bereikt.
In de Algemene Introductie (Hoofdstuk 1) wordt het ontwikkelingsproces van een primordiale
follikel tot een pre-ovulatoire follikel beschreven. Dit proces wordt gereguleerd door follikelstimulerend
hormoon (FSH) en luteiniserend hormoon (LH), welke door de hypofyse geproduceerd worden.
Verder wordt de ontwikkeling van een follikel gereguleerd door groeifactoren die in het ovarium
geproduceerd worden. Een zeer belangrijke familie van groei- en ontwikkelingsfactoren is de transforming
growth factor b (TGFb) superfamilie. Hoofdstuk 1 geeft een overzicht van de betrokkenheid van meerdere
TGFb familieleden bij follikelontwikkeling. De nadruk van dit hoofdstuk ligt op de reeds bekende
effecten van AMH op follikelontwikkeling en de klinische relevantie van deze bevindingen. AMH is lid
van de TGFb superfamilie van groei- en ontwikkelingsfactoren. Groeifactoren die bij de TGFb familie
horen geven hun signaal in de cel door via een receptorcomplex bestaande uit type II en type I
transmembraan serine/threonine kinase receptoren. Hoofdstuk 2 beschrijft de productie van TGFb
familieleden in de cel, het mechanisme van de activatie van hun receptor en het doorgeven van hun
receptor signaal in de cel. 
Het remmend effect van AMH op de uitgroei primordiale follikels werd onderzocht in een
kweeksysteem, waarbij ovaria van 2 dagen oude muizen werden gekweekt in de af- en aanwezigheid
van AMH (Hoofdstuk 3). De ovaria van 2 dagen oude muizen bevatten alleen primordiale follikels en
zijn om die reden een zeer goed studieobject voor het meten van de effecten van AMH op de primordiale
follikel uitgroei. Na 2 of 4 dagen worden minder groeiende follikels gevonden in ovaria die gekweekt
zijn in aanwezigheid van AMH vergeleken met de ovaria die in afwezigheid van AMH zijn gekweekt.
Verder toonden we met behulp van immunohistochemische technieken aan dat de inhibine a-subunit
wordt geproduceerd door kleine groeiende follikels. Dat AMH de uitgroei van primordiale follikels in
de gekweekte ovaria remt werd bevestigd door metingen van inhibine a-subunit mRNA. 
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oude muizen bevatten alleen primordiale follikels. De eerste primaire follikels worden gevonden in
ovaria van 6 dagen oude muizen. Ovaria van 12 dagen oude muizen bevatten pre-antrale follikels en
antrale follikels zijn aanwezig in 18 dagen oude muizen. Alle grote pre-antrale en antrale follikels zijn
atretisch in ovaria van 25 dagen oude muizen. In ovaria van muizen met deze 5 verschillende leeftijden
hebben we de localizatie van eiwit en de hoogte van expressie van het mRNA van een aantal groeifactoren
bepaald. Granulosa cellen van kleine groeiende follikels bevatten AMH, activines, inhibines en kit-ligand,
terwijl de GDF9 en bone morphogenetic protein 15 (BMP15) tot expressie komen in de oocyten van
deze kleine groeiende follikels. Deze groeifactoren kunnen dus betrokken zijn bij primordiale follikel
uitgroei. De intra-ovariële groeifactoren basic fibroblast growth factor (bFGF) en nerve growth factor
(NGF) komen tot expressie in de oocyten en in granulosa, theca en interstitiële cellen. Omdat deze
groeifactoren zo algemeen tot expressie komen is het onwaarschijnlijk dat bFGF en NGF een specifiek
regulerende rol spelen bij primordiale follikel uitgroei.
AMH remt de uitgroei van primordiale follikels en remt de gevoeligheid van grote pre-antrale en
antrale follikels voor FSH. De moleculaire mechanismen waardoor AMH dit effect bereikt zijn onbekend.
Om de effecten van AMH te ontrafelen wilden we AMH-gereguleerde genen opsporen (Hoofdstuk 7).
We kweekten neonatale ovaria en de muizen granulosa cellijn KK-1/AMHRII voor 24 uur in af- of
aanwezigheid van AMH. Genexpressieverschillen in de neonatale ovaria werden bestudeerd met de Atlas™
mouse cDNA expressie array en de genexpressie verschillen in de KK-1/AMHRII cellen werden bestudeerd
met de Agilent mouse development oligo microarray. Verschillen in genexpressie gevonden met de arrays
werden gecontroleerd met quantitatieve real-time PCR. De AMH-gereguleerde genen gevonden in de
neonatale muizen ovaria konden niet worden bevestigd met de quantitatieve real-time PCR. De genen
welke zijn geïdentificeerd in de KK-1/AMHRII cellen worden op dit moment gecontroleerd.
De Algemene Discussie (Hoofdstuk 8) geeft tenslotte een overzicht van de mechanismen waardoor
AMH zijn effecten kan bereiken. Ook de rol van AMH in follikelontwikkeling wordt vergeleken met
de rol van LH en FSH. Als laatste wordt de klinische relevantie van het meten van AMH concentraties
in het bloed besproken.
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De ovaria die gekweekt werden in afwezigheid van AMH bevatten meer inhibine a-subunit mRNA
dan de ovaria gekweekt in aanwezigheid van AMH. AMH had geen effect op de mRNA expressie van de
AMH type II receptor (AMHRII) of de door oocyten geproduceerde eiwitten zona pellucida 3 (ZP3)
en growth differentiation factor 9 (GDF9).
Het signaal van AMH wordt doorgegeven d.m.v. een receptorcomplex dat een type II en type I
receptoren bevat. De AMH type II receptor (AMHRII) is verantwoordelijk voor het doorgeven van
het signaal van AMH in de Müllerse gangen tijdens de embryonale periode, resulterend in regressie
van de Müllerse gangen in mannen. Vrouwen maken geen AMH tijdens de embryonale periode en
daardoor gaan de Müllerse gangen niet in regressie en ontwikkelen zich in de eileiders, baarmoeder
en het bovenste deel van de vagina. Wij onderzochten of dezelfde AMHRII ook verantwoordelijk is
voor het doorgeven van het signaal van AMH in de ovaria. Hiervoor bestudeerden we de follikel
populatie in ovaria van 4 maanden oude (MRKI(-/-)) muizen die geen AMHRII tot expressie brengen
(Hoofdstuk 4). De ovaria van MRKI(-/-) muizen bevatten meer groeiende en minder primordiale
follikels dan in de controle dieren en deze resultaten zijn vergelijkbaar met de resultaten gevonden in
de ovaria van muizen die geen AMH (AMH(-/-)) tot expressie brengen. Het toegenomen aantal
groeiende follikels ging vergezeld met toegenomen serumconcentraties van inhibine A en inhibine B
en afgenomen serumconcentratie van FSH. Deze verschillen waren niet significant, waarschijnlijk als
gevolg van het kleine aantal controle dieren dat tot nu toe in de studie was opgenomen. Ovaria van
MRKI(-/-) muizen bevatten minder follikels in totaal en minder primordiale follikels dan gevonden
werden in AMH(-/-) dieren. Het fenotype van de MRKI(-/-) muizen is sterker dan de AMH(-/-)
muizen. Dit resultaat zou kunnen wijzen op basale activiteit van de AMHRII. Dus, de experimenten
in de MRKI muizen hebben laten zien dat AMH in de ovaria signaleert door middel van de AMHRII.
Twee algemene signaaltransductie routes voor de TGFb superfamilie leden kunnen worden
onderscheiden: de BMP- en de TGFb/activine-signaaltransductie route. In Hoofdstuk 5 onderzochten
we via welke signaaltransductie route het signaal van AMH wordt doorgegeven in het ovarium.
Vervolgens hebben we onderzocht of AMH de sterkte van zijn eigen signaal in de cel kan reguleren
door de expressie van zijn type I en type II receptoren en downstream eiwitten te beïnvloeden. Voor
dit onderzoek gebruikten we de muizen granulosa cellijn KK-1. We ontdekten dat AMH zijn signaal
in de cel doorgeeft via de BMP-signaaltransductie route. De verschillende kandidaat type I receptoren,
receptor-specifieke en remmende Smads komen tot expressie in de ovaria van postnatale muizen, en
kunnen dus allemaal betrokken zijn bij het doorgeven van het AMH signaal en dus ook bij primordiale
follikel uitgroei. Met in situ hybridisatie hebben we aangetoond dat de AMHRII en één van de
kandidaat type I receptors, ALK2, tot expressie komen in granulosa cellen van pre-antrale en antrale
follikels. Ook hebben we door middel van quantitative real-time PCR laten zien dat AMH de genexpressie
van de remmende Smads (Smad6 en Smad7) stimuleert en op deze manier wordt een intracellulair
negatief terugkoppelingsmechanisme gevormd. De genexpressie van de receptor-specifieke Smad8
wordt ook gestimuleerd door AMH. Het belang van deze bevinding moet echter verder onderzocht
worden omdat het expressieniveau van Smad8 erg laag is.
Primordiale follikeluitgroei wordt deels gereguleerd door de groeiende follikels. Om het belang
van verschillende intra-ovariële groeifactoren in dit proces te bestuderen, hebben we de eiwit lokalisatie
en mRNA expressie van een aantal belangrijke groeifactoren bestudeerd in postnatale ovaria. De leeftijd
van de ovaria is gekozen op basis van aanwezigheid van verschillende type follikels. Ovaria van 2 dagen
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oude muizen bevatten alleen primordiale follikels. De eerste primaire follikels worden gevonden in
ovaria van 6 dagen oude muizen. Ovaria van 12 dagen oude muizen bevatten pre-antrale follikels en
antrale follikels zijn aanwezig in 18 dagen oude muizen. Alle grote pre-antrale en antrale follikels zijn
atretisch in ovaria van 25 dagen oude muizen. In ovaria van muizen met deze 5 verschillende leeftijden
hebben we de localizatie van eiwit en de hoogte van expressie van het mRNA van een aantal groeifactoren
bepaald. Granulosa cellen van kleine groeiende follikels bevatten AMH, activines, inhibines en kit-ligand,
terwijl de GDF9 en bone morphogenetic protein 15 (BMP15) tot expressie komen in de oocyten van
deze kleine groeiende follikels. Deze groeifactoren kunnen dus betrokken zijn bij primordiale follikel
uitgroei. De intra-ovariële groeifactoren basic fibroblast growth factor (bFGF) en nerve growth factor
(NGF) komen tot expressie in de oocyten en in granulosa, theca en interstitiële cellen. Omdat deze
groeifactoren zo algemeen tot expressie komen is het onwaarschijnlijk dat bFGF en NGF een specifiek
regulerende rol spelen bij primordiale follikel uitgroei.
AMH remt de uitgroei van primordiale follikels en remt de gevoeligheid van grote pre-antrale en
antrale follikels voor FSH. De moleculaire mechanismen waardoor AMH dit effect bereikt zijn onbekend.
Om de effecten van AMH te ontrafelen wilden we AMH-gereguleerde genen opsporen (Hoofdstuk 7).
We kweekten neonatale ovaria en de muizen granulosa cellijn KK-1/AMHRII voor 24 uur in af- of
aanwezigheid van AMH. Genexpressieverschillen in de neonatale ovaria werden bestudeerd met de Atlas™
mouse cDNA expressie array en de genexpressie verschillen in de KK-1/AMHRII cellen werden bestudeerd
met de Agilent mouse development oligo microarray. Verschillen in genexpressie gevonden met de arrays
werden gecontroleerd met quantitatieve real-time PCR. De AMH-gereguleerde genen gevonden in de
neonatale muizen ovaria konden niet worden bevestigd met de quantitatieve real-time PCR. De genen
welke zijn geïdentificeerd in de KK-1/AMHRII cellen worden op dit moment gecontroleerd.
De Algemene Discussie (Hoofdstuk 8) geeft tenslotte een overzicht van de mechanismen waardoor
AMH zijn effecten kan bereiken. Ook de rol van AMH in follikelontwikkeling wordt vergeleken met
de rol van LH en FSH. Als laatste wordt de klinische relevantie van het meten van AMH concentraties
in het bloed besproken.
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De ovaria die gekweekt werden in afwezigheid van AMH bevatten meer inhibine a-subunit mRNA
dan de ovaria gekweekt in aanwezigheid van AMH. AMH had geen effect op de mRNA expressie van de
AMH type II receptor (AMHRII) of de door oocyten geproduceerde eiwitten zona pellucida 3 (ZP3)
en growth differentiation factor 9 (GDF9).
Het signaal van AMH wordt doorgegeven d.m.v. een receptorcomplex dat een type II en type I
receptoren bevat. De AMH type II receptor (AMHRII) is verantwoordelijk voor het doorgeven van
het signaal van AMH in de Müllerse gangen tijdens de embryonale periode, resulterend in regressie
van de Müllerse gangen in mannen. Vrouwen maken geen AMH tijdens de embryonale periode en
daardoor gaan de Müllerse gangen niet in regressie en ontwikkelen zich in de eileiders, baarmoeder
en het bovenste deel van de vagina. Wij onderzochten of dezelfde AMHRII ook verantwoordelijk is
voor het doorgeven van het signaal van AMH in de ovaria. Hiervoor bestudeerden we de follikel
populatie in ovaria van 4 maanden oude (MRKI(-/-)) muizen die geen AMHRII tot expressie brengen
(Hoofdstuk 4). De ovaria van MRKI(-/-) muizen bevatten meer groeiende en minder primordiale
follikels dan in de controle dieren en deze resultaten zijn vergelijkbaar met de resultaten gevonden in
de ovaria van muizen die geen AMH (AMH(-/-)) tot expressie brengen. Het toegenomen aantal
groeiende follikels ging vergezeld met toegenomen serumconcentraties van inhibine A en inhibine B
en afgenomen serumconcentratie van FSH. Deze verschillen waren niet significant, waarschijnlijk als
gevolg van het kleine aantal controle dieren dat tot nu toe in de studie was opgenomen. Ovaria van
MRKI(-/-) muizen bevatten minder follikels in totaal en minder primordiale follikels dan gevonden
werden in AMH(-/-) dieren. Het fenotype van de MRKI(-/-) muizen is sterker dan de AMH(-/-)
muizen. Dit resultaat zou kunnen wijzen op basale activiteit van de AMHRII. Dus, de experimenten
in de MRKI muizen hebben laten zien dat AMH in de ovaria signaleert door middel van de AMHRII.
Twee algemene signaaltransductie routes voor de TGFb superfamilie leden kunnen worden
onderscheiden: de BMP- en de TGFb/activine-signaaltransductie route. In Hoofdstuk 5 onderzochten
we via welke signaaltransductie route het signaal van AMH wordt doorgegeven in het ovarium.
Vervolgens hebben we onderzocht of AMH de sterkte van zijn eigen signaal in de cel kan reguleren
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Figure 3.3: Immunohistochemical localization of AMH and inhibin a-subunit in freshly isolated (control) and
cultured neonatal C57Bl/6J mouse ovaries.
A-B. Section of a 2-day-old control mouse ovary. No AMH (A) and inhibin a-subunit (B) protein expression
is found in naked oocytes (no), primordial follicles (pr) and interstitial tissue (I). Scale bar 20 µm.
C-D. Section of a 4-day-old control mouse ovary. AMH protein expression (C) and inhibin a-subunit
protein expression (D) are found in several granulosa cells of early primary follicles. Scale bar 20 µm.
E-F. Section of a 6-day-old control mouse ovary. Abundant AMH protein expression (E) and inhibin a-
subunit protein expression (F) are found in granulosa cells of primary follicles (P) and early secondary
follicles (S). Scale bar 20 µm.
G-H. Section of a 2-day-old mouse ovary cultured for 2 days in the absence of added AMH. High AMH
protein expression (G) and inhibin a-subunit protein expression (H) are found in granulosa cells of
primary follicles (P). Scale bar 20 µm.
I-J. Section of a 4-day-old control mouse ovary. For AMH some background staining is found in the
interstitium (I) and the oocytes, while for inhibin a-subunit very low background staining is only
found in the oocytes (J). Scale bar 20 µm.
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Figure 6.2: Immunohistochemical localization of AMH in postnatal C57Bl/6J mouse ovaries of different ages. 
Magnification x 100.
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Figure 6.3: Immunohistochemical localization of inhibin a-, bA- and bB-subunits in postnatal C57Bl/6J mouse
ovaries of different ages.
Histology of the inhibin bB-subunits differs from the inhibin a and bA-subunit immunohistochemistry
due to fixation differences (formaldehyde vs. bouin). Magnification x 100.
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Figure 6.4: Immunohistochemical localization of GDF9 in postnatal C57Bl/6J mouse ovaries of different ages. 
Magnification x 100.
Figure 6.5: Immunohistochemical localization of bFGF and NGF in postnatal C57Bl/6J mouse ovaries of different ages.
Magnification x 100.
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Figure 6.6: bFGF protein is expressed in the interstitial cells surrounding primordial follicles in an 18-day-old
mouse ovary. Magnification x 200.
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1 AMH en BMP4 geven beide hun signaal door via de BMP signaal transductieroute maar hebben een
tegengesteld effect op de primordiale follikeluitgroei. Dit gegeven suggereert een belangrijke rol voor de
type II receptor in het doorgeven van het signaal.
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